-DOCSTART- -X- O O

Allelic JJ B-OC
imbalance NN I-OC
in IN O
the DT O
clonal JJ O
evolution NN O
of IN O
prostate NN B-POPU
carcinoma NN I-POPU
. . O

BACKGROUND NNP O
To TO O
understand VB O
better JJR O
the DT O
genetic JJ O
basis NN O
of IN O
the DT O
clonal JJ O
evolution NN O
of IN O
prostate NN O
carcinoma NN O
, , O
the DT O
authors NNS O
analyzed VBD O
the DT O
pattern NN O
of IN O
allelic JJ B-OC
loss NN I-OC
in IN O
25 CD B-POPU
matched JJ I-POPU
primary NN I-POPU
and CC I-POPU
metastatic JJ I-POPU
prostate NN I-POPU
tumors NNS I-POPU
. . O

METHODS NNP O
Twenty-five JJ B-POPU
cases NNS I-POPU
were VBD I-POPU
selected VBN I-POPU
from IN I-POPU
the DT I-POPU
surgical JJ I-POPU
pathology NN I-POPU
files NNS I-POPU
of IN I-POPU
the DT I-POPU
Mayo NNP I-POPU
Clinic NNP I-POPU
from IN I-POPU
patients NNS I-POPU
who WP I-POPU
had VBD I-POPU
undergone JJ I-POPU
radical JJ I-POPU
retropubic NN I-POPU
prostatectomy NN I-POPU
and CC I-POPU
bilateral JJ I-POPU
lymphadenectomy NN I-POPU
between IN I-POPU
1987-1991 JJ I-POPU
. . O

All DT B-POPU
patients NNS I-POPU
had VBD I-POPU
regional JJ I-POPU
lymph NN I-POPU
node NN I-POPU
metastases NNS I-POPU
at IN I-POPU
the DT I-POPU
time NN I-POPU
of IN I-POPU
surgery NN I-POPU
. . O

DNA NN O
samples NNS O
for IN O
the DT O
analysis NN O
of IN O
allelic JJ B-OC
loss NN I-OC
pattern NN O
were VBD O
prepared VBN O
from IN O
primary JJ O
tumors NNS O
and CC O
matched VBD O
synchronous JJ O
lymph NN O
node NN O
metastases NNS O
by IN O
tissue NN O
microdissection NN O
. . O

The DT O
oligonucleotide JJ O
primer NN O
pairs NNS O
for IN O
the DT O
microsatellite JJ O
DNA NN O
markers NNS O
were VBD O
D8S133 NNP O
, , O
D8S136 NNP O
, , O
D8S137 NNP O
, , O
ANK1 NNP O
on IN O
chromosome NN O
8p12-21 CD O
, , O
LPLTET NNP O
on IN O
chromosome NN O
8p22 CD O
, , O
and CC O
D17S855 NNP O
( ( O
intragenic JJ O
to TO O
the DT O
BRCA1 NNP O
gene NN O
) ) O
on IN O
chromosome NN O
17q21 CD O
. . O

One CD O
case NN O
was VBD O
not RB O
informative JJ O
at IN O
any DT O
of IN O
the DT O
loci NN O
tested VBD O
and CC O
was VBD O
excluded VBN O
from IN O
further JJ O
analysis NN O
. . O

RESULTS VB O
The DT O
overall JJ B-OC
frequency NN I-OC
of IN I-OC
allelic JJ I-OC
imbalance NN I-OC
was VBD O
79 CD O
% NN O
in IN O
primary JJ O
tumors NNS O
and CC O
88 CD O
% NN O
in IN O
paired JJ O
metastases NNS O
. . O

Of IN O
24 CD B-POPU
informative JJ I-POPU
cases NNS I-POPU
, , O
14 CD O
patients NNS O
( ( O
58 CD O
% NN O
) ) O
showed VBD O
the DT O
same JJ O
pattern NN O
of IN O
allelic JJ B-OC
loss NN I-OC
or CC I-OC
retention NN I-OC
in IN O
matched JJ O
primary NN O
and CC O
metastatic JJ O
tumors NNS O
at IN O
all DT O
marker NN O
locus NN O
; : O
discordant JJ O
allelic JJ B-OC
loss NN I-OC
was VBD O
observed VBN O
in IN O
the DT O
remaining VBG O
10 CD O
patients NNS O
( ( O
42 CD O
% NN O
) ) O
. . O

Four CD O
patients NNS O
showed VBD O
loss NN O
of IN O
the DT O
same JJ O
allele NN B-OC
at IN O
one CD O
or CC O
more JJR O
marker NN O
loci NN O
in IN O
both DT O
primary JJ O
and CC O
metastatic JJ O
tumors NNS O
, , O
but CC O
discordant JJ O
allelic JJ B-OC
loss NN I-OC
was VBD O
observed VBN O
at IN O
other JJ O
marker NN O
loci NN O
. . O

Five CD O
patients NNS O
showed VBD O
allelic JJ B-OC
loss NN I-OC
in IN O
at IN O
least JJS O
one CD O
genetic JJ O
marker NN O
in IN O
the DT O
metastatic JJ O
tumor NN O
but CC O
not RB O
in IN O
its PRP$ O
matched JJ O
primary JJ O
tumor NN O
. . O

Five CD O
patients NNS O
displayed JJ O
loss NN B-OC
of IN I-OC
one CD I-OC
allele NN I-OC
at IN I-OC
one CD I-OC
or CC O
more JJR O
marker NN O
loci NN O
in IN O
a DT O
primary JJ O
tumor NN O
but CC O
not RB O
in IN O
the DT O
matched JJ O
metastases NNS O
. . O

There EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
the DT O
frequency NN B-OC
of IN I-OC
allelic JJ I-OC
imbalance NN I-OC
between IN O
primary JJ O
and CC O
metastatic JJ O
tumors NNS O
at IN O
any DT O
marker NN O
analyzed VBN O
( ( O
P NNP O
> NNP O
0.05 CD O
) ) O
. . O

CONCLUSIONS NNP O
These DT O
data NNS O
suggest VBP O
that IN O
different JJ O
patterns NNS O
of IN O
allelic JJ B-OC
deletion NN I-OC
may MD O
be VB O
acquired VBN O
during IN O
cancer NN O
progression NN O
to TO O
metastases NNS O
. . O

The DT O
differences NNS O
in IN O
genetic JJ O
composition NN O
between IN O
primary JJ O
prostate NN O
carcinoma NN O
and CC O
its PRP$ O
metastases NNS O
may MD O
be VB O
related VBN O
to TO O
intrinsic JJ O
cancer NN O
heterogeneity NN O
, , O
overall JJ O
genetic JJ O
instability NN O
, , O
and CC O
clonal JJ O
divergence NN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
total JJ B-INTV
androgen NN I-INTV
ablation NN I-INTV
on IN O
pathologic JJ B-OC
stage NN I-OC
and CC I-OC
resection NN I-OC
limit NN I-OC
status NN I-OC
of IN I-OC
prostate NN B-POPU
cancer NN I-POPU
. . O

Initial JJ O
results NNS O
of IN O
the DT O
Italian JJ B-POPU
PROSIT NNP I-POPU
study NN I-POPU
. . O

The DT O
likelihood NN O
of IN O
finding VBG O
organ-confined JJ O
untreated JJ O
prostate NN O
cancer NN O
( ( O
PCa NNP O
) ) O
by IN O
pathological JJ O
examination NN O
at IN O
the DT O
time NN O
of IN O
radical JJ B-INTV
prostatectomy NN I-INTV
( ( I-INTV
RP NNP I-INTV
) ) I-INTV
is VBZ O
only RB O
50 CD O
% NN O
in IN O
patients NNS O
with IN O
clinically RB O
organ-confined JJ O
disease NN O
. . O

In IN O
addition NN O
, , O
tumour NN O
is VBZ O
present JJ O
at IN O
the DT O
resection NN O
margin NN O
in IN O
approximately RB O
30 CD O
% NN O
of IN O
clinical JJ O
T2 NNP O
( ( O
clinical JJ O
stage NN O
B NNP O
) ) O
cases NNS O
. . O

The DT O
issue NN O
of IN O
clinical JJ O
" NN O
understaging VBG O
" NNP O
and CC O
of IN O
resection NN O
limit NN O
positivity NN O
have VBP O
led VBN O
to TO O
the DT O
development NN O
of IN O
novel JJ O
management NN O
practices NNS O
, , O
including VBG O
" JJ B-INTV
neoadjuvant JJ I-INTV
" NNP I-INTV
hormonal JJ I-INTV
therapy NN I-INTV
( ( I-INTV
NHT NNP I-INTV
) ) I-INTV
. . O

The DT O
optimal JJ O
duration NN O
of IN O
NHT NNP O
is VBZ O
unknown JJ O
. . O

We PRP O
undertook VBD O
the DT O
present JJ O
analysis NN O
to TO O
evaluate VB O
the DT O
effect NN B-OC
of IN I-OC
NHT NNP I-OC
on IN I-OC
pathologic JJ I-OC
stage NN I-OC
of IN I-OC
PCa NNP I-OC
and CC I-OC
resection NN I-OC
limit NN I-OC
status NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
prostate JJ I-POPU
cancer NN I-POPU
and CC I-POPU
treated VBN I-POPU
with IN I-POPU
total JJ I-POPU
androgen NN I-POPU
ablation NN I-POPU
either DT I-POPU
for IN I-POPU
three CD I-POPU
or CC I-POPU
six CD I-POPU
months NNS I-POPU
before IN I-POPU
RP NNP I-POPU
. . O

Between NNP B-POPU
January NNP I-POPU
1996 CD I-POPU
and CC I-POPU
February NNP I-POPU
1998 CD I-POPU
, , I-POPU
259 CD I-POPU
men NNS I-POPU
with IN I-POPU
prostate NN I-POPU
cancer NN I-POPU
underwent JJ I-POPU
radical JJ I-POPU
retropubic NN I-POPU
prostatectomy NN I-POPU
and CC I-POPU
bilateral JJ I-POPU
pelvic JJ I-POPU
node NN I-POPU
dissection NN I-POPU
in IN I-POPU
the DT I-POPU
26 CD I-POPU
centres NNS I-POPU
participating VBG I-POPU
in IN I-POPU
the DT I-POPU
Italian JJ I-POPU
randomised VBD I-POPU
prospective JJ I-POPU
PROSIT NNP I-POPU
study NN I-POPU
. . O

Whole NNP O
mount NN O
sectioning NN O
of IN O
the DT O
complete JJ O
RP NNP O
specimens NNS O
was VBD O
adopted VBN O
in IN O
each DT O
centre NN O
for IN O
accurately RB O
evaluating VBG O
the DT O
pathologic JJ B-OC
stage NN I-OC
and CC I-OC
resection NN I-OC
limit NN I-OC
status NN I-OC
. . O

By IN O
February NNP O
1998 CD O
, , O
haematoxylin NN O
and CC O
eosin NN O
stained VBD O
sections NNS O
from IN O
155 CD O
RP NNP O
specimens NNS O
had VBD O
been VBN O
received VBN O
and CC O
evaluated VBN O
by IN O
the DT O
reviewing VBG O
pathologist NN O
( ( O
RM NNP O
) ) O
. . O

64 CD O
cases NNS O
had VBD O
not RB O
been VBN O
treated VBN O
with IN O
total JJ B-INTV
androgen NN I-INTV
ablation NN I-INTV
( ( O
e.g JJ O
. . O

NHT NNP B-INTV
) ) I-INTV
before IN O
RP NNP O
was VBD O
performed VBN O
, , O
whereas JJ O
58 CD O
and CC O
33 CD O
had VBD O
been VBN O
treated VBN O
for IN O
three CD O
and CC O
six CD O
months NNS O
, , O
respectively RB O
. . O

114 CD B-POPU
patients NNS I-POPU
were VBD O
clinical JJ O
stage NN O
B NNP O
whereas IN O
41 CD O
were VBD O
clinical JJ O
stage NN O
C. NNP O
After IN O
three CD O
months NNS O
of IN O
total JJ B-INTV
androgen NN I-INTV
ablation NN I-INTV
, , O
pathological JJ B-OC
stage NN I-OC
B NNP I-OC
was VBD O
more RBR O
prevalent JJ O
among IN O
patients NNS O
with IN O
clinical JJ O
B NNP O
tumours NN O
, , O
compared VBN O
with IN O
untreated JJ O
patients NNS O
( ( O
57 CD O
% NN O
in IN O
treated JJ O
patients NNS O
vs. FW O
36 CD O
% NN O
in IN O
untreated JJ O
) ) O
. . O

The DT O
percentage NN B-OC
of IN I-OC
cancers NNS I-OC
with IN I-OC
negative JJ I-OC
margins NNS I-OC
was VBD O
statistically RB O
significantly RB O
greater JJR O
in IN O
patients NNS O
treated VBN O
with IN O
neoadjuvant JJ B-INTV
therapy NN I-INTV
than IN O
those DT O
treated VBN O
with IN O
immediate JJ B-INTV
surgery NN I-INTV
alone RB I-INTV
( ( O
69 CD O
% NN O
vs. FW O
42 CD O
% NN O
, , O
respectively RB O
) ) O
. . O

After IN O
six CD O
months NNS O
of IN O
NHT NNP O
therapy VBP O
the DT O
proportion NN B-OC
of IN I-OC
patients NNS I-OC
with IN I-OC
pathological JJ I-OC
stage NN I-OC
B NNP I-OC
( ( O
67 CD O
% NN O
vs. FW O
36 CD O
% NN O
, , O
respectively RB O
) ) O
and CC O
negative JJ B-OC
margins NNS I-OC
was VBD O
greater JJR O
than IN O
after IN O
3 CD O
months NNS O
( ( O
92 CD O
% NN O
vs. FW O
42 CD O
% NN O
, , O
respectively RB O
) ) O
. . O

For IN O
clinical JJ O
C NNP O
tumours NN O
, , O
the DT O
prevalence NN O
of IN O
pathological JJ B-OC
stage NN I-OC
B NNP I-OC
and CC I-OC
negative JJ I-OC
margins NNS I-OC
in IN O
the DT O
patients NNS O
treated VBD O
for IN O
either DT O
3 CD O
or CC O
6 CD O
months NNS O
was VBD O
not RB O
as RB O
high JJ O
as IN O
in IN O
the DT O
clinical JJ O
B NNP O
tumours NN O
, , O
when WRB O
compared VBN O
with IN O
the DT O
untreated JJ O
group NN O
( ( O
pathological JJ O
stage NN O
B NNP O
: : O
31 CD O
% NN O
and CC O
33 CD O
% NN O
vs. FW O
6 CD O
% NN O
in IN O
the DT O
clinical JJ O
C NNP O
cases NNS O
, , O
respectively RB O
. . O

Negative JJ O
margins NNS O
: : O
56 CD O
% NN O
and CC O
67 CD O
% NN O
vs. FW O
31 CD O
% NN O
, , O
respectively RB O
) ) O
. . O

The DT O
initial JJ O
results NNS O
of IN O
this DT O
study NN O
suggest VBP O
that IN O
total JJ B-INTV
androgen NN I-INTV
ablation NN I-INTV
before IN I-INTV
RP NNP I-INTV
is VBZ O
beneficial JJ O
in IN O
men NNS O
with IN O
clinical JJ O
stage NN O
B NNP O
because IN O
of IN O
the DT O
significant JJ O
pathological JJ B-OC
downstaging NN I-OC
and CC O
decrease NN O
in IN O
the DT O
number NN O
of IN O
positive JJ B-OC
margins NNS I-OC
in IN I-OC
the DT I-OC
RP NNP I-OC
specimens NNS I-OC
. . O

These DT O
two CD O
effects NNS O
are VBP O
more RBR O
pronounced JJ O
after IN O
six CD O
months NNS O
of IN O
NHT NNP B-INTV
than IN O
after IN O
three CD O
months NNS O
of IN O
therapy NN O
. . O

The DT O
same JJ O
degree NN O
of IN O
beneficial JJ B-OC
effects NNS I-OC
are VBP O
not RB O
observed VBN O
in IN O
clinical JJ O
C NNP O
tumours NN O
. . O

-DOCSTART- -X- O O

Oral NNP O
and CC O
parenteral JJ O
glutamine NN B-INTV
in IN O
bone NN O
marrow NN O
transplantation NN O
: : O
a DT O
randomized JJ O
, , O
double-blind JJ O
study NN O
. . O

BACKGROUND NNP O
Total NNP B-INTV
parenteral JJ I-INTV
nutrition NN I-INTV
( ( I-INTV
TPN NNP I-INTV
) ) I-INTV
supplemented VBD I-INTV
with IN I-INTV
glutamine NN I-INTV
( ( I-INTV
GLN NNP I-INTV
) ) I-INTV
has VBZ O
been VBN O
reported VBN O
to TO O
be VB O
effective JJ O
for IN O
patients NNS B-POPU
with IN I-POPU
bone NN I-POPU
marrow NN I-POPU
transplantation NN I-POPU
( ( I-POPU
BMT NNP I-POPU
) ) I-POPU
. . O

Our PRP$ O
aim NN O
was VBD O
to TO O
evaluate VB O
enteral JJ O
and CC O
parenteral JJ O
glutamine NN O
in IN O
patients NNS B-POPU
undergoing JJ I-POPU
BMT NNP I-POPU
. . O

METHODS NNP O
For IN O
evaluation NN O
of IN O
GLN NNP O
in IN O
BMT NNP O
, , O
66 CD B-POPU
patients NNS I-POPU
with IN I-POPU
43 CD I-POPU
hematologic NNS I-POPU
and CC I-POPU
23 CD I-POPU
solid JJ I-POPU
malignancies NNS I-POPU
( ( I-POPU
21 CD I-POPU
breast NN I-POPU
carcinomas NN I-POPU
) ) I-POPU
, , O
were VBD O
randomized VBN O
, , O
double-blinded JJ O
, , O
to TO O
either DT O
oral JJ B-INTV
GLN NNP I-INTV
( ( O
n JJ O
= NNP O
35 CD O
) ) O
or CC O
glycine-control NN B-INTV
( ( O
GLY NNP O
) ) O
( ( O
n JJ O
= NNP O
31 CD O
) ) O
, , O
10 CD O
g NN O
three CD O
times NNS O
daily RB O
. . O

When WRB O
TPN NNP B-INTV
became VBD O
necessary JJ O
, , O
patients NNS O
who WP O
received VBD O
GLN NNP B-INTV
orally RB O
were VBD O
given VBN O
TPN NNP B-INTV
with IN I-INTV
GLN NNP I-INTV
( ( O
0.57 CD O
g/kg NN O
) ) O
. . O

Those DT O
who WP O
received VBD O
GLY NNP O
received VBD O
standard JJ O
TPN NNP B-INTV
, , O
isocaloric JJ O
and CC O
isonitrogenous JJ O
. . O

Patients NNS B-POPU
with IN I-POPU
hematologic JJ I-POPU
malignancies NNS I-POPU
received VBD O
high-dose JJ B-INTV
chemotherapy NN I-INTV
, , I-INTV
total JJ I-INTV
body NN I-INTV
irradiation NN I-INTV
, , I-INTV
and CC I-INTV
either DT I-INTV
allogeneic NN I-INTV
( ( I-INTV
ALLO NNP I-INTV
) ) I-INTV
BMT NNP I-INTV
( ( O
n JJ O
= NNP O
18 CD O
) ) O
or CC O
autologous JJ B-INTV
( ( I-INTV
AUTO NNP I-INTV
) ) I-INTV
stem NN I-INTV
cell NN I-INTV
transplantation NN I-INTV
( ( O
n JJ O
= NNP O
25 CD O
) ) O
. . O

Patients NNS B-POPU
with IN I-POPU
solid JJ I-POPU
malignancies NNS I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
23 CD I-POPU
) ) I-POPU
received VBD O
AUTO NNP B-INTV
. . O

RESULTS NNP O
There EX O
were VBD O
14 CD B-POPU
in-hospital JJ I-POPU
deaths NNS I-POPU
without IN I-POPU
relationship NN I-POPU
to TO I-POPU
GLN NNP I-POPU
administration NN I-POPU
. . O

For IN O
respective JJ O
comparisons NNS O
of IN O
ALLO NNP O
and CC O
AUTO NNP O
transplants NNS O
in IN O
the DT O
GLN NNP O
and CC O
GLY NNP O
hematologic VBP O
groups NNS O
and CC O
AUTO NNP O
in IN O
the DT O
solid JJ O
tumor NN O
groups NNS O
, , O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
hospital NN B-OC
stay NN I-OC
, , I-OC
duration NN I-OC
of IN I-OC
stay NN I-OC
after IN I-OC
BMT NNP I-OC
, , I-OC
TPN NNP I-OC
days NNS I-OC
, , I-OC
neutrophil JJ I-OC
recovery NN I-OC
> NN I-OC
500/mm3 CD I-OC
, , I-OC
incidence NN I-OC
of IN I-OC
positive JJ I-OC
blood NN I-OC
cultures NNS I-OC
, , I-OC
sepsis NN I-OC
, , I-OC
mucositis NN I-OC
, , I-OC
and CC I-OC
diarrhea NN I-OC
. . O

Acute NNP B-OC
graft VBD I-OC
us PRP I-OC
host VB I-OC
disease NN I-OC
occurred VBD O
in IN O
1 CD B-POPU
of IN I-POPU
10 CD I-POPU
hematologic JJ I-POPU
patients NNS I-POPU
receiving VBG I-POPU
GLN NNP I-POPU
and CC O
in IN O
3 CD O
of IN O
8 CD O
patients NNS O
receiving VBG O
GLY NNP O
placebo NN O
( ( O
p JJ O
> NNP O
.05 NNP O
) ) O
. . O

Possible JJ O
reduction NN B-OC
in IN I-OC
need NN I-OC
for IN I-OC
TPN NNP I-OC
and CC O
a DT O
suggestion NN O
of IN O
improved JJ B-OC
long-term JJ I-OC
survival NN I-OC
were VBD O
associated VBN O
with IN O
GLN NNP O
. . O

CONCLUSIONS NNP O
Oral NNP O
and CC O
parenteral JJ O
GLN NNP B-INTV
seemed VBD O
to TO O
be VB O
of IN O
limited JJ O
benefit NN O
for IN O
patients NNS O
having VBG O
AUTO NNP O
or CC O
ALLO NNP O
BMT NNP O
for IN O
hematologic NN O
or CC O
solid JJ O
malignancies NNS O
. . O

Further NNP O
study NN O
of IN O
long-term JJ O
effects NNS O
of IN O
GLN NNP O
in IN O
BMT NNP O
seems VBZ O
warranted VBN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
granulocyte/colony-stimulating JJ B-INTV
factor NN I-INTV
on IN O
the DT O
onset NN O
of IN O
the DT O
adult NN B-POPU
respiratory NN I-POPU
distress JJ I-POPU
syndrome NN I-POPU
. . O

To TO O
evaluate VB O
the DT O
effect NN O
of IN O
granulocyte/colony-stimulating JJ B-INTV
factor NN I-INTV
( ( I-INTV
G-CSF NNP I-INTV
) ) I-INTV
on IN O
the DT O
onset NN O
of IN O
the DT O
adult NN O
respiratory NN O
distress NN O
syndrome NN O
( ( O
ARDS NNP O
) ) O
, , O
we PRP O
investigated VBD O
whether IN O
the DT O
incidence NN O
of IN O
ARDS NNP O
due JJ O
to TO O
pulmonary JJ O
infection NN O
differed VBD O
between IN O
the DT O
G-CSF NNP B-POPU
group NN I-POPU
which WDT I-POPU
received VBD I-POPU
chemotherapy NN I-POPU
with IN I-POPU
G-CSF NNP I-POPU
and CC I-POPU
historical JJ I-POPU
controls NNS I-POPU
without IN I-POPU
G-CSF NNP I-POPU
. . O

We PRP O
evaluated VBD O
132 CD B-POPU
patients NNS I-POPU
with IN I-POPU
hematological JJ I-POPU
malignancy NN I-POPU
in IN I-POPU
complete JJ I-POPU
remission NN I-POPU
without IN I-POPU
any DT I-POPU
main JJ I-POPU
organ JJ I-POPU
dysfunction NN I-POPU
who WP I-POPU
had VBD I-POPU
been VBN I-POPU
treated VBN I-POPU
between IN I-POPU
April NNP I-POPU
1983 CD I-POPU
and CC I-POPU
December NNP I-POPU
1997 CD I-POPU
. . O

We PRP O
compared VBN O
the DT O
incidence NN O
of IN O
ARDS NNP O
due JJ O
to TO O
pulmonary JJ O
infection NN O
between IN O
those DT O
who WP B-POPU
received VBD I-POPU
G-CSF NNP I-POPU
and CC O
those DT O
who WP O
did VBD O
not RB O
. . O

There EX B-POPU
was VBD I-POPU
no DT I-POPU
remarkable JJ I-POPU
difference NN I-POPU
in IN I-POPU
the DT I-POPU
number NN I-POPU
of IN I-POPU
patients NNS I-POPU
, , I-POPU
gender NN I-POPU
, , I-POPU
age NN I-POPU
, , I-POPU
or CC I-POPU
distribution NN I-POPU
of IN I-POPU
primary JJ I-POPU
diseases NNS I-POPU
between IN I-POPU
the DT I-POPU
two CD I-POPU
groups NNS I-POPU
. . O

The DT O
intensity NN B-OC
of IN I-OC
chemotherapy NN I-OC
was VBD O
not RB O
considered VBN O
to TO O
significantly RB O
differ VB O
between IN O
the DT O
two CD O
groups NNS O
, , O
though IN O
the DT O
chemotherapy NN O
regimens VBZ O
administered VBN O
differed VBD O
slightly RB O
. . O

In IN O
the DT O
G-CSF NNP B-INTV
group NN O
, , O
the DT O
duration NN B-OC
of IN I-OC
neutropenia NN I-OC
was VBD O
significantly RB O
shorter JJR O
and CC O
the DT O
frequency NN O
of IN O
documented JJ O
infection NN O
was VBD O
significantly RB O
decreased VBN O
. . O

We PRP O
could MD O
not RB O
find VB O
any DT O
relationship NN O
between IN O
ARDS NNP O
due JJ O
to TO O
pulmonary JJ B-OC
infection NN I-OC
and CC O
any DT O
anticancer JJ O
agent NN O
or CC O
antibiotics NNS O
. . O

There EX O
was VBD O
no DT O
relationship NN O
between IN O
the DT O
kind NN O
of IN O
G-CSF NNP B-INTV
and CC O
the DT O
incidence NN O
of IN O
ARDS NNP O
due JJ O
to TO O
pulmonary JJ B-OC
infection NN I-OC
( ( O
per IN O
chemotherapy NN O
session NN O
; : O
p CC O
> $ O
0.10 CD O
, , O
per IN O
case NN O
; : O
p CC O
> $ O
0.30 CD O
, , O
chi2 JJ O
test NN O
) ) O
. . O

The DT O
incidence NN B-OC
of IN I-OC
ARDS NNP I-OC
due JJ I-OC
to TO I-OC
pulmonary JJ I-OC
infection NN I-OC
per IN I-OC
chemotherapy NN I-OC
session NN I-OC
was VBD O
4.21 CD O
% NN O
, , O
and CC O
showed VBD O
a DT O
higher JJR O
tendency NN O
in IN O
the DT O
G-CSF NNP B-INTV
group NN O
( ( O
p JJ O
< NN O
0.100 CD O
, , O
chi2 JJ O
test NN O
) ) O
. . O

The DT O
incidence NN B-OC
of IN I-OC
ARDS NNP I-OC
due JJ I-OC
to TO I-OC
pulmonary JJ I-OC
infection NN I-OC
per IN I-OC
case NN I-OC
was VBD O
25.4 CD O
% NN O
and CC O
was VBD O
significantly RB O
higher JJR O
in IN O
the DT O
G-CSF NNP B-INTV
group NN O
( ( O
p JJ O
< NN O
0.025 CD O
, , O
chi2 JJ O
test NN O
) ) O
. . O

The DT O
incidence NN B-OC
of IN I-OC
ARDS NNP I-OC
due JJ I-OC
to TO I-OC
pulmonary JJ I-OC
infection NN I-OC
was VBD I-OC
higher RBR I-OC
in IN I-OC
the DT I-OC
G-CSF NNP B-INTV
group NN B-OC
than IN O
in IN O
the DT O
controls NNS O
, , O
suggesting VBG O
that IN O
G-CSF NNP B-INTV
promotes VBZ O
the DT O
development NN O
of IN O
ARDS NNP O
due JJ O
to TO O
pulmonary JJ O
infection NN O
. . O

-DOCSTART- -X- O O

Granulocyte-macrophage JJ B-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
treatment NN I-INTV
before IN O
doxorubicin NN O
and CC O
cyclophosphamide NN O
chemotherapy NN O
priming VBG O
in IN O
women NNS B-POPU
with IN I-POPU
early-stage JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
To TO O
determine VB O
if IN O
inhibition NN O
of IN O
stem-cell JJ O
activity NN O
induced VBN O
by IN O
granulocyte-macrophage JJ B-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
( ( O
[ JJ O
GM-CSF NNP O
] NNP O
; : O
Sargramostim NNP O
; : O
Immunex NNP O
Corporation NNP O
, , O
Seattle NNP O
, , O
WA NNP O
) ) O
withdrawal NN O
or CC O
priming VBG O
protects NNS O
hematopoietic JJ O
stem NN O
cells NNS O
from IN O
the DT O
cytotoxic JJ O
effects NNS O
of IN O
adjuvant JJ O
chemotherapy NN O
for IN O
early-stage JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Serial NNP O
blood NN O
counts NNS O
were VBD O
performed VBN O
in IN O
20 CD B-POPU
women NNS I-POPU
with IN I-POPU
early-stage JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
receiving VBG I-POPU
four CD I-POPU
courses NNS I-POPU
of IN I-POPU
cyclophosphamide NN I-POPU
and CC I-POPU
doxorubicin NN I-POPU
chemotherapy NN I-POPU
. . O

By IN O
a DT O
double-blind JJ O
, , O
placebo-controlled JJ O
, , O
balanced JJ O
randomization NN O
, , O
subjects VBZ B-INTV
received VBN I-INTV
GM-CSF NNP I-INTV
priming VBG I-INTV
on IN I-INTV
days NNS I-INTV
5 CD I-INTV
to TO I-INTV
1 CD I-INTV
for IN I-INTV
courses NNS I-INTV
1 CD I-INTV
and CC I-INTV
3 CD I-INTV
or CC I-INTV
courses NNS I-INTV
2 CD I-INTV
and CC I-INTV
4 CD I-INTV
. . O

RESULTS VB O
Compared NNP O
with IN O
before RB O
priming VBG O
, , O
after IN O
priming VBG O
the DT O
times NNS B-OC
to TO I-OC
neutrophil VB I-OC
nadir NN I-OC
( ( O
12.8 CD O
+/- JJ O
2.5 CD O
days NNS O
v RB O
14.8 CD O
+/- JJ O
1.5 CD O
days NNS O
, , O
respectively RB O
; : O
P NNP O
=.0001 NNP O
) ) O
and CC O
platelet NN B-OC
nadir NN I-OC
( ( O
mean JJ O
+/- JJ O
SD NNP O
, , O
10.1 CD O
+/- JJ O
1.9 CD O
days NNS O
v RB O
11.1 CD O
+/- JJ O
2.2 CD O
days NNS O
, , O
P NNP O
< NNP O
.05 NNP O
) ) O
were VBD O
shorter JJR O
, , O
indicating VBG O
a DT O
shift NN O
of IN O
cytotoxicity NN O
to TO O
later RB O
progenitors NNS O
. . O

The DT O
neutrophil JJ B-OC
nadir NN I-OC
was VBD O
similar JJ O
with IN O
and CC O
without IN O
priming VBG O
( ( O
mean JJ O
+/- JJ O
SD NNP O
, , O
490 CD O
+/- JJ O
310/microL CD O
v JJ O
550 CD O
+/- JJ O
350/microL CD O
, , O
respectively RB O
; : O
P NNP O
=.2 NNP O
) ) O
; : O
however RB O
, , O
on IN O
day NN O
16 CD O
the DT O
mean NN O
neutrophil NN B-OC
count NN I-OC
was VBD O
higher JJR O
( ( O
mean JJ O
+/- JJ O
SD NNP O
, , O
1030 CD O
+/- JJ O
580/microL CD O
v JJ O
690 CD O
+/- JJ O
370/microL CD O
, , O
P NNP O
=.004 NNP O
) ) O
, , O
and CC O
the DT O
proportion NN O
of IN O
patients NNS O
with IN O
a DT O
neutrophil JJ B-OC
count NN I-OC
less JJR O
than IN O
500/microL CD O
was VBD O
lower JJR O
after IN O
priming VBG O
than IN O
before IN O
( ( O
six CD O
of IN O
35 CD O
or CC O
17 CD O
. . O

1 CD O
% NN O
v JJ O
12 CD O
of IN O
34 CD O
or CC O
35.3 CD O
% NN O
, , O
respectively RB O
; : O
P NNP O
=.04 NNP O
) ) O
. . O

The DT O
platelet NN B-OC
nadir NN I-OC
was VBD O
higher JJR O
( ( O
mean JJ O
+/- JJ O
SD NNP O
, , O
166,000 CD O
+/- JJ O
51,000/microL CD O
after IN O
priming VBG O
v JJ O
151,000 CD O
+/- JJ O
45,000/microL CD O
before IN O
priming NN O
, , O
P NNP O
=.007 NNP O
) ) O
, , O
and CC O
the DT O
duration NN B-OC
of IN I-OC
thrombocytopenia NN I-OC
, , O
ie NN O
, , O
a DT O
platelet NN O
count NN O
less JJR O
than IN O
150,000/microL CD O
, , O
was VBD O
shorter JJR O
( ( O
1.5 CD O
+/- JJ O
2.1 CD O
days NNS O
v RB O
2.8 CD O
+/- JJ O
2.9 CD O
days NNS O
, , O
P NNP O
=.0025 NNP O
) ) O
after IN O
priming VBG O
. . O

Episodes NNS O
of IN O
fever NN B-OC
and CC I-OC
neutropenia NN I-OC
were VBD O
not RB O
observed VBN O
. . O

CONCLUSIONS NNP O
GM-CSF NNP O
priming VBG O
from IN O
days NNS O
5 CD O
to TO O
1 CD O
before IN O
doxorubicin NN O
and CC O
cyclophosphamide NN O
chemotherapy NN O
was VBD O
associated VBN O
with IN O
an DT O
earlier JJR O
neutrophil NN B-OC
and CC I-OC
platelet NN I-OC
nadir NN I-OC
. . O

On IN O
day NN O
16 CD O
, , O
a DT O
higher JJR O
mean JJ O
neutrophil NN B-OC
count NN I-OC
and CC O
a DT O
lower JJR O
proportion NN O
of IN O
patients NNS O
with IN O
severe JJ O
( ( O
< JJ O
500/microL CD O
) ) O
neutropenia NN B-OC
were VBD O
observed VBN O
. . O

Beneficial JJ O
effects NNS O
on IN O
the DT O
severity NN O
and CC O
duration NN O
of IN O
thrombocytopenia NN B-OC
were VBD O
also RB O
noted VBN O
. . O

These DT O
observations NNS O
support VBP O
the DT O
hypothesis NN O
that IN O
GM-CSF NNP O
priming VBG O
protects NNS O
hematopoietic JJ O
progenitors NNS O
from IN O
the DT O
cytotoxic JJ O
effects NNS O
of IN O
chemotherapy NN B-INTV
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
chemotherapy NN B-INTV
with IN I-INTV
chemohormonal JJ I-INTV
therapy NN I-INTV
as IN O
first-line JJ O
therapy NN O
for IN O
metastatic JJ B-POPU
, , I-POPU
hormone-sensitive JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
An DT I-POPU
Eastern JJ I-POPU
Cooperative NNP I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
study NN I-POPU
. . O

PURPOSE NNP O
Although IN O
hormonal JJ O
therapy NN O
represents VBZ O
standard JJ O
therapy NN O
for IN O
metastatic JJ O
hormone-sensitive JJ O
disease NN O
, , O
many JJ O
patients NNS O
receive VBP O
initial JJ O
chemotherapy NN B-INTV
because IN O
of IN O
the DT O
location NN O
, , O
bulk NN O
, , O
or CC O
aggressiveness NN O
of IN O
their PRP$ O
disease NN O
. . O

It PRP O
is VBZ O
uncertain JJ O
whether IN O
simultaneous JJ B-INTV
hormonal JJ I-INTV
therapy NN I-INTV
provides VBZ O
additional JJ O
benefit NN O
compared VBN O
with IN O
chemotherapy NN O
alone RB O
. . O

Eastern JJ O
Cooperative NNP O
Oncology NNP O
Group NNP O
trial NN O
E3186 NNP O
was VBD O
initiated VBN O
to TO O
explore VB O
this DT O
question NN O
. . O

PATIENTS NN O
AND CC O
METHODS NNP O
Between NNP B-POPU
January NNP I-POPU
1988 CD I-POPU
and CC I-POPU
December NNP I-POPU
1992 CD I-POPU
, , I-POPU
231 CD I-POPU
patients NNS I-POPU
with IN I-POPU
estrogen JJ I-POPU
receptor NN I-POPU
( ( I-POPU
ER NNP I-POPU
) ) I-POPU
-positive CD I-POPU
or CC I-POPU
ER-unknown JJ I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
either DT O
chemotherapy NN B-INTV
( ( I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
and CC I-INTV
fluorouracil RB I-INTV
¿CAF NNP I-INTV
) ) I-INTV
or CC I-INTV
chemohormonal JJ I-INTV
therapy NN I-INTV
( ( I-INTV
CAF NNP I-INTV
plus CC I-INTV
tamoxifen NN I-INTV
and CC I-INTV
Halotestin NNP I-INTV
¿fluoxymesterone NN I-INTV
; : I-INTV
Pharmacia-Upjohn NNP I-INTV
, , I-INTV
Kalamazoo NNP I-INTV
, , I-INTV
MI NNP I-INTV
¿CAFTH NNP I-INTV
) ) I-INTV
as IN I-INTV
front-line JJ I-INTV
therapy NN I-INTV
for IN O
metastatic JJ O
breast NN O
cancer NN O
. . O

Patients NNS O
who WP O
experienced VBD O
a DT O
complete JJ O
response NN O
to TO O
induction NN O
therapy NN O
either CC O
received VBD O
or CC O
did VBD O
not RB O
receive JJ O
maintenance NN O
cyclophosphamide NN O
, , O
methotrexate NN O
, , O
fluorouracil NN O
, , O
prednisone NN O
, , O
and CC O
TH NNP O
as IN O
a DT O
secondary JJ O
randomization NN O
. . O

RESULTS VB O
The DT B-OC
response NN I-OC
rates NNS I-OC
( ( I-OC
complete JJ I-OC
response NN I-OC
and CC I-OC
partial JJ I-OC
response NN I-OC
) ) I-OC
of IN O
patients NNS O
who WP O
received VBD O
CAF NNP O
and CC O
CAFTH NNP O
were VBD O
similar JJ O
( ( O
69.2 CD O
% NN O
v JJ O
68.9 CD O
% NN O
, , O
respectively RB O
; : O
P NNP O
=.99 NNP B-OC
) ) I-OC
. . O

Time NN B-OC
to TO I-OC
treatment NN I-OC
failure NN I-OC
( ( I-OC
TTF NNP I-OC
) ) I-OC
was VBD O
slightly RB O
longer JJR O
for IN O
patients NNS O
who WP O
received VBD O
chemohormonal JJ O
therapy NN O
compared VBN O
with IN O
chemotherapy NN O
alone RB O
patients NNS O
( ( O
13.4 CD O
months NNS O
v RB O
10.3 CD O
months NNS O
, , O
respectively RB O
; : O
P NNP O
=.087 NNP O
) ) O
, , O
and CC B-OC
TTF NNP I-OC
was VBD O
significantly RB O
longer RBR O
in IN O
ER-positive JJ O
compared VBN O
with IN O
ER-negative JJ O
patients NNS O
( ( O
17.4 CD O
months NNS O
v RB O
10.3 CD O
months NNS O
, , O
respectively RB O
; : O
P NNP O
=.048 NNP O
) ) O
. . O

However RB O
, , O
ER NNP O
status NN O
had VBD O
no DT O
effect NN O
on IN B-OC
overall JJ I-OC
survival NN I-OC
( ( O
30.0 CD O
months NNS O
for IN O
CAF NNP O
v FW O
29.3 CD O
months NNS O
for IN O
CAFTH NNP O
) ) O
. . O

CONCLUSION NNP O
In IN O
patients NNS O
with IN O
potentially RB O
hormone-sensitive JJ O
metastatic JJ O
breast NN O
cancer NN B-INTV
, , I-INTV
chemohormonal JJ I-INTV
therapy NN I-INTV
prolongs NNS O
TTF NNP O
for IN O
ER-positive JJ O
patients NNS O
without IN O
improving VBG O
overall JJ O
survival NN O
. . O

-DOCSTART- -X- O O

Granulocyte-macrophage JJ B-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
as IN O
immunomodulating VBG O
factor NN O
together RB O
with IN O
influenza JJ B-INTV
vaccination NN I-INTV
in IN O
stem NN B-POPU
cell NN I-POPU
transplant NN I-POPU
patients NNS I-POPU
. . O

The DT O
effect NN O
of IN O
granulocyte-macrophage JJ B-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
( ( I-INTV
GM-CSF NNP I-INTV
) ) I-INTV
on IN O
the DT O
serological JJ B-OC
response NN I-OC
at IN O
influenza JJ B-INTV
vaccination NN I-INTV
was VBD O
studied VBN O
in IN O
117 CD B-POPU
patients NNS I-POPU
who WP I-POPU
had VBD I-POPU
undergone JJ I-POPU
stem NN I-POPU
cell NN I-POPU
transplantation NN I-POPU
( ( I-POPU
SCT NNP I-POPU
) ) I-POPU
. . O

The DT O
vaccine NN B-OC
response NN I-OC
was VBD O
evaluated VBN O
as IN O
significant JJ O
increases NNS O
in IN O
levels NNS B-OC
of IN I-OC
influenza JJ I-OC
hemagglutination-inhibition NN I-OC
( ( I-OC
HAI NNP I-OC
) ) I-OC
antibodies NNS I-OC
and CC O
of IN O
IgG NNP B-OC
antibodies NNS I-OC
measured VBN O
by IN O
enzyme-linked JJ O
immunosorbent NN O
assay NN O
( ( O
ELISA NNP O
) ) O
. . O

There EX O
was VBD O
no DT O
difference NN O
in IN O
antibody NN B-OC
response NN I-OC
to TO O
either DT O
influenza VB O
A NNP O
or CC O
B NNP O
in IN O
64 CD O
patients NNS O
who WP O
received VBD O
GM-CSF NNP B-INTV
at IN O
vaccination NN O
, , O
compared VBN O
with IN O
the DT O
53 NNS O
who WP O
did VBD O
not RB O
. . O

In IN O
the DT O
subgroup NN B-POPU
of IN I-POPU
allogeneic JJ I-POPU
SCT NNP I-POPU
patients NNS I-POPU
, , O
HAI NNP O
showed VBD O
that IN O
the DT O
response NN B-OC
rate NN I-OC
to TO O
the DT O
influenza NN B-INTV
B NNP I-INTV
vaccine NN I-INTV
was VBD O
significantly RB O
higher JJR O
in IN O
the DT O
treatment NN O
group NN O
( ( O
P NNP O
< NNP O
.05 NNP O
) ) O
. . O

ELISA NN B-OC
showed VBD O
that IN O
autologous JJ B-POPU
SCT NNP I-POPU
patients NNS I-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
who WP O
received VBD O
GM-CSF NNP O
had VBD O
a DT O
better JJR O
response NN B-OC
to TO O
influenza VB B-OC
A NNP I-OC
( ( O
P NNP O
< NNP O
.05 NNP O
) ) O
and CC O
B NNP B-OC
( ( O
P NNP O
< NNP O
.01 NNP O
) ) O
. . O

At IN O
early JJ O
vaccination NN O
, , O
4-12 JJ O
months NNS O
after IN O
stem NN O
cell NN O
transplantation NN O
, , O
these DT O
responses NNS O
were VBD O
more RBR O
pronounced JJ O
. . O

GM-CSF JJ B-INTV
appears VBZ O
to TO O
improve VB O
the DT O
response NN B-OC
to TO I-OC
influenza VB I-OC
vaccination NN I-OC
in IN O
some DT O
groups NNS O
of IN O
SCT NNP B-POPU
patients NNS I-POPU
, , O
but CC O
only RB O
to TO O
a DT O
limited JJ O
extent NN O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
ATP NNP B-INTV
infusion NN I-INTV
on IN O
glucose JJ O
turnover NN O
and CC O
gluconeogenesis NN O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

Cancer NNP O
cachexia NN O
is VBZ O
associated VBN O
with IN O
elevated JJ O
lipolysis NN O
, , O
proteolysis NN O
and CC O
gluconeogenesis NN O
. . O

ATP NNP B-INTV
infusion NN O
has VBZ O
been VBN O
found VBN O
to TO O
significantly RB O
inhibit VB O
loss NN O
of IN O
body NN O
weight NN O
, , O
fat JJ O
mass NN O
and CC O
fat-free JJ O
mass NN O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

The DT O
present JJ O
study NN O
was VBD O
aimed VBN O
at IN O
exploring VBG O
the DT O
effects NNS O
of IN O
ATP NNP B-INTV
on IN O
whole-body NN O
glucose NN O
turnover NN O
, , O
alanine JJ O
turnover NN O
and CC O
gluconeogenesis NN O
from IN O
alanine NN O
. . O

Twelve CD B-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
NSCLC NNP I-POPU
) ) I-POPU
were VBD O
studied VBN O
1 CD O
week NN O
before RB O
and CC O
during IN O
22-24 JJ O
h NN O
of IN O
continuous JJ B-INTV
ATP NNP I-INTV
infusion NN I-INTV
. . O

After IN O
an DT O
overnight JJ O
fast NN O
, , O
turnover NN O
rates NNS O
of IN O
glucose NN O
and CC O
alanine NN O
, , O
and CC O
gluconeogenesis NN O
from IN O
alanine NN O
, , O
were VBD O
determined VBN O
using VBG O
primed VBN O
constant JJ O
infusions NNS O
of IN O
¿6 NN B-INTV
, , I-INTV
6- JJ I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
H NNP I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
ğlucose NN I-INTV
and CC I-INTV
¿3- NN B-POPU
( ( I-POPU
13 CD I-POPU
) ) I-POPU
Călanine NNP I-POPU
. . O

Thirteen NNP B-POPU
NSCLC NNP I-POPU
patients NNS I-POPU
and CC I-POPU
eleven RB I-POPU
healthy JJ I-POPU
subjects NNS I-POPU
were VBD O
studied VBN O
as IN O
control NN O
groups NNS O
without IN O
ATP NNP O
infusion NN O
. . O

During IN O
high-dose JJ B-INTV
ATP NNP O
infusion NN O
( ( O
75 CD O
microg.min NN B-OC
( ( I-OC
-1 NNP I-OC
) ) I-OC
.kg NNP I-OC
( ( I-OC
-1 NNP I-OC
) ) I-OC
) ) I-OC
, , I-OC
glucose JJ I-OC
turnover NN I-OC
was VBD O
0.62+/-0.07 JJ O
mmol.h NN O
( ( O
-1 NNP O
) ) O
.kg NNP O
( ( O
-1 NNP O
) ) O
, , O
compared VBN O
with IN O
0 CD O
. . O

44+/-0.13 JJ O
mmol.h NN O
( ( O
-1 NNP O
) ) O
.kg NNP O
( ( O
-1 NN O
) ) O
at IN O
baseline NN O
( ( O
P=0.04 NNP O
) ) O
. . O

For IN B-OC
gluconeogenesis NN I-OC
a DT O
similar JJ O
, , O
but CC O
non-significant JJ O
, , O
trend NN O
was VBD O
observed VBN O
¿baseline JJ O
, , O
0.30+/-0.16 JJ O
mmol.h NN O
( ( O
-1 NNP O
) ) O
.kg NNP O
( ( O
-1 NNP O
) ) O
; : O
during IN O
ATP NNP O
, , O
0.37+/-0.13 JJ O
mmol.h NN O
( ( O
-1 NNP O
) ) O
.kg NNP O
( ( O
-1 NNP O
) ) O
( ( O
P=0.08 NNP O
) ) O
. . O

At IN O
lower JJR B-INTV
ATP NNP O
doses NNS O
( ( O
37-50 JJ O
microg NN O
. . O

min NN O
( ( O
-1 NNP O
) ) O
.kg NNP O
( ( O
-1 NNP O
) ) O
) ) O
these DT O
effects NNS O
were VBD O
not RB O
detected VBN O
. . O

The DT O
relative JJ B-OC
increase NN I-OC
in IN I-OC
glucose JJ I-OC
turnover NN I-OC
during IN B-INTV
ATP NNP B-OC
infusion NN I-OC
compared VBN O
with IN O
baseline NN O
showed VBD O
a DT O
significant JJ O
correlation NN O
with IN B-INTV
the DT I-INTV
ATP NNP O
dose NN O
( ( O
r=0.58 NN O
, , O
P=0.02 NNP B-OC
) ) I-OC
. . O

No DT B-OC
change NN I-OC
in IN I-OC
alanine NN I-OC
turnover NN I-OC
was VBD O
observed VBN O
at IN B-INTV
any DT I-INTV
ATP NNP O
dose NN O
. . O

The DT O
results NNS O
of IN O
this DT O
study NN O
indicate VBP O
an DT O
increase NN B-OC
in IN I-OC
glucose JJ I-OC
turnover NN I-OC
during IN O
high-dose JJ O
ATP NNP O
infusion NN O
compared VBN O
with IN O
baseline NN O
levels NNS O
. . O

During IN O
high-dose JJ B-INTV
ATP NNP O
infusion NN B-OC
, , I-OC
glucose JJ I-OC
turnover NN I-OC
was VBD O
similar JJ O
to TO O
that DT O
during IN O
low-dose JJ O
ATP NNP O
infusion NN O
and CC O
to TO O
that DT O
in IN O
control NN O
NSCLC NNP O
patients NNS O
. . O

Between NNP B-INTV
ATP NNP O
infusions NNS O
, , O
however RB B-OC
, , I-OC
glucose JJ I-OC
turnover NN I-OC
in IN O
patients NNS O
treated VBN O
with IN O
high-dose JJ O
ATP NNP O
was VBD O
significantly RB O
lower JJR O
than IN O
that DT O
in IN O
the DT O
low-dose JJ O
and CC O
control VB O
NSCLC NNP O
patients NNS O
( ( O
P=0.04 NNP O
and CC O
P=0.03 NNP O
respectively RB O
) ) O
, , O
and CC O
similar JJ O
to TO O
that DT O
in IN O
healthy JJ O
subjects NNS O
. . O

This DT O
would MD O
suggest VB O
that IN O
repeated JJ O
high-dose JJ B-INTV
ATP NNP O
infusions NNS O
may MD O
inhibit VB O
glucose JJ O
turnover NN O
between IN O
infusion NN O
periods NNS O
. . O

-DOCSTART- -X- O O

Reduction NN B-OC
of IN I-OC
oral JJ I-OC
mucositis NN I-OC
by IN O
filgrastim NN B-INTV
( ( I-INTV
r-metHuG-CSF JJ I-INTV
) ) I-INTV
in IN O
patients NNS B-POPU
receiving VBG I-POPU
chemotherapy NN I-POPU
. . O

Mucositis NNP B-OC
, , O
the DT O
inflammation NN O
and CC O
necrosis NN O
of IN O
mucosal NN O
membranes NNS O
, , O
is VBZ O
a DT O
serious JJ O
and CC O
debilitating VBG O
consequence NN O
of IN O
many JJ O
cancer NN O
therapies NNS O
. . O

We PRP O
were VBD O
interested JJ O
in IN O
the DT O
potential JJ O
role NN O
of IN O
filgrastim NN B-INTV
( ( I-INTV
recombinant JJ I-INTV
methionyl NN I-INTV
human JJ I-INTV
granulocyte NN I-INTV
colony-stimulating NN I-INTV
factor NN I-INTV
, , I-INTV
r-metHuG-CSF NN I-INTV
) ) I-INTV
in IN O
the DT O
reduction NN B-OC
of IN I-OC
mucositis NN I-OC
. . O

Patients NNS B-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
small-cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
SCLC NNP I-POPU
) ) I-POPU
were VBD O
treated VBN O
with IN O
CAE NNP B-INTV
chemotherapy NN I-INTV
( ( I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
and CC I-INTV
etoposide RB I-INTV
) ) I-INTV
and CC I-INTV
placebo NN I-INTV
or CC I-INTV
filgrastim NN I-INTV
. . O

If IN O
patients NNS O
had VBD O
an DT O
episode NN O
of IN O
febrile JJ O
neutropenia NNS O
, , O
they PRP O
received VBD O
unblinded JJ O
filgrastim NN O
in IN O
subsequent JJ O
CAE NNP O
cycles NNS O
. . O

Oral NNP B-OC
mucositis NN I-OC
was VBD O
considered VBN O
to TO O
have VB O
occurred VBN O
if IN O
a DT O
patient NN O
reported VBD O
any DT O
clinical JJ O
sign NN O
or CC O
symptom NN B-OC
of IN I-OC
oral JJ I-OC
mucositis NN I-OC
with IN I-OC
or CC I-OC
without IN I-OC
oral JJ I-OC
candidiasis NN I-OC
. . O

Oral NNP B-OC
mucositis NN I-OC
was VBD O
analyzed VBN O
using VBG O
the DT O
unadjusted JJ O
chi-square JJ O
test NN O
, , O
and CC O
time NN B-OC
to TO I-OC
first JJ I-OC
episode NN I-OC
of IN I-OC
mucositis NN I-OC
was VBD O
analyzed VBN O
using VBG O
the DT O
stratified JJ O
log-rank JJ O
test NN O
as RB O
well RB O
as IN O
the DT O
Cox NNP O
proportional JJ O
hazards NNS O
regression NN O
model NN O
. . O

During IN O
cycle NN O
1 CD O
, , O
placebo-treated JJ O
patients NNS O
had VBD O
more RBR O
episodes NNS O
of IN O
mucositis NN B-OC
( ( O
47 CD O
% NN O
) ) O
compared VBN O
with IN O
those DT O
patients NNS O
randomized VBN O
to TO O
filgrastim VB O
( ( O
28 CD O
% NN O
) ) O
. . O

Across IN O
all DT O
cycles NNS O
of IN O
treatment NN O
, , O
70 CD O
% NN O
of IN O
placebo-treated JJ O
patients NNS O
experienced VBD O
mucositis NN B-OC
, , O
compared VBN O
with IN O
53 CD O
% NN O
of IN O
patients NNS O
randomized VBN O
to TO O
filgrastim VB O
. . O

A DT O
significant JJ O
reduction NN O
in IN O
the DT O
incidence NN O
of IN O
chemotherapy-related JJ O
oral JJ B-OC
mucositis NN I-OC
occurred VBD O
across IN O
multiple JJ O
cycles NNS O
of IN O
treatment NN O
in IN O
patients NNS O
treated VBN O
with IN O
filgrastim NN O
. . O

-DOCSTART- -X- O O

Epirubicin-based JJ B-INTV
chemotherapy NN I-INTV
in IN O
metastatic JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
: : I-POPU
role NN O
of IN O
dose-intensity NN O
and CC O
duration NN O
of IN O
treatment NN O
. . O

PURPOSE NNP O
To TO O
determine VB O
whether IN O
the DT O
duration NN O
and CC O
the DT O
dose NN O
of IN O
epirubicin JJ B-INTV
modify VB B-OC
the DT I-OC
long-term JJ I-OC
outcome NN I-OC
of IN O
patients NNS B-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
( ( I-POPU
MBC NNP I-POPU
) ) I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Four NNP B-POPU
hundred VBD I-POPU
seventeen JJ I-POPU
anthracycline-naive JJ I-POPU
MBC NNP I-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
one CD O
of IN O
the DT O
following JJ O
regimens NNS O
: : O
arm NN O
A NN O
: : O
11 CD O
cycles NNS O
of IN O
fluorouracil NN B-INTV
500 CD O
mg/m NN O
( ( O
2 CD O
) ) O
, , O
epirubicin $ B-INTV
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
, , O
and CC O
cyclophosphamide RB B-INTV
500 CD O
mg/m NN O
( ( O
2 CD O
) ) O
( ( B-INTV
FEC NNP I-INTV
75 CD O
) ) O
every DT O
21 CD O
days NNS O
; : O
arm NN O
B NN O
: : O
four CD O
cycles NNS O
of IN O
FEC NNP B-INTV
100 CD I-INTV
( ( O
same JJ O
regimen NNS O
but CC O
with IN O
epirubicin JJ B-INTV
100 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
then RB O
eight CD O
cycles NNS O
of IN O
FEC NNP B-INTV
50 CD I-INTV
( ( I-INTV
epirubicin JJ I-INTV
50 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
; : O
and CC O
arm JJ O
C NNP O
: : O
four CD O
cycles NNS O
of IN O
FEC NNP B-INTV
100 CD I-INTV
then RB O
restart VB O
the DT O
same JJ O
regimen NN O
at IN O
disease NN O
progression NN O
in IN O
case NN O
of IN O
prior JJ O
response NN O
or CC O
stabilization NN O
. . O

RESULTS NNP O
Hematologic NNP B-OC
toxicity NN I-OC
was VBD O
similar JJ O
. . O

Nausea/vomiting NN B-OC
and CC I-OC
stomatitis NN I-OC
were VBD O
significantly RB O
less RBR O
frequent JJ O
in IN O
arm NN O
A NN O
as IN O
was VBD O
left VBN B-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
decrease NN O
in IN O
arm NN O
C NNP O
( ( O
A NNP O
= NNP O
six CD O
patients NNS O
, , O
B NNP O
= NNP O
five CD O
patients NNS O
, , O
and CC O
C NNP O
= NNP O
one CD O
patient NN O
) ) O
. . O

Six CD O
patients NNS O
died VBD B-OC
of IN I-OC
infections NNS I-OC
( ( O
A DT O
= RB O
four CD O
patients NNS O
and CC O
C NNP O
= NNP O
two CD O
patients NNS O
) ) O
. . O

After IN O
four CD O
cycles NNS O
, , O
the DT O
objective JJ B-OC
response NN I-OC
rate NN I-OC
( ( I-OC
ORR NNP I-OC
) ) I-OC
was VBD O
better RBR O
with IN O
FEC NNP B-INTV
100 CD O
than IN O
with IN O
FEC NNP B-INTV
75 CD O
( ( O
49.2 CD O
% NN O
v JJ O
40 CD O
% NN O
, , O
respectively RB O
; : O
P NNP O
: : O
=.07 NN O
) ) O
. . O

The DT O
ORR NNP B-OC
was VBD O
better RBR O
with IN O
the DT O
longer JJR O
regimens NNS O
( ( O
arm NN O
A NNP O
, , O
56.9 CD O
% NN O
; : O
B NNP O
, , O
64 CD O
% NN O
; : O
and CC O
C NNP O
, , O
47.6 CD O
% NN O
; : O
P NNP O
: : O
=.06 NN O
) ) O
and CC O
was VBD O
41 CD O
% NN O
after IN O
second-line JJ O
FEC NNP B-INTV
100 CD O
. . O

After IN O
a DT O
median JJ O
follow-up NN O
of IN O
41 CD O
months NNS O
, , O
the DT O
response NN B-OC
duration NN I-OC
and CC I-OC
time NN I-OC
to TO I-OC
progression NN I-OC
( ( I-OC
TTP NNP I-OC
) ) I-OC
were VBD O
significantly RB O
better RBR O
with IN O
arm NN O
B NNP O
, , O
the DT O
longer JJR O
regimen NNS O
( ( O
P NNP O
: : O
=.012 NN O
and CC O
P NNP O
: : O
< NN O
10 CD O
( ( O
-3 NN O
) ) O
, , O
respectively RB O
) ) O
. . O

The DT O
median JJ B-OC
survival NN I-OC
times NNS I-OC
for IN O
arms NNS O
A NNP O
, , O
B NNP O
, , O
and CC O
C NNP O
were VBD O
similar JJ O
( ( O
17.9 CD O
, , O
18.9 CD O
, , O
and CC O
16 CD O
. . O

3 CD O
months NNS O
, , O
respectively RB O
; : O
P NNP O
: : O
=.49 NN O
) ) O
. . O

CONCLUSION NNP O
In IN O
MBC NNP O
, , O
longer JJR O
epirubicin-based JJ O
regimens NNS O
are VBP O
better RBR O
in IN O
terms NNS O
of IN O
response NN B-OC
duration NN I-OC
and CC I-OC
TTP NNP I-OC
. . O

FEC NNP B-INTV
100 CD O
regimens NNS O
improve VBP O
the DT O
ORR NNP B-OC
. . O

However RB O
, , O
four CD O
initial JJ O
cycles NNS O
of IN O
FEC NNP B-INTV
100 CD O
and CC O
identical JJ O
retreatment NN O
at IN O
disease NN O
progression NN O
yielded VBN O
equivalent JJ O
overall JJ B-OC
survival NN I-OC
to TO O
longer JJR O
regimens NNS O
. . O

-DOCSTART- -X- O O

Paclitaxel NNP B-INTV
( ( O
175 CD O
mg/m2 NN O
) ) O
plus CC B-INTV
carboplatin NN I-INTV
( ( O
6 CD O
AUC NNP O
) ) O
versus NN B-INTV
paclitaxel NN I-INTV
( ( O
225 CD O
mg/m2 NN O
) ) O
plus CC B-INTV
carboplatin NN I-INTV
( ( O
6 CD O
AUC NNP O
) ) O
in IN O
advanced JJ B-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
NSCLC NNP I-POPU
) ) I-POPU
: : I-POPU
a DT O
multicenter NN O
randomized VBN O
trial NN O
. . O

Hellenic NNP O
Cooperative NNP O
Oncology NNP O
Group NNP O
( ( O
HeCOG NNP O
) ) O
. . O

PURPOSE VB O
The DT O
combination NN O
of IN O
paclitaxel NN B-INTV
and CC I-INTV
carboplatin NN I-INTV
has VBZ O
become VBN O
a DT O
widely RB O
used VBN O
regimen NNS O
in IN O
NSCLC NNP O
due JJ O
to TO O
phase VB O
II NNP O
reports NNS O
of IN O
moderate JJ O
toxicity NN O
, , O
reasonable JJ O
activity NN O
and CC O
easy JJ O
outpatient JJ O
administration NN O
. . O

Purpose NNP O
of IN O
our PRP$ O
present JJ O
prospective JJ O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
dose JJ B-OC
response NN I-OC
relationship NN O
of IN O
paclitaxel NN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Since IN B-POPU
July NNP I-POPU
1996 CD I-POPU
, , I-POPU
198 CD I-POPU
patients NNS I-POPU
with IN I-POPU
non-operable JJ I-POPU
NSCLC NNP I-POPU
and CC I-POPU
measurable JJ I-POPU
disease NN I-POPU
without IN I-POPU
previous JJ I-POPU
chemotherapy NN I-POPU
entered VBD I-POPU
the DT I-POPU
trial NN I-POPU
. . O

Ninety NNP B-POPU
nine CD I-POPU
patients NNS I-POPU
( ( I-POPU
group NN I-POPU
A DT I-POPU
) ) I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
paclitaxel NN B-INTV
175 CD O
mg/m2 NN O
in IN O
three-hour JJ O
infusion NN O
plus CC B-INTV
carboplatin NN I-INTV
dosed VBD O
to TO O
an DT O
area NN O
under IN O
the DT O
concentration-time JJ O
curve NN O
of IN O
6 CD O
every DT O
3 CD O
weeks NNS O
and CC O
99 CD O
( ( O
group NN O
B NNP O
) ) O
to TO O
receive VB O
the DT O
same JJ O
regimen NN O
with IN O
paclitaxel NN B-INTV
increased VBN O
to TO O
225 CD O
mg/m2 NN O
. . O

Eligibility NNP O
criteria NNS O
included VBD O
WHO NNP O
performance NN O
status NN O
0-2 CD O
, , O
documented VBN O
inoperable JJ O
stage NN O
IIIA NNP O
and CC O
IIIB NNP O
, , O
IV NNP O
, , O
no DT O
brain NN O
metastasis NN O
, , O
no DT O
prior JJ O
chemotherapy NN B-INTV
and CC O
adequate JJ O
renal NN O
and CC O
hepatic JJ O
function NN O
. . O

Patients NNS O
in IN O
both DT O
groups NNS O
were VBD O
well-matched JJ O
with IN O
baseline JJ O
disease NN O
characteristics NNS O
. . O

RESULTS NNP O
In IN O
group NN O
A NNP O
with IN O
90 CD O
evaluable JJ O
patients NNS O
, , O
the DT O
response NN B-OC
rate NN I-OC
was VBD O
25.6 CD O
% NN O
( ( O
6 CD O
CR NNP O
, , O
17 CD O
PR NNP O
) ) O
whereas VBP O
in IN O
group NN O
B NNP O
with IN O
88 CD O
evaluable JJ O
patients NNS O
, , O
the DT O
response NN B-OC
rate NN I-OC
was VBD O
31.8 CD O
% NN O
( ( O
3 CD O
CR NNP O
, , O
25 CD O
PR NNP O
) ) O
, , O
P NNP O
= VBZ O
0.733 CD O
. . O

Median JJ B-OC
time NN I-OC
to TO I-OC
progression NN I-OC
favored VBD O
the DT O
high-dose JJ O
paclitaxel NN O
( ( O
4.3 CD O
vs. FW O
6.4 CD O
months NNS O
, , O
P NNP O
= NNP O
0.044 CD O
) ) O
. . O

The DT O
median JJ B-OC
survival NN I-OC
was VBD O
9.5 CD O
months NNS O
for IN O
group NN O
A NNP O
versus NN O
11.4 CD O
months NNS O
for IN O
group NN O
B NNP O
( ( O
P NNP O
= NNP O
0.16 CD O
) ) O
. . O

The DT O
one-year JJ B-OC
survival NN I-OC
was VBD O
37 CD O
% NN O
for IN O
group NN O
A NNP O
and CC O
44 CD O
% NN O
for IN O
group NN O
B NNP O
( ( O
P NNP O
= NNP O
0.35 CD O
) ) O
. . O

The DT O
best JJS O
prognostic JJ O
factor NN O
for IN O
one-year JJ B-OC
survival NN I-OC
was VBD O
the DT O
response NN B-OC
rate NN I-OC
( ( O
P NNP O
< NNP O
0.0001 CD O
) ) O
. . O

With IN O
a DT O
relative JJ O
dose JJ O
intensity NN O
of IN O
paclitaxel NN B-INTV
0.94 CD O
in IN O
both DT O
groups NNS O
, , O
neurotoxicity NN B-OC
( ( O
P NNP O
= NNP O
0.025 CD O
) ) O
and CC O
leucopenia $ B-OC
( ( O
P NNP O
= NNP O
0.038 CD O
) ) O
were VBD O
more RBR O
pronounced JJ O
in IN O
group NN O
B NNP O
patients NNS O
. . O

No DT O
toxic JJ B-OC
death NN I-OC
was VBD O
observed VBN O
. . O

CONCLUSIONS NNP O
Higher NNP O
dose VBD O
paclitaxel JJ B-INTV
prolongs NNS O
the DT O
median JJ O
time NN O
to TO O
progression NN O
but CC O
causes VBZ O
more JJR O
neurotoxicity NN O
and CC O
leucopenia NN O
. . O

The DT O
better JJR O
response NN O
rate NN O
, , O
the DT O
longer JJR O
overall JJ O
and CC O
better JJR O
one-year JJ O
survival NN O
seen VBN O
with IN O
the DT O
higher JJR O
dose NN O
of IN O
paclitaxel NNS B-INTV
are VBP O
not RB O
statistically RB O
significant JJ O
. . O

-DOCSTART- -X- O O

Phase NNP O
III NNP O
comparative JJ O
study NN O
of IN O
high-dose JJ B-INTV
cisplatin NN I-INTV
versus IN O
a DT O
combination NN O
of IN O
paclitaxel NN B-INTV
and CC I-INTV
cisplatin NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
New NNP O
effective JJ O
chemotherapy NN O
is VBZ O
needed VBN O
to TO O
improve VB O
the DT O
outcome NN O
of IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
NSCLC NNP I-POPU
) ) I-POPU
. . O

Paclitaxel NNP B-INTV
administered VBD O
as IN O
a DT O
single JJ O
agent NN O
or CC O
in IN O
combination NN O
with IN O
cisplatin NN B-INTV
has VBZ O
been VBN O
shown VBN O
to TO O
be VB O
a DT O
potentially RB O
new JJ O
useful JJ O
agent NN O
for IN O
the DT O
treatment NN O
of IN O
NSCLC NNP O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Between NNP B-POPU
January NNP I-POPU
1995 CD I-POPU
and CC I-POPU
April NNP I-POPU
1996 CD I-POPU
, , I-POPU
414 CD I-POPU
patients NNS I-POPU
with IN I-POPU
stage NN I-POPU
IIIB NNP I-POPU
or CC I-POPU
IV NNP I-POPU
NSCLC NNP I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
received VB I-POPU
either RB I-POPU
a DT I-POPU
control NN I-POPU
arm NN I-POPU
of IN I-POPU
high-dose JJ I-POPU
cisplatin NN I-POPU
( ( I-POPU
100 CD I-POPU
mg/m NN I-POPU
( ( I-POPU
2 CD I-POPU
) ) I-POPU
) ) I-POPU
or CC I-POPU
a DT I-POPU
combination NN I-POPU
of IN I-POPU
paclitaxel NN I-POPU
( ( I-POPU
175 CD I-POPU
mg/m NN I-POPU
( ( I-POPU
2 CD I-POPU
) ) I-POPU
, , I-POPU
3-hour JJ I-POPU
infusion NN I-POPU
) ) I-POPU
and CC I-POPU
cisplatin NN I-POPU
( ( I-POPU
80 CD I-POPU
mg/m NN I-POPU
( ( I-POPU
2 CD I-POPU
) ) I-POPU
) ) I-POPU
every DT I-POPU
21 CD I-POPU
days NNS I-POPU
. . O

RESULTS NNP O
Compared VBD O
with IN O
the DT O
cisplatin-only JJ O
arm NN O
, , O
there EX O
was VBD O
a DT O
9 CD O
% NN O
improvement NN O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
0 CD O
% NN O
to TO O
19 CD O
% NN O
) ) O
in IN O
overall JJ B-OC
response NN I-OC
rate NN I-OC
for IN O
the DT O
paclitaxel/cisplatin NN B-INTV
arm NN O
( ( O
17 CD O
% NN O
v JJ O
26 CD O
% NN O
, , O
respectively RB O
; : O
P=.028 NNP O
) ) O
. . O

Median JJ B-OC
time NN I-OC
to TO I-OC
progression NN I-OC
was VBD O
2.7 CD O
and CC O
4.1 CD O
months NNS O
in IN O
the DT O
control NN O
and CC O
paclitaxel/cisplatin NN B-INTV
arm NN O
, , O
respectively RB O
( ( O
P=.026 NNP O
) ) O
. . O

The DT O
study NN O
, , O
however RB O
, , O
failed VBD O
to TO O
show VB O
a DT O
significant JJ O
improvement NN O
in IN O
median JJ B-OC
survival NN I-OC
for IN O
the DT O
paclitaxel/cisplatin NN B-INTV
arm NN O
( ( O
8.6 CD O
months NNS O
in IN O
the DT O
control NN O
arm NN O
v NN O
8.1 CD O
months NNS O
in IN O
the DT O
paclitaxel/cisplatin NN O
arm NN O
, , O
P=.862 NNP O
) ) O
. . O

There EX O
was VBD O
more JJR O
hematotoxicity NN B-OC
, , I-OC
peripheral JJ I-OC
neuropathy NN I-OC
, , I-OC
and CC I-OC
arthralgia/myalgia NN I-OC
on IN O
the DT O
paclitaxel/cisplatin NN B-INTV
arm NN O
, , O
whereas IN O
the DT O
high-dose JJ O
cisplatin NN B-INTV
arm NN O
produced VBD O
more JJR O
ototoxicity NN B-OC
, , I-OC
nausea NN I-OC
, , I-OC
vomiting NN I-OC
, , I-OC
and CC I-OC
nephrotoxicity NN I-OC
. . O

Quality NN B-OC
of IN I-OC
life NN I-OC
( ( I-OC
QOL NNP I-OC
) ) I-OC
was VBD O
similar JJ O
overall JJ O
between IN O
the DT O
two CD O
arms NNS O
. . O

CONCLUSION NN O
This DT O
large JJ O
randomized JJ O
phase NN O
III NNP O
trial NN O
failed VBD O
to TO O
show VB O
a DT O
significant JJ O
improvement NN O
in IN O
survival NN O
for IN O
the DT O
paclitaxel/cisplatin NN B-INTV
combination NN O
compared VBN O
with IN O
high-dose JJ O
cisplatin NN B-INTV
in IN O
patients NNS O
with IN O
advanced JJ O
NSCLC NNP O
. . O

However RB O
, , O
the DT O
paclitaxel/cisplatin NN B-INTV
combination NN O
did VBD O
produce VB O
a DT O
better JJR O
clinical JJ O
response NN O
, , O
resulting VBG O
in IN O
an DT O
increased JJ O
time NN O
to TO O
progression NN O
while IN O
providing VBG O
a DT O
similar JJ O
QOL NNP O
. . O

-DOCSTART- -X- O O

Treatment NN O
of IN O
brain NN O
metastases NNS O
of IN O
small-cell JJ O
lung NN O
cancer NN O
: : O
comparing NN O
teniposide NN B-INTV
and CC O
teniposide NN B-INTV
with IN I-INTV
whole-brain JJ I-INTV
radiotherapy NN I-INTV
-- : I-INTV
a DT I-INTV
phase NN O
III NNP O
study NN O
of IN O
the DT O
European JJ O
Organization NNP O
for IN O
the DT O
Research NNP O
and CC O
Treatment NNP O
of IN O
Cancer NNP O
Lung NNP O
Cancer NNP O
Cooperative NNP O
Group NNP O
. . O

PURPOSE NNP O
Approximately RB O
60 CD O
% NN O
of IN O
patients NNS B-POPU
with IN I-POPU
small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
SCLC NNP I-POPU
) ) I-POPU
develop VB O
brain NN O
metastases NNS O
. . O

Whole-brain JJ B-INTV
radiotherapy NN I-INTV
( ( I-INTV
WBRT NNP I-INTV
) ) I-INTV
gives VBZ O
symptomatic JJ O
improvement NN O
in IN O
more JJR O
than IN O
50 CD O
% NN O
of IN O
these DT O
patients NNS O
. . O

Because IN O
brain NN O
metastases NNS O
are VBP O
a DT O
sign NN O
of IN O
systemic JJ O
progression NN O
, , O
and CC O
chemotherapy NN O
was VBD O
found VBN O
to TO O
be VB O
effective JJ O
as IN O
well RB O
, , O
it PRP O
becomes VBZ O
questionable JJ O
whether IN O
WBRT NNP B-INTV
is VBZ O
the DT O
only JJ O
appropriate JJ O
therapy NN O
in IN O
this DT O
situation NN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
In IN O
a DT O
phase NN O
III NNP O
study NN O
, , O
SCLC NNP B-POPU
patients NNS I-POPU
with IN I-POPU
brain NN I-POPU
metastases NNS I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
teniposide NN B-INTV
with IN O
or CC O
without IN O
WBRT NNP B-INTV
. . O

Teniposide NNP B-INTV
120 CD O
mg/m NN O
( ( O
2 CD O
) ) O
was VBD O
given VBN O
intravenously RB O
three CD O
times NNS O
a DT O
week NN O
, , O
every DT O
3 CD O
weeks NNS O
. . O

WBRT NNP B-INTV
( ( O
10 CD O
fractions NNS O
of IN O
3 CD O
Gy NNP O
) ) O
had VBD O
to TO O
start VB O
within IN O
3 CD O
weeks NNS O
from IN O
the DT O
start NN O
of IN O
chemotherapy NN B-INTV
. . O

Response NNP O
was VBD O
measured VBN O
clinically RB B-OC
and CC O
by IN O
computed JJ B-OC
tomography NN I-OC
of IN I-OC
the DT I-OC
brain NN I-OC
. . O

RESULTS NNP O
One CD B-POPU
hundred VBD I-POPU
twenty NN I-POPU
eligible JJ I-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
. . O

A DT O
57 CD O
% NN O
response NN B-OC
rate NN I-OC
was VBD O
seen VBN O
in IN O
the DT O
combined-modality NN O
arm NN O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
43 CD O
% NN O
to TO O
69 CD O
% NN O
) ) O
, , O
and CC O
a DT O
22 CD O
% NN O
response NN B-OC
rate NN I-OC
was VBD O
seen VBN O
in IN O
the DT O
teniposide-alone JJ B-INTV
arm NN O
( ( O
95 CD O
% NN O
CI NNP O
, , O
12 CD O
% NN O
to TO O
34 CD O
% NN O
) ) O
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

Time NN B-OC
to TO I-OC
progression NN I-OC
in IN I-OC
the DT I-OC
brain NN I-OC
was VBD O
longer RBR B-OC
in IN O
the DT O
combined-modality NN O
group NN O
( ( O
P=.005 NNP O
) ) O
. . O

Clinical JJ B-OC
response NN I-OC
and CC O
response NN B-OC
outside IN O
the DT O
brain NN O
were VBD O
not RB O
different JJ O
. . O

The DT O
median JJ B-OC
survival NN I-OC
time NN I-OC
was VBD O
3.5 CD O
months NNS O
in IN O
the DT O
combined-modality NN O
arm NN O
and CC O
3.2 CD O
months NNS O
in IN O
the DT O
teniposide-alone JJ B-INTV
arm NN O
. . O

Overall JJ B-OC
survival NN I-OC
in IN O
both DT O
groups NNS O
was VBD O
not RB O
different JJ O
( ( O
P=.087 NNP O
) ) O
. . O

CONCLUSION NNP O
Adding NNP O
WBRT NNP B-INTV
to TO O
teniposide VB O
results NNS O
in IN O
a DT O
much RB O
higher JJR O
response NN B-OC
rate NN I-OC
of IN O
brain NN O
metastases NNS O
and CC O
in IN O
a DT O
longer JJR O
time NN O
to TO O
progression NN O
of IN O
brain NN O
metastases NNS O
than IN O
teniposide RB B-INTV
alone JJ O
. . O

Survival NNP B-OC
was VBD O
poor JJ O
in IN O
both DT O
groups NNS O
and CC O
not RB O
significantly RB O
different JJ O
. . O

-DOCSTART- -X- O O

Cardiovascular JJ O
effects NNS O
of IN O
tamoxifen NN B-INTV
in IN O
women NNS B-POPU
with IN I-POPU
and CC I-POPU
without IN I-POPU
heart NN I-POPU
disease NN I-POPU
: : I-POPU
breast NN O
cancer NN O
prevention NN O
trial NN O
. . O

National NNP O
Surgical NNP O
Adjuvant NNP O
Breast NNP O
and CC O
Bowel NNP O
Project NNP O
Breast NNP O
Cancer NNP O
Prevention NNP O
Trial NNP O
Investigators NNP O
. . O

BACKGROUND NNP O
The DT O
overall JJ O
effect NN O
of IN O
prophylactic JJ O
tamoxifen NN O
in IN O
women NNS O
depends NNS O
on IN O
the DT O
balance NN O
between IN O
the DT O
effects NNS O
of IN O
the DT O
drug NN O
, , O
which WDT O
include VBP O
preventing VBG B-OC
breast NN I-OC
cancer NN I-OC
and CC O
altering VBG O
cardiovascular JJ B-OC
risk NN I-OC
. . O

In IN O
a DT O
recent JJ O
clinical JJ O
trial NN O
, , O
postmenopausal JJ O
estrogen-progestin JJ O
therapy NN O
was VBD O
shown VBN O
to TO O
increase VB O
the DT O
risk NN O
of IN O
early JJ B-OC
cardiovascular JJ I-OC
events NNS I-OC
among IN O
women NNS B-POPU
with IN I-POPU
a DT I-POPU
history NN I-POPU
of IN I-POPU
coronary JJ I-POPU
heart NN I-POPU
disease NN I-POPU
( ( I-POPU
CHD NNP I-POPU
) ) I-POPU
. . O

The DT O
cardiovascular JJ B-OC
effects NNS I-OC
of IN O
tamoxifen NN O
in IN O
women NNS B-POPU
with IN I-POPU
and CC I-POPU
without IN I-POPU
CHD NNP I-POPU
are VBP O
not RB O
known VBN O
. . O

The DT O
National NNP O
Surgical NNP O
Adjuvant NNP O
Breast NNP O
and CC O
Bowel NNP O
Project NNP O
Breast NNP O
Cancer NNP O
Prevention NNP O
Trial NNP O
( ( O
BCPT NNP O
) ) O
is VBZ O
the DT O
only JJ O
clinical JJ O
trial NN O
that WDT O
provides VBZ O
data NNS O
to TO O
assess VB O
the DT O
cardiovascular JJ B-OC
effects NNS I-OC
of IN O
tamoxifen NN O
in IN O
women NNS O
with IN O
and CC O
without IN O
CHD NNP O
. . O

METHODS NNP O
A NNP O
total NN O
of IN O
13 CD B-POPU
388 CD I-POPU
women NNS I-POPU
at IN I-POPU
increased VBN I-POPU
risk NN I-POPU
for IN I-POPU
breast NN I-POPU
cancer NN I-POPU
were VBD O
randomly RB O
assigned VBN O
in IN O
the DT O
BCPT NNP O
to TO O
receive VB O
either DT O
tamoxifen NN B-INTV
( ( I-INTV
20 CD I-INTV
mg/day NN I-INTV
) ) I-INTV
or CC I-INTV
placebo NN I-INTV
. . O

Cardiovascular JJ B-POPU
follow-up NN I-POPU
was VBD I-POPU
available JJ I-POPU
for IN I-POPU
13 CD I-POPU
194 CD I-POPU
women NNS I-POPU
, , I-POPU
1048 CD I-POPU
of IN I-POPU
whom WP I-POPU
had VBD I-POPU
prior RB I-POPU
clinical JJ I-POPU
CHD NNP I-POPU
. . O

Fatal NNP B-OC
and CC I-OC
nonfatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
unstable JJ I-OC
angina NN I-OC
, , I-OC
and CC I-OC
severe JJ I-OC
angina NN I-OC
were VBD O
tabulated VBN O
( ( O
mean JJ O
follow-up NN O
: : O
49 CD O
months NNS O
) ) O
. . O

All DT O
statistical JJ O
tests NNS O
were VBD O
two-sided JJ O
. . O

RESULTS NNP O
Cardiovascular JJ B-OC
event NN I-OC
rates NNS I-OC
were VBD O
not RB O
statistically RB O
significantly RB O
different JJ O
between IN O
women NNS O
assigned VBN O
to TO O
receive VB O
tamoxifen NN O
and CC O
those DT O
assigned VBN O
to TO O
receive VB O
placebo NN O
, , O
independent JJ O
of IN O
pre-existing JJ O
CHD NNP O
. . O

Among IN O
women NNS O
without IN O
CHD NNP O
( ( O
6074 CD O
on IN O
tamoxifen NN O
versus NN O
6072 CD O
on IN O
placebo NN O
) ) O
, , O
risk JJ O
ratios NNS O
( ( O
95 CD O
% NN O
confidence NN O
intervals NNS O
[ VBP O
CIs NNP O
] NNP O
) ) O
for IN O
tamoxifen NN O
users NNS O
were VBD O
1.75 CD O
( ( O
0.44 CD O
to TO O
8.13 CD O
) ) O
for IN O
fatal JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
1.11 CD O
( ( O
0.55 CD O
to TO O
2.28 CD O
) ) O
for IN O
nonfatal JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
0.69 CD O
( ( O
0.29 CD O
to TO O
1.57 CD O
) ) O
for IN O
unstable JJ B-OC
angina NN I-OC
, , O
and CC O
0.83 CD O
( ( O
0.32 CD O
to TO O
2.10 CD O
) ) O
for IN O
severe JJ B-OC
angina NN I-OC
. . O

In IN O
women NNS O
with IN O
CHD NNP O
( ( O
516 CD O
on IN O
tamoxifen NNS O
versus $ O
532 CD O
on IN O
placebo NN O
) ) O
, , O
risk JJ B-OC
ratios NNS I-OC
( ( O
95 CD O
% NN O
CIs NNP O
) ) O
for IN O
tamoxifen NN O
users NNS O
were VBD O
0.00 CD O
( ( O
0 CD O
to TO O
1.58 CD O
) ) O
for IN O
fatal JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
1.25 CD O
( ( O
0.32 CD O
to TO O
5.18 CD O
) ) O
for IN O
nonfatal JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
2.26 CD O
( ( O
0.87 CD O
to TO O
6.55 CD O
) ) O
for IN O
unstable JJ B-OC
angina NN I-OC
, , O
and CC O
1.39 CD O
( ( O
0.23 CD O
to TO O
9.47 CD O
) ) O
for IN O
severe JJ B-OC
angina NN I-OC
. . O

There EX O
was VBD O
no DT O
evidence NN O
that IN O
the DT O
lack NN O
of IN O
association NN O
between IN O
tamoxifen NN O
and CC O
cardiovascular JJ B-OC
events NNS I-OC
was VBD O
related VBN O
to TO O
an DT O
early JJ O
increase NN B-OC
in IN I-OC
risk NN I-OC
that WDT O
may MD O
have VB O
been VBN O
offset VBN O
by IN O
a DT O
late JJ O
decrease NN O
in IN O
risk NN O
. . O

CONCLUSION NN O
When WRB O
used VBN O
for IN O
breast NN O
cancer NN O
prevention NN O
in IN O
women NNS B-POPU
with IN I-POPU
or CC I-POPU
without IN I-POPU
heart NN I-POPU
disease NN I-POPU
, , O
tamoxifen NN O
is VBZ O
not RB O
associated VBN O
with IN O
beneficial JJ O
or CC O
adverse JJ O
cardiovascular JJ B-OC
effects NNS I-OC
. . O

-DOCSTART- -X- O O

A DT O
randomized VBN O
intervention NN O
to TO O
improve VB O
ongoing VBG B-OC
participation NN I-OC
in IN I-OC
mammography NN B-POPU
. . O

OBJECTIVE UH O
To TO O
test VB O
the DT O
effectiveness NN O
of IN O
interventions NNS B-INTV
intended VBN I-INTV
to TO O
increase VB O
rates NNS B-OC
of IN I-OC
regular JJ I-OC
breast NN I-OC
cancer NN I-OC
screening NN I-OC
, , O
according VBG O
to TO O
recommended VBN O
guidelines NNS O
. . O

STUDY NNP O
DESIGN NNP O
A NNP O
randomized VBD O
controlled JJ O
trial NN O
of IN O
2 CD O
outreach NN B-INTV
interventions NNS I-INTV
( ( I-INTV
a DT I-INTV
mail NN I-INTV
reminder NN I-INTV
and CC I-INTV
a DT I-INTV
telephone NN I-INTV
reminder NN I-INTV
plus CC I-INTV
appointment JJ I-INTV
scheduling NN I-INTV
) ) I-INTV
compared VBN O
with IN O
a DT O
routine JJ B-INTV
publicity NN I-INTV
campaign NN I-INTV
to TO O
encourage VB O
continued JJ B-OC
participation NN I-OC
in IN I-OC
mammography NN B-INTV
screening NN B-OC
. . O

PARTICIPANTS NNP O
AND CC O
METHODS NNP O
Participants NNS B-POPU
were VBD I-POPU
1908 CD I-POPU
women NNS I-POPU
aged VBD I-POPU
50 CD I-POPU
to TO I-POPU
75 CD I-POPU
years NNS I-POPU
continuously RB I-POPU
enrolled VBD I-POPU
in IN I-POPU
a DT I-POPU
large JJ I-POPU
group-model JJ I-POPU
HMO NNP I-POPU
during IN I-POPU
the DT I-POPU
study NN I-POPU
who WP I-POPU
underwent VBD I-POPU
a DT I-POPU
bilateral JJ I-POPU
mammogram NN I-POPU
during IN I-POPU
the DT I-POPU
first JJ I-POPU
quarter NN I-POPU
of IN I-POPU
1994 CD I-POPU
and CC I-POPU
no DT I-POPU
subsequent JJ I-POPU
mammogram NN I-POPU
during IN I-POPU
the DT I-POPU
next JJ I-POPU
18 CD I-POPU
to TO I-POPU
21 CD I-POPU
months NNS I-POPU
. . O

Data NNS O
were VBD O
obtained VBN O
from IN O
health NN O
plan NN O
administrative JJ O
data NNS O
files NNS O
supplemented VBN O
by IN O
medical JJ O
chart NN O
review NN O
. . O

Women NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
( ( O
1 CD O
) ) O
a DT B-INTV
mail NN I-INTV
reminder NN I-INTV
, , I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
a DT I-INTV
telephone NN I-INTV
reminder NN I-INTV
, , I-INTV
or CC I-INTV
( ( I-INTV
3 CD I-INTV
) ) I-INTV
routine JJ I-INTV
publicity NN I-INTV
on IN I-INTV
mammography NN I-INTV
for IN I-INTV
all DT I-INTV
women NNS I-INTV
. . O

The DT O
outcome NN O
measure NN O
was VBD O
a DT O
mammogram NN B-OC
received VBN I-OC
after IN I-OC
the DT I-OC
intervention NN I-OC
period NN I-OC
and CC I-OC
within IN I-OC
2 CD I-OC
years NNS I-OC
of IN I-OC
the DT I-OC
initial JJ I-OC
mammogram NN I-OC
date NN I-OC
. . O

RESULTS NNP O
Bivariate NNP O
and CC O
multivariate VB O
statistical JJ O
analyses NNS O
showed VBD O
that IN O
participation NN O
was VBD O
significantly RB O
higher JJR O
for IN O
women NNS O
contacted VBN O
by IN O
telephone NN O
than IN O
through IN O
routine JJ O
publicity NN O
. . O

Mail NN O
reminders NNS O
were VBD O
no DT O
more RBR O
effective JJ O
than IN O
a DT O
routine JJ B-INTV
publicity NN I-INTV
campaign NN I-INTV
. . O

Primary NNP O
care NN O
physician NN O
and CC O
gynecologist JJ O
visits NNS O
increased VBD O
the DT O
likelihood NN O
of IN O
a DT O
subsequent JJ B-OC
mammogram NN I-OC
for IN O
women NNS O
in IN O
all DT O
intervention NN O
groups NNS O
. . O

CONCLUSIONS NNP O
Telephone NNP B-INTV
contact NN I-INTV
by IN O
regular JJ O
health NN O
plan NN O
staff NN O
was VBD O
more RBR O
successful JJ O
than IN O
publicity NN O
in IN O
encouraging VBG O
continued JJ O
participation NN B-OC
in IN O
mammography NN B-OC
screening NN I-OC
in IN O
women NNS O
enrolled VBN O
in IN O
a DT O
group-model JJ O
managed NN O
health NN O
care NN O
plan NN O
. . O

Because IN O
mailings NNS O
did VBD O
not RB O
influence VB O
participation NN O
in IN O
mammography NN B-OC
screening NN I-OC
, , O
health NN O
plans NNS O
should MD O
be VB O
cautious JJ O
about IN O
investing VBG O
in IN O
member NN O
mailings NNS O
without IN O
first JJ O
evaluating VBG O
their PRP$ O
effectiveness NN O
in IN O
the DT O
context NN O
of IN O
existing VBG O
outreach NN O
efforts NNS O
. . O

-DOCSTART- -X- O O

Physical JJ B-INTV
activity NN I-INTV
in IN O
first-degree JJ B-POPU
relatives NNS I-POPU
of IN I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

This DT O
study NN O
sought VBD O
to TO O
evaluate VB O
physical JJ B-INTV
activity NN I-INTV
in IN O
women NNS B-POPU
at IN I-POPU
moderate JJ I-POPU
risk NN I-POPU
for IN I-POPU
breast NN I-POPU
cancer NN I-POPU
, , O
the DT O
correlates NNS O
of IN O
engaging VBG O
in IN O
regular JJ O
physical JJ B-INTV
activity NN I-INTV
, , O
and CC O
whether IN O
physical JJ B-INTV
activity NN I-INTV
relates VBZ O
to TO O
psychological JJ B-OC
well-being NN I-OC
. . O

The DT O
results NNS O
revealed VBD O
that IN O
55 CD B-POPU
% NN I-POPU
of IN I-POPU
women NNS I-POPU
were VBD I-POPU
regularly RB I-POPU
active JJ I-POPU
. . O

Logistic JJ O
regression NN O
models NNS O
indicated VBD O
that IN O
positive JJ O
affect NN O
was VBD O
associated VBN O
with IN O
increased JJ O
and CC O
negative JJ O
affect NN O
was VBD O
associated VBN O
with IN O
decreased JJ O
overall JJ O
and CC O
leisure NN B-OC
activity NN I-OC
. . O

Older JJR O
, , O
married VBN O
, , O
and CC O
employed JJ O
women NNS O
were VBD O
more RBR O
likely JJ O
to TO O
engage VB O
in IN O
household/occupational JJ B-OC
activity NN I-OC
, , O
whereas JJ O
women NNS O
who WP O
perceived VBD O
their PRP$ O
risk NN O
for IN O
breast NN O
cancer NN O
as IN O
high JJ O
were VBD O
less RBR O
likely JJ O
. . O

More RBR O
educated JJ O
women NNS O
and CC O
those DT O
with IN O
higher JJR O
perceived VBN O
risk NN O
were VBD O
more RBR O
likely JJ O
to TO O
engage VB O
in IN O
leisure NN B-OC
activity NN I-OC
, , O
and CC O
married JJ O
women NNS O
were VBD O
less RBR O
likely JJ O
. . O

These DT O
results NNS O
suggest VBP O
a DT O
need NN O
to TO O
increase VB B-INTV
activity NN I-INTV
levels NNS I-INTV
in IN O
women NNS B-POPU
at IN I-POPU
moderate JJ I-POPU
risk NN I-POPU
for IN I-POPU
breast NN I-POPU
cancer NN I-POPU
, , O
provide VBP O
variables NNS O
upon IN O
which WDT O
interventions NNS O
can MD O
be VB O
tailored VBN O
to TO O
promote VB O
activity NN O
, , O
and CC O
point NN O
to TO O
psychological JJ O
benefits NNS O
of IN O
activity NN O
in IN O
this DT O
population NN O
. . O

-DOCSTART- -X- O O

Liposome-encapsulated JJ B-INTV
doxorubicin NNS I-INTV
compared VBN O
with IN O
conventional JJ B-INTV
doxorubicin NN I-INTV
in IN O
a DT O
randomized JJ O
multicenter NN O
trial NN O
as IN O
first-line JJ O
therapy NN O
of IN O
metastatic JJ B-POPU
breast NN I-POPU
carcinoma NN I-POPU
. . O

BACKGROUND IN O
The DT O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
compare VB O
the DT O
efficacy NN O
and CC O
toxicity NN O
of IN O
the DT O
liposome-encapsulated JJ B-INTV
doxorubicin NN I-INTV
, , I-INTV
TLC NNP I-INTV
D-99 NNP I-INTV
( ( I-INTV
Myocet NNP I-INTV
, , I-INTV
Elan NNP I-INTV
Pharmaceuticals NNP I-INTV
, , I-INTV
Princeton NNP I-INTV
, , I-INTV
NJ NNP I-INTV
) ) I-INTV
, , O
and CC O
conventional JJ B-INTV
doxorubicin NN I-INTV
in IN O
first-line JJ O
treatment NN O
of IN O
metastatic JJ O
breast NN O
carcinoma NN O
( ( O
MBC NNP O
) ) O
. . O

METHODS NNP O
Two CD B-POPU
hundred VBD I-POPU
twenty-four JJ I-POPU
patients NNS I-POPU
with IN I-POPU
MBC NNP I-POPU
and CC I-POPU
no DT I-POPU
prior JJ I-POPU
therapy NN I-POPU
for IN I-POPU
metastatic JJ I-POPU
disease NN I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
either DT O
TLC NNP B-INTV
D-99 NNP I-INTV
( ( I-INTV
75 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
) ) I-INTV
or CC I-INTV
doxorubicin NN I-INTV
( ( O
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
every DT O
3 CD O
weeks NNS O
, , O
in IN O
the DT O
absence NN O
of IN O
disease NN O
progression NN O
or CC O
unacceptable JJ O
toxicity NN O
. . O

The DT O
primary JJ O
efficacy NN O
endpoint NN O
was VBD O
response NN O
rate NN O
. . O

Responses NNS O
were VBD O
assessed VBN O
using VBG O
World NNP O
Health NNP O
Organization NNP O
criteria NNS O
and CC O
were VBD O
required VBN O
to TO O
be VB O
of IN O
at IN O
least JJS O
6 CD O
weeks NNS O
' POS O
duration NN O
. . O

The DT O
primary JJ O
safety NN O
endpoint NN O
was VBD O
cardiotoxicity NN O
. . O

Cardiac NNP O
function NN O
was VBD O
monitored VBN O
by IN O
multiple-gated JJ B-INTV
radionuclide NN I-INTV
cardioangiography NN I-INTV
scan JJ I-INTV
, , O
and CC O
the DT O
left JJ O
ventricular JJ O
ejection NN O
fraction NN O
( ( O
LVEF NNP O
) ) O
was VBD O
scored VBN O
at IN O
a DT O
central JJ O
laboratory NN O
. . O

Patients NNS B-POPU
were VBD I-POPU
removed VBN I-POPU
from IN I-POPU
study NN I-POPU
if IN I-POPU
LVEF NNP I-POPU
declined VBD I-POPU
20 CD I-POPU
or CC I-POPU
more JJR I-POPU
EF JJ I-POPU
units NNS I-POPU
from IN I-POPU
baseline NN I-POPU
to TO I-POPU
a DT I-POPU
final JJ I-POPU
value NN I-POPU
of IN I-POPU
greater JJR I-POPU
than IN I-POPU
or CC I-POPU
equal JJ I-POPU
to TO I-POPU
50 CD I-POPU
% NN I-POPU
, , I-POPU
or CC I-POPU
by IN I-POPU
10 CD I-POPU
or CC I-POPU
more JJR I-POPU
units NNS I-POPU
to TO I-POPU
a DT I-POPU
final JJ I-POPU
value NN I-POPU
of IN I-POPU
less JJR I-POPU
than IN I-POPU
50 CD I-POPU
% NN I-POPU
, , I-POPU
or CC I-POPU
onset NN I-POPU
of IN I-POPU
clinical JJ I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
CHF NNP I-POPU
) ) I-POPU
. . O

RESULTS NNP O
Median JJ B-POPU
age NN I-POPU
was VBD I-POPU
54 CD I-POPU
years NNS I-POPU
in IN I-POPU
both DT I-POPU
treatment NN I-POPU
groups NNS I-POPU
. . O

All DT O
relevant JJ O
prognostic JJ O
factors NNS O
were VBD O
balanced VBN O
, , O
with IN O
the DT O
exception NN O
that IN O
there EX O
were VBD O
significantly RB O
more JJR O
progesterone JJ O
receptor NN O
positive JJ O
patients NNS O
in IN O
the DT O
doxorubicin-treated JJ B-INTV
group NN O
. . O

Protocol-defined JJ B-OC
cardiotoxicity NN I-OC
was VBD O
observed VBN O
in IN O
13 CD O
% NN O
of IN O
TLC NNP O
D-99 NNP O
patients NNS O
( ( O
including VBG O
2 CD O
cases NNS O
of IN O
CHF NNP O
) ) O
compared VBN O
to TO O
29 CD O
% NN O
of IN O
doxorubicin NN B-INTV
patients NNS O
( ( O
including VBG O
9 CD O
cases NNS O
of IN O
CHF NNP O
) ) O
. . O

Median JJ B-OC
cumulative JJ I-OC
doxorubicin NN B-INTV
dose NN B-OC
at IN I-OC
onset NN I-OC
of IN I-OC
cardiotoxicity NN I-OC
was VBD O
785 CD O
mg/m NN O
( ( O
2 CD O
) ) O
for IN O
TLC NNP B-INTV
D-99 NNP I-INTV
versus NN O
570 CD O
mg/m NN O
( ( O
2 CD O
) ) O
for IN O
doxorubicin NN B-INTV
( ( O
P NNP O
= NNP O
0.0001 CD O
; : O
hazard NN O
ratio NN O
, , O
3.56 CD O
) ) O
. . O

The DT O
overall JJ B-OC
response NN I-OC
rate NN I-OC
was VBD O
26 CD O
% NN O
in IN O
both DT O
treatment NN O
groups NNS O
. . O

The DT O
median JJ B-OC
TTP NNP I-OC
was VBD O
2.9 CD O
months NNS O
on IN O
TLC NNP O
D-99 NNP O
versus NN O
3.1 CD O
months NNS O
on IN O
doxorubicin NN B-INTV
. . O

Median JJ B-OC
survival NN I-OC
was VBD O
16 CD O
versus NN O
20 CD O
months NNS O
with IN O
a DT O
nonsignificant JJ O
trend NN O
in IN O
favor NN O
of IN O
doxorubicin NN B-INTV
( ( O
P NNP O
= NNP O
0.09 CD O
) ) O
. . O

Clinical JJ B-OC
toxicities NNS I-OC
, , O
commonly RB O
associated VBN O
with IN O
doxorubicin NN O
, , O
appeared VBD O
less RBR O
common JJ O
with IN O
TLC NNP O
D-99 NNP O
, , O
although IN O
the DT O
difference NN O
was VBD O
not RB O
statistically RB O
significant JJ O
. . O

There EX O
was VBD O
only RB O
one CD O
report NN O
of IN O
palmar-plantar JJ B-OC
erythrodysesthesia NN I-OC
( ( O
Grade NNP O
2 CD O
) ) O
with IN O
this DT O
liposomal JJ O
formulation NN O
of IN O
doxorubicin NN B-INTV
. . O

CONCLUSIONS NNP O
Single-agent JJ O
TLC NNP B-INTV
D-99 NNP I-INTV
produces VBZ O
less JJR O
cardiotoxicity NN O
than IN O
doxorubicin NNS B-INTV
, , O
while IN O
providing VBG O
comparable JJ O
antitumor NN O
activity NN O
. . O

-DOCSTART- -X- O O

Mediastinal JJ O
lymphadenectomy NN B-INTV
in IN O
non-small JJ B-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
: : I-POPU
effectiveness NN O
in IN O
patients NNS B-POPU
with IN I-POPU
or CC I-POPU
without IN I-POPU
nodal JJ I-POPU
micrometastases NNS I-POPU
- : O
results NNS O
of IN O
a DT O
preliminary JJ O
study NN O
. . O

OBJECTIVES NNP O
So RB O
far RB O
it PRP O
has VBZ O
not RB O
clearly RB O
been VBN O
demonstrated VBN O
that IN O
systematic JJ O
mediastinal JJ O
lymphadenectomy NN B-INTV
improves VBZ O
survival JJ B-OC
in IN O
patients NNS B-POPU
with IN I-POPU
non-small JJ I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

One CD O
explanation NN O
might MD O
be VB O
that IN O
in IN O
some DT O
patients NNS O
an DT O
early JJ O
spread NN O
of IN O
tumor NN O
cells NNS O
has VBZ O
occurred VBN O
which WDT O
might MD O
not RB O
be VB O
curable JJ O
by IN O
surgical JJ O
means NNS O
. . O

To TO O
test VB O
this DT O
hypothesis NN O
lymph VBZ O
nodes NNS O
of IN O
patients NNS O
which WDT O
were VBD O
treated VBN O
either RB O
by IN O
lymph NN B-INTV
node NN I-INTV
sampling VBG I-INTV
or CC O
systematic JJ B-INTV
lymphadenectomy NN I-INTV
were VBD O
screened VBN O
for IN O
micrometastatic JJ O
spread NN O
of IN O
tumor NN O
cells NNS O
and CC O
the DT O
influence NN O
of IN O
nodal JJ O
micrometastases NNS O
on IN O
the DT O
efficacy NN O
of IN O
lymphadenectomy NN B-INTV
was VBD O
analyzed VBN O
. . O

METHODS NNP O
Lymph NNP B-POPU
nodes NNS I-POPU
from IN I-POPU
patients NNS I-POPU
( ( I-POPU
n=94 NN I-POPU
) ) I-POPU
which WDT O
were VBD O
included VBN O
in IN O
a DT O
randomized JJ O
trial NN O
of IN O
lymph NN B-INTV
node NN I-INTV
sampling NN I-INTV
( ( I-INTV
LS NNP I-INTV
, , O
n=41 NN O
) ) O
versus NN O
radical JJ B-INTV
systematic JJ I-INTV
lymphadenectomy NN I-INTV
( ( I-INTV
LA NNP I-INTV
, , O
n=53 RB O
) ) O
were VBD O
screened VBN O
by IN O
immunohistochemistry NN O
for IN O
disseminated JJ O
tumor NN O
cells NNS O
using VBG O
the DT O
antibody NN O
Ber-Ep4 NNP O
. . O

The DT O
median JJ B-OC
observation NN I-OC
time NN I-OC
was VBD O
longer JJR O
than IN O
5 CD O
years NNS O
and CC O
follow-up JJ O
data NNS O
were VBD O
available JJ O
from IN O
all DT O
94 CD O
patients NNS O
. . O

Kaplan-Meier NNP B-OC
curves NNS I-OC
were VBD O
calculated VBN O
and CC O
tested VBN O
for IN O
statistical JJ O
significance NN O
using VBG O
the DT O
log-rank JJ O
test NN O
. . O

RESULTS NNP O
Standard NNP O
histopathological JJ O
analysis NN O
revealed VBD O
no DT B-OC
lymph NN I-OC
node RB I-OC
involvement NN I-OC
( ( O
pN0 NN O
) ) O
in IN O
61 CD O
patients NNS O
, , O
pN1 JJ O
disease NN O
in IN O
13 CD O
patients NNS O
and CC O
pN2 JJ O
disease NN O
in IN O
20 CD O
patients NNS O
without IN O
significant JJ O
differences NNS O
between IN O
LA NNP O
and CC O
LS NNP O
with IN O
respect NN O
to TO O
T-stage NN O
, , O
N-stage NN O
or CC O
age NN O
and CC O
sex NN O
of IN O
the DT O
patients NNS O
. . O

By IN O
immunohistochemistry NN O
a DT O
minimal JJ O
nodal JJ B-OC
spread NN I-OC
of IN I-OC
tumor NN I-OC
cells NNS I-OC
was VBD O
detected VBN O
in IN O
21 CD O
out IN O
of IN O
94 CD O
patients NNS O
( ( O
LS NNP O
, , O
n=10 NN O
( ( O
24 CD O
% NN O
) ) O
; : O
LA NNP O
, , O
n=11 NN O
( ( O
21 CD O
% NN O
) ) O
) ) O
. . O

Similar JJ O
to TO O
the DT O
entire JJ O
group NN O
of IN O
patients NNS O
also RB O
in IN O
the DT O
subset NN O
of IN O
patients NNS O
with IN O
nodal JJ O
micrometastases VBZ O
the DT O
type NN O
of IN O
lymphadenectomy NN O
did VBD O
not RB O
significantly RB O
influence VB O
the DT O
long-term JJ B-OC
survival NN I-OC
( ( O
P=0.27 NNP O
and CC O
P=0.39 NNP O
, , O
respectively RB O
) ) O
. . O

In IN O
contrast NN O
, , O
in IN O
patients NNS O
with IN O
a DT O
negative JJ O
immunohistochemical JJ O
analysis NN O
systematic JJ O
lymphadenectomy NN B-INTV
resulted VBD O
in IN O
an DT O
improved JJ B-OC
overall JJ I-OC
survival NN I-OC
( ( O
P=0.044 NNP O
) ) O
. . O

CONCLUSIONS VB O
Our PRP$ O
data NNS O
provide VB O
some DT O
evidence NN O
that IN O
systematic JJ B-INTV
lymphadenectomy NN I-INTV
improves VBZ O
survival JJ B-OC
in IN O
patients NNS B-POPU
without IN I-POPU
an DT I-POPU
early JJ I-POPU
locoregional JJ I-POPU
spread NN I-POPU
of IN I-POPU
cancer NN I-POPU
cells NNS I-POPU
. . O

As RB O
long RB O
as IN O
these DT O
patients NNS O
can MD O
not RB O
be VB O
identified VBN O
preoperatively RB O
all DT O
patients NNS O
should MD O
undergo VB O
a DT O
systematic JJ O
mediastinal JJ O
lymphadenectomy NN B-INTV
. . O

-DOCSTART- -X- O O

The DT O
specific JJ O
role NN O
of IN O
isoflavones NNS B-INTV
on IN O
estrogen NN O
metabolism NN O
in IN B-POPU
premenopausal JJ I-POPU
women NNS I-POPU
. . O

BACKGROUND NNP O
There EX O
is VBZ O
increasing VBG O
evidence NN O
that IN O
dietary JJ O
factors NNS O
may MD O
play VB O
a DT O
role NN O
in IN O
the DT O
production NN O
, , O
metabolism NN O
, , O
and CC O
bioavailability NN O
of IN O
sex NN O
hormones NNS O
and CC O
their PRP$ O
impact NN O
on IN O
target NN O
tissues NNS O
. . O

The DT O
specific JJ O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
effectiveness NN O
of IN O
supplementing VBG O
a DT B-POPU
group NN I-POPU
of IN I-POPU
premenopausal JJ I-POPU
women NNS I-POPU
who WP I-POPU
were VBD I-POPU
free JJ I-POPU
of IN I-POPU
breast NN I-POPU
carcinoma NN I-POPU
with IN O
a DT O
dietary JJ O
supplement NN O
of IN O
isoflavones NNS B-INTV
( ( O
40 CD O
mg NNS O
per IN O
day NN O
) ) O
in IN O
producing VBG O
a DT O
change NN O
in IN O
steroid JJ O
hormones NNS O
and CC O
menstrual JJ O
cycle NN O
length NN O
. . O

METHODS NNP O
Sixty-eight NNP B-POPU
consecutively RB I-POPU
recruited VBD I-POPU
, , I-POPU
premenopausal NN I-POPU
, , I-POPU
omnivorous JJ I-POPU
women NNS I-POPU
of IN I-POPU
all DT I-POPU
races NNS I-POPU
and CC I-POPU
ethnicities NNS I-POPU
between IN I-POPU
the DT I-POPU
ages NNS I-POPU
of IN I-POPU
25 CD I-POPU
years NNS I-POPU
and CC I-POPU
55 CD I-POPU
years NNS I-POPU
were VBD I-POPU
admitted VBN I-POPU
to TO I-POPU
the DT I-POPU
study NN I-POPU
and CC O
randomized VBN O
to TO O
an DT O
experimental JJ O
group NN O
supplemented VBD O
with IN O
soy NN B-INTV
( ( I-INTV
40 CD I-INTV
mg NN O
genistein NNS O
per IN O
day NN O
) ) O
or CC O
to TO O
a DT O
control NN O
group NN O
that WDT O
consumed VBD O
a DT O
placebo NN B-INTV
for IN O
a DT O
12-week JJ O
period NN O
. . O

Changes NNS O
in IN O
their PRP$ O
anthropometric NN B-OC
, , I-OC
nutritional JJ I-OC
, , I-OC
and CC I-OC
hormonal JJ I-OC
biomarkers NNS I-OC
from IN O
early JJ O
follicular JJ O
phase NN O
were VBD O
analyzed VBN O
at IN O
baseline NN O
and CC O
post-intervention NN O
. . O

RESULTS NNP O
Serum-free JJ B-OC
estradiol NN I-OC
and CC I-OC
estrone NN I-OC
levels NNS I-OC
decreased VBN O
moderately RB O
in IN O
the DT O
experimental JJ O
group NN O
. . O

Serum NNP B-OC
hormone-binding JJ I-OC
globulin NN I-OC
levels NNS I-OC
increased VBN O
in IN O
41.4 CD O
% NN O
of IN O
women NNS O
in IN O
the DT O
experimental JJ O
group NN O
compared VBN O
with IN O
37.5 CD O
% NN O
of IN O
women NNS O
in IN O
the DT O
placebo NN B-INTV
group NN O
. . O

Free JJ B-OC
estradiol NN I-OC
decreased VBN O
in IN O
53.85 CD O
% NN O
of IN O
women NNS O
in IN O
the DT O
experimental JJ O
group NN O
compared VBN O
with IN O
37.5 CD O
% NN O
of IN O
women NNS O
in IN O
the DT O
placebo NN B-INTV
group NN O
. . O

Estrone CD B-OC
decreased VBD O
in IN O
55.56 CD O
% NN O
of IN O
women NNS O
in IN O
the DT O
experimental JJ O
group NN O
compared VBN O
with IN O
42.86 CD O
% NN O
in IN O
the DT O
placebo NN B-INTV
group NN O
. . O

Those DT O
women NNS O
in IN O
the DT O
experimental JJ O
group NN O
who WP O
were VBD O
consuming VBG O
soy NN B-INTV
had VBD O
their PRP$ O
mean JJ B-OC
menstrual JJ I-OC
cycle NN I-OC
length NN I-OC
increased VBN O
by IN O
3.52 CD O
days NNS O
compared VBN O
with IN O
a DT O
mean JJ O
decrease NN O
of IN O
0.06 CD O
days NNS O
for IN O
women NNS O
in IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
P NNP O
= NNP O
0.04 CD O
) ) O
from IN O
baseline NN O
to TO O
the DT O
third JJ O
menstrual JJ O
cycle NN O
. . O

In IN O
addition NN O
, , O
women NNS O
who WP O
were VBD O
taking VBG O
soy NN B-INTV
had VBD O
their PRP$ O
mean JJ B-OC
follicular JJ I-OC
phase NN I-OC
increase NN I-OC
by IN O
1.46 CD O
days NNS O
compared VBN O
with IN O
a DT O
mean JJ O
increase NN O
of IN O
0.14 CD O
days NNS O
for IN O
women NNS O
who WP O
were VBD O
taking VBG O
the DT O
placebo NN B-INTV
( ( O
P NNP O
= NNP O
0.08 CD O
) ) O
. . O

CONCLUSIONS NNP O
These DT O
data NNS O
suggest VBP O
that IN O
increased VBD O
isoflavone NN B-INTV
intake NN O
affects NNS O
estrogen VBP O
metabolism NN O
by IN O
altering VBG O
the DT O
steroid NN O
hormone NN O
concentrations NNS O
and CC O
menstrual JJ O
cycle NN O
length NN O
, , O
thereby RB O
demonstrating VBG O
a DT O
potential JJ O
to TO O
reduce VB O
the DT O
risk NN O
for IN O
breast NN B-POPU
carcinoma NN I-POPU
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
clonidine NN B-INTV
on IN O
postoperative JJ O
nausea NN O
and CC O
vomiting NN O
in IN O
breast NN B-POPU
cancer NN I-POPU
surgery NN I-POPU
. . O

BACKGROUND NNP O
Postoperative NNP O
nausea NN O
and CC O
vomiting NN O
( ( O
PONV NNP O
) ) O
is VBZ O
still RB O
common JJ O
, , O
especially RB O
among IN O
female JJ B-POPU
patients NNS I-POPU
. . O

Our PRP$ O
hypothesis NN O
is VBZ O
that IN O
coinduction NN O
with IN O
clonidine NN B-INTV
reduces VBZ O
the DT O
incidence NN O
of IN O
PONV NNP O
in IN O
adult NN B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
breast NN I-POPU
cancer NN I-POPU
surgery NN I-POPU
. . O

METHODS NNP O
Sixty-eight JJ B-POPU
women NNS I-POPU
premedicated VBN I-POPU
with IN I-POPU
midazolam NNS I-POPU
were VBD O
randomly RB O
allocated VBN O
to TO O
coinduction NN O
with IN O
intravenous JJ O
clonidine NN B-INTV
( ( O
group NN O
C NNP O
) ) O
or CC O
placebo NN B-INTV
( ( O
group NN O
P NNP O
) ) O
in IN O
this DT O
prospective JJ O
, , O
double-blind JJ O
study NN O
. . O

Anesthesia NNP O
was VBD O
standardized VBN O
( ( B-INTV
laryngeal JJ I-INTV
mask NN I-INTV
airway NN I-INTV
, , I-INTV
fentanyl NN I-INTV
, , I-INTV
propofol NN I-INTV
, , I-INTV
sevoflurane NN I-INTV
, , I-INTV
nitrous JJ I-INTV
oxide NN I-INTV
, , I-INTV
and CC I-INTV
oxygen NN I-INTV
) ) I-INTV
. . O

Hemodynamic JJ O
parameters NNS O
and CC O
the DT O
requirements NNS O
for IN O
propofol NN O
, , O
sevoflurane NN O
, , O
and CC O
the DT O
postoperative JJ O
need NN O
for IN O
ketobemidone NN O
were VBD O
noted VBN O
. . O

The DT O
primary JJ O
endpoints NNS O
studied VBN O
were VBD O
the DT O
number NN B-OC
of IN I-OC
PONV-free JJ I-OC
patients NNS I-OC
and CC I-OC
patient JJ I-OC
satisfaction NN I-OC
with IN I-OC
respect NN I-OC
to TO I-OC
PONV NNP I-OC
. . O

RESULTS NNP O
Patients NNPS O
in IN O
group NN O
C NNP O
had VBD O
a DT O
significantly RB O
reduced VBN B-OC
need NN I-OC
for IN I-OC
propofol NN I-OC
( ( O
P NNP O
< NNP O
0.04 CD O
) ) O
and CC O
sevoflurane NN B-OC
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
and CC O
a DT O
reduced VBN O
early JJ B-OC
need NN I-OC
for IN I-OC
ketobemidone NN I-OC
( ( O
P NNP O
< NNP O
0.04 CD O
) ) O
. . O

There EX O
were VBD O
significantly RB O
more RBR O
PONV-free JJ B-OC
patients NNS I-OC
in IN O
group NN O
C NNP O
compared VBN O
with IN O
group NN O
P NNP O
( ( O
20 CD O
and CC O
11 CD O
of IN O
30 CD O
, , O
respectively RB O
; : O
P NNP O
< NNP O
0.04 CD O
) ) O
. . O

The DT O
number NN O
needed VBN O
to TO O
treat VB O
was VBD O
3.3 CD O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
1.8 CD O
, , O
16.9 CD O
) ) O
. . O

Intraoperative JJ B-OC
blood NN I-OC
pressure NN I-OC
, , I-OC
postoperative JJ I-OC
heart NN I-OC
rate NN I-OC
, , I-OC
and CC I-OC
postoperative JJ I-OC
blood NN I-OC
pressure NN I-OC
were VBD O
all DT O
significantly RB O
lower JJR O
in IN O
group NN O
C NNP O
compared VBN O
with IN O
group NN O
P NNP O
, , O
but CC O
were VBD O
not RB O
considered VBN O
to TO O
be VB O
of IN O
clinical JJ O
importance NN O
. . O

No DT O
negative JJ O
side NN B-OC
effects NNS I-OC
were VBD O
recorded VBN O
. . O

CONCLUSION NNP O
Coinduction NNP O
with IN O
clonidine NN B-INTV
significantly RB O
increased VBD O
the DT O
number NN O
of IN O
PONV-free JJ B-OC
patients NNS B-POPU
after IN I-POPU
breast NN I-POPU
cancer NN I-POPU
surgery NN I-POPU
with IN I-POPU
general JJ I-POPU
anesthesia NN I-POPU
. . O

-DOCSTART- -X- O O

Superior JJ O
survival NN B-OC
with IN O
capecitabine JJ B-INTV
plus CC I-INTV
docetaxel JJ I-INTV
combination NN I-INTV
therapy NN I-INTV
in IN O
anthracycline-pretreated JJ B-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
phase NN O
III NNP O
trial NN O
results NNS O
. . O

PURPOSE NNP O
Docetaxel NNP B-INTV
and CC I-INTV
capecitabine NN I-INTV
, , O
a DT O
tumor-activated JJ O
oral JJ O
fluoropyrimidine NN O
, , O
show VBP O
high JJ O
single-agent JJ O
efficacy NN O
in IN O
metastatic JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
( ( O
MBC NNP O
) ) O
and CC O
synergy NN O
in IN O
preclinical JJ O
studies NNS O
. . O

This DT O
international JJ O
phase NN O
III NNP O
trial NN O
compared VBN O
efficacy NN B-OC
and CC I-OC
tolerability NN I-OC
of IN O
capecitabine/docetaxel JJ B-INTV
therapy NN I-INTV
with IN O
single-agent JJ B-INTV
docetaxel NN I-INTV
in IN O
anthracycline-pretreated JJ B-POPU
patients NNS I-POPU
with IN I-POPU
MBC NNP I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Patients NNPS O
were VBD O
randomized VBN O
to TO O
21-day JJ O
cycles NNS O
of IN O
oral JJ O
capecitabine NN B-INTV
1,250 CD O
mg/m NN O
( ( O
2 CD O
) ) O
twice RB O
daily RB O
on IN O
days NNS O
1 CD O
to TO O
14 CD O
plus CC O
docetaxel JJ B-INTV
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
on IN O
day NN O
1 CD O
( ( O
n JJ O
= NNP O
255 CD O
) ) O
or CC O
to TO O
docetaxel VB B-INTV
100 CD O
mg/m NN O
( ( O
2 CD O
) ) O
on IN O
day NN O
1 CD O
( ( O
n JJ O
= NNP O
256 CD O
) ) O
. . O

RESULTS NNP O
Capecitabine/docetaxel NNP B-INTV
resulted VBD O
in IN O
significantly RB O
superior JJ O
efficacy NN B-OC
in IN O
time NN B-OC
to TO I-OC
disease VB I-OC
progression NN I-OC
( ( I-OC
TTP NNP I-OC
) ) I-OC
( ( O
hazard JJ O
ratio NN O
, , O
0.652 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
0.545 CD O
to TO O
0.780 CD O
; : O
P NNP O
=.0001 NNP O
; : O
median JJ O
, , O
6.1 CD O
v NN O
4.2 CD O
months NNS O
) ) O
, , O
overall JJ B-OC
survival NN I-OC
( ( O
hazard JJ O
ratio NN O
, , O
0.775 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.634 CD O
to TO O
0.947 CD O
; : O
P NNP O
=.0126 NNP O
; : O
median JJ O
, , O
14.5 CD O
v NN O
11.5 CD O
months NNS O
) ) O
, , O
and CC O
objective JJ B-OC
tumor NN I-OC
response NN I-OC
rate NN I-OC
( ( O
42 CD O
% NN O
v JJ O
30 CD O
% NN O
, , O
P NNP O
=.006 NNP O
) ) O
compared VBN O
with IN O
docetaxel NN B-INTV
. . O

Gastrointestinal JJ B-OC
side NN I-OC
effects NNS I-OC
and CC I-OC
hand-foot JJ I-OC
syndrome NN I-OC
were VBD O
more JJR O
common JJ O
with IN O
combination NN B-INTV
therapy NN I-INTV
, , O
whereas JJ O
myalgia NN B-OC
, , I-OC
arthralgia NN I-OC
, , O
and CC O
neutropenic JJ B-OC
fever/sepsis NN I-OC
were VBD O
more JJR O
common JJ O
with IN O
single-agent JJ B-INTV
docetaxel NN I-INTV
. . O

More JJR O
grade JJ B-OC
3 CD I-OC
adverse JJ I-OC
events NNS I-OC
occurred VBD O
with IN O
combination NN B-INTV
therapy NN I-INTV
( ( O
71 CD O
% NN O
v JJ O
49 CD O
% NN O
, , O
respectively RB O
) ) O
, , O
whereas JJ O
grade VBP B-OC
4 CD I-OC
events NNS I-OC
were VBD O
slightly RB O
more RBR O
common JJ O
with IN O
docetaxel NN B-INTV
( ( O
31 CD O
% NN O
v JJ O
25 CD O
% NN O
with IN O
combination NN O
) ) O
. . O

CONCLUSION VB O
The DT O
significantly RB O
superior JJ O
TTP NNP B-OC
and CC I-OC
survival NN I-OC
achieved VBN O
with IN O
the DT O
addition NN B-INTV
of IN I-INTV
capecitabine NN I-INTV
to TO I-INTV
docetaxel VB I-INTV
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
, , O
with IN O
the DT O
manageable JJ O
toxicity NN B-OC
profile NN I-OC
, , O
indicate VBP O
that IN O
this DT O
combination NN B-INTV
provides VBZ O
clear JJ O
benefits NNS O
over IN O
single-agent JJ B-INTV
docetaxel NN I-INTV
100 CD O
mg/m NN O
( ( O
2 CD O
) ) O
. . O

Docetaxel/capecitabine NNP B-INTV
therapy NN I-INTV
is VBZ O
an DT O
important JJ O
treatment NN O
option NN O
for IN O
women NNS B-POPU
with IN I-POPU
anthracycline-pretreated JJ I-POPU
MBC NNP I-POPU
. . O

-DOCSTART- -X- O O

Combining VBG O
weight-loss JJ O
counseling NN O
with IN O
the DT O
weight NN O
watchers NNS O
plan VBP O
for IN O
obese JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
survivors NNS I-POPU
. . O

OBJECTIVE IN O
The DT O
objective NN O
was VBD O
to TO O
develop VB O
effective JJ O
weight-loss JJ O
methods NNS O
for IN O
women NNS B-POPU
who WP I-POPU
have VBP I-POPU
had VBN I-POPU
breast VBN I-POPU
cancer NN I-POPU
, , O
because IN O
obesity NN O
may MD O
result VB O
in IN O
an DT O
adverse JJ O
prognosis NN O
. . O

RESEARCH NNP O
METHODS NNP O
AND NNP O
PROCEDURES NNP O
This DT O
randomized VBN O
pilot NN O
study NN O
tested VBD O
an DT O
individualized JJ O
approach NN O
toward IN O
weight JJ B-OC
loss NN I-OC
in IN O
obese JJ B-POPU
women NNS I-POPU
who WP I-POPU
have VBP I-POPU
had VBD I-POPU
a DT I-POPU
diagnosis NN I-POPU
of IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

An DT O
individualized JJ O
approach NN O
was VBD O
applied VBN O
either CC O
alone RB B-INTV
or CC I-INTV
combined VBN I-INTV
with IN I-INTV
the DT I-INTV
commercial JJ I-INTV
Weight NNP I-INTV
Watchers NNP I-INTV
program NN I-INTV
. . O

Forty-eight JJ B-POPU
women NNS I-POPU
( ( I-POPU
body NN I-POPU
mass NN I-POPU
index NN I-POPU
of IN I-POPU
30 CD I-POPU
to TO I-POPU
44 CD I-POPU
kg/m NNS I-POPU
( ( I-POPU
2 CD I-POPU
) ) I-POPU
) ) I-POPU
were VBD I-POPU
enrolled VBN I-POPU
. . O

RESULTS NNP O
Weight NNP B-OC
change NN I-OC
after IN O
12 CD O
months NNS O
of IN O
intervention NN O
was VBD O
as IN O
follows VBZ O
( ( O
mean JJ O
+/- NNP O
SD NNP O
) ) O
: : O
0.85 CD O
+/- JJ O
6.0 CD O
kg NN O
in IN O
the DT O
control NN B-INTV
group NN I-INTV
, , O
-2.6 VBZ O
+/- JJ O
5.9 CD O
kg NN O
in IN O
the DT O
Weight NNP B-INTV
Watchers NNP I-INTV
group NN I-INTV
, , O
-8.0 VBZ O
+/- JJ O
5.5 CD O
kg NN O
in IN O
the DT O
individualized JJ O
group NN O
, , O
and CC O
-9.4 VBD O
+/- JJ O
8.6 CD O
kg NN O
in IN O
the DT O
comprehensive JJ B-INTV
group NN I-INTV
that WDT I-INTV
used VBD I-INTV
both DT I-INTV
individualized JJ I-INTV
counseling NN I-INTV
and CC I-INTV
Weight NNP I-INTV
Watchers NNP I-INTV
. . O

Weight NNP B-OC
loss NN I-OC
relative NN O
to TO O
control VB O
was VBD O
statistically RB O
significant JJ O
in IN O
the DT O
comprehensive JJ O
group NN O
3 CD O
, , O
6 CD O
, , O
and CC O
12 CD O
months NNS O
after IN O
randomization NN O
, , O
whereas JJ O
weight NN B-OC
loss NN I-OC
in IN O
the DT O
individualized JJ O
group NN O
was VBD O
significant JJ O
only RB O
at IN O
12 CD O
months NNS O
. . O

Weight NNP B-OC
loss NN I-OC
of IN O
10 CD O
% NN O
or CC O
more JJR O
of IN O
initial JJ O
body NN O
weight NN O
was VBD O
observed VBN O
in IN O
6 CD O
of IN O
10 CD O
women NNS O
in IN O
the DT O
comprehensive JJ O
group NN O
at IN O
12 CD O
months NNS O
. . O

In IN O
the DT O
comprehensive JJ O
and CC O
Weight NNP O
Watchers-only NNP O
groups NNS O
, , O
weight JJ B-OC
loss NN I-OC
was VBD O
significantly RB O
related VBN O
to TO O
frequency NN O
of IN O
attendance NN O
at IN O
Weight NNP O
Watchers NNP O
meetings NNS O
, , O
and CC O
attendance NN O
was VBD O
more RBR O
frequent JJ O
in IN O
the DT O
comprehensive JJ O
group NN O
. . O

DISCUSSION NNP O
These DT O
data NNS O
indicate VBP O
that IN O
the DT O
most RBS O
weight JJ B-OC
loss NN I-OC
was VBD O
achieved VBN O
when WRB O
the DT O
counseling NN O
approach NN O
combined VBD O
both DT O
Weight NNP O
Watchers NNPS O
and CC O
individualized JJ O
contacts NNS O
. . O

This DT O
was VBD O
effective JJ O
even RB O
though IN O
most JJS O
of IN O
the DT O
individualized JJ O
contacts NNS O
were VBD O
by IN O
telephone NN O
. . O

-DOCSTART- -X- O O

Monitoring VBG O
tumour NN O
cells NNS O
in IN O
the DT O
peripheral JJ O
blood NN O
of IN O
small JJ B-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

BACKGROUND NNP O
Flow NNP B-INTV
cytometry NN I-INTV
was VBD O
used VBN O
to TO O
enumerate VB O
tumour JJ O
cells NNS O
in IN O
longitudinal JJ O
studies NNS O
of IN O
peripheral JJ O
blood NN O
from IN O
small JJ B-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
SCLC NNP I-POPU
) ) I-POPU
patients NNS I-POPU
, , O
together RB O
with IN O
magnetic JJ O
bead NN O
selection NN O
to TO O
isolate VB O
and CC O
identify VB O
these DT O
cells NNS O
. . O

As IN O
part NN O
of IN O
a DT O
trial NN O
, , O
11 CD B-POPU
patients NNS I-POPU
received VBD I-POPU
either RB I-POPU
standard JJ I-POPU
( ( I-POPU
four CD I-POPU
weekly RB I-POPU
) ) I-POPU
chemotherapy NN I-POPU
with IN I-POPU
ifosfamide NN I-POPU
, , I-POPU
carboplatin NN I-POPU
, , I-POPU
and CC I-POPU
etoposide RB I-POPU
( ( I-POPU
ICE NNP I-POPU
) ) I-POPU
or CC I-POPU
accelerated VBN I-POPU
( ( I-POPU
two CD I-POPU
weekly RB I-POPU
) ) I-POPU
ICE NNP I-POPU
with IN I-POPU
filgrastim NN I-POPU
( ( I-POPU
granulocyte JJ I-POPU
colony-stimulating NN B-INTV
factor NN I-INTV
[ IN I-INTV
G-CSF NNP I-INTV
] NNP I-INTV
) ) I-INTV
and CC I-INTV
autologous JJ I-INTV
stem NN I-INTV
cell NN I-INTV
support NN I-INTV
. . O

METHODS NNP O
Fresh NNP O
venous JJ O
blood NN O
was VBD O
taken VBN O
throughout IN O
treatment NN O
and CC O
follow-up NN O
. . O

Aliquots NNS O
were VBD O
stained VBN O
with IN O
a DT O
" JJ O
tumour-specific JJ O
" NN O
antibody NN O
against IN O
epithelial JJ O
tissue NN O
( ( O
Ber NNP O
EP4 NNP O
) ) O
, , O
verified VBD O
as IN O
a DT O
good JJ O
marker NN O
of IN O
SCLC NNP O
cells NNS O
by IN O
immunohistochemistry NN O
. . O

Matched NNP O
samples NNS O
labelled VBD O
with IN O
Ber NNP O
EP4 NNP O
were VBD O
separated VBN O
magnetically RB O
by IN O
adding VBG O
a DT O
secondary JJ O
bead-antibody NN O
conjugate NN O
for IN O
confirmation NN O
of IN O
tumour NN O
cell NN O
identity NN O
. . O

RESULTS NNP O
Circulating NNP B-OC
tumour JJ I-OC
cells NNS I-OC
were VBD O
detected VBN O
and CC O
monitored VBN O
throughout IN O
treatment NN O
periods NNS O
. . O

An DT O
initial JJ B-OC
rise NN I-OC
in IN I-OC
circulating VBG I-OC
cells NNS I-OC
after IN I-OC
the DT I-OC
first JJ I-OC
cycle NN I-OC
was VBD O
followed VBN O
by IN O
a DT O
fall NN O
in IN O
both DT O
treatment NN O
arms NNS O
to TO O
baseline NN O
levels NNS O
set VBN O
by IN O
normal JJ O
controls NNS O
. . O

This DT O
was VBD O
achieved VBN O
by IN O
week NN O
12 CD O
in IN O
the DT O
accelerated JJ O
treatment NN O
arm NN O
and CC O
by IN O
week NN O
24 CD O
in IN O
the DT O
standard JJ O
arm NN O
. . O

CONCLUSIONS NNP O
Flow NNP O
cytometry NN O
and CC O
magnetic JJ O
bead NN O
isolation NN O
can MD O
be VB O
used VBN O
to TO O
identify VB O
changes NNS O
in IN O
numbers NNS O
of IN O
circulating VBG O
tumour JJ O
cells NNS O
in IN O
patients NNS O
undergoing JJ O
chemotherapy NN B-INTV
for IN O
SCLC NNP O
and CC O
thereafter RB O
during IN O
follow-up JJ O
periods NNS O
. . O

Absence NN O
of IN O
tumour JJ O
cells NNS O
may MD O
indicate VB O
a DT O
more RBR O
favourable JJ O
patient NN O
group NN O
who WP O
would MD O
benefit VB O
from IN O
a DT O
more RBR O
intense JJ O
course NN O
of IN O
treatment NN O
. . O

-DOCSTART- -X- O O

Intramuscular JJ O
depot NN O
medroxyprogesterone NN B-INTV
versus IN O
oral JJ O
megestrol NN B-INTV
for IN O
the DT O
control NN O
of IN O
postmenopausal NN O
hot JJ B-OC
flashes NNS I-OC
in IN O
breast NN B-POPU
cancer NN I-POPU
patients NNS I-POPU
: : I-POPU
a DT O
randomized JJ O
study NN O
. . O

BACKGROUND NNP O
Hot NNP B-OC
flashes NNS I-OC
are VBP O
frequent JJ O
in IN O
postmenopausal JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
, , O
especially RB O
when WRB O
treated VBN O
with IN O
tamoxifen NN O
. . O

Estrogen NNP B-INTV
replacement NN I-INTV
therapy NN I-INTV
is VBZ O
the DT O
most RBS O
effective JJ O
treatment NN O
for IN O
hot JJ B-OC
flashes NNS I-OC
, , O
but CC O
its PRP$ O
use NN O
is VBZ O
controversial JJ O
in IN O
breast NN O
cancer NN O
survivors NNS O
. . O

Progestins NNS O
may MD O
offer VB O
a DT O
good JJ O
alternative NN O
for IN O
the DT O
control NN O
of IN O
hot JJ B-OC
flashes NNS I-OC
in IN O
this DT O
setting NN O
; : O
in IN O
particular JJ O
, , O
oral JJ O
megestrol NN O
acetate NN O
has VBZ O
been VBN O
proven RB O
effective JJ O
in IN O
a DT O
randomized JJ O
, , O
placebo-controlled JJ O
clinical JJ O
trial NN O
. . O

With IN O
the DT O
aim NN O
of IN O
further JJ O
improving VBG O
these DT O
results NNS O
, , O
we PRP O
have VBP O
designed VBN O
a DT O
randomized VBN O
study NN O
comparing VBG O
oral JJ O
megestrol NN B-INTV
acetate NN I-INTV
with IN O
depot NN O
intramuscular NN O
( ( O
i.m JJ O
. . O

) ) O
medroxyprogesterone NN B-INTV
acetate NN I-INTV
( ( I-INTV
MPA NNP I-INTV
) ) I-INTV
for IN O
the DT O
control NN O
of IN O
hot JJ O
flashes NNS O
in IN O
postmenopausal NN B-POPU
patients NNS I-POPU
with IN I-POPU
a DT I-POPU
history NN I-POPU
of IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Seventy-one NNP B-POPU
postmenopausal NN I-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
an DT O
i.m NN B-INTV
. . O

injection NN B-INTV
of IN I-INTV
depot NN I-INTV
MPA NNP I-INTV
500 CD I-INTV
mg NN I-INTV
on IN I-INTV
days NNS I-INTV
1 CD I-INTV
, , I-INTV
14 CD I-INTV
and CC I-INTV
28 CD I-INTV
, , I-INTV
or CC I-INTV
oral JJ I-INTV
megestrol NN I-INTV
acetate VBP I-INTV
40 CD I-INTV
mg JJ I-INTV
daily RB I-INTV
for IN I-INTV
6 CD I-INTV
weeks NNS I-INTV
. . O

Patients NNS O
recorded VBD O
daily RB O
the DT O
number NN O
and CC O
severity NN O
of IN O
their PRP$ O
hot JJ B-OC
flashes NNS I-OC
; : I-OC
response NN O
was VBD O
defined VBN O
as IN O
a DT O
> NN O
or CC O
=50 CD O
% NN O
decrease NN O
in IN O
the DT O
number NN O
and CC O
severity NN O
of IN O
hot JJ B-OC
flashes NNS I-OC
. . O

RESULTS NN O
At IN O
week NN O
6 CD O
, , O
hot JJ B-OC
flashes NNS I-OC
were VBD O
reduced VBN O
by IN O
86 CD O
% NN O
on IN O
average NN O
in IN O
the DT O
whole JJ O
group NN O
of IN O
patients NNS O
, , O
without IN O
significant JJ O
differences NNS O
between IN O
the DT O
two CD O
progestins NNS O
. . O

Response NNP O
was VBD O
obtained VBN O
by IN O
75 CD O
and CC O
67 CD O
% NN O
of IN O
patients NNS O
receiving VBG O
MPA NNP O
or CC O
megestrol NN O
, , O
respectively RB O
( ( O
P NNP O
= NNP O
0.5 CD O
) ) O
. . O

Responders NNPS O
were VBD O
followed VBN O
to TO O
assess VB O
maintenance NN O
of IN O
response NN O
( ( O
without IN O
further RB O
treatment NN O
) ) O
, , O
which WDT O
was VBD O
significantly RB O
better RBR O
with IN O
i.m NN O
. . O

MPA NN B-INTV
: : I-INTV
in IN O
this DT O
group NN O
, , O
89 CD O
% NN O
of IN O
responders NNS O
still RB O
showed VBD O
a DT O
benefit NN O
at IN O
week NN O
24 CD O
, , O
compared VBN O
with IN O
45 CD O
% NN O
in IN O
the DT O
megestrol NN B-INTV
group NN O
( ( O
P NNP O
= NNP O
0.03 CD O
) ) O
. . O

CONCLUSIONS NNP O
Our PRP$ O
study NN O
shows VBZ O
that IN O
a DT O
short JJ O
cycle NN O
of IN O
i.m NN O
. . O

depot NN O
MPA NNP B-INTV
injections NNS O
provides VBZ O
significant JJ O
and CC O
long-lasting JJ O
relief NN B-OC
from IN O
postmenopausal NN B-OC
hot JJ I-OC
flashes NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
a DT I-POPU
history NN I-POPU
of IN I-POPU
breast NN I-POPU
cancer NN I-POPU
, , O
offering VBG O
an DT O
alternative JJ O
to TO O
estrogen VB O
replacement NN O
therapy NN O
or CC O
prolonged JJ O
administration NN O
of IN O
oral JJ O
megestrol NN B-INTV
. . O

-DOCSTART- -X- O O

Prognostic JJ O
factor NN O
analysis NN O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
treated VBN I-POPU
by IN I-POPU
castration NN I-POPU
plus CC I-POPU
anandron NN I-POPU
or CC I-POPU
placebo NN I-POPU
: : I-POPU
a DT O
final JJ O
update NN O
. . O

PURPOSE NNP O
Different NNP O
outcome NN O
results NNS O
have VBP O
been VBN O
published VBN O
in IN O
trials NNS O
comparing VBG O
maximal JJ O
androgen NN O
blockade NN O
( ( O
MAB NNP O
) ) O
with IN O
chemical NN B-INTV
or CC I-INTV
surgical JJ I-INTV
castration NN I-INTV
alone RB I-INTV
. . O

The DT O
conflicting NN O
results NNS O
could MD O
be VB O
explained VBN O
by IN O
the DT O
fact NN O
that IN O
patients NNS O
were VBD O
included VBN O
with IN O
different JJ O
prognostic JJ O
factors NNS O
. . O

In IN O
this DT O
new JJ O
analysis NN O
of IN O
the DT O
Anandron NNP O
European NNP O
Study NNP O
, , O
independent JJ O
prognostic JJ O
factors NNS O
have VBP O
been VBN O
evaluated VBN O
in IN O
order NN O
to TO O
identify VB O
those DT O
which WDT O
could MD O
influence VB O
the DT O
study NN O
outcome NN O
and CC O
the DT O
impact NN O
of IN O
the DT O
treatment NN O
. . O

MATERIAL NNP O
AND NNP O
METHODS NNP O
399 CD B-POPU
out IN I-POPU
of IN I-POPU
457 CD I-POPU
patients NNS I-POPU
recruited VBN I-POPU
in IN I-POPU
this DT I-POPU
study NN I-POPU
were VBD I-POPU
divided VBN I-POPU
in IN I-POPU
a DT I-POPU
good JJ I-POPU
or CC I-POPU
poor JJ I-POPU
prognostic JJ I-POPU
group NN I-POPU
depending VBG I-POPU
on IN I-POPU
the DT I-POPU
presence NN I-POPU
of IN I-POPU
two CD I-POPU
or CC I-POPU
more JJR I-POPU
poor JJ I-POPU
prognostic JJ I-POPU
factors NNS I-POPU
, , I-POPU
these DT I-POPU
were VBD I-POPU
pain NN I-POPU
requiring VBG I-POPU
treatment NN I-POPU
, , I-POPU
> VBZ I-POPU
5 CD I-POPU
bone NN I-POPU
metastases NNS I-POPU
, , I-POPU
hydronephrosis NN I-POPU
, , I-POPU
and CC I-POPU
alkaline JJ I-POPU
phosphatase NN I-POPU
> VBD I-POPU
2 CD I-POPU
ULN NNP I-POPU
. . O

RESULTS NNP O
When WRB O
expressed VBN O
as IN O
a DT O
percentage NN O
, , O
the DT O
improvement NN B-OC
in IN I-OC
time NN I-OC
to TO I-OC
progression NN I-OC
, , I-OC
overall JJ I-OC
and CC I-OC
cancer NN I-OC
specific JJ I-OC
survival NN I-OC
in IN O
the DT O
Anandron NNP B-INTV
treated VBD O
patients NNS O
was VBD O
identical JJ O
in IN O
both DT O
groups NNS O
. . O

In IN O
absolute JJ O
terms NNS O
this DT O
improvement NN O
, , O
however RB O
, , O
was VBD O
greater JJR O
in IN O
the DT O
good JJ O
prognostic JJ O
group NN O
. . O

CONCLUSION NNP O
In IN O
comparison NN O
with IN O
surgical JJ B-INTV
castration NN I-INTV
MAB NNP I-INTV
using VBG I-INTV
Anandron NNP I-INTV
, , O
in IN O
patients NNS B-POPU
with IN I-POPU
metastatic JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
improves VBZ O
the DT O
time NN O
to TO O
objective VB B-OC
progression NN I-OC
, , I-OC
overall JJ I-OC
and CC I-OC
cancer NN I-OC
specific JJ I-OC
survival NN I-OC
, , O
irrespective NN O
of IN O
certain JJ O
poor JJ O
prognostic JJ O
factors NNS O
. . O

-DOCSTART- -X- O O

Adherence NN O
to TO O
moderate-intensity NN B-INTV
exercise NN I-INTV
during IN O
breast NN B-POPU
cancer NN I-POPU
therapy NN B-INTV
. . O

PURPOSE VB O
The DT O
aims NNS O
of IN O
this DT O
pilot NN O
study NN O
were VBD O
the DT O
following JJ O
: : O
1 CD O
) ) O
to TO O
examine VB O
patterns NNS O
of IN O
adherence NN O
to TO O
a DT O
brisk JJ B-INTV
walking VBG I-INTV
program NN I-INTV
in IN O
women NNS B-POPU
receiving VBG I-POPU
adjuvant JJ I-POPU
chemotherapy NN I-POPU
or CC I-POPU
radiation NN I-POPU
therapy NN I-POPU
for IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
breast NN I-POPU
cancer NN I-POPU
using VBG O
a DT O
prospective JJ O
, , O
randomized VBN O
, , O
controlled VBD O
experimental JJ O
design NN O
; : O
2 CD O
) ) O
to TO O
examine VB O
the DT O
influence NN O
of IN O
disease NN O
symptoms NNS O
and CC O
treatment NN O
side NN O
effects NNS O
on IN O
exercise NN B-INTV
levels NNS O
; : O
and CC O
3 CD O
) ) O
to TO O
suggest VB O
methods NNS O
that WDT O
may MD O
improve VB O
future NN O
clinical JJ O
trials NNS O
of IN O
moderate-intensity NN O
exercise NN O
in IN O
similar JJ O
populations NNS O
. . O

DESCRIPTION NNP O
OF IN O
STUDY NNP O
Fifty-two NNP B-POPU
patients NNS I-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
breast NN I-POPU
cancer NN I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
one CD O
of IN O
two CD O
treatment NN O
arms NNS O
: : O
usual JJ B-INTV
care NN I-INTV
or CC O
usual JJ B-INTV
care NN I-INTV
plus CC I-INTV
exercise NN I-INTV
. . O

Those DT O
assigned VBN O
to TO O
the DT O
exercise NN B-INTV
group NN O
received VBD O
a DT O
standardized JJ B-INTV
, , I-INTV
self-administered JJ I-INTV
, , I-INTV
home-based JJ I-INTV
brisk NN I-INTV
walking VBG I-INTV
intervention NN I-INTV
in IN O
addition NN O
to TO O
usual JJ O
care NN O
. . O

Each DT O
day NN O
subjects VBZ O
completed VBN O
self-report JJ O
diary JJ O
forms NNS O
that WDT O
elicited VBD O
information NN O
about IN O
activity NN O
levels NNS O
, , O
and CC O
the DT O
occurrence NN O
of IN O
symptoms NNS O
and CC O
side JJ O
effects NNS O
during IN O
cancer NN O
treatment NN O
. . O

RESULTS NNP O
Analyses NNP O
of IN O
self-reported JJ O
daily JJ O
activity NN O
levels NNS O
revealed VBD O
a DT O
diffusion NN O
of IN O
treatment NN O
effect NN O
. . O

Fifty NNP O
percent NN O
of IN O
the DT O
usual-care JJ O
group NN O
reported VBD O
maintaining NN B-OC
or CC I-OC
increasing VBG I-OC
their PRP$ I-OC
physical JJ I-OC
activity NN I-OC
to TO I-OC
a DT I-OC
moderate-intensity JJ I-OC
level NN I-OC
, , O
while IN O
33 CD O
% NN O
of IN O
the DT O
exercise NN O
group NN O
did VBD O
not RB O
exercise NN O
at IN O
the DT O
prescribed NN O
levels NNS O
. . O

Analyses NNS O
of IN O
self-reported JJ B-OC
disease NN I-OC
symptoms NNS I-OC
and CC I-OC
treatment NN I-OC
side NN I-OC
effects NNS I-OC
did VBD O
not RB O
reveal VB O
clinically RB O
meaningful JJ O
differences NNS O
between IN O
the DT O
two CD O
groups NNS O
. . O

CLINICAL JJ O
IMPLICATIONS NNP O
The DT O
results NNS O
of IN O
this DT O
study NN O
suggest VBP O
that IN O
women NNS B-POPU
who WP O
exercised VBD O
regularly RB O
before RB O
receiving VBG O
a DT O
breast NN O
cancer NN O
diagnosis NN O
attempted VBD O
to TO O
maintain VB O
their PRP$ O
exercise NN B-INTV
programs NNS I-INTV
. . O

Women NNS B-POPU
who WP O
lead VBP O
sedentary JJ O
lifestyles NNS O
may MD O
benefit VB O
from IN O
a DT O
structured JJ B-INTV
exercise NN I-INTV
program NN I-INTV
that WDT O
includes VBZ O
information NN O
and CC O
support NN O
related VBN O
to TO O
exercise VB O
adherence NN O
strategies NNS O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
two CD O
types NNS O
of IN O
social JJ B-INTV
support NN I-INTV
and CC I-INTV
education NN I-INTV
on IN O
adaptation NN O
to TO O
early-stage JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

A DT B-INTV
Roy NNP I-INTV
adaptation NN I-INTV
model-based JJ I-INTV
support NN I-INTV
and CC I-INTV
education NN I-INTV
intervention NN I-INTV
for IN O
women NNS B-POPU
with IN I-POPU
early-stage JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
was VBD I-POPU
tested VBN I-POPU
in IN O
a DT B-POPU
three-group JJ I-POPU
, , I-POPU
three-phase JJ I-POPU
randomized JJ I-POPU
clinical JJ I-POPU
trial NN I-POPU
of IN I-POPU
a DT I-POPU
sample NN I-POPU
of IN I-POPU
125 CD I-POPU
women NNS I-POPU
. . O

The DT O
experimental JJ O
group NN O
received VBD O
13 CD O
months NNS O
of IN O
combined JJ B-INTV
individual JJ I-INTV
telephone NN I-INTV
and CC I-INTV
in-person NN I-INTV
group NN I-INTV
support NN I-INTV
and CC I-INTV
education NN I-INTV
, , O
Control NNP O
Group NNP O
1 CD O
received VBD O
13 CD O
months NNS O
of IN O
telephone-only JJ B-INTV
individual JJ I-INTV
support NN I-INTV
and CC I-INTV
education NN I-INTV
, , O
and CC O
Control NNP O
Group NNP O
2 CD O
received VBD O
one-time RB B-INTV
mailed JJ I-INTV
educational JJ I-INTV
information NN I-INTV
. . O

The DT O
experimental JJ O
group NN O
and CC O
Control NNP O
Group NNP O
1 CD O
reported VBD O
less JJR O
mood NN B-OC
disturbance NN I-OC
at IN O
the DT O
end NN O
of IN O
all DT O
three CD O
phases NNS O
, , O
less JJR B-OC
loneliness NN I-OC
at IN O
the DT O
end NN O
of IN O
Phases NNP O
II NNP O
and CC O
III NNP O
, , O
and CC O
a DT O
higher-quality NN B-OC
relationship NN I-OC
with IN I-OC
a DT I-OC
significant JJ I-OC
other JJ I-OC
at IN O
the DT O
end NN O
of IN O
Phase NNP O
II NNP O
than IN O
did VBD O
Control NNP O
Group NNP O
2 CD O
. . O

No DT O
group NN O
differences NNS O
were VBD O
found VBN O
for IN O
cancer-related JJ B-OC
worry NN I-OC
or CC I-OC
well-being NN I-OC
. . O

The DT O
findings NNS O
suggest VBP O
that IN O
individual JJ O
telephone NN O
support NN O
may MD O
provide VB O
an DT O
effective JJ O
alternative NN O
to TO O
in-person JJ O
support NN O
groups NNS O
. . O

Further NNP O
study NN O
of IN O
telephone NN O
interventions NNS O
is VBZ O
recommended VBN O
using VBG O
ethnically RB O
and CC O
economically RB O
heterogeneous JJ O
samples NNS O
. . O

-DOCSTART- -X- O O

[ IN O
The DT O
problems NNS O
of IN O
prophylactic JJ B-INTV
chemotherapy NN I-INTV
, , O
the DT O
second-look JJ O
operation NN O
and CC O
the DT O
maintenance NN O
of IN O
the DT O
remission NN O
in IN O
the DT O
treatment NN O
of IN O
ovarian JJ O
cancer NN O
( ( O
author NN O
's POS O
transl NN O
) ) O
] NN O
. . O

The DT O
results NNS O
of IN O
the DT O
treatment NN O
of IN O
1022 CD B-POPU
ovarian JJ I-POPU
cancers NNS I-POPU
were VBD O
reviewed VBN O
and CC O
the DT O
problems NNS O
of IN O
prophylactic JJ B-INTV
chemotherapy NN I-INTV
, , O
a DT O
second JJ O
look NN O
operation NN O
and CC O
the DT O
maintenance NN O
of IN O
the DT O
remission NN O
were VBD O
studied VBN O
. . O

In IN O
ovarian JJ B-POPU
cancers NNS I-POPU
of IN I-POPU
stage NN I-POPU
1 CD I-POPU
and CC I-POPU
stage NN I-POPU
2 CD I-POPU
, , O
a DT O
post-operative JJ B-INTV
prophylactic JJ I-INTV
chemotherapy NN I-INTV
is VBZ O
useful JJ O
only RB O
in IN O
cases NNS O
with IN O
tumor NN O
cells NNS O
in IN O
the DT O
secretions NNS O
of IN O
the DT O
pouch NN O
of IN O
Douglas NNP O
or CC O
in IN O
the DT O
ascites NNS O
and CC O
in IN O
cases NNS O
where WRB O
a DT O
sensitivity NN O
to TO O
the DT O
chemotherapy NN O
can MD O
be VB O
assumed VBN O
. . O

In IN O
about RB O
50 CD O
% NN O
of IN O
primarily RB B-POPU
inoperable JJ I-POPU
stage NN I-POPU
3 CD I-POPU
ovarian JJ I-POPU
cancers NNS I-POPU
, , O
the DT O
random NN O
treatment NN O
with IN O
cyclophosphamide NN B-INTV
( ( I-INTV
Endoxan NNP I-INTV
) ) I-INTV
results NNS O
in IN O
a DT O
clinical JJ B-OC
remission NN I-OC
. . O

A DT O
significant JJ O
five CD B-OC
year NN I-OC
cure NN I-OC
rate NN I-OC
can MD O
only RB O
be VB O
obtained VBN O
if IN O
the DT O
uterus NN O
and CC O
the DT O
adnexa NN O
are VBP O
removed VBN O
. . O

Radical JJ O
operation NN O
during IN O
the DT O
remission NN O
appears VBZ O
to TO O
be VB O
very RB O
important JJ O
for IN O
survival NN B-OC
of IN O
the DT O
patient NN O
. . O

For IN O
the DT O
maintenance NN O
of IN O
the DT O
remission NN O
continuous JJ O
chemotherapy NN B-INTV
for IN O
at IN O
least JJS O
2 CD O
years NNS O
following VBG O
treatment NN O
by IN O
operation NN O
and CC O
radiotherapy NN B-INTV
is VBZ O
necessary JJ O
. . O

-DOCSTART- -X- O O

Phase NNP O
III NNP O
trial NN O
comparing VBG O
whole-pelvic JJ O
versus NN O
prostate-only JJ O
radiotherapy NN B-INTV
and CC O
neoadjuvant JJ B-INTV
versus NN I-INTV
adjuvant NN I-INTV
combined VBN I-INTV
androgen JJ I-INTV
suppression NN I-INTV
: : I-INTV
Radiation NN I-INTV
Therapy NNP I-INTV
Oncology NNP O
Group NNP O
9413 CD O
. . O

PURPOSE VB O
This DT O
trial NN O
tested VBD O
the DT O
hypothesis NN O
that WDT O
combined VBD O
androgen DT B-INTV
suppression NN I-INTV
( ( I-INTV
CAS NNP I-INTV
) ) I-INTV
and CC I-INTV
whole-pelvic JJ I-INTV
( ( I-INTV
WP NNP I-INTV
) ) I-INTV
radiotherapy NN I-INTV
( ( I-INTV
RT NNP I-INTV
) ) I-INTV
followed VBN O
by IN O
a DT O
boost NN O
to TO O
the DT O
prostate NN O
improves VBZ O
progression-free JJ B-OC
survival NN I-OC
( ( I-OC
PFS NNP I-OC
) ) I-OC
by IN O
10 CD O
% NN O
compared VBN O
with IN O
CAS NNP O
and CC O
prostate-only RB O
( ( O
PO NNP O
) ) O
RT NNP O
. . O

This DT O
trial NN O
also RB O
tested VBD O
the DT O
hypothesis NN O
that WDT O
neoadjuvant JJ B-INTV
and CC I-INTV
concurrent JJ I-INTV
hormonal JJ I-INTV
therapy NN I-INTV
( ( I-INTV
NCHT NNP I-INTV
) ) I-INTV
improves VBZ O
PFS NNP O
compared VBN O
with IN O
adjuvant JJ B-INTV
hormonal JJ I-INTV
therapy NN I-INTV
( ( I-INTV
AHT NNP I-INTV
) ) I-INTV
by IN O
10 CD O
% NN O
. . O

MATERIALS NNP O
AND CC O
METHODS NNP O
Eligibility NNP B-POPU
included VBD I-POPU
localized JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
with IN I-POPU
an DT I-POPU
elevated JJ I-POPU
prostate-specific JJ I-POPU
antigen NN I-POPU
( ( I-POPU
PSA NNP I-POPU
) ) I-POPU
< VBD I-POPU
or CC I-POPU
= $ I-POPU
100 CD I-POPU
ng/mL NN I-POPU
and CC I-POPU
an DT I-POPU
estimated VBN I-POPU
risk NN I-POPU
of IN I-POPU
lymph JJ I-POPU
node NN I-POPU
( ( I-POPU
LN NNP I-POPU
) ) I-POPU
involvement NN I-POPU
of IN I-POPU
15 CD I-POPU
% NN I-POPU
. . O

Between NNP B-POPU
April NNP I-POPU
1 CD I-POPU
, , I-POPU
1995 CD I-POPU
, , I-POPU
and CC I-POPU
June NNP I-POPU
1 CD I-POPU
, , I-POPU
1999 CD I-POPU
, , I-POPU
1,323 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
accrued VBN I-POPU
. . O

Patients NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
WP NNP O
+ NNP O
NCHT NNP O
, , O
PO NNP O
+ NNP O
NCHT NNP O
, , O
WP NNP O
+ NNP O
AHT NNP O
, , O
or CC O
PO NNP O
+ NNP O
AHT NNP O
. . O

Failure NN B-OC
for IN I-OC
PFS NNP I-OC
was VBD O
defined VBN O
as IN O
the DT O
first JJ O
occurrence NN O
of IN O
local JJ B-OC
, , I-OC
regional JJ I-OC
, , I-OC
or CC I-OC
distant JJ I-OC
disease NN I-OC
; : I-OC
PSA NNP I-OC
failure NN I-OC
; : I-OC
or CC O
death NN B-OC
for IN O
any DT O
cause NN O
. . O

RESULTS NNP O
With IN O
a DT O
median JJ O
follow-up NN O
of IN O
59.5 CD O
months NNS O
, , O
WP NNP O
RT NNP O
was VBD O
associated VBN O
with IN O
a DT O
4-year JJ B-OC
PFS NNP I-OC
of IN O
54 CD O
% NN O
compared VBN O
with IN O
47 CD O
% NN O
in IN O
patients NNS O
treated VBN O
with IN O
PO NNP O
RT NNP O
( ( O
P NNP O
=.022 NNP O
) ) O
. . O

Patients NNS O
treated VBD O
with IN O
NCHT NNP B-INTV
experienced VBD O
a DT O
4-year JJ B-OC
PFS NNP I-OC
of IN O
52 CD O
% NN O
versus IN O
49 CD O
% NN O
for IN O
AHT NNP B-INTV
( ( O
P NNP O
=.56 NNP O
) ) O
. . O

When WRB O
comparing VBG O
all DT O
four CD O
arms NNS O
, , O
there EX O
was VBD O
a DT O
progression-free JJ B-OC
difference NN I-OC
among IN O
WP NNP B-INTV
RT NNP I-INTV
+ NNP I-INTV
NCHT NNP I-INTV
, , I-INTV
PO NNP I-INTV
RT NNP I-INTV
+ NNP I-INTV
NCHT NNP I-INTV
, , I-INTV
WP NNP I-INTV
RT NNP I-INTV
+ NNP I-INTV
AHT NNP I-INTV
, , O
and CC O
PO NNP B-INTV
RT NNP I-INTV
+ NNP I-INTV
AHT NNP I-INTV
( ( O
60 CD O
% NN O
v JJ O
44 CD O
% NN O
v JJ O
49 CD O
% NN O
v JJ O
50 CD O
% NN O
, , O
respectively RB O
; : O
P NNP O
=.008 NNP O
) ) O
. . O

No UH O
survival JJ B-OC
advantage NN I-OC
has VBZ O
yet RB O
been VBN O
seen VBN O
. . O

CONCLUSION NNP O
WP NNP B-INTV
RT NNP I-INTV
+ NNP I-INTV
NCHT NNP I-INTV
improves VBZ O
PFS NNP B-OC
compared VBN O
with IN O
PO NNP B-INTV
RT NNP I-INTV
and CC O
NCHT NNP B-INTV
or CC O
PO NNP B-INTV
RT NNP I-INTV
and CC O
AHT NNP B-INTV
, , O
and CC O
compared VBN O
with IN O
WP NNP B-INTV
RT NNP I-INTV
+ NNP I-INTV
AHT NNP I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
a DT I-POPU
risk NN I-POPU
of IN I-POPU
LN NNP I-POPU
involvement NN I-POPU
of IN I-POPU
15 CD I-POPU
% NN I-POPU
. . O

-DOCSTART- -X- O O

Recombinant JJ B-INTV
human JJ I-INTV
thrombopoietin NN I-INTV
augments NNS O
mobilization NN O
of IN O
peripheral JJ B-OC
blood NN I-OC
progenitor NN I-OC
cells NNS I-OC
for IN O
autologous JJ B-POPU
transplantation NN I-POPU
. . O

This DT O
study NN O
assessed VBD O
the DT O
ability NN O
of IN O
various JJ O
schedules NNS O
of IN O
recombinant JJ B-INTV
human JJ I-INTV
thrombopoietin NN I-INTV
( ( I-INTV
rhTPO NN I-INTV
) ) I-INTV
to TO O
enhance VB O
mobilization NN O
of IN O
peripheral JJ O
blood NN O
progenitor NN O
cells NNS O
( ( O
PBPCs NNP O
) ) O
in IN O
134 CD B-POPU
patients NNS I-POPU
with IN I-POPU
cancer NN I-POPU
undergoing VBG I-POPU
high-dose JJ I-POPU
chemotherapy NN I-POPU
and CC I-POPU
autologous JJ I-POPU
PBPC NNP I-POPU
transplantation NN I-POPU
. . O

Patients NNS O
received VBD O
the DT O
study NN O
drug NN O
on IN O
days NNS O
1 CD O
, , O
3 CD O
, , O
and CC O
5 CD O
before IN O
initiation NN O
of IN O
granulocyte JJ O
colony-stimulating JJ O
factor NN O
( ( O
G-CSF NNP O
) ) O
10 CD O
microg/kg/day NN O
on IN O
day NN O
5 CD O
and CC O
pheresis NN O
starting VBG O
on IN O
day NN O
9 CD O
. . O

Randomly RB O
assigned JJ O
treatments NNS O
on IN O
days NNS O
1 CD O
, , O
3 CD O
, , O
and CC O
5 CD O
were VBD O
: : O
group NN O
1 CD O
( ( O
n=27 NN O
) ) O
placebo NN B-INTV
, , I-INTV
placebo NN I-INTV
, , I-INTV
rhTPO VBZ I-INTV
1.5 CD O
microg/kg NN O
; : O
group NN O
2 CD O
( ( O
n=27 NN O
) ) O
rhTPO VBZ O
1.5 CD O
microg/kg NN O
, , O
placebo NN O
, , O
placebo NN O
; : O
groups NNS O
3 CD O
( ( O
n=28 NN O
) ) O
and CC O
4 CD O
( ( O
n=22 NN O
) ) O
rhTPO VBZ O
0.5 CD O
microg/kg NN O
on IN O
all DT O
3 CD O
treatment NN O
days NNS O
; : O
and CC O
group NN O
5 CD O
( ( O
n=30 NN O
) ) O
placebo NN O
on IN O
all DT O
3 CD O
treatment NN O
days NNS O
. . O

After IN O
high-dose JJ B-INTV
chemotherapy NN I-INTV
and CC I-INTV
PBPC NNP I-INTV
transplantation NN I-INTV
, , O
groups NNS O
1 CD O
through IN O
4 CD O
received VBD O
rhTPO NN O
1.5 CD O
microg/kg NN O
days NNS O
0 CD O
, , O
+2 NNP O
, , O
+4 NNP O
, , O
and CC O
+6 VBZ O
with IN O
either DT O
G-CSF NNP O
5 CD O
microg/kg/day NN O
( ( O
groups NNS O
1-3 CD O
) ) O
or CC O
granulocyte-macrophage JJ O
colony-stimulating JJ O
factor NN O
250 CD O
microg/m NN O
( ( O
2 CD O
) ) O
/day NN O
( ( O
group NN O
4 CD O
) ) O
. . O

Group NNP O
5 CD O
received VBD O
placebo JJ B-INTV
plus CC O
G-CSF JJ O
5 CD O
microg/kg/day NN O
. . O

The DT O
addition NN O
of IN O
rhTPO NN B-INTV
to TO O
G-CSF NNP O
increased JJ O
median JJ B-OC
CD34+ NNP I-OC
cell NN I-OC
yield/pheresis NN I-OC
in IN O
cohorts NNS O
in IN O
which WDT O
rhTPO NN B-INTV
was VBD O
started VBN O
before IN O
day NN O
5 CD O
, , O
with IN O
higher JJR O
yields NNS O
in IN O
groups NNS O
2 CD O
( ( O
2.67 CD O
x RB O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
) ) O
and CC O
groups NNS O
3 CD O
and CC O
4 CD O
( ( O
3.10 CD O
x RB O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
) ) O
than IN O
in IN O
group NN O
1 CD O
( ( O
1.86 CD O
x RB O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
) ) O
or CC O
group NN O
5 CD O
( ( O
1.65 CD O
x RB O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
) ) O
( ( O
P=.006 NNP O
across IN O
groups NNS O
) ) O
. . O

Comparing VBG O
rhTPO NN B-INTV
to TO O
placebo VB B-INTV
, , O
higher JJR O
percentages NNS O
of IN O
patients NNS O
achieved VBN O
the DT O
minimum JJ B-OC
yield NN I-OC
of IN I-OC
CD34+ NNP I-OC
> NNP O
or CC O
=2 NNP O
x VBP O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
( ( O
92 CD O
% NN O
v JJ O
75 CD O
% NN O
; : O
P=.050 NNP O
) ) O
as RB O
well RB O
as IN O
the DT O
target NN O
yield NN O
of IN O
CD34+ NNP O
> NNP O
or CC O
=5 NNP O
x VBP O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
( ( O
73 CD O
% NN O
v JJ O
46 CD O
% NN O
; : O
P= NNP O
.041 NNP O
) ) O
. . O

rhTPO-treated JJ B-INTV
patients NNS O
required VBN O
fewer JJR O
phereses NNS O
to TO O
achieve VB O
minimum NN O
( ( O
P= NNP O
.011 NNP O
) ) O
and CC O
target NN O
( ( O
P= NNP O
.015 NNP O
) ) O
CD34+ NNP B-OC
cell NN I-OC
values NNS I-OC
. . O

rhTPO VB B-INTV
given VBN O
after IN O
transplantation NN O
did VBD O
not RB O
speed VB O
platelet NN B-OC
recovery NN I-OC
. . O

No UH O
neutralizing JJ O
antibodies NNS O
were VBD O
observed VBN O
. . O

We PRP O
conclude VBP O
that IN O
rhTPO NN B-INTV
can MD O
safely RB O
enhance VB O
mobilization NN O
of IN O
PBPC NNP B-OC
, , O
reduce VB O
the DT O
number NN O
of IN O
leukapheresis NN B-OC
, , O
and CC O
allow VB O
more JJR O
patients NNS O
to TO O
meet VB O
minimal JJ O
cell NN O
yield NN O
requirements NNS O
to TO O
receive VB O
high-dose JJ O
chemotherapy NN B-INTV
with IN O
PBPC NNP B-INTV
transplantation NN I-INTV
. . O

-DOCSTART- -X- O O

Virtual JJ B-INTV
reality NN I-INTV
intervention NN I-INTV
for IN O
older JJR B-POPU
women NNS I-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

This DT O
study NN O
examined VBD O
the DT O
effects NNS O
of IN O
a DT O
virtual JJ B-INTV
reality NN I-INTV
distraction NN I-INTV
intervention NN I-INTV
on IN O
chemotherapy-related JJ B-POPU
symptom NN I-POPU
distress NN I-POPU
levels NNS I-POPU
in IN I-POPU
16 CD I-POPU
women NNS I-POPU
aged VBD I-POPU
50 CD I-POPU
and CC I-POPU
older JJR I-POPU
. . O

A DT O
cross-over JJ O
design NN O
was VBD O
used VBN O
to TO O
answer VB O
the DT O
following JJ O
research NN O
questions NNS O
: : O
( ( O
1 CD O
) ) O
Is VBZ O
virtual JJ O
reality NN O
an DT O
effective JJ O
distraction NN O
intervention NN O
for IN O
reducing VBG O
chemotherapy-related JJ O
symptom NN O
distress NN O
levels NNS O
in IN O
older JJR B-POPU
women NNS I-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
? . O
( ( O
2 CD O
) ) O
Does NNP O
virtual JJ B-INTV
reality NN I-INTV
have VBP O
a DT O
lasting JJ O
effect NN O
? . O
Chemotherapy NN O
treatments NNS O
are VBP O
intensive JJ O
and CC O
difficult JJ O
to TO O
endure VB O
. . O

One CD O
way NN O
to TO O
cope VB O
with IN O
chemotherapy-related JJ O
symptom NN O
distress NN O
is VBZ O
through IN O
the DT O
use NN O
of IN O
distraction NN O
. . O

For IN O
this DT O
study NN O
, , O
a DT B-INTV
head-mounted JJ I-INTV
display NN I-INTV
( ( I-INTV
Sony NNP I-INTV
PC NNP I-INTV
Glasstron NNP I-INTV
PLM NNP I-INTV
- : I-INTV
S700 NN I-INTV
) ) I-INTV
was VBD I-INTV
used VBN I-INTV
to TO I-INTV
display VB I-INTV
encompassing VBG I-INTV
images NNS I-INTV
and CC I-INTV
block NN I-INTV
competing VBG I-INTV
stimuli NNS I-INTV
during IN I-INTV
chemotherapy JJ I-INTV
infusions NNS I-INTV
. . O

The DT O
Symptom NNP B-INTV
Distress NNP I-INTV
Scale NNP I-INTV
( ( I-INTV
SDS NNP I-INTV
) ) I-INTV
, , I-INTV
Revised VBN I-INTV
Piper NNP I-INTV
Fatigue NNP I-INTV
Scale NNP I-INTV
( ( I-INTV
PFS NNP I-INTV
) ) I-INTV
, , I-INTV
and CC I-INTV
the DT I-INTV
State NNP I-INTV
Anxiety NNP I-INTV
Inventory NNP I-INTV
( ( I-INTV
SAI NNP I-INTV
) ) I-INTV
were VBD I-INTV
used VBN I-INTV
to TO I-INTV
measure VB I-INTV
symptom JJ I-INTV
distress NN I-INTV
. . O

For IN O
two CD O
matched JJ O
chemotherapy NN O
treatments NNS O
, , O
one CD O
pre-test NN O
and CC O
two CD O
post-test JJ O
measures NNS O
were VBD O
employed VBN O
. . O

Participants NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
the DT O
VR NNP B-INTV
distraction NN I-INTV
intervention NN I-INTV
during IN I-INTV
one CD I-INTV
chemotherapy NN I-INTV
treatment NN I-INTV
and CC I-INTV
received VBD I-INTV
no DT I-INTV
distraction NN I-INTV
intervention NN I-INTV
( ( I-INTV
control VB I-INTV
condition NN I-INTV
) ) I-INTV
during IN I-INTV
an DT I-INTV
alternate JJ I-INTV
chemotherapy NN I-INTV
treatment NN I-INTV
. . O

Analysis NN O
using VBG O
paired VBN O
t-tests NNS O
demonstrated VBD O
a DT O
significant JJ O
decrease NN B-OC
in IN O
the DT O
SAI NNP B-OC
( ( O
p JJ O
= NNP O
0.10 CD O
) ) O
scores NNS O
immediately RB O
following VBG O
chemotherapy NN O
treatments NNS O
when WRB O
participants NNS O
used VBD O
VR NNP O
. . O

No NNP O
significant JJ O
changes NNS O
were VBD O
found VBN O
in IN O
SDS NNP B-OC
or CC I-OC
PFS NNP I-OC
values NNS I-OC
. . O

There EX O
was VBD O
a DT O
consistent JJ O
trend NN O
toward IN O
improved VBN B-OC
symptoms NNS I-OC
on IN O
all DT O
measures NNS O
48 CD O
h NN O
following VBG O
completion NN O
of IN O
chemotherapy NN O
. . O

Evaluation NN O
of IN O
the DT O
intervention NN O
indicated VBD O
that IN O
women NNS B-POPU
thought VBD O
the DT O
head NN O
mounted VBD O
device NN O
was VBD O
easy JJ O
to TO O
use VB O
, , O
they PRP O
experienced VBD O
no DT O
cybersickness NN B-OC
, , O
and CC O
100 CD O
% NN O
would MD O
use VB O
VR NNP O
again RB O
. . O

-DOCSTART- -X- O O

Randomized VBN O
, , O
double-blind JJ O
, , O
multicenter JJ O
trial NN O
comparing VBG O
two CD O
doses NNS O
of IN O
arzoxifene NN B-INTV
( ( I-INTV
LY353381 NNP I-INTV
) ) I-INTV
in IN O
hormone-sensitive JJ B-POPU
advanced JJ I-POPU
or CC I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

BACKGROUND NNP O
This DT O
randomized VBN O
, , O
double-blind JJ O
, , O
phase NN O
II NNP O
study NN O
assessed VBD O
two CD O
doses NNS O
of IN O
the DT O
selective JJ B-INTV
estrogen NN I-INTV
receptor NN I-INTV
modulator NN I-INTV
arzoxifene NN I-INTV
in IN O
women NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
to TO O
choose VB O
the DT O
best JJS O
of IN O
two CD O
doses NNS O
of IN O
arzoxifene NN B-INTV
based VBN O
on IN O
the DT O
response NN B-OC
rate NN I-OC
or CC I-OC
the DT I-OC
clinical JJ I-OC
benefit NN I-OC
rate NN I-OC
( ( I-OC
CBR NNP I-OC
) ) I-OC
. . O

Pharmacokinetics NNPS B-OC
and CC I-OC
toxicities NNS I-OC
were VBD O
also RB O
assessed VBN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Ninety-two NNP B-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
received VBD I-POPU
arzoxifene JJ I-POPU
20 CD I-POPU
or CC I-POPU
50 CD I-POPU
mg/day NN I-POPU
. . O

Tumor NNP B-INTV
response NN I-INTV
was VBD I-INTV
assessed VBN I-INTV
using VBG I-INTV
World NNP I-INTV
Health NNP I-INTV
Organization NNP I-INTV
criteria NNS I-INTV
. . O

Toxicities NNS B-INTV
were VBD I-INTV
graded VBN I-INTV
according VBG I-INTV
to TO I-INTV
the DT I-INTV
National NNP I-INTV
Cancer NNP I-INTV
Institute NNP I-INTV
Common NNP I-INTV
Toxicity NNP I-INTV
Criteria NNP I-INTV
( ( I-INTV
NCI-CTC NNP I-INTV
) ) I-INTV
system NN I-INTV
. . O

Pharmacokinetic JJ B-OC
data NNS I-OC
were VBD O
analyzed VBN O
using VBG O
the DT O
NONMEM NNP O
software NN O
program NN O
( ( O
GloboMax NNP O
, , O
Hanover NNP O
, , O
MD NNP O
, , O
USA NNP O
) ) O
. . O

RESULTS JJ O
Response JJ B-OC
rates NNS I-OC
in IN O
the DT O
20 CD O
mg NN O
arm NN O
were VBD O
numerically RB O
higher JJR O
than IN O
the DT O
50-mg JJ O
arm NN O
according VBG O
to TO O
the DT O
investigator NN O
( ( O
40.5 CD O
% NN O
versus IN O
36.4 CD O
% NN O
) ) O
and CC O
the DT O
independent JJ O
review NN O
panel NN O
( ( O
42.9 CD O
% NN O
versus IN O
27.3 CD O
% NN O
) ) O
. . O

CBR NNP B-OC
was VBD O
higher RBR O
in IN O
the DT O
20 CD O
mg NN O
arm NN O
according VBG O
to TO O
the DT O
investigator NN O
( ( O
64.3 CD O
% NN O
versus IN O
61.4 CD O
% NN O
) ) O
and CC O
the DT O
independent JJ O
review NN O
panel NN O
( ( O
59.5 CD O
% NN O
versus IN O
47.7 CD O
% NN O
) ) O
. . O

Arzoxifene NNP B-INTV
was VBD O
well RB O
tolerated VBN O
. . O

There EX O
were VBD O
no DT O
study NN O
drug-related JJ B-OC
deaths NNS I-OC
. . O

Mean NNP O
observed VBD O
steady-state JJ B-OC
plasma JJ I-OC
concentrations NNS I-OC
of IN O
arzoxifene NN B-INTV
were VBD O
3.62 CD O
and CC O
7.48 CD O
ng/ml NN O
for IN O
the DT O
20 CD O
and CC O
50 CD O
mg NN O
doses NNS O
, , O
respectively RB O
. . O

CONCLUSIONS VB O
There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
efficacy NN B-OC
or CC O
safety NN B-OC
between IN O
20 CD O
and CC O
50 CD O
mg NN O
of IN O
arzoxifene NN B-INTV
. . O

Accordingly RB O
, , O
arzoxifene VBZ B-INTV
20 CD O
mg/day NN O
was VBD O
selected VBN O
for IN O
further JJ O
study NN O
in IN O
patients NNS O
with IN O
breast JJ O
cancer NN O
. . O

-DOCSTART- -X- O O

Randomized VBN O
phase NN O
II NNP O
trial NN O
of IN O
high-dose JJ O
4'-epi-doxorubicin JJ B-INTV
+ NNP O
cyclophosphamide NN B-INTV
versus IN O
high-dose JJ O
4'-epi-doxorubicin JJ B-INTV
+ NN I-INTV
cisplatin NN I-INTV
in IN O
previously RB B-POPU
untreated JJ I-POPU
patients NNS I-POPU
with IN I-POPU
extensive JJ I-POPU
small JJ I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

One CD B-POPU
hundred CD I-POPU
and CC I-POPU
eleven RB I-POPU
previously RB I-POPU
untreated JJ I-POPU
patients NNS I-POPU
with IN I-POPU
extensive JJ I-POPU
small JJ I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
were VBD O
included VBN O
in IN O
a DT O
prospective JJ O
randomized VBN O
study NN O
with IN O
the DT O
aim NN O
to TO O
assess VB O
the DT O
efficacy NN B-OC
and CC O
tolerance NN B-OC
of IN O
high-dose JJ B-INTV
epirubicin NN I-INTV
( ( O
120 CD O
mg/m2 NN O
) ) O
in IN O
combination NN O
with IN O
either DT O
cyclophosphamide NN B-INTV
( ( O
800 CD O
mg/m2 NN O
; : O
arm CC O
1 CD O
) ) O
or CC O
cisplatin NN B-INTV
( ( O
60 CD O
mg/m2 NN O
; : O
arm CC O
2 CD O
) ) O
. . O

Ninety-six JJ B-POPU
patients NNS I-POPU
were VBD I-POPU
evaluable JJ I-POPU
for IN I-POPU
response NN I-POPU
and CC I-POPU
toxicity NN I-POPU
and CC I-POPU
additional JJ I-POPU
12 CD I-POPU
patients NNS I-POPU
for IN I-POPU
toxicity NN I-POPU
only RB I-POPU
. . O

The DT O
overall JJ B-OC
response NN I-OC
rate NN I-OC
( ( I-OC
CR+PR NNP I-OC
) ) I-OC
in IN O
arm NN O
1 CD O
and CC O
2 CD O
were VBD O
61.4 CD O
( ( O
27/44 CD O
) ) O
and CC O
67.3 CD O
% NN O
( ( O
35/52 CD O
) ) O
, , O
respectively RB O
. . O

The DT O
mean JJ B-OC
duration NN I-OC
of IN I-OC
remission NN I-OC
was VBD O
4.4 CD O
months NNS O
( ( O
arm JJ O
1 CD O
) ) O
and CC O
4.9 CD O
months NNS O
( ( O
arm JJ O
2 CD O
) ) O
. . O

The DT O
mean JJ B-OC
survival NN I-OC
time NN I-OC
was VBD O
6.6 CD O
months NNS O
in IN O
arm NN O
1 CD O
and CC O
7.7 CD O
months NNS O
in IN O
arm NN O
2. CD O
WHO NNP B-OC
grade VBD I-OC
4 CD I-OC
toxicity NN I-OC
was VBD O
encountered VBN O
in IN O
25.5 CD O
and CC O
15.8 CD O
% NN O
of IN O
patients NNS O
in IN O
arm JJ O
1 CD O
and CC O
2 CD O
, , O
respectively RB O
. . O

One CD O
case NN O
of IN O
cardiotoxicity NN B-OC
resulting VBG O
in IN O
the DT O
patient NN O
's POS O
death NN B-OC
was VBD O
observed VBN O
in IN O
arm NN O
1 CD O
. . O

Both DT O
combinations NNS O
showed VBD O
considerable JJ O
antitumor NN B-OC
activity NN I-OC
. . O

Toxicity NN B-OC
was VBD O
acceptable JJ O
. . O

-DOCSTART- -X- O O

Intraperitoneal NNP B-INTV
cisplatin NN I-INTV
versus NN O
no DT O
further JJ O
treatment NN O
: : O
8-year JJ O
results NNS O
of IN O
EORTC NNP O
55875 CD O
, , O
a DT O
randomized JJ O
phase NN O
III NNP O
study NN O
in IN O
ovarian JJ B-POPU
cancer NN I-POPU
patients NNS I-POPU
with IN I-POPU
a DT I-POPU
pathologically RB I-POPU
complete JJ I-POPU
remission NN I-POPU
after IN I-POPU
platinum-based JJ I-POPU
intravenous JJ I-POPU
chemotherapy NN I-POPU
. . O

First-line NNP B-INTV
intravenous JJ I-INTV
chemotherapy NN I-INTV
( ( O
CT NNP O
) ) O
following VBG O
debulking VBG O
surgery NN O
is VBZ O
associated VBN O
with IN O
prolonged JJ B-OC
survival NN I-OC
, , O
in IN O
particular JJ O
in IN O
patients NNS B-POPU
who WP I-POPU
achieve VBP I-POPU
a DT I-POPU
pathological JJ I-POPU
complete JJ I-POPU
remission NN I-POPU
( ( I-POPU
pCR NN I-POPU
) ) I-POPU
at IN I-POPU
second-look NN I-POPU
surgery NN I-POPU
but CC I-POPU
in IN I-POPU
whom WP I-POPU
a DT I-POPU
high JJ I-POPU
rate NN I-POPU
of IN I-POPU
relapses NNS I-POPU
still RB I-POPU
occurs VBZ I-POPU
. . O

Between JJ B-POPU
1988 CD I-POPU
and CC I-POPU
1997 CD I-POPU
, , I-POPU
153 CD I-POPU
patients NNS I-POPU
in IN I-POPU
pCR JJ I-POPU
following VBG I-POPU
platinum-based JJ I-POPU
intravenous JJ I-POPU
CT NNP I-POPU
were VBD O
randomized VBN O
between IN O
four CD B-INTV
courses NNS I-INTV
of IN I-INTV
intraperitoneal NN I-INTV
cisplatin NN I-INTV
( ( I-INTV
P NNP I-INTV
) ) I-INTV
( ( I-INTV
90 CD I-INTV
mg/m2 NN I-INTV
every DT I-INTV
3 CD I-INTV
weeks NNS I-INTV
) ) I-INTV
or CC I-INTV
observation NN I-INTV
. . O

Overall JJ B-OC
survival NN I-OC
( ( I-OC
OS NNP I-OC
) ) I-OC
was VBD O
the DT O
primary JJ O
endpoint NN O
, , O
while IN O
progression-free JJ O
survival NN O
( ( O
PFS NNP O
) ) O
was VBD O
a DT O
secondary JJ O
endpoint NN O
. . O

This DT O
intent-to-treat JJ O
analysis NN O
includes VBZ B-POPU
16 CD I-POPU
patients NNS I-POPU
who WP I-POPU
were VBD I-POPU
not RB I-POPU
eligible JJ I-POPU
and CC I-POPU
17 CD I-POPU
patients NNS I-POPU
who WP I-POPU
had VBD I-POPU
protocol NN I-POPU
violations NNS I-POPU
. . O

The DT O
two CD B-POPU
groups NNS I-POPU
were VBD I-POPU
well RB I-POPU
balanced VBN I-POPU
in IN I-POPU
terms NNS I-POPU
of IN I-POPU
age NN I-POPU
( ( I-POPU
median JJ I-POPU
= VBZ I-POPU
55 CD I-POPU
years NNS I-POPU
) ) I-POPU
, , I-POPU
performance NN I-POPU
status NN I-POPU
( ( I-POPU
78 CD I-POPU
% NN I-POPU
P.S NNP I-POPU
. . O

O NNP B-POPU
) ) I-POPU
, , I-POPU
FIGO NNP I-POPU
stage NN I-POPU
( ( I-POPU
96 CD I-POPU
% NN I-POPU
stage NN I-POPU
III NNP I-POPU
) ) I-POPU
, , I-POPU
histology NN I-POPU
( ( I-POPU
serous JJ I-POPU
in IN I-POPU
66 CD I-POPU
% NN I-POPU
) ) I-POPU
, , I-POPU
grade VBD I-POPU
( ( I-POPU
2 CD I-POPU
or CC I-POPU
3 CD I-POPU
in IN I-POPU
80 CD I-POPU
% NN I-POPU
) ) I-POPU
, , I-POPU
and CC I-POPU
residuum NN I-POPU
before RB I-POPU
intravenous JJ I-POPU
CT NNP I-POPU
( ( I-POPU
> $ I-POPU
1 CD I-POPU
cm NN I-POPU
in IN I-POPU
40 CD I-POPU
% NN I-POPU
) ) I-POPU
. . O

Intraperitoneal NNP B-INTV
CT NNP I-INTV
was VBD O
delivered VBN O
mainly RB O
through IN O
intraperitoneal JJ O
catheters NNS O
( ( O
Port-a-Cath JJ O
61 CD O
% NN O
and CC O
Tenckhoff NNP O
25 CD O
% NN O
) ) O
. . O

Side JJ O
effects NNS O
of IN O
intraperitoneal NN B-INTV
cisplatin NN I-INTV
included VBD O
vomiting VBG B-OC
[ NNP O
> NNP O
or CC O
=grade VB O
2 CD O
( ( O
82 CD O
% NN O
) ) O
] NN O
, , O
rise NN B-OC
in IN I-OC
serum JJ I-OC
creatinine NN I-OC
[ NNP O
> NNP O
or CC O
=grade VB O
2 CD O
( ( O
14 CD O
% NN O
) ) O
] NN O
, , O
abdominal JJ B-OC
pain NN I-OC
[ JJ O
grade NN O
1-2 JJ O
( ( O
38 CD O
% NN O
) ) O
] NN O
, , O
and CC O
neurotoxicity NN B-OC
[ NNP O
grade VBD O
2-3 CD O
( ( O
15 CD O
% NN O
) ) O
] NN O
. . O

After IN O
a DT O
median JJ O
follow-up NN O
of IN O
8 CD O
years NNS O
, , O
80 CD O
patients NNS O
( ( O
52 CD O
% NN O
) ) O
have VBP O
progressed VBN O
with IN O
no DT O
difference NN O
in IN O
the DT O
pattern NN B-OC
of IN I-OC
relapse NN I-OC
between IN O
the DT O
two CD O
groups NNS O
and CC O
75 CD O
patients NNS O
( ( O
49 CD O
% NN O
) ) O
have VBP O
died VBN B-OC
; : I-OC
the DT O
respective JJ O
hazard NN O
ratios NNS O
for IN O
PFS NNP O
and CC O
OS NNP O
with IN O
95 CD O
% NN O
CI NNP O
are VBP O
0.89 CD O
( ( O
0.59-1.33 NN O
) ) O
and CC O
0.82 CD O
( ( O
0.52-1.29 NN O
) ) O
. . O

These DT O
results NNS O
are VBP O
suggestive JJ O
of IN O
a DT O
treatment NN O
benefit NN O
but CC O
do VBP O
not RB O
support VB O
a DT O
change NN O
in IN O
clinical JJ O
practice NN O
. . O

Other JJ O
randomized JJ O
clinical JJ O
trials NNS O
of IN O
intraperitoneal JJ B-INTV
CT NNP I-INTV
are VBP O
reviewed VBN O
and CC O
briefly NN O
discussed VBN O
. . O

-DOCSTART- -X- O O

Randomized VBN O
Phase NNP O
II NNP O
trial NN O
assessing VBG O
estramustine NN B-INTV
and CC I-INTV
vinblastine JJ I-INTV
combination NN I-INTV
chemotherapy NN I-INTV
vs JJ I-INTV
estramustine NN I-INTV
alone RB I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
progressive JJ I-POPU
hormone-escaped JJ I-POPU
metastatic JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

Based VBN O
on IN O
the DT O
results NNS O
of IN O
combined JJ O
data NNS O
from IN O
three CD O
North JJ O
American JJ O
Phase NNP O
II NNP O
studies NNS O
, , O
a DT O
randomised JJ O
Phase NNP O
II NNP O
study NN O
in IN O
the DT O
same JJ O
patient JJ O
population NN O
was VBD O
performed VBN O
, , O
using VBG O
combination NN O
chemotherapy NN B-INTV
with IN I-INTV
estramustine JJ I-INTV
phosphate NN I-INTV
( ( I-INTV
EMP NNP I-INTV
) ) I-INTV
and CC I-INTV
vinblastine NN I-INTV
( ( I-INTV
VBL NNP I-INTV
) ) I-INTV
in IN O
hormone NN O
refractory NN O
prostate NN O
cancer NN O
patients NNS O
. . O

In IN O
all DT O
, , O
92 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
randomised VBN I-POPU
into IN I-POPU
a DT I-POPU
Phase NNP I-POPU
II NNP I-POPU
study NN I-POPU
of IN O
oral JJ B-INTV
EMP NNP I-INTV
( ( I-INTV
10 CD I-INTV
mg NNS I-INTV
kg JJ I-INTV
day NN I-INTV
continuously RB I-INTV
) ) I-INTV
or CC I-INTV
oral JJ I-INTV
EMP NNP I-INTV
in IN I-INTV
combination NN I-INTV
with IN I-INTV
intravenous JJ I-INTV
VBL NNP I-INTV
( ( O
4 CD O
mg NN O
m NN O
( ( O
2 CD O
) ) O
week NN O
for IN O
6 CD O
weeks NNS O
, , O
followed VBN O
by IN O
2 CD O
weeks NNS O
rest NN O
) ) O
. . O

The DT O
end NN O
points NNS O
were VBD O
toxicity NN B-OC
and CC I-OC
PSA NNP I-OC
response NN I-OC
in IN O
both DT O
groups NNS O
, , O
with IN O
the DT O
option NN O
to TO O
continue VB O
the DT O
trial NN O
as IN O
a DT O
Phase NNP O
III NNP O
study NN O
with IN O
time NN B-OC
to TO I-OC
progression NN I-OC
and CC O
survival NN B-OC
as IN O
end NN O
points NNS O
, , O
if IN O
sufficient JJ O
responses NNS O
were VBD O
observed VBN O
. . O

Toxicity NNP B-OC
was VBD O
unexpectedly RB O
high JJ O
in IN O
both DT O
treatment NN O
arms NNS O
and CC O
led VBD O
to TO O
treatment NN O
withdrawal NN O
or CC O
refusal NN O
in IN O
49 CD O
% NN O
of IN O
all DT O
patients NNS O
, , O
predominantly RB O
already RB O
during IN O
the DT O
first JJ O
treatment NN O
cycle NN O
. . O

The DT O
mean JJ B-OC
treatment NN I-OC
duration NN I-OC
was VBD O
10 CD O
and CC O
14 CD O
weeks NNS O
, , O
median JJ B-OC
time NN I-OC
to TO I-OC
PSA NNP I-OC
progression NN I-OC
was VBD O
27.2 CD O
and CC O
30.8 CD O
weeks NNS O
, , O
median JJ B-OC
survival NN I-OC
time NN I-OC
was VBD O
44 CD O
and CC O
50.9 CD O
weeks NNS O
, , O
and CC O
PSA NNP B-OC
response NN I-OC
rate NN I-OC
was VBD O
only RB O
24.6 CD O
and CC O
28.9 CD O
% NN O
in IN O
the DT O
EMP/VBL NNP B-INTV
and CC O
EMP NNP B-INTV
arms NNS O
, , O
respectively RB O
. . O

There EX O
was VBD O
no DT O
correlation NN O
between IN O
PSA NNP B-OC
response NN I-OC
and CC I-OC
survival NN I-OC
. . O

While IN O
the DT O
PSA NNP B-OC
response NN I-OC
in IN O
the DT O
patients NNS O
tested VBD O
was VBD O
less JJR O
than IN O
half NN O
that WDT O
recorded VBD O
in IN O
the DT O
North JJ O
American JJ O
studies NNS O
, , O
the DT O
toxicity NN B-OC
of IN I-OC
EMP NNP B-INTV
monotherapy NN B-OC
or CC O
in IN O
combination NN O
with IN O
VBL NNP B-INTV
was VBD O
much RB O
higher JJR O
than IN O
expected VBN O
. . O

Further NNP O
research NN O
on IN O
more RBR O
effective JJ B-OC
and CC O
less RBR O
toxic JJ B-OC
treatment NN O
strategies NNS O
for IN O
hormone NN O
refractory NN O
prostate NN O
cancer NN O
is VBZ O
mandatory JJ O
. . O

-DOCSTART- -X- O O

Psychoeducational NNP B-INTV
group NN I-INTV
intervention NN I-INTV
for IN O
wives NNS B-POPU
of IN I-POPU
men NNS I-POPU
with IN I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

OBJECTIVE CC O
The DT O
effects NNS O
of IN O
a DT O
6-week JJ O
psychoeducational JJ B-INTV
group NN I-INTV
intervention NN I-INTV
on IN O
the DT O
distress NN O
, , O
coping NN O
, , O
personal JJ O
growth NN O
, , O
and CC O
marital JJ O
communication NN O
of IN O
wives NNS B-POPU
of IN I-POPU
men NNS I-POPU
diagnosed VBN I-POPU
with IN I-POPU
prostate JJ I-POPU
cancer NN I-POPU
were VBD O
evaluated VBN O
using VBG O
a DT O
randomized JJ O
clinical JJ O
trial NN O
. . O

METHODS NNP O
Sixty NNP B-POPU
wives NNS I-POPU
completed VBD O
measures NNS O
prior RB O
to TO O
random VB O
assignment NN O
to TO O
either VB O
the DT O
psychoeducational JJ B-INTV
group NN I-INTV
intervention NN I-INTV
or CC I-INTV
a DT I-INTV
no-treatment JJ I-INTV
control NN I-INTV
group NN I-INTV
, , O
and CC O
1 CD O
month NN O
after IN O
completion NN O
of IN O
the DT O
group NN O
. . O

RESULTS NNP O
No NNP O
differences NNS O
with IN O
regard NN O
to TO O
wives NNS O
' POS O
general JJ B-OC
distress NN I-OC
or CC I-OC
cancer-specific JJ I-OC
distress NN I-OC
were VBD O
noted VBN O
. . O

In IN O
comparison NN O
with IN O
the DT O
control NN O
group NN O
, , O
participants NNS O
receiving VBG O
the DT O
intervention NN O
perceived VBD O
that IN O
having VBG O
a DT O
spouse NN O
with IN O
prostate NN O
cancer NN O
had VBD O
made VBN O
positive JJ O
contributions NNS O
to TO O
their PRP$ O
lives NNS O
, , O
reported VBD O
gains NNS O
in IN O
the DT O
use NN O
of IN O
positive JJ B-OC
reappraisal NN I-OC
coping VBG I-OC
and CC O
reductions NNS O
in IN O
denial JJ B-OC
coping NN I-OC
. . O

CONCLUSION NNP O
Although IN O
the DT O
psychoeducational JJ B-INTV
intervention NN I-INTV
did VBD O
not RB O
result VB O
in IN O
changes NNS O
in IN O
psychological JJ B-OC
distress NN I-OC
, , O
improvements NNS O
in IN O
adaptive JJ B-OC
coping NN I-OC
and CC I-OC
indicators NNS I-OC
of IN I-OC
psychological JJ I-OC
growth NN I-OC
were VBD O
found VBN O
. . O

The DT O
utility NN O
of IN O
group NN O
interventions NNS O
for IN O
spouses NNS B-POPU
of IN I-POPU
men NNS I-POPU
with IN I-POPU
prostate NN I-POPU
cancer NN I-POPU
is VBZ O
discussed VBN O
. . O

-DOCSTART- -X- O O

Reduced VBN O
cardiotoxicity NN O
and CC O
comparable JJ O
efficacy NN O
in IN O
a DT O
phase NN O
III NNP O
trial NN O
of IN O
pegylated VBN B-INTV
liposomal JJ I-INTV
doxorubicin NN I-INTV
HCl NNP I-INTV
( ( I-INTV
CAELYX/Doxil NNP I-INTV
) ) I-INTV
versus VBP O
conventional JJ B-INTV
doxorubicin NN I-INTV
for IN O
first-line JJ O
treatment NN O
of IN O
metastatic JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

BACKGROUND NNP O
This DT O
study NN O
was VBD O
designed VBN O
to TO O
demonstrate VB O
that IN O
efficacy NN O
[ JJ B-OC
progression-free JJ I-OC
survival NN I-OC
( ( I-OC
PFS NNP I-OC
) ) I-OC
] NN I-OC
of IN O
CAELYX NNP B-INTV
[ NNP I-INTV
pegylated VBD I-INTV
liposomal JJ I-INTV
doxorubicin NN I-INTV
HCl NNP I-INTV
( ( I-INTV
PLD NNP I-INTV
) ) I-INTV
] NN I-INTV
is VBZ O
non-inferior JJ O
to TO O
doxorubicin VB B-INTV
with IN O
significantly RB O
less JJR O
cardiotoxicity NN O
in IN O
first-line JJ B-POPU
treatment NN I-POPU
of IN I-POPU
women NNS I-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
( ( I-POPU
MBC NNP I-POPU
) ) I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Women NNP B-POPU
( ( I-POPU
n=509 JJ I-POPU
) ) I-POPU
with IN I-POPU
MBC NNP I-POPU
and CC I-POPU
normal JJ I-POPU
cardiac JJ I-POPU
function NN I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO O
receive VB O
either DT O
PLD NNP B-INTV
50 CD O
mg/m2 NN O
( ( O
every DT O
4 CD O
weeks NNS O
) ) O
or CC O
doxorubicin $ B-INTV
60 CD I-INTV
mg/m2 NN I-INTV
( ( O
every DT O
3 CD O
weeks NNS O
) ) O
. . O

Cardiac JJ B-OC
event NN I-OC
rates NNS I-OC
were VBD O
based VBN O
on IN O
reductions NNS O
in IN O
left JJ O
ventricular JJ O
ejection NN O
fraction NN O
as IN O
a DT O
function NN O
of IN O
cumulative JJ O
anthracycline NN B-INTV
dose NN O
. . O

RESULTS NNP O
PLD NNP B-INTV
and CC O
doxorubicin NNS B-INTV
were VBD O
comparable JJ O
with IN O
respect NN O
to TO O
PFS NNP B-OC
[ NNP O
6.9 CD O
versus NN O
7.8 CD O
months NNS O
, , O
respectively RB O
; : O
hazard NN O
ratio NN O
( ( O
HR NNP O
) ) O
=1.00 VBP O
; : O
95 CD O
% NN O
confidence NN B-OC
interval NN I-OC
( ( I-OC
CI NNP I-OC
) ) I-OC
0.82-1.22 CD O
] NN O
. . O

Subgroup NNP O
results NNS O
were VBD O
consistent JJ O
. . O

Overall JJ B-OC
risk NN I-OC
of IN I-OC
cardiotoxicity NN I-OC
was VBD O
significantly RB O
higher JJR O
with IN O
doxorubicin NN B-INTV
than IN O
PLD NNP B-INTV
( ( O
HR=3.16 NNP O
; : O
95 CD O
% NN O
CI NNP O
1.58-6.31 CD O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

Overall JJ B-OC
survival NN I-OC
was VBD O
similar JJ O
( ( O
21 CD O
and CC O
22 CD O
months NNS O
for IN O
PLD NNP B-INTV
and CC O
doxorubicin NN B-INTV
, , O
respectively RB O
; : O
HR=0.94 NNP O
; : O
95 CD O
% NN O
CI NNP O
0.74-1.19 NN O
) ) O
. . O

Alopecia NNP B-OC
( ( O
overall JJ O
, , O
66 CD O
% NN O
versus IN O
20 CD O
% NN O
; : O
pronounced VBN O
, , O
54 CD O
% NN O
versus IN O
7 CD O
% NN O
) ) O
, , O
nausea NN B-OC
( ( O
53 CD O
% NN O
versus IN O
37 CD O
% NN O
) ) O
, , O
vomiting VBG B-OC
( ( O
31 CD O
% NN O
versus IN O
19 CD O
% NN O
) ) O
and CC O
neutropenia $ B-OC
( ( O
10 CD O
% NN O
versus IN O
4 CD O
% NN O
) ) O
were VBD O
more RBR O
often RB O
associated VBN O
with IN O
doxorubicin NN B-INTV
than IN O
PLD NNP B-INTV
. . O

Palmar-plantar NNP B-OC
erythrodysesthesia NN I-OC
( ( O
48 CD O
% NN O
versus IN O
2 CD O
% NN O
) ) O
, , O
stomatitis NN B-OC
( ( O
22 CD O
% NN O
versus IN O
15 CD O
% NN O
) ) O
and CC O
mucositis NN B-OC
( ( O
23 CD O
% NN O
versus IN O
13 CD O
% NN O
) ) O
were VBD O
more RBR O
often RB O
associated VBN O
with IN O
PLD NNP B-INTV
than IN O
doxorubicin NN B-INTV
. . O

CONCLUSIONS NNP O
In IN O
first-line JJ O
therapy NN O
for IN O
MBC NNP O
, , O
PLD NNP B-INTV
provides VBZ O
comparable JJ O
efficacy NN O
to TO O
doxorubicin VB B-INTV
, , O
with IN O
significantly RB O
reduced VBN O
cardiotoxicity NN B-OC
, , I-OC
myelosuppression NN I-OC
, , I-OC
vomiting VBG I-OC
and CC I-OC
alopecia NN I-OC
. . O

-DOCSTART- -X- O O

Chemotherapy NNP B-INTV
for IN O
patients NNS B-POPU
with IN I-POPU
non-small JJ I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
: : I-POPU
the DT O
surgical JJ O
setting NN O
of IN O
the DT O
Big NNP O
Lung NNP O
Trial NNP O
. . O

OBJECTIVES VB O
The DT O
non-small JJ B-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
NSCLC NNP I-POPU
) ) I-POPU
meta-analysis NN O
suggested VBD O
a DT O
survival JJ O
benefit NN O
for IN O
cisplatin-based JJ B-INTV
chemotherapy NN I-INTV
when WRB O
given VBN O
in IN O
addition NN O
to TO O
surgery NN B-INTV
, , O
radical JJ O
radiotherapy NN O
or CC O
'best JJS O
supportive JJ O
care NN O
' POS O
. . O

However RB O
, , O
it PRP O
included VBD O
many JJ O
small JJ O
trials NNS O
and CC O
trials NNS O
with IN O
differing VBG O
eligibility NN O
criteria NNS O
and CC O
chemotherapy NN O
regimens NNS O
. . O

The DT O
aim NN O
of IN O
the DT O
Big NNP O
Lung NNP O
Trial NNP O
was VBD O
therefore RB O
to TO O
run VB O
a DT O
large JJ O
pragmatic JJ O
trial NN O
to TO O
confirm VB O
the DT O
survival NN B-OC
benefits NNS I-OC
seen VBN O
in IN O
the DT O
meta-analysis NN O
. . O

METHODS NNP O
In IN O
the DT O
surgery NN B-INTV
setting NN O
, , O
a DT O
total NN O
of IN O
381 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
randomised VBN I-POPU
to TO I-POPU
chemotherapy VB I-POPU
( ( I-POPU
C NNP I-POPU
, , I-POPU
192 CD I-POPU
patients NNS I-POPU
) ) I-POPU
or CC I-POPU
no DT I-POPU
chemotherapy NN I-POPU
( ( I-POPU
NoC NNP I-POPU
, , I-POPU
189 CD I-POPU
patients NNS I-POPU
) ) I-POPU
. . O

C NNP O
was VBD O
three CD O
3-weekly JJ O
cycles NNS O
of IN O
cisplatin/vindesine NN B-INTV
, , I-INTV
mitomycin/ifosfamide/cisplatin NN I-INTV
, , I-INTV
mitomycin/vinblastine/cisplatin NN I-INTV
or CC I-INTV
vinorelbine/cisplatin NN I-INTV
. . O

RESULTS NNP O
Chemotherapy NNP B-INTV
was VBD O
given VBN O
before RB O
surgery NN B-INTV
in IN O
3 CD O
% NN O
of IN O
patients NNS O
whilst VBP O
97 CD O
% NN O
received VBD O
adjuvant JJ B-INTV
chemotherapy NN I-INTV
. . O

Baseline NNP O
characteristics NNS O
were VBD O
: : O
median JJ O
age NN O
61 CD O
years NNS O
, , O
69 CD O
% NN O
male NN O
, , O
48 CD O
% NN O
squamous JJ O
cell NN O
, , O
93 CD O
% NN O
WHO NNP O
PS NNP O
0-1 NNP O
, , O
27 CD O
% NN O
stage NN O
I PRP O
, , O
38 CD O
% NN O
stage NN O
II NNP O
, , O
and CC O
34 CD O
% NN O
stage NN O
III NNP O
. . O

Complete NNP B-OC
resection NN I-OC
was VBD O
achieved VBN O
in IN O
approximately RB O
95 CD O
% NN O
of IN O
patients NNS O
. . O

In IN O
the DT O
C NNP O
group NN O
, , O
13 CD O
% NN O
received VBD O
no DT B-INTV
chemotherapy NN I-INTV
, , O
21 CD O
% NN O
one CD O
or CC O
two CD O
cycles NNS O
, , O
and CC O
64 CD O
% NN O
all DT O
three CD O
cycles NNS O
of IN O
their PRP$ O
prescribed JJ O
chemotherapy NN B-INTV
( ( O
60 CD O
% NN O
of IN O
the DT O
latter NN O
with IN O
no DT O
delays NNS O
or CC O
modification NN O
) ) O
. . O

30 CD O
% NN O
had VBD O
grade VBN O
3/4 CD O
toxicity NN B-OC
, , I-OC
mainly RB I-OC
haematological JJ I-OC
, , I-OC
nausea/vomiting JJ I-OC
and CC I-OC
neutropenic JJ I-OC
fever NN I-OC
, , O
and CC O
six CD O
patients NNS O
were VBD O
reported VBN O
as IN O
having VBG O
a DT O
treatment-related JJ O
death NN B-OC
. . O

198 CD O
( ( O
52 CD O
% NN O
) ) O
of IN O
patients NNS O
have VBP O
died VBN O
, , O
but CC O
there EX O
is VBZ O
currently RB O
no DT O
evidence NN O
of IN O
a DT O
benefit NN B-OC
in IN I-OC
overall JJ I-OC
survival NN I-OC
to TO O
the DT O
C NNP O
group NN O
: : O
HR $ O
1.02 CD O
( ( O
95 CD O
% NN O
CI NNP O
0.77-1.35 NN O
) ) O
, , O
P NNP O
= NNP O
0.90 CD O
) ) O
. . O

CONCLUSIONS VB O
This DT O
trial NN O
has VBZ O
failed VBN O
to TO O
observe VB O
a DT O
survival JJ B-OC
benefit NN I-OC
with IN O
adjuvant JJ B-INTV
chemotherapy NN I-INTV
following VBG O
complete JJ O
resection NN O
of IN O
stage NN O
I-III JJ O
NSCLC NNP O
. . O

However RB O
, , O
the DT O
hazard NN O
ratio NN O
and CC O
95 CD O
% NN O
confidence NN O
intervals NNS O
are VBP O
consistent JJ O
with IN O
the DT O
previously RB O
reported VBN O
meta-analysis NN O
and CC O
two CD O
large JJ O
recently RB O
reported VBD O
trials NNS O
, , O
which WDT O
suggest VBP O
a DT O
small JJ O
survival NN O
benefit NN O
with IN O
cisplatin-based JJ B-INTV
chemotherapy NN I-INTV
. . O

-DOCSTART- -X- O O

[ JJ O
Comparison NNP O
of IN O
two CD O
methods NNS O
of IN O
local JJ B-INTV
anaesthesia NN I-INTV
prior RB O
to TO O
transrectal VB O
ultrasound-guided JJ O
prostate NN O
biopsies NNS O
] VBP O
. . O

OBJECTIVE NNP O
To TO O
compare VB O
the DT O
analgesic JJ O
efficacy NN O
of IN O
rectal JJ O
administration NN O
of IN O
Lidocaïne NNP B-INTV
gel NN I-INTV
with IN I-INTV
Lidocaïne NNP I-INTV
periprostatic JJ I-INTV
infiltration NN I-INTV
prior RB O
to TO O
transrectal VB O
ultrasound-guided JJ O
prostate NN O
biopsies NNS O
. . O

MATERIAL NNP O
AND CC O
METHODS NNP B-POPU
Between NNP I-POPU
July NNP I-POPU
2002 CD I-POPU
and CC I-POPU
July NNP I-POPU
2003 CD I-POPU
, , I-POPU
candidates NNS I-POPU
to TO I-POPU
prostate VB I-POPU
biopsies NNS I-POPU
were VBD O
randomised VBN O
into IN O
two CD O
groups NNS O
. . O

In IN O
group NN O
1 CD B-INTV
, , I-INTV
15 CD I-INTV
ml VBD I-INTV
2 CD I-INTV
% NN I-INTV
Lidocaïne NNP I-INTV
gel NN I-INTV
was VBD I-INTV
administered VBN O
intra-rectally RB O
10 CD O
minutes NNS O
prior RB O
to TO O
biopsies NNS O
and CC O
patients NNS O
included VBD O
in IN O
group NN O
2 CD O
received VBD O
10 CD O
ml NN O
of IN B-INTV
1 CD I-INTV
% NN I-INTV
Lidocaïne NNP I-INTV
in IN I-INTV
two CD I-INTV
périprostatique JJ I-INTV
equivalent JJ I-INTV
injections NNS I-INTV
, , O
4 CD O
minutes NNS O
prior RB O
to TO O
prostate VB O
biopsies NNS O
. . O

Pain NN O
was VBD O
assessed VBN O
with IN B-OC
a DT I-OC
Visual JJ I-OC
Analog NNP I-OC
Scale NNP I-OC
, , O
during IN O
anaesthesia NN O
( ( O
VAS NNP O
1 CD O
) ) O
, , O
during IN O
the DT O
biopsies NNS O
procedure NN O
( ( O
VAS NNP O
2 CD O
) ) O
and CC O
30 CD O
minutes NNS O
after IN O
them PRP O
( ( O
VAS NNP O
3 CD O
) ) O
. . O

RESULTS $ B-POPU
308 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
included VBN I-POPU
in IN I-POPU
this DT I-POPU
trial NN I-POPU
with IN I-POPU
156 CD I-POPU
patients NNS I-POPU
in IN I-POPU
group NN I-POPU
1 CD I-POPU
and CC I-POPU
152 CD I-POPU
in IN I-POPU
group NN I-POPU
2 CD O
. . O

Group NNP O
1 CD O
experienced VBD O
statistically RB O
less JJR O
pain NN B-OC
for IN I-OC
VAS NNP I-OC
1 CD O
( ( O
0.1 CD O
versus NN O
1.4 CD O
, , O
p NN O
< NNP O
0.0001 CD B-OC
) ) I-OC
and CC I-OC
VAS $ I-OC
3 CD O
( ( O
0.8 CD O
versus NN O
1.4 CD O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
but CC O
no DT O
significative JJ O
difference NN O
could MD O
be VB O
demonstrated VBN B-OC
for IN I-OC
VAS NNP I-OC
2 CD O
( ( O
1.8 CD O
versus IN O
2.0 CD B-OC
) ) I-OC
. . O

No DT B-OC
major JJ I-OC
complication NN I-OC
was VBD O
noted VBN O
. . O

CONCLUSION NNP O
Rectal NNP O
administration NN B-INTV
of IN I-INTV
Lidocaïne NNP I-INTV
gel NN O
and CC O
infiltration NN B-INTV
of IN I-INTV
Lidocaïne NNP I-INTV
lead NN O
to TO O
a DT O
comparable JJ O
level NN O
of IN O
anaesthesia NN O
during IN O
prostatic JJ O
biopsies NNS O
procedure NN O
. . O

However RB B-INTV
, , I-INTV
the DT I-INTV
Lidocaïne NNP I-INTV
gel NN O
, , O
being VBG O
both DT O
safe JJ O
and CC O
simple JJ O
, , O
tends VBZ O
to TO O
maintain VB O
a DT O
better JJR O
comfort NN O
of IN O
the DT O
patient NN O
30 CD O
minutes NNS O
after IN O
the DT O
end NN O
of IN O
the DT O
biopsies NNS O
. . O

-DOCSTART- -X- O O

Untreated VBN B-POPU
silicone NN I-POPU
breast NN I-POPU
implant JJ I-POPU
rupture NN I-POPU
. . O

Implant JJ O
rupture NN O
is VBZ O
a DT O
well-known JJ O
complication NN O
of IN O
breast NN O
implant NN O
surgery NN O
that WDT O
can MD O
pass VB O
unnoticed JJ O
by IN O
both DT O
patient NN O
and CC O
physician NN O
. . O

To TO O
date NN O
, , O
no DT O
prospective JJ O
study NN O
has VBZ O
addressed VBN O
the DT O
possible JJ O
health NN O
implications NNS O
of IN O
silicone NN O
breast NN O
implant JJ O
rupture NN O
. . O

The DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
evaluate VB O
whether IN O
untreated JJ O
ruptures NNS O
are VBP O
associated VBN O
with IN O
changes NNS O
over IN O
time NN O
in IN O
magnetic JJ O
resonance NN O
imaging NN O
findings NNS O
, , O
serologic JJ O
markers NNS O
, , O
or CC O
self-reported JJ O
breast NN O
symptoms NNS O
. . O

A DT O
baseline JJ O
magnetic JJ O
resonance NN O
imaging VBG O
examination NN O
was VBD O
performed VBN O
in IN O
1999 CD O
on IN O
271 CD B-POPU
women NNS I-POPU
who WP I-POPU
were VBD I-POPU
randomly RB I-POPU
chosen VBN I-POPU
from IN I-POPU
a DT I-POPU
larger JJR I-POPU
cohort NN I-POPU
of IN I-POPU
women NNS I-POPU
having VBG I-POPU
cosmetic JJ I-POPU
breast NN I-POPU
implants NNS I-POPU
for IN I-POPU
a DT I-POPU
median JJ I-POPU
period NN I-POPU
of IN I-POPU
12 CD I-POPU
years NNS I-POPU
( ( I-POPU
range NN I-POPU
, , I-POPU
3 CD I-POPU
to TO I-POPU
25 CD I-POPU
years NNS I-POPU
) ) I-POPU
. . O

A DT O
follow-up JJ O
magnetic JJ O
resonance NN O
imaging VBG O
examination NN O
was VBD O
carried VBN O
out RP O
in IN O
2001 CD O
, , O
excluding VBG O
women NNS O
who WP O
underwent JJ O
explantation NN O
in IN O
the DT O
period NN O
between IN O
the DT O
two CD O
magnetic JJ O
resonance NN O
imaging NN O
examinations NNS O
( ( O
n JJ O
= NNP O
44 CD O
) ) O
. . O

On IN O
the DT O
basis NN O
of IN O
these DT O
examinations NNS O
, , O
the DT O
authors NNS O
identified VBD O
64 CD B-POPU
women NNS I-POPU
who WP I-POPU
had VBD I-POPU
at IN I-POPU
least JJS I-POPU
one CD I-POPU
ruptured VBN I-POPU
implant NN I-POPU
at IN I-POPU
the DT I-POPU
first JJ I-POPU
magnetic JJ I-POPU
resonance NN I-POPU
imaging VBG I-POPU
examination NN I-POPU
and CC O
, , O
for IN O
comparison NN O
, , O
all DT O
women NNS O
who WP O
had VBD O
intact JJ O
implants NNS O
at IN O
both DT O
examinations NNS O
( ( O
n JJ O
= NNP O
98 CD O
) ) O
. . O

Magnetic JJ O
resonance NN O
images NNS O
from IN O
the DT O
two CD O
examinations NNS O
were VBD O
compared VBN O
and CC O
changes NNS O
in IN O
rupture NN O
configuration NN O
were VBD O
evaluated VBN O
. . O

Comparisons NNS O
were VBD O
also RB O
made VBN O
for IN O
self-reported JJ O
breast NN O
symptoms NNS O
occurring VBG O
during IN O
the DT O
study NN O
period NN O
and CC O
for IN O
changes NNS O
in IN O
serum NN O
values NNS O
of IN O
antinuclear JJ O
antibodies NNS O
, , O
rheumatoid JJ O
factor NN O
, , O
and CC O
cardiolipin NN O
antibodies NNS O
immunoglobulin VBP O
G NNP O
and CC O
immunoglobulin NN O
M. NNP O
The DT O
majority NN O
of IN O
the DT O
women NNS O
with IN O
implant JJ O
rupture NN O
had VBD O
no DT O
visible JJ O
magnetic JJ B-OC
resonance NN I-OC
imaging NN I-OC
changes NNS I-OC
of IN O
their PRP$ O
ruptured JJ O
implants NNS O
. . O

For IN O
11 CD O
implants NNS O
( ( O
11 CD O
percent NN O
) ) O
in IN O
10 CD O
women NNS O
, , O
the DT O
authors NNS O
observed VBD O
progression NN O
of IN O
silicone NN B-OC
seepage NN I-OC
, , O
either RB O
as IN O
a DT O
conversion NN O
from IN O
intracapsular JJ O
into IN O
extracapsular JJ O
rupture NN O
( ( O
n JJ O
= NNP O
7 CD O
) ) O
, , O
as IN O
progression NN O
of IN O
extra-capsular JJ O
silicone NN O
( ( O
n JJ O
= NNP O
3 CD O
) ) O
, , O
or CC O
as IN O
increasing VBG O
herniation NN B-OC
of IN I-OC
the DT I-OC
silicone NN I-OC
within IN I-OC
the DT I-OC
fibrous JJ I-OC
capsule NN I-OC
( ( O
n JJ O
= NNP O
1 CD O
) ) O
; : O
however RB O
, , O
in IN O
most JJS O
cases NNS O
, , O
these DT O
changes NNS O
were VBD O
minor JJ O
. . O

Some DT O
changes NNS O
could MD O
be VB O
ascribed VBN O
to TO O
trauma VB O
, , O
but CC O
others NNS O
seemed VBD O
spontaneous JJ O
. . O

There EX O
was VBD O
no DT O
increase NN O
in IN O
levels NNS B-OC
of IN I-OC
autoantibodies NNS I-OC
during IN O
the DT O
study NN O
period NN O
in IN O
either DT O
study NN O
group NN O
. . O

Women NNS O
with IN O
untreated JJ O
implant NN B-INTV
ruptures NNS I-INTV
reported VBD O
a DT O
significant JJ O
increase NN O
in IN O
nonspecific JJ B-OC
breast NN I-OC
changes NNS I-OC
( ( O
odds NNS O
ratio NN O
, , O
2.1 CD O
; : O
95 CD O
percent NN O
confidence NN O
interval NN O
, , O
1.2 CD O
to TO O
3.8 CD O
) ) O
compared VBN O
with IN O
women NNS O
without IN O
ruptures NNS O
. . O

On IN O
the DT O
basis NN O
of IN O
this DT O
first JJ O
study NN O
of IN O
women NNS O
with IN O
untreated JJ O
silicone NN O
breast NN O
implant JJ O
rupture NN O
, , O
the DT O
authors NNS O
conclude VBP O
that IN O
implant JJ O
rupture NN O
is VBZ O
a DT O
relatively RB O
harmless JJ O
condition NN O
, , O
which WDT O
only RB O
rarely RB O
progresses VBZ O
and CC O
gives VBZ O
rise NN O
to TO O
notable JJ O
symptoms NNS O
. . O

Even RB O
so RB O
, , O
because IN O
of IN O
a DT O
small JJ O
risk NN O
of IN O
silicone NN O
spread NN O
, , O
the DT O
authors NNS O
suggest VBP O
that IN O
women NNS O
with IN O
implant JJ O
ruptures NNS O
be VB O
followed VBN O
clinically RB O
, , O
if IN O
not RB O
operated VBN O
on IN O
. . O

Because IN O
implant JJ O
ruptures NNS O
often RB O
occur VBP O
asymptomatically RB O
, , O
any DT O
woman NN O
with IN O
silicone NN O
implants NNS O
, , O
regardless RB O
of IN O
rupture NN O
status NN O
, , O
should MD O
be VB O
evaluated VBN O
at IN O
regular JJ O
intervals NNS O
. . O

-DOCSTART- -X- O O

A DT O
randomised JJ O
comparison NN O
of IN O
UK NNP B-POPU
genetic JJ I-POPU
risk NN I-POPU
counselling NN I-POPU
services NNS I-POPU
for IN I-POPU
familial JJ I-POPU
cancer NN I-POPU
: : I-POPU
psychosocial JJ B-OC
outcomes NNS I-OC
. . O

The DT O
aim NN O
of IN O
the DT O
study NN O
was VBD O
to TO O
compare VB O
psychosocial JJ B-OC
outcomes NNS I-OC
for IN O
50 CD B-POPU
new JJ I-POPU
clinic JJ I-POPU
attendees NNS I-POPU
, , I-POPU
referred VBD I-POPU
for IN I-POPU
cancer NN I-POPU
genetic JJ I-POPU
counselling NN I-POPU
to TO I-POPU
five CD I-POPU
UK NNP I-POPU
centres NNS I-POPU
. . O

The DT B-POPU
centres NNS I-POPU
represented VBD I-POPU
England NNP I-POPU
, , I-POPU
Scotland NNP I-POPU
and CC I-POPU
Wales NNP I-POPU
, , I-POPU
and CC I-POPU
were VBD I-POPU
randomly RB I-POPU
selected VBN I-POPU
from IN I-POPU
groups NNS I-POPU
ranked VBN I-POPU
by IN I-POPU
different JJ I-POPU
levels NNS I-POPU
of IN I-POPU
clinical JJ I-POPU
activity NN I-POPU
in IN I-POPU
cancer NN I-POPU
genetics NNS I-POPU
practice NN I-POPU
. . O

Questionnaires NNS O
assessed VBD O
demographic JJ B-OC
data NNS I-OC
, , I-OC
risk NN I-OC
perception NN I-OC
, , I-OC
mental JJ I-OC
health NN I-OC
and CC I-OC
use NN I-OC
of IN I-OC
health NN I-OC
services NNS I-OC
pre-consultation NN I-OC
and CC O
at IN O
1 CD O
and CC O
12 CD O
months NNS O
follow-up RB O
. . O

Satisfaction NN B-OC
was VBD O
measured VBN O
for IN O
attendees NNS O
and CC O
referring VBG O
doctors NNS O
at IN O
follow-up NN O
. . O

A DT B-POPU
total NN I-POPU
of IN I-POPU
256 CD I-POPU
unaffected JJ I-POPU
adults NNS I-POPU
fulfilled VBD I-POPU
the DT I-POPU
study NN I-POPU
criteria NNS I-POPU
. . O

The DT O
five CD O
centres NNS O
varied VBD O
widely RB O
with IN O
respect NN O
to TO O
service NN O
organisation NN O
and CC O
activity NN O
, , O
but CC O
all DT O
had VBD O
a DT O
greater JJR O
proportion NN O
of IN O
unaffected JJ O
attendees NNS O
with IN O
a DT O
breast NN O
cancer NN O
risk NN O
( ( O
61-91 CD O
% NN O
) ) O
than IN O
either CC O
a DT O
bowel NN O
cancer NN O
risk NN O
( ( O
0-33 CD O
% NN O
) ) O
or CC O
ovarian JJ O
cancer NN O
risk NN O
( ( O
3-25 CD O
% NN O
) ) O
. . O

There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
the DT O
psychosocial JJ B-OC
data NN I-OC
between IN O
centres NNS O
pre-counselling VBG B-INTV
. . O

No DT O
significant JJ O
change NN O
over IN O
time NN O
occurred VBN O
for IN O
any DT O
of IN O
the DT O
centres NNS O
for IN O
risk NN B-OC
perception NN I-OC
or CC I-OC
general JJ I-OC
psychological JJ I-OC
distress NN I-OC
. . O

There EX O
were VBD O
significant JJ O
differences NNS O
between IN O
centres NNS O
in IN O
reduction NN O
of IN O
cancer NN B-OC
worry NN O
from IN O
baseline NN O
to TO O
12 CD O
months NNS O
and CC O
with IN O
the DT O
number NN O
of IN O
women NNS O
who WP O
were VBD O
recommended VBN O
to TO O
have VB O
mammographic JJ O
surveillance NN O
who WP O
had VBD O
not RB O
received VBN O
this DT O
. . O

Overall JJ O
, , O
one-third JJ O
of IN O
women NNS O
for IN O
whom WP O
mammography NN O
had VBD O
been VBN O
recommended VBN O
had VBD O
not RB O
been VBN O
screened VBN O
within IN O
1 CD O
year NN O
of IN O
follow-up NN O
. . O

Subsequent JJ O
attendance NN O
at IN O
the DT O
GP NNP O
, , O
but CC O
not RB O
at IN O
a DT O
hospital NN O
, , O
was VBD O
associated VBN O
with IN O
risk NN O
level NN O
, , O
but CC O
differences NNS O
between IN O
centres NNS O
could MD O
not RB O
be VB O
analysed VBN O
. . O

Satisfaction NN B-OC
differed VBD O
significantly RB O
between IN O
centres NNS O
for IN O
4 CD O
: : O
14 CD O
aspects NNS O
of IN O
service NN O
provision NN O
and CC O
with IN O
3 CD O
: : O
17 CD O
items NNS O
concerning VBG O
communication NN O
; : O
satisfaction NN O
was VBD O
high JJ O
overall JJ O
. . O

Over IN O
90 CD O
% NN O
of IN O
referring VBG O
doctors NNS O
were VBD O
moderately/very RB O
satisfied VBN O
with IN O
the DT O
service NN O
, , O
but CC O
23 CD O
% NN O
were VBD O
dissatisfied VBN O
with IN O
waiting VBG O
times NNS O
and CC O
19 CD O
% NN O
with IN O
access NN O
to TO O
preventive VB O
treatment NN O
. . O

Results NNS O
differed VBD O
significantly RB O
between IN O
centres NNS O
for IN O
doctor NN O
's POS O
satisfaction NN O
with IN O
the DT O
provision NN O
of IN O
referral JJ O
criteria NNS O
and CC O
prescribing VBG O
information NN O
. . O

In IN O
conclusion NN O
, , O
there EX O
were VBD O
relatively RB O
few JJ O
significant JJ O
differences NNS O
in IN O
psychosocial JJ B-OC
outcomes NNS I-OC
between IN O
centres NNS O
, , O
considering VBG O
the DT O
wide JJ O
variation NN O
in IN O
service NN O
organisation NN O
and CC O
activity NN O
. . O

These DT O
significant JJ O
differences NNS O
were VBD O
not RB O
consistent JJ O
across IN O
the DT O
centres NNS O
, , O
therefore RB O
, , O
differences NNS O
could MD O
not RB O
be VB O
linked VBN O
to TO O
specific JJ O
aspects NNS O
of IN O
service NN O
provision NN O
. . O

-DOCSTART- -X- O O

Enhanced NNP O
induction NN B-OC
of IN O
apoptosis NN O
in IN O
lung NN B-POPU
adenocarcinoma NN I-POPU
after IN O
preoperative JJ O
chemotherapy NN O
with IN O
tegafur NN B-INTV
and CC O
uracil NN B-INTV
( ( O
UFT NNP O
) ) O
. . O

PURPOSE NN O
To TO O
determine VB O
if IN O
the DT O
preoperative JJ O
administration NN O
of IN O
tegafur NN B-INTV
and CC I-INTV
uracil NN I-INTV
( ( I-INTV
UFT NNP I-INTV
) ) I-INTV
to TO O
patients NNS B-POPU
with IN I-POPU
lung NN I-POPU
adenocarcinoma NN I-POPU
could MD O
induce VB O
apoptosis NN O
. . O

METHODS NNP O
We PRP O
conducted VBD O
a DT O
randomized JJ O
prospective JJ B-POPU
study NN I-POPU
on IN I-POPU
30 CD I-POPU
patients NNS I-POPU
with IN I-POPU
lung NN I-POPU
adenocarcinoma NN I-POPU
, , I-POPU
divided VBN I-POPU
into IN I-POPU
two CD I-POPU
groups NNS I-POPU
of IN I-POPU
15 CD I-POPU
patients NNS I-POPU
each DT I-POPU
. . O

One CD O
group NN O
received VBD O
UFT NNP O
600 CD O
mg/day NN O
preoperatively RB O
for IN O
7 CD O
consecutive JJ O
days NNS O
and CC O
a DT O
control NN O
group NN O
received VBD O
no DT B-INTV
chemotherapy NN I-INTV
or CC I-INTV
radiotherapy NN I-INTV
. . O

The DT O
apoptotic JJ B-OC
index NN I-OC
( ( I-OC
AI NNP I-OC
) ) I-OC
was VBD O
determined VBN O
by IN O
the DT O
terminal JJ O
deoxynucleotidyl NN O
transferase-mediated JJ B-OC
deoxyuridine NN I-OC
triphosphate NN I-OC
biotin NN I-OC
nick JJ I-OC
end-labeling NN I-OC
( ( I-OC
TUNEL NNP I-OC
) ) I-OC
method NN O
. . O

Expression NN B-OC
of IN I-OC
Ki-67 NNP I-OC
was VBD O
examined VBN O
by IN O
immunohistochemical JJ B-OC
staining NN I-OC
. . O

The DT O
concentration NN B-OC
of IN I-OC
5-fluorouracil JJ I-OC
( ( I-OC
5-FU JJ I-OC
) ) I-OC
in IN I-OC
tumor NN I-OC
tissue NN I-OC
was VBD I-OC
measured VBN I-OC
by IN I-OC
chemical NN I-OC
assay NN I-OC
. . O

RESULTS VB O
The DT O
AI NNP B-OC
of IN I-OC
lung NN I-OC
adenocarcinoma NN I-OC
cells NNS I-OC
increased VBD O
significantly RB O
in IN O
the DT O
UFT-treated JJ O
group NN O
but CC O
not RB O
in IN O
the DT O
control NN O
group NN O
. . O

A DT O
significant JJ O
positive JJ O
correlation NN O
was VBD O
seen VBN O
between IN O
the DT O
AI NNP B-OC
and CC I-OC
the DT I-OC
5-FU JJ I-OC
concentrations NNS I-OC
in IN O
the DT O
tumor NN O
tissue NN O
. . O

CONCLUSIONS VB O
The DT O
continuous JJ O
oral JJ O
administration NN O
of IN O
UFT NNP O
for IN O
7 CD O
days NNS O
preoperatively RB O
resulted VBD O
in IN O
enhanced JJ O
apoptosis NN B-OC
and CC O
a DT O
significant JJ O
positive JJ O
correlation NN O
between IN O
the DT O
AI NNP B-OC
and CC I-OC
5-FU JJ I-OC
concentrations NNS O
in IN O
lung NN O
adenocarcinoma NN O
. . O

Therefore RB O
, , O
it PRP O
may MD O
be VB O
possible JJ O
to TO O
evaluate VB O
the DT O
effects NNS O
of IN O
adjuvant JJ O
chemotherapy NN O
based VBN O
on IN O
the DT O
AI NNP O
. . O

-DOCSTART- -X- O O

The DT O
relationship NN O
of IN O
changes NNS O
in IN O
EORTC NNP O
QLQ-C30 NNP O
scores NNS O
to TO O
ratings NNS O
on IN O
the DT O
Subjective JJ B-OC
Significance NNP I-OC
Questionnaire NNP B-INTV
in IN O
men NNS B-POPU
with IN I-POPU
localized JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
To TO O
examine VB O
the DT O
relationship NN O
between IN O
changes NNS B-OC
in IN O
health-related JJ B-OC
quality-of-life NN I-OC
( ( B-INTV
HRQOL NNP I-INTV
) ) I-INTV
on IN I-INTV
the DT I-INTV
EORTC NNP I-INTV
Quality NNP I-INTV
of IN I-INTV
Life NNP I-INTV
Questionnaire NNP I-INTV
( ( I-INTV
QLQ-C30 NNP I-INTV
) ) I-INTV
, , O
and CC O
patients NNS O
' POS O
perceptions NNS O
of IN O
HRQOL NNP O
changes NNS O
as IN O
measured VBN O
by IN O
the DT O
Subjective NNP B-INTV
Significance NNP I-INTV
Questionnaire NNP I-INTV
( ( I-INTV
SSQ NNP I-INTV
) ) I-INTV
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
101 CD I-POPU
patients NNS I-POPU
completed VBD O
the DT O
QLQ-C30 NNP B-INTV
on IN O
weeks NNS O
1 CD O
, , O
4 CD O
and CC O
7 CD O
of IN O
radical JJ B-POPU
external-beam NN I-POPU
radiation NN I-POPU
therapy NN I-POPU
( ( I-POPU
RT NNP I-POPU
) ) I-POPU
for IN I-POPU
localized JJ I-POPU
cancer NN I-POPU
of IN I-POPU
the DT I-POPU
prostate NN I-POPU
. . O

Patients NNS O
rated VBD O
their PRP$ O
change NN O
in IN O
physical JJ B-OC
functioning NN I-OC
, , I-OC
emotional JJ I-OC
functioning NN I-OC
, , I-OC
social JJ I-OC
functioning NN I-OC
, , I-OC
and CC I-OC
overall/global JJ I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
( ( I-OC
QOL NNP I-OC
) ) I-OC
by IN I-OC
completing VBG I-OC
a DT I-OC
seven-category JJ I-OC
SSQ NNP B-INTV
at IN O
weeks NNS O
4 CD O
and CC O
7 CD O
. . O

The DT O
association NN O
between IN O
changes NNS O
in IN O
the DT O
QLQ-C30 JJ O
change NN O
and CC O
the DT O
corresponding JJ O
SSQ NNP B-INTV
ratings NNS O
were VBD O
determined VBN O
by IN O
calculation NN O
of IN O
mean JJ O
change NN O
scores NNS O
for IN O
each DT O
SSQ NNP B-INTV
category NN O
and CC O
by IN O
Spearman NNP O
rank NN O
correlation NN O
coefficient NN O
analysis NN O
. . O

RESULTS JJ O
Patients NNPS O
' POS O
completion NN O
of IN O
the DT O
QLQ-C30 NNP O
and CC O
SSQ NNP B-INTV
exceeded VBD O
95 CD O
% NN O
. . O

Statistically NNP O
significant JJ O
changes NNS O
in IN O
fatigue NN B-OC
, , I-OC
pain NN I-OC
, , I-OC
appetite NN I-OC
, , I-OC
diarrhea NN I-OC
, , I-OC
and CC I-OC
global JJ I-OC
QOL NNP I-OC
scores NNS I-OC
were VBD O
detected VBN O
during IN O
RT NNP O
. . O

For IN O
patients NNS O
reporting VBG O
'a JJ O
little JJ O
' POS O
change NN O
in IN O
global JJ B-OC
QOL NNP I-OC
on IN O
the DT O
SSQ NNP B-INTV
, , O
absolute JJ O
mean JJ O
QLQ-C30 JJ O
change NN O
scores NNS O
ranged VBD O
between IN O
0 CD O
to TO O
15 CD O
points NNS O
with IN O
12/16 CD O
mean JJ O
change NN O
scores NNS O
between IN O
2.5 CD O
and CC O
8.5 CD O
points NNS O
. . O

In IN O
the DT O
entire JJ O
study NN O
sample NN O
, , O
correlations NNS O
between IN O
SSQ NNP B-INTV
patient JJ O
ratings NNS O
and CC O
QLQ-C30 JJ B-OC
change NN I-OC
scores NNS I-OC
were VBD O
lower JJR O
than IN O
previously RB O
reported VBN O
, , O
ranging VBG O
between IN O
0.15 CD O
and CC O
0.24 CD O
for IN O
the DT O
four CD O
different JJ O
domains NNS O
, , O
but CC O
were VBD O
higher JJR O
when WRB O
QOL NNP B-OC
scores VBZ I-OC
producing VBG O
ceiling NN O
effects NNS O
were VBD O
omitted VBN O
. . O

CONCLUSION VB O
The DT O
SSQ NNP B-INTV
and CC O
QLQ-C30 NNP B-INTV
may MD O
measure VB O
related JJ O
concepts NNS O
that WDT O
could MD O
assist VB O
in IN O
the DT O
interpretation NN O
of IN O
changes NNS O
in IN O
scores NNS O
and CC O
in IN O
the DT O
calibration NN O
of IN O
the DT O
QLQ-C30 NNP B-INTV
. . O

However RB O
, , O
the DT O
nature NN O
of IN O
this DT O
relationship NN O
could MD O
not RB O
be VB O
elucidated VBN O
in IN O
this DT O
data NN O
set NN O
because IN O
of IN O
a DT O
lack NN O
of IN O
variance NN O
in IN O
HRQOL NNP O
scores NNS O
in IN O
the DT O
study NN O
sample NN O
. . O

Further JJ O
investigation NN O
should MD O
be VB O
carried VBN O
out RP O
in IN O
study NN O
samples NNS O
with IN O
sufficient JJ O
variance NN O
to TO O
allow VB O
more JJR O
robust JJ O
conclusions NNS O
. . O

-DOCSTART- -X- O O

Neridronate NNP B-INTV
prevents NNS O
bone NN B-OC
loss NN I-OC
in IN O
patients NNS B-POPU
receiving VBG I-POPU
androgen JJ I-POPU
deprivation NN I-POPU
therapy NN I-POPU
for IN I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

UNLABELLED VBN O
Today NN O
, , O
androgen NN B-INTV
deprivation NN I-INTV
therapy NN I-INTV
is VBZ O
a DT O
cornerstone NN O
of IN O
treatment NN O
for IN O
advanced JJ B-POPU
prostate NN I-POPU
cancer NN I-POPU
, , O
although IN O
it PRP O
presents VBZ O
important JJ O
complications NNS O
such JJ O
as IN O
osteoporosis NN B-OC
. . O

Neridronate NNP B-INTV
, , I-INTV
a DT I-INTV
relatively RB I-INTV
new JJ I-INTV
bisphosphonate NN I-INTV
, , O
is VBZ O
able JJ O
to TO O
prevent VB O
bone NN B-OC
loss NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
prostate JJ I-POPU
cancer NN I-POPU
during IN I-POPU
androgen JJ I-POPU
ablation NN I-POPU
. . O

INTRODUCTION NNP O
Androgen-deprivation NNP O
therapy NN O
( ( O
ADT NNP O
) ) O
is VBZ O
a DT O
cornerstone NN O
of IN O
treatment NN O
for IN O
advanced JJ B-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

This DT O
therapy NN O
has VBZ O
iatrogenic JJ O
complications NNS O
, , O
such JJ O
as IN O
osteoporosis NN O
. . O

The DT O
aim NN O
of IN O
our PRP$ O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
efficacy NN B-OC
of IN O
neridronate NN O
, , O
a DT O
relatively RB O
new JJ O
bisphosphonate NN O
, , O
to TO O
prevent VB O
bone JJ O
loss NN O
during IN O
androgen JJ O
ablation NN O
. . O

MATERIALS NNP O
AND CC O
METHODS NNP O
Forty-eight NNP B-POPU
osteoporotic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
prostate JJ I-POPU
cancer NN I-POPU
, , I-POPU
treated VBN I-POPU
with IN I-POPU
3-month JJ I-POPU
depot NN I-POPU
triptorelina NN I-POPU
, , O
were VBD O
enrolled VBN O
and CC O
randomly RB O
assigned VBN O
to TO O
two CD O
different JJ O
treatment NN O
groups NNS O
: : O
group NN O
A NNP O
( ( B-POPU
n JJ I-POPU
= NNP I-POPU
24 CD I-POPU
) ) I-POPU
was VBD O
treated VBN O
with IN O
a DT O
daily JJ B-INTV
calcium NN I-INTV
and CC I-INTV
cholecalciferol NN I-INTV
supplement NN I-INTV
( ( O
500 CD O
mg NN O
of IN O
elemental JJ O
calcium NN O
and CC O
400 CD O
IU NNP O
cholecalciferol NN O
) ) O
, , O
and CC O
group NN O
B NNP O
( ( B-POPU
n JJ I-POPU
= NNP I-POPU
24 CD I-POPU
) ) I-POPU
received VBN O
in IN O
addition NN O
to TO O
the DT O
same JJ O
daily JJ B-INTV
calcium NN I-INTV
and CC I-INTV
cholecalciferol NN I-INTV
supplement NN I-INTV
, , O
25 CD O
mg NN O
of IN O
neridronate JJ B-INTV
given VBN O
intramuscularly RB O
every DT O
month NN O
. . O

All DT O
patients NNS O
also RB O
received VBD O
bicalutamide RB B-INTV
for IN O
4 CD O
weeks NNS O
. . O

Lumbar NNP B-OC
and CC I-OC
femoral JJ I-OC
BMD NNP I-OC
was VBD O
evaluated VBN O
by IN O
DXA NNP O
at IN O
baseline NN O
and CC O
after IN O
1 CD O
year NN O
of IN O
therapy NN O
; : O
moreover CC O
, , O
deoxypyridinoline NN B-OC
( ( I-OC
DPD NNP I-OC
) ) I-OC
and CC I-OC
bone $ I-OC
alkaline JJ I-OC
phosphatase NN I-OC
( ( I-OC
BALP NNP I-OC
) ) I-OC
were VBD O
determined VBN O
at IN O
the DT O
beginning NN O
, , O
midway RB O
through IN O
, , O
and CC O
at IN O
the DT O
end NN O
of IN O
the DT O
study NN O
. . O

RESULTS NNP O
After IN O
6 CD O
and CC O
12 CD O
months NNS O
, , O
whereas JJ O
patients NNS O
treated VBD O
only RB O
with IN O
calcium NN O
and CC O
cholecalciferol NN O
( ( O
group NN O
A NNP O
) ) O
showed VBD O
a DT O
marked JJ B-OC
bone NN I-OC
loss NN I-OC
, , O
with IN O
increased JJ B-OC
levels NNS I-OC
of IN I-OC
DPD NNP I-OC
and CC I-OC
BALP NNP I-OC
compared VBN O
with IN O
baseline NN O
values NNS O
, , O
patients NNS O
treated VBD O
also RB O
with IN O
neridronate NN O
( ( O
group NN O
B NNP O
) ) O
had VBD O
substantially RB O
unchanged JJ O
levels NNS O
of IN O
these DT O
markers NNS O
. . O

After IN O
1 CD O
year NN O
of IN O
treatment NN O
, , O
lumbar NN B-OC
and CC I-OC
total JJ I-OC
hip NN I-OC
BMD NNP I-OC
decreased VBD I-OC
significantly RB I-OC
in IN O
patients NNS O
treated VBN O
only RB O
with IN O
calcium NN O
and CC O
cholecalciferol NN O
( ( O
group NN O
A NNP O
) ) O
, , O
whereas IN O
it PRP O
did VBD O
not RB O
change VB B-OC
significantly RB I-OC
at IN O
any DT O
skeletal JJ O
site NN O
in IN O
patients NNS O
treated VBN O
also RB O
with IN O
neridronate NN O
( ( O
group NN O
B NNP O
) ) O
. . O

No DT O
relevant JJ B-OC
side NN I-OC
effects NNS I-OC
were VBD O
recorded VBN O
during IN O
our PRP$ O
study NN O
. . O

CONCLUSIONS NNP O
Neridronate NNP B-INTV
is VBZ O
an DT O
effective JJ O
treatment NN O
in IN O
preventing VBG O
bone NN B-OC
loss NN I-OC
in IN O
the DT O
hip NN O
and CC O
lumbar NN O
spine NN O
in IN O
men NNS B-POPU
receiving VBG I-POPU
ADT NNP I-POPU
for IN I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

-DOCSTART- -X- O O

Reducing VBG O
blood NN B-OC
loss NN I-OC
at IN O
open JJ B-POPU
myomectomy NN I-POPU
using VBG O
triple JJ B-INTV
tourniquets NNS I-INTV
: : I-INTV
a DT O
randomised JJ O
controlled VBN O
trial NN O
. . O

OBJECTIVES UH O
To TO O
evaluate VB O
triple JJ B-INTV
tourniquets NNS I-INTV
in IN O
controlled JJ O
conditions NNS O
and CC O
for IN O
the DT O
first JJ O
time NN O
to TO O
investigate VB O
the DT O
hypothesis NN O
that IN O
leaving VBG O
a DT O
semi-permanent JJ O
tourniquet NN O
around IN O
the DT O
uterine JJ O
artery NN O
reduces VBZ O
post-operative JJ O
bleeding NN O
from IN O
the DT O
uterine JJ O
incisions NNS O
. . O

DESIGN VB O
A DT O
randomised JJ O
controlled VBN O
trial NN O
. . O

SETTING NN O
Two CD B-POPU
University NNP I-POPU
teaching NN I-POPU
hospitals NNS I-POPU
. . O

POPULATION NNP O
Twenty-eight JJ B-POPU
patients NNS I-POPU
with IN I-POPU
symptomatic JJ I-POPU
fibroids NNS I-POPU
and CC I-POPU
uterine JJ I-POPU
sizes NNS I-POPU
ranging VBG I-POPU
from IN I-POPU
14 CD I-POPU
to TO I-POPU
24 CD I-POPU
weeks NNS I-POPU
of IN I-POPU
gestation NN I-POPU
undergoing VBG I-POPU
open JJ I-POPU
myomectomy NN I-POPU
. . O

METHODS NNP O
A NNP O
number NN B-INTV
1 CD I-INTV
polyglactin JJ I-INTV
suture NN I-INTV
was VBD I-INTV
tied VBN I-INTV
around IN I-INTV
the DT I-INTV
cervix NN I-INTV
to TO I-INTV
occlude VB I-INTV
the DT I-INTV
uterine JJ I-INTV
arteries NNS I-INTV
, , O
and CC O
polythene JJ B-INTV
tourniquets NNS I-INTV
were VBD I-INTV
tied VBN I-INTV
around IN I-INTV
the DT I-INTV
infundibulopelvic JJ I-INTV
ligament NN I-INTV
to TO I-INTV
obstruct VB I-INTV
the DT I-INTV
ovarian JJ I-INTV
vessels NNS I-INTV
. . O

At IN O
the DT O
end NN O
of IN O
the DT O
procedure NN O
, , O
the DT O
ovarian JJ O
ties NNS O
were VBD O
released VBN O
but CC O
the DT O
uterine JJ O
artery NN O
suture NN O
remained VBD O
in IN O
situ NN O
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
Intra-operative JJ B-OC
blood NN I-OC
loss NN I-OC
, , I-OC
post-operative JJ I-OC
blood NN I-OC
loss NN I-OC
, , I-OC
blood NN I-OC
transfusion NN I-OC
rates NNS I-OC
, , I-OC
operative JJ I-OC
morbidity NN I-OC
, , I-OC
uterine JJ I-OC
blood NN I-OC
flow NN I-OC
and CC I-OC
ovarian JJ I-OC
function NN I-OC
. . O

RESULTS NNP O
There EX O
was VBD O
significantly RB O
less JJR B-OC
blood NN I-OC
lost VBN I-OC
in IN O
the DT O
tourniquet NN O
group NN O
than IN O
in IN O
the DT O
control NN O
group NN O
( ( O
difference NN O
between IN O
means NNS O
1870 CD O
mL NN O
, , O
95 CD O
% NN O
CI NNP O
1159-2580 CD O
mL NN O
, , O
P NNP O
< NNP O
0.0001 CD O
; : O
transfusion NN O
rates NNS O
of IN O
7 CD O
% NN O
and CC O
79 CD O
% NN O
, , O
P= NNP O
0.0003 CD O
) ) O
. . O

The DT O
volume NN B-OC
in IN I-OC
the DT I-OC
pelvic JJ I-OC
drain NN I-OC
20 CD O
min NN O
post-operatively RB O
and CC O
after IN O
48 CD O
hours NNS O
failed VBD O
to TO O
reach VB O
statistical JJ O
significance NN O
between IN O
the DT O
two CD O
groups NNS O
( ( O
P= NNP O
0.10 CD O
and CC O
P= NNP O
0.165 CD O
) ) O
. . O

There EX O
were VBD O
no DT B-OC
differences NNS I-OC
in IN O
uterine JJ B-OC
artery NN I-OC
Doppler NNP I-OC
resistance NN I-OC
indices NNS I-OC
at IN O
five CD O
days NNS O
( ( O
P= NNP O
0.54 CD O
) ) O
, , O
six CD O
weeks NNS O
( ( O
P= NNP O
0.47 CD O
) ) O
, , O
three CD O
months NNS O
( ( O
P= NNP O
0.49 CD O
) ) O
and CC O
at IN O
six CD O
months NNS O
( ( O
P= NNP O
0.18 CD O
) ) O
. . O

Day NNP O
two CD O
serum NN B-OC
FSH NNP I-OC
concentrations NNS I-OC
after IN O
surgery NN O
were VBD O
unchanged JJ B-OC
( ( O
P= NNP O
0.45 CD O
) ) O
, , O
compared VBN O
with IN O
baseline NN O
values NNS O
. . O

CONCLUSIONS NNP O
Triple NNP B-INTV
tourniquets NNS I-INTV
are VBP O
effective JJ O
in IN O
reducing VBG O
bleeding NN B-OC
and CC I-OC
transfusion NN I-OC
rates NNS I-OC
. . O

There EX O
appears VBZ O
no DT O
obvious JJ O
adverse JJ O
effect NN O
on IN O
uterine JJ B-OC
perfusion NN I-OC
or CC I-OC
ovarian JJ I-OC
function NN I-OC
. . O

-DOCSTART- -X- O O

Multi-institutional JJ O
randomized JJ O
phase NN O
II NNP O
trial NN O
of IN O
the DT O
epothilone NN B-INTV
B NNP I-INTV
analog NN I-INTV
ixabepilone NN I-INTV
( ( I-INTV
BMS-247550 NNP I-INTV
) ) I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
estramustine JJ I-INTV
phosphate NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
progressive JJ I-POPU
castrate NN I-POPU
metastatic JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
To TO O
evaluate VB O
the DT O
antitumor NN B-OC
activity NN I-OC
and CC O
safety NN B-OC
of IN O
the DT O
epothilone NN B-INTV
B NNP I-INTV
analog NN I-INTV
, , I-INTV
ixabepilone NN I-INTV
, , I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
estramustine JJ I-INTV
phosphate NN I-INTV
( ( I-INTV
EMP NNP I-INTV
) ) I-INTV
, , O
in IN O
chemotherapy-naive JJ B-POPU
patients NNS I-POPU
with IN I-POPU
progressive JJ I-POPU
castrate NN I-POPU
metastatic JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Patients NNPS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
ixabepilone NN B-INTV
( ( O
35 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
by IN O
intravenous JJ B-INTV
infusion NN I-INTV
every DT I-INTV
3 CD I-INTV
weeks NNS I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
EMP NNP I-INTV
280 CD I-INTV
mg NN I-INTV
orally RB I-INTV
three CD O
times NNS O
daily RB O
on IN O
days NNS O
1 CD O
to TO O
5 CD O
. . O

RESULTS NN O
Between NNP B-POPU
December NNP I-POPU
2001 CD I-POPU
and CC I-POPU
October NNP I-POPU
2003 CD I-POPU
, , I-POPU
92 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
enrolled VBN I-POPU
and CC I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO O
treatment NN B-POPU
with IN I-POPU
ixabepilone NN I-POPU
alone RB I-POPU
( ( I-POPU
45 CD I-POPU
patients NNS I-POPU
) ) I-POPU
or CC I-POPU
in IN I-POPU
combination NN I-POPU
with IN I-POPU
EMP NNP I-POPU
( ( I-POPU
47 CD I-POPU
patients NNS I-POPU
) ) I-POPU
. . O

Grades $ B-OC
3 CD I-OC
and CC I-OC
4 CD I-OC
toxicities NNS I-OC
experienced VBN O
by IN O
more JJR O
than IN O
5 CD O
% NN O
of IN O
patients NNS O
included VBN O
neutropenia RB B-OC
( ( O
22 CD O
% NN O
) ) O
, , O
fatigue NN B-OC
( ( O
9 CD O
% NN O
) ) O
, , O
and CC O
neuropathy JJ B-OC
( ( O
13 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN B-OC
arm NN I-OC
, , I-OC
and CC I-OC
neutropenia NN I-OC
( ( O
29 CD O
% NN O
) ) O
, , O
febrile JJ B-OC
neutropenia NN I-OC
( ( O
9 CD O
% NN O
) ) O
, , O
fatigue NN B-OC
( ( O
9 CD O
% NN O
) ) O
, , O
neuropathy JJ B-OC
( ( O
7 CD O
% NN O
) ) O
, , O
and CC O
thrombosis NN B-OC
( ( O
6 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
+ NNP O
EMP NNP O
arm NN O
. . O

Post-treatment JJ O
declines NNS O
in IN O
prostate-specific JJ B-OC
antigen NN I-OC
of IN O
> NN O
or CC O
= VB O
50 CD O
% NN O
were VBD O
achieved VBN O
in IN O
21 CD O
of IN O
44 CD O
patients NNS O
( ( O
48 CD O
% NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
33 CD O
% NN O
to TO O
64 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
arm NN O
, , O
and CC O
31 CD O
of IN O
45 CD O
patients NNS O
( ( O
69 CD O
% NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
55 CD O
% NN O
to TO O
82 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
+ NNP O
EMP NNP O
arm NN O
. . O

In IN O
patients NNS O
with IN O
measurable JJ O
disease NN O
, , O
partial JJ B-OC
responses NNS I-OC
were VBD O
observed VBN O
in IN O
eight CD O
of IN O
25 CD O
patients NNS O
( ( O
32 CD O
% NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
14 CD O
% NN O
to TO O
50 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
arm NN O
, , O
and CC O
11 CD O
of IN O
23 CD O
( ( O
48 CD O
% NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
27 CD O
% NN O
to TO O
68 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
+ NNP O
EMP NNP O
arm NN O
. . O

Time NN B-OC
to TO I-OC
prostate-specific JJ I-OC
antigen NN I-OC
progression NN I-OC
was VBD O
4.4 CD O
months NNS O
( ( O
95 CD O
% NN O
CI NNP O
, , O
3.1 CD O
to TO O
6.9 CD O
months NNS O
) ) O
on IN O
the DT O
ixabepilone-alone JJ O
arm NN O
and CC O
5.2 CD O
months NNS O
( ( O
95 CD O
% NN O
CI NNP O
, , O
4.5 CD O
to TO O
6.8 CD O
months NNS O
) ) O
on IN O
the DT O
combination NN O
arm NN O
. . O

CONCLUSION NNP O
Ixabepilone NNP B-INTV
, , O
with IN O
or CC O
without IN O
estramustine JJ B-INTV
phosphate NN I-INTV
, , O
is VBZ O
well RB B-OC
tolerated VBN I-OC
and CC O
has VBZ O
antitumor VBN B-OC
activity NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
castrate JJ I-POPU
metastatic JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

-DOCSTART- -X- O O

Zoledronic JJ B-INTV
acid NN I-INTV
significantly RB O
reduces VBZ O
skeletal JJ O
complications NNS O
compared VBN O
with IN O
placebo NN B-INTV
in IN O
Japanese JJ B-POPU
women NNS I-POPU
with IN I-POPU
bone NN I-POPU
metastases NNS I-POPU
from IN I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
randomized JJ O
, , O
placebo-controlled JJ O
trial NN O
. . O

PURPOSE NNP O
To TO O
investigate VB O
the DT O
efficacy NN O
and CC O
safety NN O
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
for IN O
the DT O
treatment NN O
of IN O
bone NN O
metastases NNS O
from IN O
breast NN O
cancer NN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Women NNP B-POPU
with IN I-POPU
bone NN I-POPU
metastases NNS I-POPU
( ( I-POPU
N NNP I-POPU
= NNP I-POPU
228 CD I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
4 CD B-INTV
mg NN I-INTV
zoledronic JJ I-INTV
acid NN I-INTV
( ( O
n JJ O
= NNP O
114 CD O
) ) O
or CC O
placebo NN B-INTV
( ( O
n JJ O
= NNP O
114 CD O
) ) O
via IN O
15-minute JJ O
infusions NNS O
every DT O
4 CD O
weeks NNS O
for IN O
1 CD O
year NN O
. . O

The DT O
primary JJ O
efficacy JJ O
end NN O
point NN O
was VBD O
the DT O
skeletal-related JJ O
event NN O
( ( O
SRE NNP O
) ) O
rate NN O
ratio NN O
between IN O
treatment NN O
groups NNS O
. . O

An DT O
SRE NNP O
was VBD O
defined VBN O
as IN O
pathologic JJ O
fracture NN O
, , O
spinal JJ O
cord NN O
compression NN O
, , O
and CC O
radiation NN O
or CC O
surgery NN O
to TO O
bone VB O
. . O

Secondary JJ O
end NN O
points NNS O
included VBD O
percentage NN O
of IN O
patients NNS O
with IN O
at IN O
least JJS O
one CD O
SRE NNP O
, , O
time-to-first JJ O
SRE NNP O
, , O
and CC O
Andersen-Gill NNP O
multiple-event JJ O
analysis NN O
. . O

RESULTS VB O
The DT O
SRE NNP B-OC
rate NN I-OC
ratio NN I-OC
at IN O
1 CD O
year NN O
( ( O
excluding VBG O
HCM NNP O
and CC O
adjusted VBN O
for IN O
prior JJ O
fracture NN O
) ) O
was VBD O
0.61 CD O
( ( O
permutation NN O
test NN O
; : O
P NNP O
= NNP O
.027 NNP O
) ) O
, , O
indicating VBG O
that IN O
zoledronic JJ B-INTV
acid NN I-INTV
reduced VBD O
the DT O
rate NN B-OC
of IN I-OC
SRE NNP I-OC
by IN O
39 CD O
% NN O
compared VBN O
with IN O
placebo NN B-INTV
. . O

The DT O
percentage NN B-OC
of IN I-OC
patients NNS I-OC
with IN I-OC
at IN I-OC
least JJS I-OC
one CD I-OC
SRE NNP I-OC
( ( I-OC
excluding VBG I-OC
HCM NNP I-OC
) ) I-OC
was VBD I-OC
significantly RB I-OC
reduced VBN I-OC
by IN O
20 CD O
% NN O
by IN O
zoledronic JJ O
acid NN O
( ( O
29.8 CD O
% NN O
v JJ O
49.6 CD O
% NN O
for IN O
placebo NN O
; : O
P NNP O
= NNP O
.003 NNP O
) ) O
. . O

Zoledronic JJ B-INTV
acid NN I-INTV
significantly RB B-OC
delayed VBN I-OC
time-to-first JJ I-OC
SRE NNP I-OC
( ( O
median JJ O
not RB O
reached VBN O
v RB O
364 CD O
days NNS O
; : O
Cox NNP O
regression NN O
; : O
P NNP O
= NNP O
.007 NNP O
) ) O
and CC O
reduced VBD B-OC
the DT I-OC
risk NN I-OC
of IN I-OC
SREs NNP I-OC
by IN O
41 CD O
% NN O
in IN O
multiple JJ O
event NN O
analysis NN O
( ( O
risk NN O
ratio NN O
= NNP O
0.59 CD O
; : O
P NNP O
= NNP O
.019 NNP O
) ) O
compared VBN O
with IN O
placebo NN B-INTV
. . O

Zoledronic JJ B-INTV
acid NN I-INTV
was VBD O
well RB O
tolerated VBN B-OC
with IN O
a DT O
safety NN O
profile NN O
similar JJ O
to TO O
placebo VB O
. . O

No DT O
patient NN O
treated VBD O
with IN O
zoledronic JJ O
acid NN O
had VBD O
grade VBN O
3 CD O
or CC O
4 CD O
serum JJ O
creatinine NN O
increase NN O
. . O

CONCLUSION NNP O
Zoledronic NNP B-INTV
acid NN I-INTV
significantly RB O
reduced VBD O
skeletal JJ O
complications NNS O
compared VBN O
with IN O
placebo NN B-INTV
across IN O
multiple JJ O
end NN O
points NNS O
in IN O
Japanese JJ B-POPU
women NNS I-POPU
with IN I-POPU
bone NN I-POPU
metastases NNS I-POPU
from IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

-DOCSTART- -X- O O

Phase NNP O
III NNP O
trial NN O
of IN O
satraplatin NN B-INTV
, , O
an DT O
oral JJ O
platinum NN B-INTV
plus CC I-INTV
prednisone NN I-INTV
vs. FW I-INTV
prednisone NN I-INTV
alone RB I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
hormone-refractory JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

Satraplatin NNP B-INTV
is VBZ O
a DT O
novel JJ O
oral JJ O
platinum NN B-INTV
( ( O
IV NNP O
) ) O
complex VBP O
that DT O
shows VBZ O
activity NN O
against IN O
hormone-refractory JJ B-POPU
prostate NN I-POPU
cancer NN I-POPU
( ( I-POPU
HRPC NNP I-POPU
) ) I-POPU
in IN O
cisplatin-resistant JJ B-INTV
human JJ O
tumor NN O
lines NNS O
in IN O
phase NN O
I PRP O
and CC O
phase VB O
II NNP O
trials NNS O
. . O

A DT O
randomized JJ O
multicenter NN O
phase NN O
III NNP O
trial NN O
with IN O
a DT O
target NN O
sample JJ O
size NN O
of IN O
380 CD B-POPU
patients NNS I-POPU
was VBD I-POPU
initiated VBN I-POPU
in IN I-POPU
men NNS I-POPU
with IN I-POPU
HRPC NNP I-POPU
. . O

After IN O
50 CD B-POPU
randomized JJ I-POPU
patients NNS I-POPU
, , O
the DT O
trial NN O
was VBD O
closed VBN O
to TO O
further RBR O
accrual JJ O
by IN O
the DT O
sponsoring VBG O
company NN O
. . O

An DT O
ad NN O
hoc NN O
analysis NN O
of IN O
all DT O
available JJ O
data NNS O
is VBZ O
reported VBN O
here RB O
. . O

Eligibility NNP O
criteria NNS O
included VBD O
pathological JJ O
proof NN O
of IN O
prostate NN B-POPU
cancer NN I-POPU
, , O
documented VBN O
progression NN O
despite IN O
prior JJ O
hormonal JJ O
manipulation NN O
, , O
WHO WP O
PS NNP O
0-2 NN O
, , O
and CC O
no DT O
daily JJ O
intake NN O
of IN O
narcotic JJ B-INTV
analgesics NNS I-INTV
. . O

Patients NNS O
were VBD O
randomized VBN O
between IN O
satraplatin NN B-INTV
100 CD O
mg/m NN O
( ( O
2 CD O
) ) O
for IN O
5 CD O
days NNS O
plus CC O
prednisone JJ B-INTV
10 CD O
mg NNS O
orally RB O
BID NNP O
or CC O
prednisone VB B-INTV
alone RB O
. . O

Compliance NN O
was VBD O
excellent JJ O
. . O

48/50 CD O
patients NNS O
have VBP O
progressed VBN B-OC
and CC O
42 CD O
have VBP O
died VBN B-OC
, , O
mostly RB O
due JJ O
to TO O
prostate VB O
cancer NN O
. . O

Median JJ B-OC
overall JJ I-OC
survival NN I-OC
was VBD O
14.9 CD O
months NNS O
( ( O
95 CD O
% NN O
CI NNP O
: : O
13.7-28.4 JJ O
) ) O
on IN O
the DT O
satraplatin NN B-INTV
plus CC O
prednisone NN B-INTV
arm NN O
and CC O
11.9 CD O
months NNS O
( ( O
95 CD O
% NN O
CI NNP O
: : O
8.4-23.1 JJ O
) ) O
on IN O
prednisone NN B-INTV
alone RB O
( ( O
hazard JJ O
ratio NN O
, , O
HR NNP O
= NNP O
0.84 CD O
, , O
95 CD O
% NN O
CI NNP O
: : O
0.46-1.55 NN O
) ) O
. . O

A DT O
> JJ O
50 CD O
% NN O
decrease NN O
in IN O
prostrate NN B-OC
specific JJ I-OC
antigen NN I-OC
( ( O
PSA NNP O
) ) O
was VBD O
seen VBN O
in IN O
9/27 CD O
( ( O
33.3 CD O
% NN O
) ) O
in IN O
the DT O
satraplatin NN B-INTV
plus CC I-INTV
prednisone NN I-INTV
arm NN O
vs. FW O
2/23 CD O
( ( O
8.7 CD O
% NN O
) ) O
on IN O
the DT O
prednisone NN B-INTV
alone RB O
arm NN O
. . O

Progression-free JJ B-OC
survival NN I-OC
was VBD O
5.2 CD O
months NNS O
( ( O
95 CD O
% NN O
CI NNP O
: : O
2.8-13.7 JJ O
) ) O
on IN O
the DT O
satraplatin NN B-INTV
plus CC O
prednisone NN B-INTV
arm NN O
as IN O
compared VBN O
to TO O
2.5 CD O
months NNS O
( ( O
95 CD O
% NN O
CI NNP O
: : O
2.1- JJ O
4.7 CD O
) ) O
on IN O
the DT O
prednisone NN B-INTV
alone RB O
arm NN O
( ( O
HR NNP O
= NNP O
0.50 CD O
, , O
95 CD O
% NN O
CI NNP O
: : O
0.28-0.92 NN O
) ) O
. . O

This DT O
difference NN O
is VBZ O
statistically RB O
significant JJ O
( ( O
p JJ O
= NNP O
0.023 CD O
) ) O
. . O

Toxicity NN B-OC
was VBD O
generally RB O
minimal JJ O
in IN O
both DT O
arms NNS O
. . O

This DT O
randomized JJ O
comparison NN O
of IN O
a DT O
combination NN O
of IN O
satraplatin NN B-INTV
and CC I-INTV
prednisone NN I-INTV
versus NN O
prednisone NN O
alone RB O
supports VBZ O
the DT O
antitumor NN O
activity NN O
of IN O
the DT O
combination NN O
. . O

Its PRP$ O
role NN O
in IN O
the DT O
treatment NN O
of IN O
HPRC NNP O
remains VBZ O
to TO O
be VB O
elucidated VBN O
in IN O
an DT O
appropriate JJ O
phase NN O
III NNP O
setting NN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
a DT O
nutritional JJ B-INTV
supplement NN I-INTV
containing VBG I-INTV
vitamin NN I-INTV
E NNP I-INTV
, , I-INTV
selenium NN I-INTV
, , I-INTV
vitamin FW I-INTV
c NNS I-INTV
and CC I-INTV
coenzyme JJ I-INTV
Q10 NNP I-INTV
on IN O
serum NN B-OC
PSA NNP I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
hormonally RB I-POPU
untreated JJ I-POPU
carcinoma NN I-POPU
of IN I-POPU
the DT I-POPU
prostate NN I-POPU
: : I-POPU
a DT O
randomised JJ O
placebo-controlled JJ O
study NN O
. . O

OBJECTIVE NNP O
To TO O
assess VB O
the DT O
effect NN O
of IN O
a DT O
nutritional JJ O
supplement NN O
containing VBG O
vitamin NN B-INTV
E NNP I-INTV
, , I-INTV
selenium NN I-INTV
, , I-INTV
vitamin FW I-INTV
C NNP I-INTV
and CC O
coenzyme JJ B-INTV
Q10 NNP I-INTV
on IN O
changes NNS O
in IN O
serum NN B-OC
levels NNS I-OC
of IN I-OC
PSA NNP I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
hormonally RB I-POPU
untreated JJ I-POPU
carcinoma NN I-POPU
of IN I-POPU
the DT I-POPU
prostate NN I-POPU
and CC I-POPU
rising VBG I-POPU
serum NN I-POPU
PSA NNP I-POPU
levels NNS I-POPU
. . O

METHODS NNP O
Eighty NNP B-POPU
patients NNS I-POPU
were VBD I-POPU
randomised VBN I-POPU
to TO O
receive VB O
a DT O
daily JJ O
supplement NN O
with IN O
either DT O
vitamin NN B-INTV
E NNP I-INTV
, , I-INTV
selenium NN I-INTV
, , I-INTV
vitamin FW I-INTV
C NNP I-INTV
, , I-INTV
coenzyme NN I-INTV
Q10 NNP I-INTV
( ( O
intervention NN O
group NN O
) ) O
or CC O
placebo NN B-INTV
over IN O
21 CD O
weeks NNS O
. . O

Serum NNP B-OC
levels NNS I-OC
of IN I-OC
PSA NNP I-OC
were VBD O
assessed VBN O
at IN O
baseline NN O
( ( O
-2 UH O
, , O
-1 NNP O
, , O
0 CD O
weeks NNS O
) ) O
and CC O
after IN O
6 CD O
, , O
13 CD O
, , O
19 CD O
, , O
20 CD O
and CC O
21 CD O
weeks NNS O
. . O

Mean JJ O
changes NNS O
in IN O
log NN O
serum JJ B-OC
level NN I-OC
of IN I-OC
PSA NNP I-OC
, , I-OC
testosterone NN I-OC
, , I-OC
dihydrotestosterone NN I-OC
, , I-OC
luteinizing VBG I-OC
hormone NN I-OC
and CC I-OC
sex NN I-OC
hormone NN I-OC
binding VBG I-OC
globulin NN I-OC
over IN O
21 CD O
weeks NNS O
between IN O
the DT O
verum NN O
and CC O
the DT O
placebo NN O
group NN O
were VBD O
compared VBN O
by IN O
analysis NN O
of IN O
covariance NN O
. . O

RESULTS NNP O
Seventy NNP B-POPU
patients NNS I-POPU
completed VBD I-POPU
the DT I-POPU
study NN I-POPU
( ( I-POPU
36 CD I-POPU
verum NN I-POPU
; : I-POPU
34 CD I-POPU
placebo NN I-POPU
) ) I-POPU
. . O

Compliance NN O
was VBD O
> JJ O
90 CD O
% NN O
in IN O
all DT O
patients NNS O
. . O

In IN O
the DT O
intervention NN O
group NN O
, , O
plasma NN B-OC
levels NNS I-OC
of IN I-OC
vitamin NN B-INTV
E NNP I-INTV
, , I-INTV
selenium NN I-INTV
and CC B-OC
coenzyme JJ B-INTV
Q10 NNP I-INTV
increased VBD O
significantly RB O
over IN O
the DT O
21 CD O
weeks NNS O
study JJ O
period NN O
. . O

No DT O
significant JJ O
differences NNS O
in IN O
serum NN B-OC
levels NNS I-OC
of IN I-OC
PSA NNP I-OC
, , I-OC
testosterone NN I-OC
, , I-OC
dihydrotestosterone NN I-OC
, , I-OC
luteinizing VBG I-OC
hormone NN I-OC
or CC I-OC
sex NN I-OC
hormone NN I-OC
binding VBG I-OC
globulin NN I-OC
( ( O
p JJ O
> NNP O
0.2 CD O
) ) O
were VBD O
observed VBN O
between IN O
the DT O
intervention NN O
and CC O
control NN O
group NN O
. . O

CONCLUSION NNP O
Our PRP$ O
results NNS O
indicate VBP O
that DT O
supplementation NN O
of IN O
a DT O
combination NN O
of IN O
vitamin NN B-INTV
E NNP I-INTV
, , I-INTV
selenium NN I-INTV
, , I-INTV
vitamin FW I-INTV
C NNP I-INTV
and CC O
coenzyme-Q10 NN B-INTV
does VBZ O
not RB O
affect VB O
serum JJ B-OC
level NN I-OC
of IN I-OC
PSA NNP I-OC
or CC I-OC
hormone NN I-OC
levels NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
hormonally RB I-POPU
untreated JJ I-POPU
carcinoma NN I-POPU
of IN I-POPU
the DT I-POPU
prostate NN I-POPU
. . O

-DOCSTART- -X- O O

Phase NNP O
III NNP O
study NN O
of IN O
the DT O
Eastern NNP O
Cooperative NNP O
Oncology NNP O
Group NNP O
( ( O
ECOG NNP O
2597 CD O
) ) O
: : O
induction NN B-INTV
chemotherapy NN I-INTV
followed VBN I-INTV
by IN I-INTV
either DT I-INTV
standard JJ I-INTV
thoracic NN I-INTV
radiotherapy NN I-INTV
or CC I-INTV
hyperfractionated VBN I-INTV
accelerated JJ I-INTV
radiotherapy NN I-INTV
for IN O
patients NNS B-POPU
with IN I-POPU
unresectable JJ I-POPU
stage NN I-POPU
IIIA NNP I-POPU
and CC I-POPU
B NNP I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
To TO O
compare VB O
once-daily JJ B-INTV
radiation NN I-INTV
therapy NN I-INTV
( ( I-INTV
qdRT NN I-INTV
) ) I-INTV
with IN O
hyperfractionated VBN B-INTV
accelerated JJ I-INTV
radiation NN I-INTV
therapy NN I-INTV
( ( I-INTV
HART NNP I-INTV
) ) I-INTV
after IN O
two CD O
cycles NNS O
of IN O
induction NN B-INTV
chemotherapy NN I-INTV
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Eligible JJ B-POPU
patients NNS I-POPU
were VBD I-POPU
treatment NN I-POPU
naive JJ I-POPU
, , I-POPU
and CC I-POPU
had VBD I-POPU
stage NN I-POPU
IIIA NNP I-POPU
and CC I-POPU
B NNP I-POPU
unresectable JJ I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
, , I-POPU
Eastern NNP I-POPU
Cooperative NNP I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
performance NN I-POPU
status NN I-POPU
0/1 CD I-POPU
, , I-POPU
and CC I-POPU
normal JJ I-POPU
organ JJ I-POPU
function NN I-POPU
. . O

Induction NNP B-INTV
chemotherapy NN I-INTV
consisted VBD O
of IN O
two CD O
cycles NNS O
of IN O
carboplatin JJ B-INTV
area NN O
under IN O
time-concentration NN O
curve NN O
6 CD O
mg/mL NN O
. . O

min NN O
plus CC O
paclitaxel JJ B-INTV
225 CD O
mg/m2 NN O
on IN O
day NN O
1 CD O
. . O

RT NNP O
consisted VBD O
of IN O
arm NN O
1 CD O
( ( O
qdRT NN O
) ) O
, , O
64 CD O
Gy NNP O
( ( O
2 CD O
Gy/d NNP O
) ) O
, , O
versus JJ O
arm NN O
2 CD O
( ( O
HART NNP O
) ) O
, , O
57.6 CD O
Gy NNP O
( ( O
1.5 CD O
Gy NNP O
tid NN O
for IN O
2.5 CD O
weeks NNS O
) ) O
. . O

A DT O
total NN B-POPU
of IN I-POPU
388 CD I-POPU
patients NNS I-POPU
were VBD O
needed VBN O
to TO O
detect VB O
a DT O
50 CD O
% NN O
increase NN O
in IN O
median JJ O
survival NN O
from IN O
14 CD O
months NNS O
of IN O
qdRT NN B-INTV
to TO O
21 CD O
months NNS O
of IN O
HART NNP B-INTV
; : I-INTV
accrual NN O
was VBD O
not RB O
achieved VBN O
and CC O
the DT O
study NN O
closed VBD O
prematurely RB O
. . O

RESULTS NNP O
Of IN O
141 CD B-POPU
patients NNS I-POPU
enrolled VBD I-POPU
, , O
83 CD O
% NN O
were VBD O
randomly RB O
assigned VBN O
after IN O
chemotherapy NN O
to TO O
qdRT VB B-INTV
( ( O
n JJ O
= NNP O
59 CD O
) ) O
or CC O
HART NNP B-INTV
( ( O
n JJ O
= NNP O
60 CD O
) ) O
. . O

Median JJ B-OC
survival NN I-OC
was VBD O
20.3 CD O
and CC O
14.9 CD O
months NNS O
for IN O
HART NNP B-INTV
and CC O
qdRT NN B-INTV
, , O
respectively RB O
( ( O
P NNP O
= NNP O
.28 NNP O
) ) O
. . O

Overall JJ B-OC
response NN I-OC
was VBD O
25 CD O
% NN O
and CC O
22 CD O
% NN O
for IN O
HART NNP B-INTV
and CC O
qdRT NN B-INTV
, , O
respectively RB O
( ( O
P NNP O
= NNP O
.69 NNP O
) ) O
. . O

Two- JJ B-OC
and CC I-OC
3-year JJ I-OC
survival NN I-OC
was VBD O
44 CD O
% NN O
and CC O
34 CD O
% NN O
for IN O
HART NNP B-INTV
, , O
and CC O
24 CD O
% NN O
and CC O
14 CD O
% NN O
for IN O
qdRT NN B-INTV
, , O
respectively RB O
. . O

Grade VB B-OC
> NN I-OC
or CC I-OC
= $ I-OC
3 CD I-OC
toxicities NNS I-OC
included VBD O
esophagitis NN O
in IN O
14 CD O
v JJ O
nine CD B-POPU
patients NNS I-POPU
, , O
and CC O
pneumonitis NN O
in IN O
0 CD O
v NNS O
6 CD O
patients NNS O
for IN O
HART NNP B-INTV
and CC O
qdRT NN B-INTV
, , O
respectively RB O
. . O

Any DT O
subsequent JJ O
trials NNS O
of IN O
the DT O
HART NNP B-INTV
regimen NNS O
must MD O
address VB O
the DT O
issues NNS O
that WDT O
led VBD O
to TO O
early JJ O
closure NN O
, , O
including VBG O
slow JJ B-OC
accrual NN I-OC
, , I-OC
logistics NNS I-OC
of IN I-OC
HART NNP B-INTV
, , B-OC
mucosal NN I-OC
toxicity NN I-OC
, , O
and CC O
the DT O
fact NN O
that IN O
concurrent JJ O
chemoradiotherapy NN O
now RB O
seems VBZ O
more RBR O
effective JJ O
than IN O
sequential JJ O
treatment NN O
. . O

CONCLUSION NNP O
After IN O
two CD O
cycles NNS O
of IN O
induction NN B-INTV
chemotherapy NN I-INTV
with IN O
carboplatin-paclitaxel NN B-INTV
, , I-INTV
HART NNP I-INTV
is VBZ O
feasible JJ O
with IN O
an DT O
acceptable JJ O
toxicity NN O
profile NN O
. . O

Although IN O
statistical JJ O
significance NN O
was VBD O
not RB O
achieved VBN O
and CC O
the DT O
study NN O
closed VBD O
early RB O
, , O
there EX O
was VBD O
a DT O
positive JJ O
statistical JJ O
trend NN O
suggesting VBG O
a DT O
survival JJ O
advantage NN O
with IN O
the DT O
HART NNP B-INTV
regimen NNS O
. . O

-DOCSTART- -X- O O

Acustimulation NNP B-INTV
wrist NN I-INTV
bands NNS I-INTV
are VBP O
not RB O
effective JJ O
for IN O
the DT O
control NN O
of IN O
chemotherapy-induced JJ B-INTV
nausea NN B-OC
in IN O
women NNS B-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

This DT O
experiment NN O
examined VBD O
the DT O
efficacy NN O
of IN O
an DT O
acustimulation NN B-INTV
wrist NN I-INTV
band NN I-INTV
for IN O
the DT O
relief NN O
of IN O
chemotherapy-induced JJ B-INTV
nausea NN B-OC
using VBG O
a DT O
randomized JJ O
three-arm JJ O
clinical JJ O
trial NN O
( ( B-INTV
active JJ I-INTV
acustimulation NN I-INTV
, , I-INTV
sham JJ I-INTV
acustimulation NN I-INTV
, , O
and CC O
no DT B-INTV
acustimulation NN I-INTV
) ) I-INTV
in IN O
96 CD B-POPU
women NNS I-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
who WP I-POPU
experienced VBD I-POPU
nausea NN I-POPU
at IN I-POPU
their PRP$ I-POPU
first JJ I-POPU
chemotherapy NN I-POPU
treatment NN I-POPU
. . O

Five CD O
outcomes NNS O
related VBN O
to TO O
wrist VB B-INTV
band NN I-INTV
efficacy NN B-OC
( ( I-OC
acute JJ I-OC
nausea NN I-OC
, , I-OC
delayed VBN I-OC
nausea NN I-OC
, , I-OC
vomiting VBG I-OC
, , I-OC
QOL NNP I-OC
, , I-OC
and CC I-OC
total JJ I-OC
amount NN I-OC
of IN I-OC
antiemetic JJ B-INTV
medication NN I-INTV
used VBN B-OC
) ) I-OC
were VBD O
examined VBN O
. . O

The DT O
five CD O
outcomes NNS O
were VBD O
examined VBN O
separately RB O
using VBG O
analysis NN O
of IN O
covariance NN O
controlling VBG O
for IN O
age NN O
and CC O
severity NN B-OC
of IN I-OC
past JJ I-OC
nausea NN I-OC
. . O

There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
any DT O
of IN O
these DT O
study NN O
measures NNS O
among IN O
the DT O
three CD O
treatment NN O
conditions NNS O
( ( O
P NNP O
> VBZ O
0.1 CD O
for IN O
all DT O
) ) O
. . O

Study NNP O
results NNS O
do VBP O
not RB O
support VB O
the DT O
hypothesis NN O
that WDT O
acustimulation NN B-INTV
bands NNS I-INTV
are VBP O
efficacious JJ O
as IN O
an DT O
adjunct NN O
to TO O
pharmacological JJ O
antiemetics NNS O
for IN O
control NN O
of IN O
chemotherapy-related JJ B-OC
nausea NN I-OC
in IN O
female JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Fulvestrant NNP B-INTV
versus NN O
anastrozole NN B-INTV
for IN O
the DT O
treatment NN O
of IN O
advanced JJ O
breast NN O
carcinoma NN O
: : O
a DT O
prospectively RB O
planned VBN O
combined VBN O
survival JJ O
analysis NN O
of IN O
two CD O
multicenter NN O
trials NNS O
. . O

BACKGROUND NNP O
Fulvestrant NNP B-INTV
is VBZ O
an DT O
estrogen NN O
receptor NN O
antagonist NN O
with IN O
no DT O
agonist JJ O
effects NNS O
. . O

In IN O
the DT O
second-line JJ O
treatment NN O
of IN O
advanced JJ O
breast NN O
carcinoma NN O
, , O
fulvestrant NN O
was VBD O
shown VBN O
previously RB O
to TO O
be VB O
as RB O
effective JJ O
as IN O
the DT O
third-generation NN O
aromatase NN O
inhibitor NN O
, , O
anastrozole NN O
, , O
in IN O
terms NNS O
of IN O
time NN O
to TO O
disease VB O
progression NN O
and CC O
objective JJ O
response NN O
rates NNS O
. . O

The DT O
authors NNS O
reported VBD O
the DT O
overall JJ B-OC
survival JJ I-OC
results NNS O
from IN O
these DT O
studies NNS O
. . O

METHODS VB O
A DT O
prospectively RB O
planned VBN O
, , O
combined VBN O
, , O
overall JJ B-OC
survival NN I-OC
analysis NN O
was VBD O
performed VBN O
, , O
including VBG O
data NNS O
from IN O
two CD O
Phase NNP O
III NNP O
trials NNS O
that WDT O
compared VBN O
the DT O
efficacy NN B-OC
and CC I-OC
tolerability NN I-OC
of IN O
fulvestrant NN B-INTV
( ( I-INTV
250 CD I-INTV
mg NN I-INTV
monthly RB I-INTV
; : I-INTV
n CC I-INTV
= VB I-INTV
428 CD I-INTV
) ) I-INTV
with IN I-INTV
anastrozole NN I-INTV
( ( I-INTV
1 CD I-INTV
mg NNS I-INTV
daily RB I-INTV
; : I-INTV
n CC O
= VB O
423 CD O
) ) O
in IN O
the DT O
treatment NN O
of IN O
postmenopausal JJ B-POPU
women NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
breast NN I-POPU
carcinoma NN I-POPU
who WP I-POPU
had VBD I-POPU
disease NN I-POPU
progression NN I-POPU
after IN I-POPU
receipt NN I-POPU
of IN I-POPU
previous JJ I-POPU
endocrine NN I-POPU
treatment NN I-POPU
. . O

RESULTS NNP O
At IN O
an DT O
extended JJ O
median JJ O
follow-up NN O
of IN O
27.0 CD O
months NNS O
( ( O
range NN O
, , O
0-66.9 JJ O
months NNS O
) ) O
, , O
319 CD B-POPU
( ( I-POPU
74.5 CD I-POPU
% NN I-POPU
) ) I-POPU
patients NNS I-POPU
in IN I-POPU
the DT I-POPU
fulvestrant JJ I-POPU
group NN I-POPU
and CC I-POPU
322 CD I-POPU
( ( I-POPU
76.1 CD I-POPU
% NN I-POPU
) ) I-POPU
patients NNS I-POPU
in IN I-POPU
the DT I-POPU
anastrozole JJ I-POPU
group NN I-POPU
had VBD O
died VBN B-OC
. . O

Prolonged NNP B-OC
survival NN I-OC
was VBD O
observed VBN O
with IN O
both DT O
drugs NNS O
, , O
with IN O
10-20 JJ O
% NN O
of IN O
patients NNS O
still RB O
alive JJ B-OC
> JJ O
5 CD O
years NNS O
after IN O
randomization NN O
. . O

The DT O
median JJ B-OC
overall JJ I-OC
survival NN I-OC
was VBD O
similar JJ O
between IN O
treatments NNS O
, , O
being VBG O
27.4 CD O
months NNS O
and CC O
27.7 CD O
months NNS O
in IN O
fulvestrant JJ B-INTV
and CC O
anastrozole-treated JJ B-INTV
patients NNS O
, , O
respectively RB O
( ( O
hazards NNS O
ratio NN O
, , O
0.98 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
0.84-1.15 JJ O
; : O
P NNP O
= NNP O
0.809 CD O
) ) O
. . O

Fulvestrant NNP O
continued VBD O
to TO O
be VB O
well RB O
tolerated VBN O
, , O
and CC O
was VBD O
associated VBN O
with IN O
a DT O
significantly RB O
lower JJR O
incidence NN B-OC
of IN I-OC
joint JJ I-OC
disorders NNS I-OC
compared VBN O
with IN O
anastrozole NN O
( ( O
P NNP O
= NNP O
0.0234 CD O
) ) O
. . O

CONCLUSIONS VB O
The DT O
current JJ O
analysis NN O
showed VBD O
that IN O
fulvestrant NN B-INTV
was VBD O
similar JJ O
to TO O
anastrozole VB O
with IN O
respect NN O
to TO O
overall JJ O
survival NN O
in IN O
the DT O
second-line JJ O
treatment NN O
of IN O
postmenopausal JJ B-POPU
women NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
breast NN I-POPU
carcinoma NN I-POPU
. . O

-DOCSTART- -X- O O

Clinical JJ O
trials NNS O
of IN O
intrasplenic JJ O
arterial JJ O
infusion NN O
of IN O
interleukin-2 NN B-INTV
( ( I-INTV
IS-IL-2 NNP I-INTV
) ) I-INTV
to TO O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
cancer NN I-POPU
. . O

We PRP O
tried VBD O
a DT O
infusion NN O
of IN O
interleukin-2 NN O
( ( O
IL-2 NNP O
) ) O
of IN O
a DT O
relatively RB O
low JJ O
dose NN O
via IN O
an DT O
intrasplenic JJ O
arterial JJ O
catheter NN O
connected VBN O
to TO O
a DT O
chronometric JJ O
infusion NN O
( ( O
IS-IL-2 NNP O
) ) O
. . O

Eighteen JJ B-POPU
patients NNS I-POPU
of IN I-POPU
colorectal JJ I-POPU
cancer NN I-POPU
with IN I-POPU
metastases NNS I-POPU
to TO I-POPU
the DT I-POPU
liver NN I-POPU
or CC I-POPU
lung NN I-POPU
or CC I-POPU
of IN I-POPU
unresectable JJ I-POPU
hepatoma NN I-POPU
received VBD O
a DT O
24 CD O
hour NN O
continuous JJ B-INTV
infusion NN I-INTV
with IN I-INTV
low JJ I-INTV
dose JJ I-INTV
recombinant NN I-INTV
of IN I-INTV
IL-2 NNP I-INTV
( ( O
mainly RB O
8 CD O
x JJ O
10 CD O
( ( O
5 CD O
) ) O
JRU/day NN O
) ) O
for IN O
25-40 JJ O
days NNS O
. . O

All DT O
patients NNS O
tolerated VBD B-OC
this DT O
protocol NN O
of IN O
the DT O
therapy NN O
and CC O
the DT O
main JJ B-OC
toxic NN I-OC
effects NNS I-OC
were VBD I-OC
fever RB I-OC
and CC I-OC
general JJ I-OC
fatigue NN I-OC
. . O

Such JJ O
serious JJ O
toxicity NN B-OC
as IN O
previously RB O
reported VBN O
by IN O
high JJ O
dose JJ O
IL-2 NNP O
therapy NN O
was VBD O
not RB O
observed VBN O
. . O

Data NNP O
of IN O
hepatic JJ B-OC
and CC I-OC
renal JJ I-OC
functions NNS I-OC
were VBD O
normal JJ O
. . O

IS-IL-2 JJ O
therapy NN O
induced VBD O
a DT O
high JJ O
incidence NN O
of IN O
eosinophilia NN B-OC
( ( I-OC
12/18 CD I-OC
) ) I-OC
and CC I-OC
thrombocythemia NN I-OC
( ( O
12/18 CD O
) ) O
. . O

Peripheral JJ B-OC
natural JJ I-OC
killer NN I-OC
( ( I-OC
NK NNP I-OC
) ) I-OC
and CC I-OC
LAK NNP I-OC
activities NNS I-OC
were VBD O
augmented VBN O
in IN O
all DT O
patients NNS O
and CC O
total JJ B-OC
white JJ I-OC
blood NN I-OC
cell NN I-OC
counts NNS I-OC
were VBD O
increased VBN O
during IN O
IS-IL-2 NNP O
therapy NN O
. . O

An DT O
increase NN O
in IN O
IL-2 NNP B-OC
receptor NN I-OC
expression NN I-OC
of IN I-OC
peripheral JJ I-OC
blood NN I-OC
mononuclear NN I-OC
cells NNS I-OC
and CC I-OC
significant JJ I-OC
rises NNS I-OC
in IN I-OC
numbers NNS I-OC
of IN I-OC
Leu11 NNP I-OC
( ( I-OC
CD16 NNP I-OC
) ) I-OC
+ NN I-OC
, , I-OC
OKM1 NNP I-OC
( ( I-OC
CD11 NNP I-OC
) ) I-OC
+ NN I-OC
and CC I-OC
OKIa1 NNP I-OC
( ( I-OC
HLA-DR NNP I-OC
) ) I-OC
+ NN I-OC
were VBD O
observed VBN O
. . O

Of IN B-POPU
18 CD I-POPU
patients NNS I-POPU
12 CD I-POPU
were VBD I-POPU
evaluable JJ I-POPU
for IN I-POPU
their PRP$ I-POPU
response NN I-POPU
to TO I-POPU
therapy NN I-POPU
. . O

Partial JJ O
response NN O
( ( O
PR NNP O
) ) O
was VBD O
observed VBN O
in IN O
one CD O
unresectable JJ B-OC
hepatoma NN I-OC
and CC O
11 CD O
demonstrated VBD O
no DT B-OC
change NN I-OC
( ( I-OC
NC NNP I-OC
) ) I-OC
or CC I-OC
progressive JJ I-OC
disease NN I-OC
( ( I-OC
PD NNP I-OC
) ) I-OC
. . O

Six CD O
patients NNS O
were VBD O
not RB O
evaluable JJ O
because IN O
of IN O
additional JJ O
therapy NN O
( ( O
3 CD O
cases NNS O
) ) O
or CC O
decreasing VBG O
tumor NN O
cell NN O
markers NNS O
having VBG O
no DT O
measurable JJ O
lesions NNS O
( ( O
3 CD O
cases NNS O
) ) O
. . O

Three CD O
patients NNS O
of IN O
colorectal JJ O
cancer NN O
from IN O
an DT O
unresectable JJ O
group NN O
were VBD O
presumed VBN O
to TO O
have VB O
micrometastases NNS O
to TO O
the DT O
liver NN O
as IN O
suggested VBN O
by IN O
an DT O
elevated JJ O
serum NN O
CEA NNP O
level NN O
. . O

After IN O
receiving VBG O
IS-IL-2 JJ O
therapy NN O
they PRP O
demonstrated VBD O
a DT O
decrease NN O
in IN O
the DT O
serum NN O
CEA NNP O
level NN O
for IN O
more JJR O
than IN O
3 CD O
years NNS O
after IN O
treatment NN O
. . O

( ( O
ABSTRACT NNP O
TRUNCATED NNP O
AT NNP O
250 CD O
WORDS NNP O
) ) O
-DOCSTART- -X- O O

Pathology NN O
parameters NNS O
and CC O
adjuvant JJ B-OC
tamoxifen NN B-INTV
response NN B-OC
in IN O
a DT O
randomised JJ O
premenopausal NN B-POPU
breast NN I-POPU
cancer NN I-POPU
trial NN O
. . O

BACKGROUND NNP O
Subgroups NNP O
of IN O
breast NN O
cancer NN O
that WDT O
have VBP O
an DT O
impaired JJ O
response NN O
to TO O
endocrine VB O
treatment NN O
, , O
despite IN O
hormone NN O
receptor NN O
positivity NN O
, , O
are VBP O
still RB O
poorly RB O
defined VBN O
. . O

Breast NNP O
cancer NN O
can MD O
be VB O
subdivided VBN O
according VBG O
to TO O
standard JJ O
pathological JJ O
parameters NNS O
including VBG O
histological JJ O
type NN O
, , O
grade NN O
, , O
and CC O
assessment NN O
of IN O
proliferation NN O
. . O

These DT O
parameters NNS O
are VBP O
the DT O
net JJ O
result NN O
of IN O
combinations NNS O
of IN O
genetic JJ O
alterations NNS O
effecting VBG O
tumour JJ O
behaviour NN O
and CC O
could MD O
potentially RB O
reflect VB O
subtypes NNS O
that IN O
respond NN O
differently RB O
to TO O
endocrine VB O
treatment NN O
. . O

AIMS NNP O
To TO O
investigate VB O
the DT O
usefulness NN O
of IN O
these DT O
parameters NNS O
as IN O
predictors NNS O
of IN O
the DT O
response NN O
to TO O
tamoxifen VB B-INTV
in IN O
premenopausal JJ B-POPU
women NNS I-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

MATERIALS/METHODS NNP O
Clinically NNP O
established VBD O
pathological JJ O
parameters NNS O
were VBD O
assessed VBN O
and CC O
related VBN O
to TO O
the DT O
tamoxifen NN B-INTV
response NN O
in IN O
500 CD B-POPU
available JJ I-POPU
tumour NN I-POPU
specimens NNS I-POPU
from IN I-POPU
564 CD I-POPU
premenopausal NN I-POPU
patients NNS I-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
randomised VBD O
to TO O
either DT O
two CD O
years NNS O
of IN O
tamoxifen NN B-INTV
or CC O
no DT B-INTV
treatment NN I-INTV
with IN O
14 CD O
years NNS O
of IN O
follow NN O
up RB O
. . O

Proliferation NN O
was VBD O
further RB O
evaluated VBN O
by IN O
immunohistochemical JJ O
Ki-67 NNP O
expression NN O
. . O

RESULTS NNP O
Oestrogen NNP B-OC
receptor NN I-OC
positive JJ I-OC
ductal JJ I-OC
carcinomas NN I-OC
responded VBD O
as IN O
expected VBN O
to TO O
tamoxifen VB B-INTV
, , O
whereas IN O
the DT O
difference NN O
in IN O
recurrence NN B-OC
free JJ I-OC
survival NN I-OC
between IN O
control NN B-INTV
and CC O
tamoxifen NN B-INTV
treated VBD O
patients NNS O
was VBD O
less RBR O
apparent JJ O
in IN O
the DT O
relatively RB O
few JJ O
lobular JJ O
carcinomas NN O
. . O

For IN O
histological JJ O
grade NN O
, , O
there EX O
was VBD O
no DT O
obvious JJ O
difference NN O
in IN O
treatment NN O
response NN O
between IN O
the DT O
groups NNS O
. . O

The DT O
relation NN O
between IN O
proliferation NN O
and CC O
tamoxifen NN B-INTV
response NN O
seemed VBD O
to TO O
be VB O
more RBR B-OC
complex JJ I-OC
, , I-OC
with IN I-OC
a DT I-OC
clear JJ I-OC
response NN I-OC
in IN I-OC
tumours NN I-OC
with IN I-OC
high JJ I-OC
and CC I-OC
low JJ I-OC
proliferation NN I-OC
, , O
whereas JJ O
tumours NN O
with IN O
intermediate JJ O
proliferation NN O
defined VBN O
by IN O
Ki-67 NNP O
responded VBD O
more RBR O
poorly RB B-OC
. . O

CONCLUSIONS NNP O
Clinically NNP O
established VBD O
pathology NN O
parameters NNS O
seem VBP O
to TO O
mirror VB O
the DT O
endocrine NN O
treatment NN O
response NN O
and CC O
could MD O
potentially RB O
be VB O
valuable JJ O
in IN O
future JJ O
treatment NN O
decisions NNS O
for IN O
patients NNS B-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
. . O

-DOCSTART- -X- O O

Gefitinib NNP B-INTV
plus CC I-INTV
best JJS I-INTV
supportive JJ I-INTV
care NN I-INTV
in IN O
previously RB B-POPU
treated VBN I-POPU
patients NNS I-POPU
with IN I-POPU
refractory JJ I-POPU
advanced JJ I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
: : I-POPU
results NNS O
from IN O
a DT O
randomised VBN O
, , O
placebo-controlled JJ O
, , O
multicentre JJ O
study NN O
( ( O
Iressa NNP O
Survival NNP O
Evaluation NNP O
in IN O
Lung NNP O
Cancer NNP O
) ) O
. . O

BACKGROUND VB O
This DT O
placebo-controlled JJ B-INTV
phase NN O
III NNP O
study NN O
investigated VBD O
the DT O
effect NN B-OC
on IN I-OC
survival NN I-OC
of IN O
gefitinib NN B-INTV
as IN O
second-line JJ O
or CC O
third-line JJ O
treatment NN O
for IN O
patients NNS B-POPU
with IN I-POPU
locally RB I-POPU
advanced JJ I-POPU
or CC I-POPU
metastatic JJ I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

METHODS NNP O
1692 CD B-POPU
patients NNS I-POPU
who WP I-POPU
were VBD I-POPU
refractory JJ I-POPU
to TO I-POPU
or CC I-POPU
intolerant VB I-POPU
of IN I-POPU
their PRP$ I-POPU
latest JJS I-POPU
chemotherapy NN I-POPU
regimen NNS I-POPU
were VBD O
randomly RB O
assigned VBN O
in IN O
a DT O
ratio NN O
of IN O
two CD O
to TO O
one CD O
either DT O
gefitinib NN B-INTV
( ( I-INTV
250 CD I-INTV
mg/day NN I-INTV
) ) I-INTV
or CC I-INTV
placebo NN I-INTV
, , I-INTV
plus CC I-INTV
best JJS I-INTV
supportive JJ I-INTV
care NN I-INTV
. . O

The DT O
primary JJ O
endpoint NN O
was VBD O
survival VBN B-OC
in IN O
the DT O
overall JJ O
population NN O
of IN O
patients NNS O
and CC O
those DT O
with IN O
adenocarcinoma NN O
. . O

The DT O
primary JJ O
analysis NN O
of IN O
the DT O
population NN O
for IN O
survival NN B-OC
was VBD O
by IN O
intention NN O
to TO O
treat VB O
. . O

This DT O
study NN O
has VBZ O
been VBN O
submitted VBN O
for IN O
registration NN O
with IN O
ClinicalTrials.gov NNP O
, , O
number NN O
1839IL/709 CD O
. . O

FINDINGS JJ O
1129 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
assigned VBN I-POPU
gefitinib NNS I-POPU
and CC I-POPU
563 CD I-POPU
placebo NN I-POPU
. . O

At IN O
median JJ O
follow-up NN O
of IN O
7.2 CD O
months NNS O
, , O
median JJ B-OC
survival NN I-OC
did VBD O
not RB O
differ VB O
significantly RB O
between IN O
the DT O
groups NNS O
in IN O
the DT O
overall JJ O
population NN O
( ( O
5.6 CD O
months NNS O
for IN O
gefitinib NN O
and CC O
5.1 CD O
months NNS O
for IN O
placebo NN O
; : O
hazard CC O
ratio VB O
0.89 CD O
[ JJ O
95 CD O
% NN O
CI NNP O
0.77-1.02 CD O
] NNP O
, , O
p=0.087 NN O
) ) O
or CC O
among IN O
the DT O
812 CD B-POPU
patients NNS I-POPU
with IN I-POPU
adenocarcinoma NN I-POPU
( ( O
6.3 CD O
months NNS O
vs RB O
5.4 CD O
months NNS O
; : O
0.84 CD O
[ IN O
0.68-1.03 JJ O
] NN O
, , O
p=0.089 NN O
) ) O
. . O

Preplanned VBN O
subgroup NN O
analyses VBZ O
showed VBN O
significantly RB O
longer RBR O
survival NN B-OC
in IN O
the DT O
gefitinib NN O
group NN O
than IN O
the DT O
placebo NN O
group NN O
for IN O
never-smokers NNS B-POPU
( ( O
n=375 NN O
; : O
0.67 CD O
[ IN O
0.49-0.92 JJ O
] NN O
, , O
p=0.012 NN O
; : O
median JJ B-OC
survival NN I-OC
8.9 CD O
vs NN O
6.1 CD O
months NNS O
) ) O
and CC O
patients NNS O
of IN O
Asian JJ B-POPU
origin NN I-POPU
( ( O
n=342 JJ O
; : O
0.66 CD O
[ IN O
0.48-0.91 JJ O
] NN O
, , O
p=0.01 NN O
; : O
median JJ B-OC
survival NN I-OC
9.5 CD O
vs NN O
5.5 CD O
months NNS O
) ) O
. . O

Gefitinib NNP O
was VBD O
well RB O
tolerated VBN B-OC
, , O
as IN O
in IN O
previous JJ O
studies NNS O
. . O

INTERPRETATION NNP O
Treatment NNP O
with IN O
gefitinib NN B-INTV
was VBD O
not RB O
associated VBN O
with IN O
significant JJ O
improvement NN O
in IN O
survival NN B-OC
in IN O
either DT O
coprimary JJ O
population NN O
. . O

There EX O
was VBD O
pronounced JJ O
heterogeneity NN O
in IN O
survival JJ B-OC
outcomes NNS O
between IN O
groups NNS O
of IN O
patients NNS O
, , O
with IN O
some DT O
evidence NN O
of IN O
benefit NN O
among IN O
never-smokers NNS B-POPU
and CC I-POPU
patients NNS I-POPU
of IN I-POPU
Asian JJ I-POPU
origin NN I-POPU
. . O

-DOCSTART- -X- O O

Resisting VBG O
good JJ O
news NN O
: : O
reactions NNS O
to TO O
breast VB B-POPU
cancer NN I-POPU
risk NN I-POPU
communication NN O
. . O

Many JJ O
women NNS O
overestimate VBP O
their PRP$ O
percentage NN O
risk NN O
of IN O
breast NN O
cancer NN O
, , O
even RB O
after IN O
they PRP O
have VBP O
received VBN O
careful JJ B-INTV
estimates NNS I-INTV
from IN O
health NN O
professionals NNS O
. . O

In IN O
2 CD O
experiments NNS O
with IN O
134 CD B-POPU
young JJ I-POPU
adult NN I-POPU
women NNS I-POPU
, , I-POPU
6 CD I-POPU
variables NNS I-POPU
were VBD O
explored VBN O
that IN O
might MD O
influence VB O
such JJ O
risk NN B-OC
perception NN I-OC
persistence NN O
. . O

In IN O
Study NNP O
1 CD O
, , O
each DT O
of IN O
the DT O
following JJ O
explanations NNS O
was VBD O
unrelated JJ O
to TO O
persistence VB B-OC
: : I-OC
public JJ B-INTV
commitment NN I-INTV
, , I-INTV
self-consistency NN I-INTV
, , O
and CC O
unique JJ B-INTV
causal NN I-INTV
risk NN I-INTV
models NNS I-INTV
. . O

In IN O
Study NNP O
2 CD O
, , O
two CD O
individual JJ O
difference NN O
measures NNS O
, , O
pessimism NN O
and CC O
differences NNS O
in IN O
understanding JJ O
percentages NNS O
, , O
were VBD O
unrelated JJ O
to TO O
risk VB B-OC
perception NN I-OC
persistence NN I-OC
. . O

However RB O
, , O
providing VBG O
a DT O
" NN B-INTV
risk NN I-INTV
anchor NN I-INTV
" NNP I-INTV
based VBN I-INTV
on IN I-INTV
downward JJ I-INTV
social JJ I-INTV
comparison NN I-INTV
processes NNS I-INTV
resulted VBD O
in IN O
better JJR O
risk NN B-OC
acceptance NN I-OC
at IN O
posttest JJS O
that IN O
persisted VBD O
at IN O
a DT O
2-week JJ O
follow-up JJ O
assessment NN O
. . O

This DT O
article NN O
discusses VBZ O
why WRB O
comparison NN B-INTV
anchors NNS I-INTV
might MD O
be VB O
important JJ O
in IN O
risk NN O
feedback NN O
situations NNS O
and CC O
concludes NNS O
with IN O
recommendations NNS O
for IN O
professionals NNS O
who WP O
wish VBP O
to TO O
provide VB O
accurate NN O
risk NN O
information NN O
and CC O
have VBP O
patients NNS O
adopt VB O
that DT O
information NN O
. . O

-DOCSTART- -X- O O

Clinical JJ O
usefulness NN O
of IN O
serum NN B-INTV
prostate NN I-INTV
specific JJ I-INTV
antigen NN I-INTV
for IN O
the DT O
detection NN O
of IN O
prostate NN B-POPU
cancer NN I-POPU
is VBZ O
preserved VBN O
in IN O
men NNS B-POPU
receiving VBG I-POPU
the DT I-POPU
dual JJ I-POPU
5alpha-reductase JJ I-POPU
inhibitor NN I-POPU
dutasteride NN I-POPU
. . O

PURPOSE NNP O
We PRP O
determined VBD O
whether IN O
the DT O
decrease NN O
in IN O
serum NN O
PSA NNP O
seen VBN O
with IN O
5alpha-reductase JJ B-INTV
inhibitors NNS I-INTV
affects VBZ O
the DT O
clinical JJ O
usefulness NN O
of IN O
PSA NNP O
for IN O
prostate NN O
cancer NN O
screening VBG O
using VBG O
data NNS O
from IN O
2 CD O
dutasteride JJ O
benign JJ O
prostatic JJ O
hyperplasia NN O
studies NNS O
. . O

MATERIALS NNP O
AND NNP O
METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
2,802 CD I-POPU
men NNS I-POPU
50 CD I-POPU
years NNS I-POPU
or CC I-POPU
older JJR I-POPU
with IN I-POPU
a DT I-POPU
clinical JJ I-POPU
diagnosis NN I-POPU
of IN I-POPU
benign JJ I-POPU
prostatic JJ I-POPU
hyperplasia NN I-POPU
, , I-POPU
no DT I-POPU
history NN I-POPU
of IN I-POPU
prostate NN I-POPU
cancer NN I-POPU
, , I-POPU
PSA NNP I-POPU
1.5 CD I-POPU
to TO I-POPU
10 CD I-POPU
ng/ml NNS I-POPU
, , I-POPU
prostate NN I-POPU
volume NN I-POPU
30 CD I-POPU
cc NN I-POPU
or CC I-POPU
greater JJR I-POPU
, , I-POPU
an DT I-POPU
American NNP I-POPU
Urological NNP I-POPU
Association NNP I-POPU
symptom VBD I-POPU
score NN I-POPU
of IN I-POPU
12 CD I-POPU
or CC I-POPU
greater JJR I-POPU
and CC I-POPU
peak JJ I-POPU
urinary JJ I-POPU
flow NN I-POPU
rate NN I-POPU
15 CD I-POPU
ml NN I-POPU
per IN I-POPU
second NN I-POPU
or CC I-POPU
less JJR I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
0.5 CD I-POPU
mg NNS I-POPU
dutasteride JJ I-POPU
daily RB I-POPU
or CC I-POPU
matching VBG I-POPU
placebo NN I-POPU
for IN O
24 CD O
months NNS O
. . O

Increases NNS O
in IN O
PSA NNP O
from IN O
baseline NN O
and CC O
the DT O
maximum JJ O
increase NN O
from IN O
nadir JJ O
to TO O
month NN O
24 CD O
were VBD O
compared VBN O
between IN O
the DT O
groups NNS O
and CC O
analyzed VBN O
by IN O
prostate NN O
cancer NN O
status NN O
, , O
as IN O
determined VBN O
by IN O
PSA NNP O
driven JJ O
biopsy NN O
and CC O
an DT O
advised JJ O
cutoff NN O
of IN O
more JJR O
than IN O
4 CD O
ng/ml NNS O
after IN O
doubling VBG O
to TO O
correct VB O
for IN O
dutasteride JJ B-INTV
treatment NN O
with IN O
sensitivity NN O
and CC O
specificity NN O
calculated VBN O
for IN O
each DT O
. . O

RESULTS NNP O
In IN O
placebo NN B-INTV
treated VBN O
men NNS O
without IN O
prostate NN O
cancer NN O
there EX O
was VBD O
an DT O
8.3 CD O
% NN O
median JJ B-OC
increase NN I-OC
in IN I-OC
PSA NNP I-OC
at IN I-OC
month NN I-OC
24 CD I-OC
compared VBN O
with IN O
-59.5 CD O
% NN O
in IN O
those DT O
who WP O
received VBD O
dutasteride RB B-INTV
, , O
using VBG O
doubled VBD O
values NNS O
to TO O
correct VB O
for IN O
dutasteride JJ B-INTV
treatment NN O
. . O

In IN O
those DT O
with IN O
prostate JJ O
cancer NN O
these DT O
changes NNS O
were VBD O
23.8 CD O
% NN O
and CC O
-37.2 CD O
% NN O
, , O
respectively RB O
. . O

Using VBG B-OC
the DT I-OC
upper JJ I-OC
PSA NNP I-OC
limit NN I-OC
of IN I-OC
4 CD I-OC
ng/ml JJ I-OC
sensitivity NN I-OC
for IN O
prostate NN O
cancer NN O
in IN O
men NNS O
receiving VBG O
dutasteride NN B-INTV
vs NN I-INTV
placebo NN I-INTV
was VBD O
0.737 CD O
vs NN O
0.804 CD O
, , O
while IN O
specificity NN B-OC
was VBD O
0.671 CD O
vs JJ O
0.578 CD O
. . O

Using VBG B-OC
a DT I-OC
PSA NNP I-OC
increase NN I-OC
from IN I-OC
nadir NN I-OC
of IN I-OC
0.8 CD I-OC
ng/ml IN I-OC
the DT O
sensitivity NN B-OC
of IN O
dutasteride NN B-INTV
was VBD O
0.548 CD O
and CC O
its PRP$ O
specificity NN B-OC
was VBD O
0.795 CD O
. . O

CONCLUSIONS VB O
A DT O
doubling JJ O
factor NN O
is VBZ O
effective JJ O
for IN O
maintaining VBG O
the DT O
sensitivity NN O
and CC O
specificity NN O
of IN O
PSA NNP B-OC
for IN O
prostate NN O
cancer NN O
detection NN O
in IN O
men NNS O
on IN O
dutasteride NN B-INTV
. . O

Increases VBZ O
in IN O
serum NN B-OC
PSA NNP I-OC
in IN O
men NNS O
receiving VBG O
dutasteride NN B-INTV
should MD O
be VB O
considered VBN O
suspicious JJ O
and CC O
serial JJ O
PSA NNP B-OC
measurements NNS O
should MD O
be VB O
used VBN O
to TO O
evaluate VB O
changes NNS O
from IN O
nadir NN O
. . O

-DOCSTART- -X- O O

Fifteen-year JJ O
results NNS O
of IN O
a DT O
randomized JJ O
prospective JJ O
trial NN O
of IN O
hyperfractionated VBN B-INTV
chest JJS I-INTV
wall NN I-INTV
irradiation NN I-INTV
versus IN I-INTV
once-daily RB I-INTV
chest JJS I-INTV
wall NN I-INTV
irradiation NN I-INTV
after IN I-INTV
chemotherapy NN I-INTV
and CC O
mastectomy NN O
for IN O
patients NNS B-POPU
with IN I-POPU
locally RB I-POPU
advanced JJ I-POPU
noninflammatory JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
To TO O
analyze VB O
the DT O
results NNS O
of IN O
a DT O
Phase NNP O
III NNP O
clinical JJ O
trial NN O
that WDT O
investigated VBD O
whether IN O
a DT O
hyperfractionated JJ B-INTV
radiotherapy NN I-INTV
( ( I-INTV
RT NNP I-INTV
) ) I-INTV
schedule NN O
could MD O
reduce VB O
the DT O
risk NN O
of IN O
locoregional JJ O
recurrence NN O
in IN O
patients NNS B-POPU
with IN I-POPU
locally RB I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
treated VBN I-POPU
with IN I-POPU
chemotherapy NN I-POPU
and CC I-POPU
mastectomy NN I-POPU
. . O

METHODS NNP O
AND CC O
MATERIALS NNP O
Between NNP B-POPU
1985 CD I-POPU
and CC I-POPU
1989 CD I-POPU
, , I-POPU
200 CD I-POPU
patients NNS I-POPU
with IN I-POPU
clinical JJ I-POPU
Stage NNP I-POPU
III NNP I-POPU
noninflammatory JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
were VBD O
enrolled VBN O
in IN O
a DT O
prospective JJ O
study NN O
investigating VBG O
neoadjuvant JJ O
and CC O
adjuvant JJ O
chemotherapy NN O
. . O

Of IN B-POPU
the DT I-POPU
179 CD I-POPU
patients NNS I-POPU
treated VBN I-POPU
with IN I-POPU
mastectomy NN I-POPU
after IN I-POPU
neoadjuvant JJ I-POPU
chemotherapy NN I-POPU
, , I-POPU
108 CD I-POPU
participated VBN I-POPU
in IN O
a DT O
randomized JJ O
component NN O
of IN O
the DT O
trial NN O
that WDT O
compared VBN O
a DT O
dose-escalated JJ O
, , O
hyperfractionated VBN B-INTV
( ( I-INTV
twice-daily JJ I-INTV
, , I-INTV
b.i.d NN I-INTV
. . O

) ) B-INTV
chest JJS I-INTV
wall NN I-INTV
RT NNP I-INTV
schedule NN O
( ( O
72 CD O
Gy NNP O
in IN O
1.2-Gy JJ O
b.i.d NN O
. . O

fractions NNS O
) ) O
with IN O
a DT O
once-daily JJ O
( ( O
q.d JJ O
. . O

) ) O
schedule NN O
( ( O
60 CD O
Gy NNP O
in IN O
2-Gy JJ O
q.d NN O
. . O

fractions NNS O
) ) O
. . O

In IN O
both DT O
arms NNS O
of IN O
the DT O
study NN O
, , O
the DT O
supraclavicular JJ O
fossa NN O
and CC O
axillary JJ O
apex NN O
were VBD O
treated VBN O
once RB O
daily JJ O
to TO O
50 CD O
Gy NNP O
. . O

The DT O
median JJ O
follow-up JJ O
period NN O
was VBD O
15 CD O
years NNS O
. . O

RESULTS VB O
The DT O
15-year JJ B-OC
actuarial JJ I-OC
locoregional JJ I-OC
recurrence NN I-OC
rate NN I-OC
was VBD O
7 CD O
% NN O
for IN O
the DT O
q.d NN B-INTV
. . O

arm NN B-INTV
and CC O
12 CD O
% NN O
for IN O
the DT O
b.i.d NN B-INTV
. . O

arm NN B-INTV
( ( O
p=0.36 NN O
) ) O
. . O

The DT O
rates NNS B-OC
of IN I-OC
severe JJ I-OC
acute JJ I-OC
toxicity NN I-OC
were VBD O
similar JJ O
( ( O
4 CD O
% NN O
for IN O
q.d NN O
. . O

vs. FW O
5 CD O
% NN O
for IN O
b.i.d NN O
. . O

) ) O
, , O
but CC O
moist JJ O
desquamation NN O
developed VBD O
in IN O
42 CD O
% NN O
of IN O
patients NNS O
in IN O
the DT O
b.i.d NN B-INTV
. . O

arm NN B-INTV
compared VBN O
with IN O
28 CD O
% NN O
of IN O
the DT O
patients NNS O
in IN O
the DT O
q.d NN B-INTV
. . O

arm NN B-INTV
( ( O
p=0.16 NN O
) ) O
. . O

The DT O
15-year JJ B-OC
actuarial JJ I-OC
rate NN I-OC
of IN I-OC
severe JJ I-OC
late JJ I-OC
RT NNP I-OC
complications NNS I-OC
did VBD O
not RB O
differ VB O
between IN O
the DT O
two CD O
arms NNS O
( ( O
6 CD O
% NN O
for IN O
q.d NN O
. . O

vs. FW O
11 CD O
% NN O
for IN O
b.i.d. NN O
, , O
p=0.54 NN O
) ) O
. . O

CONCLUSION NNP O
Although IN O
the DT O
sample JJ O
size NN O
of IN O
this DT O
study NN O
was VBD O
small JJ O
, , O
we PRP O
found VBD O
no DT O
evidence NN O
that IN O
this DT O
hyperfractionation NN O
schedule NN O
of IN O
postmastectomy NN B-INTV
RT NNP I-INTV
offered VBD O
a DT O
clinical JJ O
advantage NN O
. . O

Therefore RB O
, , O
we PRP O
have VBP O
concluded VBN O
that IN O
it PRP O
should MD O
not RB O
be VB O
further RB O
studied VBN O
in IN O
this DT O
cohort NN O
of IN O
patients NNS O
. . O

-DOCSTART- -X- O O

Gemcitabine NNP B-INTV
and CC O
split-dose JJ O
paclitaxel NN B-INTV
or CC O
docetaxel NN B-INTV
in IN O
metastatic JJ O
breast NN O
cancer NN O
: : O
a DT O
randomised JJ O
phase NN O
II NNP O
study NN O
. . O

PURPOSE VB O
The DT O
purpose NN O
was VBD O
to TO O
evaluate VB O
the DT O
activity NN B-OC
and CC I-OC
toxicity NN I-OC
of IN O
split-dose JJ B-INTV
paclitaxel NN I-INTV
or CC I-INTV
docetaxel NN I-INTV
in IN I-INTV
combination NN I-INTV
with IN I-INTV
gemcitabine NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
( ( I-POPU
MBC NNP I-POPU
) ) I-POPU
who WP I-POPU
had VBD I-POPU
previously RB I-POPU
received VBN I-POPU
anthracyclines NNS I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
A NNP O
total NN B-POPU
of IN I-POPU
210 CD I-POPU
patients NNS I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
one CD O
of IN O
three CD O
treatment NN O
arms NNS O
: : O
gemcitabine NN B-INTV
1,250 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
Days VBZ I-INTV
1 CD I-INTV
and CC I-INTV
8 CD I-INTV
and CC I-INTV
paclitaxel VB I-INTV
175 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
as IN I-INTV
a DT I-INTV
3-h JJ I-INTV
infusion NN I-INTV
on IN I-INTV
Day NNP I-INTV
1 CD I-INTV
( ( I-INTV
GP1 NNP I-INTV
) ) I-INTV
; : I-INTV
gemcitabine $ I-INTV
1,000 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
Days VBZ I-INTV
1 CD I-INTV
and CC I-INTV
8 CD I-INTV
and CC I-INTV
paclitaxel VB I-INTV
100 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
as IN I-INTV
a DT I-INTV
1-h JJ I-INTV
infusion NN I-INTV
on IN I-INTV
Days NNP I-INTV
1 CD I-INTV
and CC I-INTV
8 CD I-INTV
( ( I-INTV
GP2 NNP I-INTV
) ) I-INTV
; : I-INTV
gemcitabine $ I-INTV
1,000 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
Days VBZ I-INTV
1 CD I-INTV
and CC I-INTV
8 CD I-INTV
and CC I-INTV
docetaxel VB I-INTV
40 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
as IN I-INTV
a DT I-INTV
1-h JJ I-INTV
infusion NN I-INTV
on IN I-INTV
Days NNP I-INTV
1 CD I-INTV
and CC I-INTV
8 CD I-INTV
( ( I-INTV
GD NNP I-INTV
) ) I-INTV
. . O

Cycles NNS O
were VBD O
repeated VBN O
every DT O
3 CD O
weeks NNS O
. . O

RESULTS NNP O
For IN O
the DT O
204 CD B-POPU
patients NNS I-POPU
evaluable JJ I-POPU
for IN I-POPU
response NN I-POPU
assessment NN I-POPU
, , I-POPU
the DT I-POPU
response NN I-POPU
rates NNS I-POPU
were VBD I-POPU
48.6 CD I-POPU
% NN I-POPU
for IN I-POPU
GP1 NNP I-POPU
, , I-POPU
52.2 CD I-POPU
% NN I-POPU
for IN I-POPU
GP2 NNP I-POPU
, , I-POPU
and CC I-POPU
52.3 CD I-POPU
% NN I-POPU
for IN I-POPU
GD NNP I-POPU
. . O

Median JJ B-OC
response NN I-OC
duration NN I-OC
, , I-OC
time NN I-OC
to TO I-OC
treatment NN I-OC
failure NN I-OC
, , I-OC
and CC I-OC
time NN I-OC
to TO I-OC
progression NN I-OC
( ( I-OC
TTP NNP I-OC
) ) I-OC
were VBD O
similar JJ O
in IN O
each DT O
arm NN O
. . O

Median JJ B-OC
TTP NNP I-OC
for IN O
GP1 NNP O
, , O
GP2 NNP O
and CC O
GD NNP O
was VBD O
7.5 CD O
, , O
7.0 CD O
and CC O
7.4 CD O
months NNS O
, , O
respectively RB O
. . O

For IN O
the DT O
208 CD B-POPU
patients NNS I-POPU
evaluable JJ I-POPU
for IN I-POPU
safety NN I-POPU
, , O
the DT O
most RBS O
common JJ O
grade NN O
3/4 CD O
toxicity NN B-OC
for IN O
each DT O
regimen NN O
was VBD O
neutropaenia RB B-OC
, , O
with IN O
64 CD O
% NN O
, , O
57 CD O
% NN O
, , O
and CC O
68 CD O
% NN O
for IN O
GP1 NNP O
, , O
GP2 NNP O
, , O
and CC O
GD NNP O
, , O
respectively RB O
. . O

Grade VB O
4 CD O
neutropaenia NN B-OC
, , O
grade VBD O
3/4 CD O
anaemia NN B-OC
, , I-OC
febrile JJ I-OC
neutropaenia NN I-OC
, , I-OC
and CC I-OC
diarrhoea NNS I-OC
were VBD O
more JJR O
common JJ O
in IN O
the DT O
docetaxel NN O
arm NN O
, , O
as IN O
was VBD O
the DT O
use NN O
of IN O
intravenous JJ O
antibiotics NNS O
and CC O
blood NN O
transfusions NNS O
. . O

CONCLUSION VB O
The DT O
study NN O
confirmed VBD O
the DT O
high JJ O
activity NN O
of IN O
gemcitabine-taxane JJ B-INTV
combinations NNS I-INTV
in IN O
MBC NNP O
. . O

Split-dose JJ O
paclitaxel NN B-INTV
had VBD O
similar JJ O
activity NN B-OC
and CC O
toxicity NN B-OC
to TO O
the DT O
3-weekly JJ O
administration NN O
. . O

The DT O
split-dose JJ O
docetaxel NN B-INTV
regimen NNS O
had VBD O
similar JJ O
activity NN B-OC
to TO O
the DT O
paclitaxel NN B-INTV
combinations NNS I-INTV
though IN O
associated VBN O
with IN O
higher JJR O
toxicity NN B-OC
. . O

-DOCSTART- -X- O O

Long-term JJ O
follow-up NN O
of IN O
the DT O
Stockholm NNP O
randomized VBD O
trials NNS O
of IN O
postoperative JJ B-INTV
radiation NN I-INTV
therapy NN I-INTV
versus NN I-INTV
adjuvant JJ I-INTV
chemotherapy NN I-INTV
among IN O
'high JJ B-POPU
risk NN I-POPU
' POS I-POPU
pre- NN I-POPU
and CC I-POPU
postmenopausal NN I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

For IN O
many JJ O
years NNS O
, , O
loco-regional JJ O
radiotherapy NN O
was VBD O
the DT O
standard JJ O
postoperative JJ O
treatment NN O
for IN O
node JJ B-POPU
positive JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
in IN I-POPU
Sweden NNP I-POPU
. . O

Because IN O
of IN O
encouraging VBG O
results NNS O
from IN O
trials NNS O
of IN O
adjuvant JJ B-INTV
chemotherapy NN I-INTV
in IN O
the DT O
mid NN O
1970s CD O
, , O
the DT B-POPU
Stockholm NNP I-POPU
Breast NNP I-POPU
Cancer NNP I-POPU
Study NNP I-POPU
Group NNP I-POPU
decided VBD O
to TO O
directly RB O
compare VB O
postoperative JJ B-INTV
radiation NN I-INTV
( ( I-INTV
RT NNP I-INTV
) ) I-INTV
with IN I-INTV
adjuvant JJ I-INTV
CMF-type JJ I-INTV
chemotherapy NN I-INTV
( ( I-INTV
CT NNP I-INTV
) ) I-INTV
. . O

Long-term JJ O
results NNS O
are VBP O
presented VBN O
from IN O
two CD O
randomized JJ O
trials NNS O
of IN O
RT NNP B-INTV
versus NN O
CT NNP B-INTV
in IN O
pre- NN B-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
547 CD I-POPU
) ) I-POPU
and CC I-POPU
postmenopausal NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
679 CD I-POPU
) ) I-POPU
patients NNS I-POPU
, , I-POPU
respectively RB I-POPU
, , I-POPU
with IN I-POPU
node JJ I-POPU
positive JJ I-POPU
disease NN I-POPU
or CC I-POPU
a DT I-POPU
tumour JJ I-POPU
diameter NN I-POPU
> VBD I-POPU
30 CD I-POPU
mm NN I-POPU
. . O

RT NNP O
substantially RB O
reduced VBD O
loco-regional JJ B-OC
recurrences NNS I-OC
among IN O
both DT O
pre- JJ O
and CC O
postmenopausal JJ O
patients NNS O
( ( O
relative JJ O
hazard NN O
RT NNP O
versus NN O
CT NNP O
: : O
0.67 CD O
and CC O
0.43 CD O
, , O
respectively RB O
) ) O
. . O

Among IN O
premenopausal JJ O
patients NNS O
distant JJ B-OC
metastases NNS I-OC
occurred VBD O
less RBR O
frequently RB O
in IN O
the DT O
CT NNP O
group NN O
( ( O
relative JJ O
hazard NN O
: : O
1.68 CD O
, , O
p NN O
> NNP O
0.001 CD O
) ) O
resulting VBG O
in IN O
an DT O
improved JJ O
recurrence-free JJ B-OC
survival NN I-OC
( ( O
p JJ O
= NNP O
0.04 CD O
) ) O
. . O

Overall JJ B-OC
survival NN I-OC
was VBD O
also RB O
better RB O
with IN O
CT NNP O
( ( O
cumulative JJ O
survival NN O
at IN O
15 CD O
years NNS O
: : O
50 CD O
% NN O
and CC O
44 CD O
% NN O
in IN O
the DT O
CT NNP O
and CC O
RT NNP O
groups NNS O
, , O
respectively RB O
) ) O
but CC O
the DT O
difference NN O
was VBD O
not RB O
statistically RB O
significant JJ O
. . O

Among IN O
the DT O
postmenopausal NN O
patients NNS O
there EX O
were VBD O
no DT O
substantial JJ O
differences NNS O
in IN O
terms NNS O
of IN O
recurrence-free NN B-OC
or CC I-OC
overall JJ I-OC
survival NN I-OC
between IN O
the DT O
treatment NN O
groups NNS O
. . O

The DT O
risk NN B-OC
of IN I-OC
a DT I-OC
second JJ I-OC
primary JJ I-OC
malignancy NN I-OC
, , O
however RB O
, , O
was VBD O
doubled VBN O
in IN O
the DT O
RT NNP O
group NN O
( ( O
p JJ O
> NNP O
0.01 CD O
) ) O
. . O

The DT O
most RBS O
pronounced JJ O
excess NN O
concerned JJ O
second JJ B-OC
lung NN I-OC
cancers NNS I-OC
occurring VBG O
after IN O
10 CD O
years NNS O
. . O

The DT O
cumulative JJ B-OC
incidence NN I-OC
at IN I-OC
20 CD I-OC
years NNS I-OC
was VBD O
estimated VBN O
at IN O
0.3 CD O
% NN O
and CC O
3.7 CD O
% NN O
in IN O
the DT O
CT NNP O
and CC O
RT NNP O
groups NNS O
, , O
respectively RB O
. . O

The DT O
trials NNS O
illustrate VBP O
the DT O
role NN O
of IN O
radiotherapy NN O
in IN O
preventing VBG O
loco-regional JJ B-OC
recurrences NNS I-OC
among IN O
high-risk JJ O
patients NNS O
, , O
as RB O
well RB O
as IN O
the DT O
need NN O
for IN O
systemic JJ O
treatment NN O
to TO O
control VB O
the DT O
disease NN O
systemically RB O
. . O

-DOCSTART- -X- O O

Efficacy NN O
and CC O
safety NN O
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
metastatic NN I-POPU
to TO I-POPU
bone NN I-POPU
: : I-POPU
a DT O
multicenter NN O
clinical JJ O
trial NN O
. . O

PURPOSE VB O
This DT O
study NN O
evaluated VBD O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
in IN O
breast NN B-POPU
cancer NN I-POPU
patients NNS I-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
bone NN I-POPU
metastases NNS I-POPU
. . O

MATERIALS NNP O
AND CC O
METHODS NNP O
Patients NNS B-POPU
diagnosed VBD I-POPU
with IN I-POPU
bone NN I-POPU
metastases NNS I-POPU
< VBP I-POPU
or CC I-POPU
= VBP I-POPU
6 CD I-POPU
weeks NNS I-POPU
prior RB I-POPU
to TO I-POPU
first JJ I-POPU
visit NN I-POPU
were VBD O
enrolled VBN O
. . O

Zoledronic JJ B-INTV
acid NN I-INTV
( ( O
4 CD O
mg NN O
) ) O
was VBD O
administered VBN O
via IN O
a DT O
15-minute JJ O
infusion NN O
every DT O
3 CD O
or CC O
4 CD O
weeks NNS O
for IN O
12 CD O
infusions NNS O
. . O

Skeletal-related JJ B-OC
events NNS I-OC
( ( I-OC
SREs NNP I-OC
) ) I-OC
were VBD O
defined VBN O
as IN O
pathologic JJ O
bone NN O
fractures NNS O
, , O
spinal JJ O
cord NN O
compression NN O
, , O
surgery NN O
to TO O
bone VB O
, , O
radiation NN O
therapy NN O
to TO O
bone VB O
, , O
and CC O
hypercalcemia NN O
of IN O
malignancy NN O
. . O

Primary NNP O
efficacy JJ O
end NN O
points NNS O
were VBD O
the DT O
proportion NN O
of IN O
patients NNS O
with IN O
at IN O
least JJS O
one CD O
SRE NNP O
and CC O
the DT O
time NN O
to TO O
first JJ O
SRE NNP O
. . O

Secondary JJ O
end NN O
points NNS O
included VBD O
pain NN B-OC
, , I-OC
analgesic JJ I-OC
use NN I-OC
, , I-OC
and CC I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
. . O

RESULTS NNP O
Among IN O
312 CD B-POPU
patients NNS I-POPU
enrolled VBD I-POPU
, , O
30 CD O
% NN O
experienced VBN O
at IN O
least JJS O
one CD O
SRE NNP B-OC
during IN O
the DT O
12-month JJ O
study NN O
, , O
and CC O
22 CD O
% NN O
experienced VBD O
only RB O
one CD O
SRE NNP B-OC
. . O

The DT O
median JJ O
time NN O
to TO O
first VB O
SRE NNP B-OC
was VBD O
not RB O
reached VBN O
in IN O
the DT O
intent-to-treat JJ O
population NN O
. . O

Mean NNP B-OC
pain NN I-OC
and CC I-OC
analgesic JJ I-OC
scores NNS I-OC
declined VBD I-OC
from IN O
baseline NN O
, , O
and CC O
quality-of-life JJ B-OC
scores NNS I-OC
remained VBD I-OC
stable JJ I-OC
to TO O
study VB O
end NN O
. . O

The DT O
most RBS O
frequently RB O
reported VBD O
adverse JJ O
events NNS O
, , O
regardless RB O
of IN O
relationship NN O
to TO O
study VB O
drug NN O
, , O
were VBD O
pyrexia VBN B-OC
( ( O
22 CD O
% NN O
) ) O
and CC O
bone NN B-OC
pain NN I-OC
( ( O
10 CD O
% NN O
) ) O
. . O

Serum NNP B-OC
creatinine NN I-OC
levels NNS I-OC
did VBD I-OC
not RB I-OC
significantly RB I-OC
increase VB I-OC
from IN O
baseline NN O
throughout IN O
the DT O
study NN O
. . O

CONCLUSIONS NNP O
Breast NNP B-POPU
cancer NN I-POPU
patients NNS I-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
bone NN I-POPU
metastases NNS I-POPU
who WP O
were VBD O
treated VBN O
with IN O
zoledronic JJ B-INTV
acid NN I-INTV
had VBD O
a DT O
low JJ O
incidence NN O
of IN O
SREs NNP B-OC
compared VBN O
with IN O
patients NNS O
who WP O
received VBD O
placebo NN B-INTV
in IN O
randomized JJ O
phase NN O
III NNP O
trials NNS O
, , O
and CC O
pain NN O
was VBD O
decreased VBN O
from IN O
baseline NN O
. . O

This DT O
study NN O
demonstrated VBD O
the DT O
favorable JJ O
risk NN O
: : O
benefit NN O
ratio NN O
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
for IN O
the DT O
prevention NN O
of IN O
skeletal JJ O
complications NNS O
. . O

-DOCSTART- -X- O O

Prevention NN O
of IN O
bone NN O
loss NN O
in IN O
survivors NNS B-POPU
of IN I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
A DT O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ O
clinical JJ O
trial NN O
. . O

BACKGROUND NNP O
Few NNP O
data NNS O
are VBP O
available JJ O
on IN O
the DT O
safety NN O
and CC O
efficacy NN O
of IN O
once-weekly JJ O
oral JJ O
bisphosphonate NN B-INTV
therapy NN I-INTV
in IN O
breast NN B-POPU
cancer NN I-POPU
survivors NNS I-POPU
. . O

OBJECTIVE NNP O
Our PRP$ O
objective NN O
was VBD O
to TO O
determine VB O
whether IN O
risedronate NN B-INTV
, , O
35 CD O
mg JJ O
weekly JJ O
, , O
is VBZ O
efficacious JJ O
and CC O
safe JJ O
in IN O
preventing VBG O
bone NN O
loss NN O
associated VBN O
with IN O
chemotherapy-induced JJ O
menopause NN O
. . O

DESIGN VB O
The DT O
study NN O
was VBD O
a DT O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
clinical JJ O
trial NN O
over IN O
12 CD O
months NNS O
. . O

SETTING NN O
AND CC O
PARTICIPANTS NNP O
Participants NNP B-POPU
included VBD I-POPU
87 CD I-POPU
newly RB I-POPU
postmenopausal JJ I-POPU
women NNS I-POPU
with IN I-POPU
status NN I-POPU
post NN I-POPU
chemotherapy NN I-POPU
, , I-POPU
recruited VBN I-POPU
from IN I-POPU
a DT I-POPU
breast NN I-POPU
cancer NN I-POPU
clinic NN I-POPU
in IN I-POPU
an DT I-POPU
academic JJ I-POPU
medical JJ I-POPU
center NN I-POPU
. . O

INTERVENTION JJ O
Participants NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
risedronate NN B-INTV
35 CD O
mg/wk NN O
or CC O
placebo NN B-INTV
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
The DT O
primary JJ O
outcomes NNS O
were VBD O
the DT O
12-month JJ B-OC
changes NNS I-OC
in IN I-OC
spine NN I-OC
and CC I-OC
hip NN I-OC
bone NN I-OC
mineral JJ I-OC
density NN I-OC
. . O

Secondary JJ O
outcomes NNS O
included VBD O
changes NNS B-OC
in IN I-OC
markers NNS I-OC
of IN I-OC
bone NN I-OC
resorption NN I-OC
( ( I-OC
urine JJ I-OC
N-telopeptide NNP I-OC
cross-linked JJ I-OC
collagen NN I-OC
type NN I-OC
I PRP I-OC
) ) I-OC
and CC I-OC
formation NN I-OC
( ( I-OC
osteocalcin JJ I-OC
, , I-OC
N-terminal JJ I-OC
propeptide NN I-OC
of IN I-OC
type NN I-OC
I PRP I-OC
procollagen VBP I-OC
, , I-OC
and CC I-OC
bone-specific JJ I-OC
alkaline NN I-OC
phosphatase NN I-OC
) ) I-OC
. . O

RESULTS NNP O
After IN O
12 CD O
months NNS O
, , O
bone JJ B-OC
mineral JJ I-OC
density NN I-OC
increased VBN O
by IN O
1.2 CD O
% NN O
at IN O
the DT O
spine NN O
and CC O
1.3 CD O
% NN O
at IN O
the DT O
hip NN O
in IN O
women NNS O
on IN O
risedronate NN B-INTV
vs. FW O
significant JJ O
decreases NNS O
for IN O
women NNS O
in IN O
the DT O
placebo NN O
group NN O
of IN O
0.9 CD O
% NN O
at IN O
the DT O
spine NN O
and CC O
0.8 CD O
% NN O
at IN O
the DT O
hip NN O
( ( O
P NNP O
< NNP O
0.01 CD O
, , O
difference NN O
between IN O
groups NNS O
) ) O
. . O

N-telopeptide JJ B-OC
cross-linked JJ I-OC
collagen NN I-OC
type NN I-OC
I PRP I-OC
, , O
a DT O
marker NN O
of IN O
bone NN O
resorption NN O
, , O
decreased VBN O
by IN O
19.3 CD O
% NN O
, , O
and CC O
N-terminal JJ O
propeptide NN O
of IN O
type NN O
I PRP O
procollagen VBP O
, , O
a DT O
marker NN O
of IN O
bone NN O
formation NN O
, , O
decreased VBN O
by IN O
26.6 CD O
% NN O
in IN O
participants NNS O
on IN O
active JJ O
therapy NN O
compared VBN O
with IN O
increases NNS O
in IN O
the DT O
control NN O
group NN O
. . O

Risedronate NNP B-INTV
was VBD O
well RB O
tolerated VBN B-OC
, , O
and CC O
the DT O
retention NN B-OC
rate NN I-OC
was VBD O
95 CD O
% NN O
at IN O
1 CD O
yr NN O
. . O

CONCLUSIONS NNP O
Risedronate NNP B-INTV
once RB O
weekly RB O
prevented VBD O
bone JJ O
loss NN O
and CC O
reduced JJ O
bone NN O
turnover NN O
in IN O
women NNS B-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
treated VBN I-POPU
with IN I-POPU
chemotherapy NN I-POPU
. . O

Early JJ O
measures NNS O
to TO O
prevent VB O
bone JJ O
loss NN O
should MD O
be VB O
considered VBN O
in IN O
this DT O
cohort NN O
of IN O
breast NN B-POPU
cancer NN I-POPU
survivors NNS I-POPU
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
age NN O
and CC O
radiation NN B-INTV
dose NN O
on IN O
local JJ B-OC
control NN I-OC
after IN O
breast NN B-INTV
conserving NN I-INTV
treatment NN I-INTV
: : I-INTV
EORTC JJ O
trial NN O
22881-10882 JJ O
. . O

PURPOSE NN O
To TO O
determine VB O
whether IN O
the DT O
effect NN O
of IN O
an DT O
additional JJ O
" NN B-INTV
boost NN I-INTV
" NN I-INTV
radiation NN I-INTV
after IN O
breast NN B-INTV
conservative JJ I-INTV
therapy NN I-INTV
( ( I-INTV
BCT NNP I-INTV
) ) I-INTV
on IN O
local JJ O
control NN O
depends VBZ O
on IN O
age NN O
and CC O
evaluate VB O
the DT O
impact NN O
of IN O
a DT O
treatment NN O
policy NN O
with IN O
a DT O
threshold NN O
for IN O
age NN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
We PRP B-POPU
used VBD I-POPU
data NNS I-POPU
from IN I-POPU
EORTC NNP I-POPU
22881-10882 JJ I-POPU
trial NN I-POPU
, , I-POPU
with IN I-POPU
median JJ I-POPU
follow-up NN I-POPU
of IN I-POPU
77.4 CD I-POPU
months NNS I-POPU
. . O

Patients NNS B-POPU
receiving VBG I-POPU
BCT NNP I-POPU
and CC I-POPU
50Gy CD I-POPU
whole JJ I-POPU
breast NN I-POPU
irradiation NN I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
no DT I-POPU
boost NN I-POPU
and CC I-POPU
16Gy CD I-POPU
boost NN I-POPU
( ( O
N=5318 NNP O
) ) O
. . O

RESULTS NNP O
In IN O
univariate JJ O
analysis NN O
, , O
a DT O
boost NN B-INTV
reduced VBN O
local JJ B-OC
failure NN I-OC
by IN O
a DT O
factor NN O
of IN O
2 CD O
( ( O
P NNP O
< NNP O
0.0001 CD O
) ) O
. . O

Multivariate NNP O
analysis NN O
showed VBD O
local JJ B-OC
control NN I-OC
increased VBD O
with IN O
age NN O
( ( O
P=0.0003 NNP O
) ) O
. . O

There EX O
was VBD O
no DT O
evidence NN O
that IN O
the DT O
relative JJ O
effect NN O
of IN O
a DT O
boost NN B-INTV
on IN O
local JJ B-OC
control NN I-OC
depends VBZ O
on IN O
age NN O
( ( O
P=0.97 NNP O
) ) O
However RB O
in IN O
younger JJR B-POPU
patients NNS I-POPU
the DT O
5-year JJ O
local JJ B-OC
failure NN I-OC
was VBD O
higher JJR O
, , O
therefore IN O
the DT O
absolute JJ O
reduction NN O
was VBD O
greater JJR O
. . O

If IN O
the DT O
threshold-age NN O
for IN O
boost NN O
treatment NN O
were VBD O
set VBN O
at IN O
40 CD O
years NNS O
, , O
8.4 CD B-POPU
% NN I-POPU
of IN I-POPU
the DT I-POPU
study NN I-POPU
population NN I-POPU
would MD I-POPU
receive VB I-POPU
a DT O
boost NN B-INTV
, , O
resulting VBG O
in IN O
a DT O
5-year JJ O
local JJ B-OC
failure NN I-OC
of IN O
6.1 CD O
% NN O
in IN O
the DT O
study NN O
population NN O
. . O

Changing VBG O
the DT O
threshold-age NN O
to TO O
60 CD O
years NNS O
, , O
67 CD B-POPU
% NN I-POPU
of IN I-POPU
the DT I-POPU
study NN I-POPU
population NN I-POPU
would MD O
receive VB O
a DT O
boost NN B-INTV
and CC O
the DT O
5-year JJ O
local JJ B-OC
failure NN I-OC
would MD O
be VB O
reduced VBN O
to TO O
4.4 CD O
% NN O
. . O

CONCLUSIONS NNP O
In IN O
younger JJR B-POPU
patients NNS I-POPU
a DT O
boost NN O
dose NN O
resulted VBD O
in IN O
a DT O
greater JJR O
absolute JJ O
reduction NN O
of IN O
local JJ B-OC
failure NN I-OC
. . O

The DT O
relative JJ B-OC
risk NN I-OC
reduction NN I-OC
was VBD O
however RB O
similar JJ O
for IN O
all DT O
ages NNS O
. . O

Applying VBG O
a DT O
treatment NN O
policy NN O
with IN O
a DT O
threshold-age NN O
of IN O
60 CD O
would MD O
result VB O
in IN O
0.6 CD O
% NN O
increase NN O
in IN O
local JJ B-OC
failure NN I-OC
in IN O
the DT O
total NN O
study NN O
population NN O
, , O
while IN O
sparing VBG O
the DT O
boost NN O
to TO O
1/3 CD O
of IN O
the DT O
patients NNS O
. . O

-DOCSTART- -X- O O

No DT O
association NN B-OC
between IN I-OC
dinucleotide JJ I-OC
repeat NN I-OC
polymorphism NN I-OC
in IN I-OC
intron NN I-OC
1 CD I-OC
of IN I-OC
the DT I-OC
epidermal JJ I-OC
growth NN I-OC
factor NN I-OC
receptor NN I-OC
gene NN I-OC
EGFR NNP I-OC
and CC I-OC
risk NN B-POPU
of IN I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

The DT O
tyrosine JJ O
kinase NN O
receptor NN O
EGFR NNP O
pathway NN O
is VBZ O
one CD O
of IN O
the DT O
oncogenic JJ O
signaling NN O
cascades NNS O
involved VBN O
in IN O
lung NN O
cancer NN O
, , O
mediating VBG O
the DT O
epidermal JJ O
growth NN O
factor NN O
receptor NN O
gene NN O
EGFR NNP O
. . O

First-intron NNP B-INTV
polymorphisms NN I-INTV
with IN O
greater JJR O
numbers NNS O
of IN O
CA NNP O
dinucleotide NN O
repeats NNS O
tend VBP O
to TO O
downregulate VB O
EGFR NNP O
expression NN O
, , O
which WDT O
suggests VBZ O
that IN O
this DT O
polymorphism NN B-INTV
may MD O
modulate VB O
susceptibility NN B-POPU
to TO I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

The DT O
present JJ O
hospital-based JJ B-POPU
case-control NN I-POPU
study NN I-POPU
evaluated VBD B-INTV
the DT I-INTV
possible JJ I-INTV
association NN I-INTV
of IN I-INTV
CA NNP B-POPU
repeat NN I-POPU
polymorphism NN I-POPU
in IN I-POPU
the DT I-POPU
EGFR NNP I-POPU
gene NN I-POPU
with IN I-POPU
risk NN I-POPU
of IN I-POPU
lung NN I-POPU
cancer NN I-POPU
in IN I-POPU
a DT I-POPU
Korean JJ I-POPU
population NN I-POPU
. . O

A DT O
bimodal JJ O
pattern NN O
appeared VBD O
, , O
with IN O
a DT O
frequency NN O
of IN O
57.1 CD O
% NN O
for IN O
20 CD O
CA NNP O
repeats NNS O
and CC O
18.6 CD O
% NN O
for IN O
16 CD O
CA NNP O
repeats NNS O
. . O

There EX O
was VBD O
, , O
however RB O
, , O
no DT O
significant JJ O
difference NN O
in IN O
distribution NN B-OC
of IN I-OC
allele JJ I-OC
genotypes NNS I-OC
between IN I-OC
all DT I-OC
lung NN I-OC
cancer NN I-OC
cases NNS I-OC
and CC I-OC
the DT I-OC
controls NNS I-OC
, , O
nor CC O
among IN O
histological JJ O
types NNS O
for IN O
the DT O
cases NNS O
. . O

-DOCSTART- -X- O O

Dofequidar NNP B-INTV
fumarate NN I-INTV
( ( O
MS-209 NNP O
) ) O
in IN O
combination NN O
with IN O
cyclophosphamide NN B-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
and CC I-INTV
fluorouracil NN I-INTV
for IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
or CC I-POPU
recurrent JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
To TO O
evaluate VB O
the DT O
efficacy NN B-OC
and CC I-OC
tolerability NN I-OC
of IN O
dofequidar NN B-INTV
plus CC I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
and CC I-INTV
fluorouracil NN I-INTV
( ( I-INTV
CAF NNP I-INTV
) ) I-INTV
therapy NN I-INTV
in IN O
comparison NN O
with IN O
CAF NNP B-INTV
alone RB I-INTV
, , O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
or CC I-POPU
recurrent JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

Dofequidar NNP O
is VBZ O
a DT O
novel NN O
, , O
orally RB O
active JJ O
quinoline NN O
derivative NN O
that WDT O
reverses VBZ O
multidrug JJ O
resistance NN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
In IN O
this DT O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
trial NN O
, , O
patients NNS O
were VBD O
treated VBN O
with IN O
six CD O
cycles NNS O
of IN O
CAF NNP B-INTV
therapy NN I-INTV
: : I-INTV
28 CD O
days/cycle NN B-INTV
, , I-INTV
with IN I-INTV
doxorubicin NN I-INTV
( ( I-INTV
25 CD I-INTV
mg/m2 NN I-INTV
) ) I-INTV
and CC I-INTV
fluorouracil NN I-INTV
( ( I-INTV
500 CD I-INTV
mg/m2 NN I-INTV
) ) I-INTV
administered VBN I-INTV
on IN I-INTV
days NNS I-INTV
1 CD I-INTV
and CC I-INTV
8 CD I-INTV
and CC I-INTV
cyclophosphamide NN I-INTV
( ( I-INTV
100 CD I-INTV
mg NN I-INTV
orally RB I-INTV
[ NNP I-INTV
PO NNP I-INTV
] NNP I-INTV
) ) I-INTV
administered VBD I-INTV
on IN I-INTV
day NN I-INTV
1 CD I-INTV
through IN I-INTV
14 CD I-INTV
. . O

Patients NNS O
received VBD O
dofequidar NN B-INTV
( ( I-INTV
900 CD I-INTV
mg RB I-INTV
PO NNP I-INTV
) ) I-INTV
30 CD O
minutes NNS O
before IN O
each DT O
dose NN O
of IN O
doxorubicin NN B-INTV
. . O

Primary JJ O
end NN O
point NN O
was VBD O
overall JJ B-OC
response NN I-OC
rate NN I-OC
( ( I-OC
ORR NNP I-OC
; : I-OC
partial JJ I-OC
or CC I-OC
complete JJ I-OC
response NN I-OC
) ) I-OC
. . O

In IN O
total JJ O
, , O
221 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
assessable JJ I-POPU
. . O

RESULTS NNP O
ORR NNP B-OC
was VBD O
42.6 CD O
% NN O
for IN O
CAF NNP B-INTV
compared VBN O
with IN O
53.1 CD O
% NN O
for IN O
dofequidar NN B-INTV
+ NNP I-INTV
CAF NNP I-INTV
, , O
a DT O
24.6 CD O
% NN O
relative JJ O
improvement NN O
and CC O
10.5 CD O
% NN O
absolute JJ O
increase NN O
( ( O
P NNP O
= NNP O
.077 NNP O
) ) O
. . O

There EX O
was VBD O
a DT O
trend NN O
for IN O
prolonged JJ B-OC
progression-free JJ I-OC
survival NN I-OC
( ( I-OC
PFS NNP I-OC
; : I-OC
median JJ O
241 CD O
days NNS O
for IN O
CAF NNP O
v $ O
366 CD O
days NNS O
for IN O
dofequidar NN O
+ NNP O
CAF NNP O
; : O
P NNP O
= NNP O
.145 NNP O
) ) O
. . O

In IN O
retrospectively RB O
defined VBN O
subgroups NNS O
, , O
significant JJ O
improvement NN O
in IN O
PFS NNP B-OC
in IN O
favor NN O
of IN O
dofequidar NN O
was VBD O
observed VBN O
in IN O
patients NNS B-POPU
who WP I-POPU
were VBD I-POPU
premenopausal NN I-POPU
, , I-POPU
had VBD I-POPU
no DT I-POPU
prior JJ I-POPU
therapy NN I-POPU
, , I-POPU
and CC I-POPU
were VBD I-POPU
stage NN I-POPU
IV NNP I-POPU
at IN I-POPU
diagnosis NN I-POPU
with IN I-POPU
an DT I-POPU
intact JJ I-POPU
primary JJ I-POPU
tumor NN I-POPU
. . O

Except IN O
for IN O
neutropenia NN B-OC
and CC I-OC
leukopenia NN I-OC
, , O
there EX O
was VBD O
no DT O
statistically RB O
significant JJ O
excess NN O
of IN O
grade NN O
3/4 CD O
adverse JJ O
events NNS O
compared VBN O
with IN O
CAF NNP O
. . O

Treatment NN O
with IN O
dofequidar NN B-INTV
did VBD O
not RB O
affect VB O
the DT O
plasma JJ B-OC
concentration NN I-OC
of IN I-OC
doxorubicin NN I-OC
. . O

CONCLUSION NNP O
Dofequidar NNP B-INTV
+ NNP I-INTV
CAF NNP I-INTV
was VBD O
well RB O
tolerated VBN O
and CC O
is VBZ O
suggested VBN O
to TO O
have VB O
efficacy NN O
in IN O
patients NNS B-POPU
who WP I-POPU
had VBD I-POPU
not RB I-POPU
received VBN I-POPU
prior JJ I-POPU
therapy NN I-POPU
. . O

-DOCSTART- -X- O O

Depression NNP B-OC
and CC I-OC
anxiety NN I-OC
in IN O
women NNS B-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
and CC I-POPU
their PRP$ I-POPU
partners NNS I-POPU
. . O

BACKGROUND NNP O
Psychosocial NNP B-INTV
interventions NNS I-INTV
can MD O
improve VB O
psychological JJ B-OC
quality NN I-OC
of IN I-OC
life NN I-OC
( ( I-OC
symptoms NNS I-OC
of IN I-OC
depression NN I-OC
and CC I-OC
anxiety NN I-OC
) ) I-OC
of IN O
both DT B-POPU
women NNS I-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
and CC I-POPU
their PRP$ I-POPU
partners NNS I-POPU
, , O
but CC O
are VBP O
not RB O
offered VBN O
routinely RB O
to TO O
women NNS B-POPU
and CC I-POPU
their PRP$ I-POPU
partners NNS I-POPU
. . O

OBJECTIVE NNP O
To TO O
test VB O
the DT O
hypotheses NNS O
that IN O
telephone-delivered JJ B-INTV
psychosocial JJ I-INTV
interventions NNS I-INTV
decrease NN O
depression NN B-OC
and CC I-OC
anxiety NN I-OC
in IN O
women NNS B-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
and CC I-POPU
their PRP$ I-POPU
partners NNS I-POPU
. . O

METHODS NNP O
The DT O
design NN O
of IN O
the DT O
study NN O
was VBD O
a DT O
three-wave JJ O
repeated JJ O
measures NNS O
with IN O
a DT O
between-subjects NNS O
factor NN O
( ( O
treatment NN O
group NN O
) ) O
. . O

Ninety-six JJ B-POPU
women NNS I-POPU
and CC I-POPU
their PRP$ I-POPU
96 CD I-POPU
partners NNS I-POPU
were VBD O
assigned VBN O
randomly RB O
to TO O
participate VB O
in IN O
one CD O
of IN O
three CD B-INTV
different JJ I-INTV
6-week JJ I-INTV
programs NNS I-INTV
: : I-INTV
( ( I-INTV
a DT I-INTV
) ) I-INTV
telephone NN I-INTV
interpersonal JJ I-INTV
counseling NN I-INTV
( ( I-INTV
TIP-C NNP I-INTV
) ) I-INTV
; : I-INTV
( ( I-INTV
b NN I-INTV
) ) I-INTV
self-managed JJ I-INTV
exercise NN I-INTV
; : I-INTV
or CC I-INTV
( ( I-INTV
c NN I-INTV
) ) I-INTV
attention NN I-INTV
control NN I-INTV
( ( I-INTV
AC NNP I-INTV
) ) I-INTV
. . O

RESULTS VB O
The DT O
mixed-model JJ O
analysis NN O
of IN O
variance NN O
for IN O
symptoms NNS B-OC
of IN I-OC
depression NN I-OC
among IN O
women NNS B-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
revealed VBD O
women NNS B-OC
's POS I-OC
depressive JJ I-OC
symptom NN I-OC
scores NNS I-OC
decreased VBN O
over IN O
time NN O
in IN O
all DT O
groups NNS O
. . O

For IN O
anxiety NN O
, , O
women NNS B-POPU
's POS I-POPU
symptoms NNS B-OC
of IN I-OC
anxiety NN I-OC
decreased VBN O
in IN O
the DT O
TIP-C NNP B-INTV
and CC O
exercise NN O
groups NNS O
over IN O
time NN O
, , O
but CC O
not RB O
in IN O
the DT O
AC NNP O
group NN O
. . O

A DT O
parallel JJ O
set NN O
of IN O
analyses NNS O
was VBD O
conducted VBN O
on IN O
partners NNS B-POPU
' POS I-POPU
depression NN B-OC
and CC I-OC
anxiety NN I-OC
data NNS I-OC
. . O

Symptoms NNS O
of IN O
depression NN B-OC
and CC I-OC
anxiety NN I-OC
among IN O
the DT O
partners NNS B-POPU
decreased VBD O
substantially RB O
over IN O
the DT O
course NN O
of IN O
the DT O
investigation NN O
. . O

Similar JJ O
to TO O
the DT O
women NNS B-POPU
, , I-POPU
partners NNS I-POPU
' POS I-POPU
symptoms NNS B-OC
of IN I-OC
anxiety NN I-OC
decreased VBN O
significantly RB O
in IN O
the DT O
TIP-C NNP B-INTV
and CC O
exercise NN O
groups NNS O
, , O
but CC O
not RB O
in IN O
the DT O
AC NNP O
group NN O
. . O

DISCUSSION NNP O
Findings NNS O
from IN O
this DT O
study NN O
support NN O
that IN O
these DT O
telephone-delivered JJ O
psychosocial NN O
interventions NNS O
were VBD O
effective JJ B-OC
for IN O
decreasing VBG O
symptoms NNS B-OC
of IN I-OC
depression NN I-OC
and CC I-OC
anxiety NN I-OC
to TO O
improve VB O
psychological JJ B-OC
quality NN I-OC
of IN I-OC
life NN I-OC
when WRB O
compared VBN O
to TO O
an DT O
AC NNP O
group NN O
. . O

-DOCSTART- -X- O O

[ JJ O
Effect NNP O
of IN O
ulinastatin NN B-INTV
on IN O
inflammatory JJ B-POPU
responses NNS I-POPU
induced VBN I-POPU
by IN I-POPU
oesophagectomy JJ I-POPU
] NNP I-POPU
. . O

OBJECTIVE NNP O
To TO O
examine VB O
the DT O
effect NN O
of IN O
ulinastatin NN B-INTV
( ( O
UTI NNP O
) ) O
on IN O
the DT O
inflammatory JJ B-POPU
responses NNS I-POPU
induced VBN I-POPU
by IN I-POPU
oesophagectomy NN I-POPU
. . O

METHODS NNP O
Forty NNP B-POPU
patients NNS I-POPU
with IN I-POPU
esophageal JJ I-POPU
cancer NN I-POPU
( ( I-POPU
without IN I-POPU
serious JJ I-POPU
hypertension NN I-POPU
, , I-POPU
heart NN I-POPU
disease NN I-POPU
, , I-POPU
or CC I-POPU
respiratory JJ I-POPU
function NN I-POPU
impairment NN I-POPU
, , I-POPU
including VBG I-POPU
34 CD I-POPU
men NNS I-POPU
and CC I-POPU
6 CD I-POPU
women NNS I-POPU
aged VBD I-POPU
46 CD I-POPU
to TO I-POPU
70 CD I-POPU
years NNS I-POPU
) ) I-POPU
scheduled VBD I-POPU
for IN I-POPU
oesophagectomy JJ I-POPU
via IN I-POPU
left JJ I-POPU
thoracotomy NN I-POPU
were VBD I-POPU
randomly RB I-POPU
divided VBN I-POPU
into IN I-POPU
control NN I-POPU
group NN I-POPU
( ( I-POPU
n=20 CC I-POPU
) ) I-POPU
and CC I-POPU
UTI NNP I-POPU
group NN I-POPU
( ( I-POPU
n=20 RB I-POPU
) ) I-POPU
. . O

Anesthesia NNP B-INTV
induction NN I-INTV
and CC O
perioperative JJ O
management NN O
followed VBD O
the DT O
same JJ O
protocols NNS O
in IN O
the DT O
two CD O
groups NNS O
, , O
and CC O
in IN O
UTI NNP O
group NN O
, , O
patients NNS O
received VBD B-INTV
5000 CD I-INTV
U/kg NNP I-INTV
UTI NNP I-INTV
while IN O
those DT O
in IN O
the DT O
control NN O
group NN O
were VBD O
given VBN O
the DT O
same JJ O
volume NN O
of IN O
saline NN O
. . O

Before IN O
operation NN O
( ( O
T NNP O
( ( O
1 CD O
) ) O
) ) O
, , O
10 CD O
min NN O
after IN O
recovery NN O
of IN O
two-lung JJ O
ventilation NN O
( ( O
T NNP O
( ( O
2 CD O
) ) O
) ) O
, , O
and CC O
24 CD O
h NN O
( ( O
T NNP O
( ( O
3 CD O
) ) O
) ) O
and CC O
48 CD O
h NN O
( ( O
T NNP O
( ( O
4 CD O
) ) O
) ) O
after IN O
operation NN O
, , O
the DT O
venous JJ B-OC
blood NN I-OC
sample NN I-OC
was VBD O
taken VBN O
from IN O
the DT O
internal JJ O
jugular NN O
vein NN O
and CC O
the DT O
plasma NN O
was VBD O
separated VBN O
and CC O
stored VBN O
at IN O
-70 NNP O
degrees NNS O
C NNP O
for IN O
later JJR O
analysis NN O
of IN O
IL-6 NNP O
and CC O
IL-8 NNP O
with IN O
enzyme-linked JJ O
immunosorbent NN O
assay NN O
( ( O
ELISA NNP O
) ) O
. . O

The DT O
bronchoalveoar NN B-OC
lavage NN I-OC
fluid NN I-OC
( ( I-OC
BAFL NNP I-OC
) ) I-OC
was VBD O
also RB O
collected VBN O
at IN O
T NNP O
( ( O
1 CD O
) ) O
and CC O
T NNP O
( ( O
2 CD O
) ) O
for IN O
IL-6 NNP O
and CC O
IL-8 NNP O
detection NN O
. . O

RESULTS NNP O
IL-6 JJ B-OC
, , I-OC
IL-8 JJ I-OC
levels NNS I-OC
in IN I-OC
the DT I-OC
plasma NN I-OC
and CC I-OC
BALF NNP I-OC
collected VBD O
at IN O
T NNP O
( ( O
2 CD O
) ) O
-T NN O
( ( O
4 CD O
) ) O
increased VBD B-OC
significantly RB I-OC
as IN O
compared VBN O
with IN O
those DT O
in IN O
samples NNS O
collected VBN O
at IN O
T NNP O
( ( O
1 CD O
) ) O
, , O
and CC O
their PRP$ O
peak JJ B-OC
concentration NN I-OC
inplasma NN I-OC
and CC I-OC
BALF NNP I-OC
samples NNS O
were VBD O
similar JJ O
. . O

IL-6 JJ B-OC
and CC I-OC
IL-8 JJ I-OC
levels NNS I-OC
in IN O
the DT O
UTI NNP O
group NN O
were VBD O
significantly RB B-OC
lower JJR I-OC
than IN O
those DT O
in IN O
the DT O
control NN O
group NN O
during IN O
the DT O
time NN O
points NNS O
of IN O
T NNP O
( ( O
2 CD O
) ) O
-T NN O
( ( O
4 CD O
) ) O
. . O

CONCLUSION NNP O
Inflammatory NNP O
responses VBZ O
occur VBP O
during IN O
and CC O
after IN O
oesophagectomy NN O
, , O
which WDT O
can MD O
be VB O
inhibited VBN O
with IN O
UTI NNP O
. . O

-DOCSTART- -X- O O

Stage NN B-POPU
II NNP I-POPU
carcinoma NN I-POPU
of IN I-POPU
the DT I-POPU
ovary JJ I-POPU
: : I-POPU
an DT O
analysis NN O
of IN O
survival NN B-OC
after IN O
comprehensive JJ O
surgical JJ B-INTV
staging NN I-INTV
and CC O
adjuvant JJ B-INTV
therapy NN I-INTV
. . O

Ninety-three JJ B-POPU
women NNS I-POPU
with IN I-POPU
FIGO NNP I-POPU
stage NN I-POPU
II NNP I-POPU
epithelial JJ I-POPU
ovarian JJ I-POPU
carcinoma NN I-POPU
underwent JJ O
comprehensive JJ O
surgical JJ O
staging NN O
and CC O
were VBD O
randomized VBN O
prospectively RB O
to TO O
therapy VB O
consisting NN O
of IN O
either DT O
intraperitoneal JJ B-INTV
radioactive JJ I-INTV
phosphorus NN I-INTV
or CC I-INTV
oral JJ I-INTV
melphalan NN I-INTV
. . O

No DT O
patient NN O
had VBD O
gross JJ O
residual JJ O
disease NN O
at IN O
the DT O
time NN O
of IN O
randomization NN O
. . O

Ten CD O
of IN O
the DT O
forty-five JJ B-POPU
women NNS I-POPU
treated VBN I-POPU
with IN I-POPU
melphalan NN I-POPU
experienced VBN O
severe JJ B-OC
bone NN I-OC
marrow NN I-OC
depression NN I-OC
at IN O
some DT O
time NN O
during IN O
therapy NN O
and CC O
two CD O
women NNS O
expired VBD B-OC
from IN I-OC
leukemia NN I-OC
. . O

Four CD O
of IN O
the DT O
forty-eight JJ B-POPU
women NNS I-POPU
treated VBN I-POPU
with IN I-POPU
intraperitoneal JJ I-POPU
phosphorus NN I-POPU
required VBN O
surgical JJ B-OC
reexploration NN I-OC
for IN I-OC
intestinal JJ I-OC
obstruction NN I-OC
or CC I-OC
bowel NN I-OC
injury NN I-OC
. . O

Twenty-one JJ O
women NNS O
died VBD B-OC
of IN O
their PRP$ O
disease NN O
. . O

Survival NNP B-OC
was VBD O
not RB O
statistically RB O
different JJ O
between IN O
the DT O
two CD O
treatment NN O
arms NNS O
. . O

The DT O
5-year JJ B-OC
actuarial JJ I-OC
survival NN I-OC
was VBD O
78 CD O
% NN O
. . O

-DOCSTART- -X- O O

Do VB O
cervical JJ O
cancer NN O
screening VBG O
rates NNS O
increase VBP O
in IN O
association NN O
with IN O
an DT O
intervention NN O
designed VBN O
to TO O
increase VB O
mammography NN O
usage NN O
? . O
OBJECTIVES UH O
To TO O
assess VB O
cervical JJ B-OC
cancer NN I-OC
screening VBG I-OC
behaviors NNS I-OC
among IN O
underserved JJ B-POPU
women NNS I-POPU
participating VBG I-POPU
in IN I-POPU
an DT I-POPU
intervention NN I-POPU
designed VBN I-POPU
to TO I-POPU
increase VB I-POPU
mammography NN I-POPU
use NN I-POPU
. . O

METHODS NNP O
This DT O
was VBD O
a DT O
randomized JJ O
trial NN O
of IN O
897 CD B-POPU
women NNS I-POPU
from IN I-POPU
three CD I-POPU
racial JJ I-POPU
groups NNS I-POPU
( ( I-POPU
white JJ I-POPU
, , I-POPU
African JJ I-POPU
American NNP I-POPU
, , I-POPU
Native JJ I-POPU
American NNP I-POPU
) ) I-POPU
living NN I-POPU
in IN I-POPU
a DT I-POPU
rural JJ I-POPU
county NN I-POPU
in IN I-POPU
North NNP I-POPU
Carolina NNP I-POPU
. . O

Baseline NNP O
and CC O
followup JJ O
surveys NNS O
were VBD O
completed VBN O
by IN O
815 CD B-POPU
women NNS I-POPU
; : I-POPU
775 CD I-POPU
women NNS I-POPU
provided VBD I-POPU
data NNS I-POPU
to TO O
be VB O
included VBN O
in IN O
these DT O
analyses NNS O
. . O

The DT O
intervention NN O
group NN O
received VBD O
an DT O
educational JJ B-INTV
program NN I-INTV
focused VBN I-INTV
on IN I-INTV
mammography NN I-INTV
delivered VBN I-INTV
by IN I-INTV
a DT I-INTV
lay NN I-INTV
health NN I-INTV
advisor NN I-INTV
, , O
and CC O
the DT O
control NN O
group NN O
received VBD O
a DT O
physician JJ B-INTV
letter/brochure NN I-INTV
focusing VBG I-INTV
on IN I-INTV
Pap NNP I-INTV
tests NNS I-INTV
. . O

RESULTS NNP O
Women NNP O
in IN O
both CC O
the DT O
intervention NN O
( ( O
OR NNP O
1.70 CD O
; : O
1.31 CD O
, , O
2.21 CD O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
and CC O
control NN O
groups NNS O
( ( O
OR NNP O
1.38 CD O
; : O
1.04 CD O
, , O
1.82 CD O
, , O
p NN O
= NNP O
0.025 CD O
) ) O
significantly RB O
increased VBD O
cervical JJ B-OC
cancer NN I-OC
screening VBG I-OC
rates NNS I-OC
within IN O
risk NN O
appropriate JJ O
guidelines NNS O
. . O

No DT O
differences NNS O
by IN O
racial JJ O
group NN O
were VBD O
documented VBN O
. . O

Women NNP O
categorized VBD O
in IN O
the DT O
high-risk JJ O
group NN O
for IN O
developing VBG O
cervical JJ O
cancer NN O
( ( O
> $ O
2 CD O
sexual JJ O
partners NNS O
, , O
age NN O
< VBD O
18 CD O
years NNS O
at IN O
first JJ O
sexual JJ O
intercourse NN O
, , O
smoker NN O
; : O
treated VBN O
for IN O
sexually RB O
transmitted VBN O
disease NN O
[ NNP O
STD NNP O
] NNP O
or CC O
partner NN O
with IN O
treated JJ O
STD NNP O
) ) O
significantly RB O
( ( O
OR NNP O
1.88 CD O
; : O
1.54 CD O
, , O
2.28 CD O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
increased VBD B-OC
Pap NNP I-OC
test NN I-OC
completion NN I-OC
. . O

However RB O
, , O
a DT O
nonsignificant JJ B-OC
increase NN I-OC
( ( O
OR NNP O
1.25 CD O
; : O
0.87 CD O
, , O
1.79 CD O
, , O
p NN O
= NNP O
0.221 CD O
) ) O
in IN O
Pap NNP B-OC
test NN I-OC
completion NN I-OC
was VBD O
demonstrated VBN O
in IN O
women NNS O
categorized VBN O
as IN O
low JJ O
risk NN O
for IN O
cervical JJ O
cancer NN O
. . O

CONCLUSIONS VB O
This DT O
study NN O
suggests VBZ O
that IN O
women NNS O
in IN O
an DT O
intensive JJ B-INTV
behavioral JJ I-INTV
intervention NN I-INTV
designed VBN I-INTV
to TO I-INTV
increase VB I-INTV
mammography NN I-INTV
use NN I-INTV
may MD O
also RB O
increase VB O
Pap NNP B-OC
test JJS I-OC
completion NN I-OC
, , O
similar JJ O
to TO O
a DT O
minimal JJ O
intervention NN O
focused VBD O
only RB O
on IN O
increasing VBG O
Pap NNP B-OC
test NN I-OC
completion NN I-OC
. . O

These DT O
results NNS O
have VBP O
implications NNS O
for IN O
the DT O
design NN O
and CC O
evaluation NN O
of IN O
behavioral JJ O
intervention NN O
studies NNS O
. . O

-DOCSTART- -X- O O

A DT O
prospective JJ O
study NN O
of IN O
plasma NN B-INTV
vitamin NN I-INTV
D NNP I-INTV
metabolites VBZ I-INTV
, , I-INTV
vitamin FW I-INTV
D NNP I-INTV
receptor NN I-INTV
polymorphisms NN I-INTV
, , O
and CC O
prostate NN O
cancer NN O
. . O

BACKGROUND NNP O
Vitamin NNP O
D NNP O
insufficiency NN O
is VBZ O
a DT O
common JJ O
public JJ O
health NN O
problem NN O
nationwide NN O
. . O

Circulating VBG O
25-hydroxyvitamin JJ B-INTV
D3 NNP I-INTV
( ( I-INTV
25 CD I-INTV
[ NNP I-INTV
OH NNP I-INTV
] NNP I-INTV
D NNP I-INTV
) ) I-INTV
, , O
the DT O
most RBS O
commonly RB O
used JJ O
index NN O
of IN O
vitamin NN O
D NNP O
status NN O
, , O
is VBZ O
converted VBN O
to TO O
the DT O
active JJ O
hormone NN O
1,25 CD O
dihydroxyvitamin NN O
D3 NNP O
( ( O
1,25 CD O
[ NNP O
OH NNP O
] NNP O
2D CD O
) ) O
, , O
which WDT O
, , O
operating VBG O
through IN O
the DT O
vitamin NN O
D NNP O
receptor NN O
( ( O
VDR NNP O
) ) O
, , O
inhibits VBZ O
in IN O
vitro NN O
cell NN O
proliferation NN O
, , O
induces NNS O
differentiation NN O
and CC O
apoptosis NN O
, , O
and CC O
may MD O
protect VB O
against IN O
prostate JJ O
cancer NN O
. . O

Despite IN O
intriguing JJ O
results NNS O
from IN O
laboratory JJ O
studies NNS O
, , O
previous JJ O
epidemiological JJ O
studies NNS O
showed VBD O
inconsistent JJ O
associations NNS O
of IN O
circulating VBG O
levels NNS O
of IN O
25 CD O
( ( O
OH NNP O
) ) O
D NNP O
, , O
1,25 CD O
( ( O
OH NNP O
) ) O
2D CD O
, , O
and CC O
several JJ O
VDR NNP O
polymorphisms NNS O
with IN O
prostate NN O
cancer NN O
risk NN O
. . O

Few JJ O
studies NNS O
have VBP O
explored VBN O
the DT O
joint JJ O
association NN O
of IN O
circulating VBG O
vitamin JJ O
D NNP O
levels NNS O
with IN O
VDR NNP O
polymorphisms NNS O
. . O

METHODS NNP O
AND CC O
FINDINGS NNP O
During IN O
18 CD O
y NNS O
of IN O
follow-up NN O
of IN O
14,916 CD B-POPU
men NNS I-POPU
initially RB I-POPU
free JJ I-POPU
of IN I-POPU
diagnosed JJ I-POPU
cancer NN I-POPU
, , I-POPU
we PRP I-POPU
identified VBD I-POPU
1,066 CD I-POPU
men NNS I-POPU
with IN I-POPU
incident JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
( ( I-POPU
including VBG I-POPU
496 CD I-POPU
with IN I-POPU
aggressive JJ I-POPU
disease NN I-POPU
, , I-POPU
defined VBD I-POPU
as IN I-POPU
stage NN I-POPU
C NNP I-POPU
or CC I-POPU
D NNP I-POPU
, , I-POPU
Gleason NNP I-POPU
7-10 CD I-POPU
, , I-POPU
metastatic JJ I-POPU
, , I-POPU
and CC I-POPU
fatal JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
) ) I-POPU
and CC I-POPU
1,618 CD I-POPU
cancer-free JJ I-POPU
, , I-POPU
age- JJ I-POPU
and CC I-POPU
smoking-matched JJ I-POPU
control NN I-POPU
participants NNS I-POPU
in IN I-POPU
the DT I-POPU
Physicians NNPS I-POPU
' POS I-POPU
Health NNP I-POPU
Study NNP I-POPU
. . O

We PRP O
examined VBD O
the DT O
associations NNS O
of IN O
prediagnostic JJ O
plasma NN O
levels NNS O
of IN O
25 CD B-INTV
( ( I-INTV
OH NNP I-INTV
) ) I-INTV
D NNP I-INTV
and CC O
1,25 CD B-INTV
( ( I-INTV
OH NNP I-INTV
) ) I-INTV
2D CD I-INTV
, , O
individually RB O
and CC O
jointly RB O
, , O
with IN O
total JJ O
and CC O
aggressive JJ O
disease NN O
, , O
and CC O
explored VBD O
whether IN O
relations NNS O
between IN O
vitamin NN O
D NNP O
metabolites NNS O
and CC O
prostate NN O
cancer NN O
were VBD O
modified VBN O
by IN O
the DT O
functional JJ O
VDR NNP O
FokI NNP O
polymorphism NN O
, , O
using VBG O
conditional JJ O
logistic JJ O
regression NN O
. . O

Among IN O
these DT O
US NNP O
physicians NNS O
, , O
the DT O
median JJ B-OC
plasma NN I-OC
25 CD I-OC
( ( I-OC
OH NNP I-OC
) ) I-OC
D NNP I-OC
levels NNS I-OC
were VBD O
25 CD O
ng/ml NNS O
in IN O
the DT O
blood NN O
samples NNS O
collected VBD O
during IN O
the DT O
winter NN O
or CC O
spring NN O
and CC O
32 CD O
ng/ml NN O
in IN O
samples NNS O
collected VBN O
during IN O
the DT O
summer NN O
or CC O
fall NN O
. . O

Nearly RB O
13 CD O
% NN O
( ( O
summer/fall NN O
) ) O
to TO O
36 CD O
% NN O
( ( O
winter/spring VBG O
) ) O
of IN O
the DT O
control NN O
participants NNS O
were VBD O
deficient JJ O
in IN O
25 CD B-OC
( ( I-OC
OH NNP I-OC
) ) I-OC
D NNP I-OC
( ( O
< JJ O
20 CD O
ng/ml NN O
) ) O
and CC O
51 CD O
% NN O
( ( O
summer/fall NN O
) ) O
and CC O
77 CD O
% NN O
( ( O
winter/spring VBG O
) ) O
had VBD O
insufficient JJ O
plasma NN B-OC
25 CD I-OC
( ( I-OC
OH NNP I-OC
) ) I-OC
D NNP I-OC
levels NNS I-OC
( ( O
< $ O
32 CD O
ng/ml NN O
) ) O
. . O

Plasma NNP B-OC
levels NNS I-OC
of IN I-OC
1,25 CD I-OC
( ( I-OC
OH NNP I-OC
) ) I-OC
2D CD I-OC
did VBD I-OC
not RB O
vary JJ O
by IN O
season NN O
. . O

Men NNP O
whose WP$ O
levels NNS O
for IN O
both DT O
25 CD O
( ( O
OH NNP O
) ) O
D NNP O
and CC O
1,25 CD O
( ( O
OH NNP O
) ) O
2D CD O
were VBD O
below IN O
( ( O
versus IN O
above IN O
) ) O
the DT O
median NN O
had VBD O
a DT O
significantly RB O
increased VBN O
risk NN B-OC
of IN I-OC
aggressive JJ I-OC
prostate NN I-OC
cancer NN I-OC
( ( O
odds NNS O
ratio VBP O
[ CD O
OR NNP O
] NNP O
= POS O
2.1 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
1.2-3.4 JJ O
) ) O
, , O
although IN O
the DT O
interaction NN O
between IN O
the DT O
two CD O
vitamin NN O
D NNP O
metabolites NNS O
was VBD O
not RB O
statistically RB O
significant JJ O
( ( O
pinteraction NN O
= RB O
0.23 CD O
) ) O
. . O

We PRP O
observed VBD O
a DT O
significant JJ O
interaction NN O
between IN O
circulating VBG O
25 CD B-OC
( ( I-OC
OH NNP I-OC
) ) I-OC
D NNP I-OC
levels NNS I-OC
and CC I-OC
the DT I-OC
VDR NNP I-OC
FokI NNP I-OC
genotype NN I-OC
( ( O
pinteraction NN O
< RB O
0.05 CD O
) ) O
. . O

Compared VBN O
with IN O
those DT O
with IN O
plasma JJ B-OC
25 CD I-OC
( ( I-OC
OH NNP I-OC
) ) I-OC
D NNP I-OC
levels NNS I-OC
above IN O
the DT O
median JJ O
and CC O
with IN O
the DT O
FokI NNP O
FF NNP O
or CC O
Ff NNP O
genotype NN O
, , O
men NNS O
who WP O
had VBD O
low JJ O
25 CD O
( ( O
OH NNP O
) ) O
D NNP O
levels NNS O
and CC O
the DT O
less JJR O
functional JJ O
FokI NNP O
ff NN O
genotype NN O
had VBD O
increased VBN O
risks NNS B-OC
of IN I-OC
total JJ I-OC
( ( O
OR NNP O
= VBZ O
1.9 CD O
, , O
95 CD O
% NN O
CI NNP O
1.1-3.3 CD O
) ) O
and CC O
aggressive JJ B-OC
prostate NN I-OC
cancer NN I-OC
( ( O
OR NNP O
= VBZ O
2.5 CD O
, , O
95 CD O
% NN O
CI NNP O
1.1-5.8 CD O
) ) O
. . O

Among IN O
men NNS B-POPU
with IN I-POPU
plasma NN I-POPU
25 CD I-POPU
( ( I-POPU
OH NNP I-POPU
) ) I-POPU
D NNP I-POPU
levels NNS I-POPU
above IN I-POPU
the DT I-POPU
median NN I-POPU
, , O
the DT O
ff NN O
genotype NN O
was VBD O
no RB O
longer RB O
associated VBN O
with IN O
risk NN O
. . O

Conversely RB O
, , O
among IN O
men NNS O
with IN O
the DT O
ff NN O
genotype NN O
, , O
high JJ B-OC
plasma NN I-OC
25 CD I-OC
( ( I-OC
OH NNP I-OC
) ) I-OC
D NNP I-OC
level NN I-OC
( ( O
above IN O
versus NN O
below IN O
the DT O
median NN O
) ) O
was VBD O
related VBN O
to TO O
significant JJ O
60 CD O
% NN O
approximately RB O
70 CD O
% NN O
lower JJR O
risks NNS B-OC
of IN I-OC
total JJ I-OC
and CC I-OC
aggressive JJ I-OC
prostate NN I-OC
cancer NN I-OC
. . O

CONCLUSIONS VB O
Our PRP$ O
data NNS O
suggest VBP O
that IN O
a DT O
large JJ O
proportion NN O
of IN O
the DT O
US NNP O
men NNS O
had VBD O
suboptimal JJ O
vitamin NN B-INTV
D NNP I-INTV
status NN I-INTV
( ( O
especially RB O
during IN O
the DT O
winter/spring NN O
season NN O
) ) O
, , O
and CC O
both DT O
25 CD O
( ( O
OH NNP O
) ) O
D NNP O
and CC O
1,25 CD O
( ( O
OH NNP O
) ) O
2D CD O
may MD O
play VB O
an DT O
important JJ O
role NN O
in IN O
preventing VBG O
prostate NN O
cancer NN O
progression NN O
. . O

Moreover RB O
, , O
vitamin FW O
D NNP O
status NN O
, , O
measured VBN O
by IN O
25 CD B-OC
( ( I-OC
OH NNP I-OC
) ) I-OC
D NNP I-OC
in IN I-OC
plasma NN I-OC
, , O
interacts VBZ O
with IN O
the DT O
VDR NNP B-INTV
FokI NNP I-INTV
polymorphism NN I-INTV
and CC O
modifies NNS O
prostate VBP O
cancer NN O
risk NN O
. . O

Men NN O
with IN O
the DT O
less RBR O
functional JJ O
FokI NNP O
ff NN O
genotype NN O
( ( O
14 CD O
% NN O
in IN O
the DT O
European-descent JJ O
population NN O
of IN O
this DT O
cohort NN O
) ) O
are VBP O
more RBR O
susceptible JJ O
to TO O
this DT O
cancer NN O
in IN O
the DT O
presence NN O
of IN O
low JJ O
25 CD O
( ( O
OH NNP O
) ) O
D NNP O
status NN O
. . O

-DOCSTART- -X- O O

[ JJ O
Evaluation NN O
on IN O
the DT O
effect NN O
of IN O
intervention NN O
regarding VBG O
breast JJ O
self-examination NN O
for IN O
decreasing VBG O
breast NN O
cancer NN O
mortality NN O
] NNP O
. . O

OBJECTIVE CC O
A DT O
randomized JJ O
trial NN O
of IN O
breast NN B-INTV
self-examination NN I-INTV
( ( I-INTV
BSE NNP I-INTV
) ) I-INTV
Program NNP I-INTV
was VBD O
carried VBN O
out IN O
to TO O
evaluate VB O
whether IN O
the DT O
intensive JJ O
BSE NNP B-INTV
could MD O
reduce VB O
the DT O
number NN O
of IN O
deaths NNS O
among IN O
women NNS B-POPU
from IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

METHODS NNP O
This DT O
study NN O
was VBD O
a DT O
randomized VBN O
controlled VBN O
trial NN O
( ( O
RCT NNP O
) ) O
. . O

A DT B-POPU
total NN I-POPU
of IN I-POPU
266 CD I-POPU
064 CD I-POPU
women NNS I-POPU
( ( I-POPU
age NN I-POPU
of IN I-POPU
30 CD I-POPU
to TO I-POPU
64 CD I-POPU
years NNS I-POPU
) ) I-POPU
associated VBD I-POPU
with IN I-POPU
519 CD I-POPU
textile NN I-POPU
factories NNS I-POPU
in IN I-POPU
Shanghai NNP I-POPU
had VBD I-POPU
been VBN I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
a DT I-POPU
BSE NNP I-POPU
group NN I-POPU
( ( I-POPU
132 CD I-POPU
979 CD I-POPU
women NNS I-POPU
) ) I-POPU
or CC I-POPU
a DT I-POPU
control NN I-POPU
group NN I-POPU
( ( I-POPU
133 CD I-POPU
085 CD I-POPU
women NNS I-POPU
) ) I-POPU
since IN I-POPU
1989 CD I-POPU
. . O

Initial JJ O
instruction NN O
in IN O
BSE NNP O
group NN O
would MD O
include VB O
demonstration NN O
of IN O
proper JJ O
palpation NN O
techniques NNS O
and CC O
was VBD O
followed VBN O
by IN O
2 CD O
reinforcement JJ O
sessions NNS O
during IN O
the DT O
subsequent JJ O
4 CD O
years NNS O
including VBG O
video NN O
shows NNS O
, , O
BSE NNP O
instruction NN O
sessions NNS O
and CC O
BSE NNP B-INTV
practice NN O
under IN O
medical JJ O
supervision NN O
. . O

These DT O
activities NNS O
were VBD O
continued VBN O
for IN O
5 CD O
years NNS O
. . O

Attendance NN O
at IN O
all DT O
events NNS O
was VBD O
recorded VBN O
. . O

The DT O
cohort NN O
was VBD O
followed VBN O
through IN O
July NNP O
2000 CD O
for IN O
development NN O
of IN O
breast NN O
diseases NNS O
, , O
and CC O
the DT O
breast NN O
cancer NN O
cases NNS O
were VBD O
followed VBN O
through IN O
2001 CD O
for IN O
vital JJ O
status NN O
. . O

Data NNP O
analysis NN O
methods NNS O
used VBN O
would MD O
include VB O
Kaplan-Meier NNP O
plots NNS O
, , O
log-rank JJ O
test NN O
and CC O
Cox NNP O
modeling NN O
. . O

RESULTS NNP O
Among IN O
women NNS O
under IN O
instruction NN O
, , O
864 CD O
breast NN O
cancers NNS O
detected VBD O
and CC O
133 CD O
breast NN O
cancer NN O
deaths NNS O
occurred VBD O
while IN O
896 CD O
breast NN O
cancers NNS O
were VBD O
detected VBN O
and CC O
130 CD O
deaths NNS O
recorded VBN O
in IN O
the DT O
control NN O
group NN O
. . O

The DT O
tumor NN O
size NN O
( ( O
P NNP O
= NNP O
0.07 CD O
) ) O
, , O
TNM NNP O
stage NN O
( ( O
P NNP O
= NNP O
0.39 CD O
) ) O
and CC O
cumulative JJ O
breast NN B-OC
cancer NN I-OC
mortality NN I-OC
rate NN I-OC
( ( O
P NNP O
= NNP O
0.72 CD O
) ) O
were VBD O
not RB O
significantly RB O
different JJ O
between IN O
the DT O
2 CD O
groups NNS O
. . O

However RB O
, , O
more JJR O
and CC O
smaller JJR O
fibroadenomas NN O
were VBD O
detected VBN O
in IN O
the DT O
instruction NN O
group NN O
than IN O
in IN O
the DT O
control NN O
group NN O
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

CONCLUSION NNP O
Intensive NNP B-OC
instruction NN I-OC
in IN I-OC
BSE NNP B-INTV
did VBD B-OC
not RB I-OC
seem VB I-OC
to TO I-OC
have VB I-OC
reduced VBN I-OC
the DT I-OC
mortality NN I-OC
rate NN I-OC
of IN I-OC
breast NN I-OC
cancer NN I-OC
, , I-OC
but CC I-OC
more JJR I-OC
and CC I-OC
smaller JJR I-OC
benign NN I-OC
breast NN I-OC
lumps NNS I-OC
could MD I-OC
be VB I-OC
detected VBN I-OC
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
three CD O
methods NNS O
to TO O
increase VB O
knowledge NN B-OC
about IN O
breast NN O
cancer NN O
and CC O
breast NN O
cancer NN O
screening VBG O
in IN O
screening VBG B-POPU
mammography NN I-POPU
patients NNS I-POPU
. . O

RATIONALE NNP O
AND CC O
OBJECTIVES NNP O
The DT O
specific JJ O
aim NN O
of IN O
the DT O
study NN O
was VBD O
to TO O
determine VB O
which WDT O
of IN O
several JJ O
cost-effective JJ O
interventions NNS O
is VBZ O
best RBS O
able JJ O
to TO O
improve VB O
the DT O
breast NN B-OC
cancer NN I-OC
knowledge NN I-OC
of IN O
women NNS B-POPU
who WP I-POPU
present VBP I-POPU
for IN I-POPU
screening VBG I-POPU
mammography NN I-POPU
. . O

MATERIALS NNP O
AND NNP O
METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
198 CD I-POPU
English-speaking JJ I-POPU
women NNS I-POPU
, , I-POPU
with IN I-POPU
no DT I-POPU
personal JJ I-POPU
or CC I-POPU
family NN I-POPU
history NN I-POPU
of IN I-POPU
breast NN I-POPU
cancer NN I-POPU
, , I-POPU
were VBD I-POPU
recruited VBN I-POPU
and CC I-POPU
randomized VBN I-POPU
to TO I-POPU
four CD I-POPU
groups NNS I-POPU
when WRB I-POPU
they PRP I-POPU
presented VBD I-POPU
to TO I-POPU
the DT I-POPU
clinic NN I-POPU
for IN I-POPU
a DT I-POPU
screening NN I-POPU
mammogram NN I-POPU
. . O

All DT O
women NNS O
filled VBN O
in IN O
a DT O
demographic JJ O
data NN O
form NN O
and CC O
answered VBD O
a DT O
questionnaire NN O
containing VBG O
nine CD O
questions NNS O
about IN O
breast NN O
cancer NN O
, , O
risk NN O
, , O
and CC O
screening VBG O
to TO O
assess VB O
their PRP$ O
knowledge NN O
and CC O
perception NN O
. . O

Three CD O
educational JJ B-INTV
interventions NNS I-INTV
were VBD O
tested VBN O
in IN O
this DT O
study NN O
. . O

The DT O
first JJ O
consisted VBN O
of IN O
a DT O
brochure NN B-INTV
, , I-INTV
which WDT I-INTV
provided VBD I-INTV
answers NNS I-INTV
to TO I-INTV
the DT I-INTV
questionnaire NN I-INTV
items NNS I-INTV
and CC I-INTV
addressed VBD I-INTV
the DT I-INTV
issues NNS I-INTV
in IN I-INTV
more JJR I-INTV
depth NN I-INTV
. . O

The DT O
second JJ O
intervention NN O
was VBD O
an DT O
educational JJ B-INTV
conversation NN I-INTV
with IN I-INTV
a DT I-INTV
specially RB I-INTV
trained JJ I-INTV
mammography NN I-INTV
technologist NN I-INTV
. . O

She PRP O
reviewed VBD O
the DT O
subject NN O
's POS O
answers NNS O
to TO O
the DT O
questionnaire NN O
items NNS O
correcting VBG O
and/or NN O
clarifying VBG O
them PRP O
. . O

The DT O
third JJ O
intervention NN O
consisted VBD O
of IN O
the DT O
brochure NN B-INTV
together RB I-INTV
with IN I-INTV
the DT I-INTV
conversation NN I-INTV
with IN I-INTV
a DT I-INTV
trained JJ I-INTV
technologist NN I-INTV
. . O

There EX O
was VBD O
also RB O
a DT O
control NN O
group NN O
that WDT O
just RB O
filled VBN O
in IN O
the DT O
study NN O
questionnaire NN O
but CC B-INTV
did VBD I-INTV
not RB I-INTV
receive VB I-INTV
an DT I-INTV
educational JJ I-INTV
intervention NN I-INTV
. . O

The DT O
same JJ O
questionnaire NN O
was VBD O
administered VBN O
by IN O
telephone NN O
4 CD O
to TO O
6 CD O
weeks NNS O
after IN O
the DT O
screening NN O
experience NN O
to TO O
all DT O
study NN O
subjects NNS O
. . O

Changes NNS O
in IN O
their PRP$ O
knowledge NN B-OC
and CC I-OC
perceptions NNS I-OC
of IN I-OC
breast NN I-OC
cancer NN I-OC
were VBD O
measured VBN O
and CC O
compared VBN O
. . O

RESULTS VB O
A NNP O
statistically RB O
significant JJ O
increase NN O
in IN O
knowledge NN B-OC
was VBD O
found VBN O
in IN O
all DT O
of IN O
the DT O
three CD O
investigated VBD O
groups NNS O
compared VBN O
to TO O
the DT O
control NN O
group NN O
. . O

There EX O
were VBD O
no DT O
statistically RB O
significant JJ O
differences NNS O
in IN O
the DT O
amount NN O
of IN O
increase NN O
between IN O
women NNS O
who WP O
underwent VBP O
different JJ O
interventions NNS O
. . O

CONCLUSIONS NNP O
All NNP O
three CD O
interventions NNS O
resulted VBD O
in IN O
increased VBN O
knowledge NN B-OC
about IN O
breast NN O
cancer NN O
and CC O
screening NN O
. . O

No DT O
differences NNS O
in IN O
the DT O
amount NN O
of IN O
knowledge NN B-OC
increase NN O
were VBD O
found VBN O
between IN O
three CD O
interventions NNS O
tested VBN O
. . O

The DT O
educational JJ O
brochure NN O
seems VBZ O
to TO O
represent VB O
the DT O
most RBS O
convenient JJ O
and CC O
least JJS O
costly JJ O
method NN O
to TO O
increase VB O
knowledge NN B-OC
about IN O
breast NN O
cancer NN O
and CC O
screening VBG O
among IN O
women NNS O
who WP O
present VBP O
for IN O
screening VBG O
mammography NN O
. . O

-DOCSTART- -X- O O

Women NNP B-POPU
's POS I-POPU
responses NNS I-POPU
to TO I-POPU
information NN I-POPU
on IN I-POPU
mammographic JJ I-POPU
breast NN I-POPU
density NN I-POPU
. . O

The DT O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
the DT O
negative JJ O
and CC O
positive JJ O
outcomes NNS O
of IN O
providing VBG O
mammographic JJ O
breast NN O
density NN O
( ( O
MBD NNP O
) ) O
information NN O
to TO O
participants NNS B-POPU
of IN I-POPU
a DT I-POPU
screening JJ I-POPU
program NN I-POPU
. . O

A DT O
randomized JJ O
experiment NN O
was VBD O
conducted VBN O
with IN O
a DT O
sample NN B-POPU
of IN I-POPU
618 CD I-POPU
women NNS I-POPU
50 CD I-POPU
years NNS I-POPU
or CC I-POPU
older JJR I-POPU
with IN I-POPU
MBD NNP I-POPU
greater JJR I-POPU
than IN I-POPU
50 CD I-POPU
% NN I-POPU
of IN I-POPU
breast NN I-POPU
volume NN I-POPU
. . O

The DT O
intervention NN O
consisted VBD O
of IN O
reporting VBG B-INTV
the DT I-INTV
presence NN I-INTV
of IN I-INTV
MBD NNP I-INTV
in IN I-INTV
the DT I-INTV
screening NN I-INTV
mammography NN I-INTV
results NNS I-INTV
letter NN I-INTV
that WDT I-INTV
was VBD I-INTV
sent VBN I-INTV
along IN I-INTV
with IN I-INTV
an DT I-INTV
information NN I-INTV
pamphlet NN I-INTV
. . O

Compared VBN O
to TO O
the DT O
controls NNS B-INTV
, , O
more JJR O
women NNS O
in IN O
the DT O
intervention NN O
group NN O
described VBD O
the DT O
term NN O
breast NN B-OC
density NN I-OC
correctly RB O
and CC O
recognized VBD O
it PRP O
as IN O
a DT O
risk NN O
factor NN O
for IN O
breast NN O
cancer NN O
. . O

Although IN O
at IN O
the DT O
4-week JJ O
follow-up NN O
the DT O
intervention NN O
group NN O
indicated VBD O
that IN O
they PRP O
were VBD O
" JJ O
very RB O
likely JJ O
" NN O
to TO O
have VB O
an DT O
annual JJ B-INTV
clinical JJ I-INTV
breast NN I-INTV
examination NN I-INTV
more RBR O
frequently RB O
than IN O
controls NNS O
, , O
no DT O
differences NNS O
were VBD O
detected VBN O
at IN O
6 CD O
months NNS O
. . O

There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
on IN O
other JJ O
behavioural JJ B-OC
or CC I-OC
psychological JJ I-OC
measures NNS I-OC
, , O
although IN O
at IN O
the DT O
4-week JJ O
follow-up JJ O
the DT O
control NN O
group NN O
perceived VBD O
their PRP$ O
risk NN O
for IN O
breast NN O
cancer NN O
, , O
relative VBP O
to TO O
other JJ O
women NNS O
their PRP$ O
age NN O
, , O
as IN O
" PDT O
a DT O
lot NN O
lower JJR O
" NN O
than IN O
did VBD O
women NNS O
in IN O
the DT O
intervention NN O
group NN O
. . O

The DT O
results NNS O
demonstrate VBP O
a DT O
feasible JJ O
and CC O
non-threatening JJ O
way NN O
to TO O
provide VB O
women NNS O
with IN O
important JJ O
personalized VBN O
information NN O
about IN O
breast NN B-OC
cancer NN I-OC
risk NN I-OC
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
split-course JJ B-INTV
radiation NN I-INTV
therapy NN I-INTV
and CC O
continuous JJ B-INTV
radiation NN I-INTV
therapy NN I-INTV
for IN O
unresectable JJ B-POPU
bronchogenic JJ I-POPU
carcinoma NN I-POPU
: : I-POPU
5 CD O
year NN O
results NNS O
. . O

One CD B-POPU
hundred CD I-POPU
and CC I-POPU
eighty-eight JJ I-POPU
patients NNS I-POPU
with IN I-POPU
inoperable JJ I-POPU
or CC I-POPU
unresectable JJ I-POPU
bronchogenic JJ I-POPU
carcinoma NN I-POPU
were VBD O
stratified VBN O
by IN O
cell NN O
type NN O
, , O
TNM NNP O
staging NN O
, , O
and CC O
prior RB O
surgery NN O
and CC O
then RB O
randomized VBN O
into IN O
two CD O
treatment NN O
groups NNS O
: : O
continuous JJ B-INTV
radiation NN I-INTV
therapy NN I-INTV
and CC I-INTV
split-course JJ I-INTV
radiation NN I-INTV
therapy NN I-INTV
. . O

There EX O
was VBD O
no DT O
difference NN O
in IN O
clinical JJ O
or CC O
objective JJ O
improvement NN O
in IN O
the DT O
two CD O
groups NNS O
. . O

Survival JJ B-OC
rates NNS I-OC
for IN O
cases NNS O
of IN O
squamous JJ O
cell NN O
carcinoma NN O
, , O
small JJ O
cell NN O
carcinoma NN O
, , O
and CC O
adrenocarcinoma NN O
were VBD O
the DT O
same JJ O
after IN O
both DT O
regimens NNS O
of IN O
therapy NN O
. . O

Split-course JJ B-OC
therapy NN I-OC
resulted VBD O
in IN O
a DT O
significantly RB O
better JJR O
survival NN O
rate NN O
in IN O
cases NNS O
of IN O
large JJ O
cell NN O
carcinoma NN O
but CC O
the DT O
number NN O
of IN O
cases NNS O
was VBD O
small JJ O
. . O

We PRP O
doubt VBP O
that IN O
the DT O
difference NN O
is VBZ O
clinically RB O
significant JJ O
. . O

Objective JJ B-OC
roentgenographic JJ I-OC
response NN I-OC
was VBD O
accompanied VBN O
by IN O
improved JJ B-OC
survival NN I-OC
in IN O
squamous JJ O
cell NN O
carcinoma NN O
, , O
but CC O
not RB O
in IN O
the DT O
other JJ O
three CD O
cell NN O
types NNS O
. . O

Split-course JJ O
radiation NN O
therapy NN O
is VBZ O
superior JJ O
to TO O
continuous JJ O
radiation NN O
therapy NN O
because IN O
it PRP O
is VBZ O
better RBR B-OC
tolerated VBN I-OC
by IN O
the DT O
patient NN O
and CC O
because IN O
re-examination NN O
of IN O
the DT O
patient NN O
prior RB O
to TO O
the DT O
second JJ O
half NN O
of IN O
split-course JJ O
therapy NN O
permits VBZ O
the DT O
detection NN O
of IN O
new JJ O
metastatic JJ O
disease NN O
that WDT O
has VBZ O
become VBN O
manifest JJS O
during IN O
the DT O
rest NN O
period NN O
and CC O
spares VBZ O
the DT O
patient NN O
the DT O
futile JJ O
second JJ O
half NN O
of IN O
radiation NN O
therapy NN O
. . O

-DOCSTART- -X- O O

A DT O
randomized JJ O
, , O
double-blind JJ O
, , O
phase NN O
II NNP O
study NN O
of IN O
two CD O
doses NNS O
of IN O
pemetrexed JJ B-INTV
as IN O
first-line JJ O
chemotherapy NN O
for IN O
advanced JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
Pemetrexed NNP B-INTV
has VBZ O
shown VBN O
varied JJ O
response NN O
rates NNS O
in IN O
advanced JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

This DT O
randomized JJ O
, , O
double-blind JJ O
, , O
phase NN O
II NNP O
study NN O
was VBD O
conducted VBN O
to TO O
assess VB O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
two CD O
doses NNS O
of IN O
pemetrexed NN B-INTV
in IN O
a DT O
homogeneous JJ O
population NN O
. . O

A DT O
secondary JJ O
objective NN O
was VBD O
to TO O
identify VB O
molecular JJ O
biomarkers NNS O
correlating VBG O
with IN O
response NN B-OC
and CC I-OC
toxicity NN I-OC
. . O

EXPERIMENTAL NNP O
DESIGN NNP O
Patients NNPS B-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
or CC I-POPU
locally RB I-POPU
recurrent JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
received VBD O
600 CD O
mg/m NN O
( ( O
2 CD O
) ) O
( ( B-INTV
P600 NNP I-INTV
arm NN O
) ) O
or CC O
900 CD O
mg/m NN O
( ( O
2 CD O
) ) O
( ( B-INTV
P900 NNP I-INTV
arm NN O
) ) O
of IN O
pemetrexed NN B-INTV
on IN O
day NN O
1 CD O
of IN O
a DT O
21-day JJ O
cycle NN O
. . O

All DT O
patients NNS O
received VBD O
folic JJ B-INTV
acid NN I-INTV
and CC I-INTV
vitamin NN I-INTV
B NNP I-INTV
( ( I-INTV
12 CD I-INTV
) ) I-INTV
supplementation NN I-INTV
. . O

RESULTS VB O
The DT B-POPU
P600 NNP I-POPU
( ( I-POPU
47 CD I-POPU
patients NNS I-POPU
) ) I-POPU
and CC I-POPU
P900 NNP I-POPU
( ( I-POPU
45 CD I-POPU
patients NNS I-POPU
) ) I-POPU
arms NNS O
had VBD O
response NN B-OC
rates NNS I-OC
of IN O
17.0 CD O
% NN O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
7.7-30.8 CD O
% NN O
) ) O
and CC O
15.6 CD O
% NN O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
6.5-29.5 CD O
% NN O
) ) O
with IN O
approximately RB O
50 CD O
% NN O
stable JJ O
disease NN O
per IN O
arm NN O
, , O
median JJ B-OC
progression-free JJ I-OC
survival NN I-OC
of IN O
4.2 CD O
and CC O
4.1 CD O
months NNS O
, , O
and CC O
median JJ B-OC
times NNS I-OC
to TO I-OC
tumor VB I-OC
progression NN I-OC
of IN O
4.2 CD O
and CC O
4.6 CD O
months NNS O
, , O
respectively RB O
. . O

Both DT O
arms NNS O
exhibited VBD O
minimal JJ B-OC
toxicity NN I-OC
( ( O
grade JJ O
3/4 CD O
neutropenia JJ B-OC
< RB O
20 CD O
% NN O
, , O
leukopenia NN B-OC
< VBD O
9 CD O
% NN O
, , O
and CC O
other JJ B-OC
toxicities NNS I-OC
< VBP O
5 CD O
% NN O
) ) O
. . O

Tumor NN O
samples NNS O
from IN O
49 CD O
patients NNS O
were VBD O
assessed VBN O
for IN O
the DT O
expression NN O
levels NNS O
of IN O
12 CD O
pemetrexed-related JJ B-INTV
genes NNS O
. . O

Folylpolyglutamate NNP O
synthetase NN O
and CC O
thymidine JJ O
phosphorylase NN O
correlated VBN O
with IN O
efficacy NN B-OC
. . O

Best JJS B-OC
response NN I-OC
rates NNS I-OC
and CC I-OC
median JJ I-OC
time NN I-OC
to TO I-OC
tumor VB I-OC
progression NN I-OC
for IN O
high JJ O
versus NN O
low JJ O
thymidine NN O
phosphorylase NN O
expression NN O
were VBD O
27.6 CD O
% NN O
versus IN O
6.3 CD O
% NN O
( ( O
P NNP O
= NNP O
0.023 CD O
) ) O
and CC O
5.4 CD O
versus NN O
1.9 CD O
months NNS O
( ( O
P NNP O
= NNP O
0.076 CD O
) ) O
, , O
and CC O
for IN O
folylpolyglutamate JJ O
synthetase NN O
were VBD O
37.5 CD O
% NN O
versus IN O
10.0 CD O
% NN O
( ( O
P NNP O
= NNP O
0.115 CD O
) ) O
and CC O
8.6 CD O
versus NN O
3.0 CD O
months NNS O
( ( O
P NNP O
= NNP O
0.019 CD O
) ) O
, , O
respectively RB O
. . O

gamma-Glutamyl JJ O
hydrolase NN O
expression NN O
correlated VBN O
with IN O
grade JJ B-OC
3/4 CD I-OC
toxicities NNS I-OC
: : I-OC
78.6 CD O
% NN O
for IN O
high JJ O
versus NN O
27.3 CD O
% NN O
for IN O
low JJ O
gamma-glutamyl JJ O
hydrolase NN O
( ( O
P NNP O
= NNP O
0.024 CD O
) ) O
. . O

CONCLUSION VB O
The DT O
two CD O
pemetrexed JJ B-INTV
doses NNS O
yielded VBD O
similar JJ O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
profiles NNS O
. . O

Exploratory NNP O
biomarker NN O
analysis NN O
identified VBN O
efficacy NN B-OC
and CC I-OC
toxicity NN I-OC
correlations NNS O
and CC O
warrants NNS O
further JJ O
evaluation NN O
. . O

-DOCSTART- -X- O O

Severe NNP O
enteropathy NN O
among IN O
patients NNS B-POPU
with IN I-POPU
stage NN I-POPU
II/III NNP I-POPU
colon NN I-POPU
cancer NN I-POPU
treated VBN O
on IN O
a DT O
randomized JJ O
trial NN O
of IN O
bolus JJ B-INTV
5-fluorouracil/leucovorin JJ I-INTV
plus CC I-INTV
or CC I-INTV
minus CC I-INTV
oxaliplatin NN I-INTV
: : I-INTV
a DT O
prospective JJ O
analysis NN O
. . O

BACKGROUND NNP O
Cases NNP O
of IN O
severe JJ O
gastrointestinal JJ O
toxicity NN O
were VBD O
monitored VBN O
prospectively RB O
during IN O
NSABP NNP O
C-07 NNP O
, , O
a DT O
randomized JJ O
clinical JJ O
trial NN O
of IN O
adjuvant JJ O
therapy NN O
for IN O
patients NNS B-POPU
with IN I-POPU
stage NN I-POPU
II/III NNP I-POPU
colon NN I-POPU
cancer NN I-POPU
. . O

METHODS NNP O
Patients NNPS O
were VBD O
treated VBN O
with IN O
weekly JJ O
bolus NN B-INTV
5-fluorouracil JJ I-INTV
( ( I-INTV
5-FU JJ I-INTV
) ) I-INTV
and CC I-INTV
leucovorin $ I-INTV
( ( O
FL NNP O
; : O
" NNP O
Roswell NNP O
Park NNP O
Regimen NNP O
" NNP O
) ) O
or CC O
the DT O
same JJ B-INTV
regimen NNS I-INTV
plus CC I-INTV
oxaliplatin NN I-INTV
( ( I-INTV
FLOX NNP I-INTV
) ) I-INTV
. . O

RESULTS NNP O
Of IN O
1857 CD B-POPU
patients NNS I-POPU
, , I-POPU
79 CD I-POPU
( ( I-POPU
4.3 CD I-POPU
% NN I-POPU
) ) I-POPU
developed VBD I-POPU
a DT I-POPU
syndrome NN I-POPU
of IN I-POPU
bowel NN I-POPU
wall NN I-POPU
injury NN I-POPU
( ( I-POPU
BWI NNP I-POPU
, , I-POPU
small JJ I-POPU
or CC I-POPU
large JJ I-POPU
) ) I-POPU
characterized VBN I-POPU
by IN I-POPU
hospitalization NN I-POPU
for IN I-POPU
the DT I-POPU
management NN I-POPU
of IN I-POPU
severe JJ I-POPU
diarrhea NN I-POPU
or CC I-POPU
dehydration NN I-POPU
and CC I-POPU
radiographic JJ I-POPU
or CC I-POPU
endoscopic JJ I-POPU
evidence NN I-POPU
of IN I-POPU
bowel NN I-POPU
wall NN I-POPU
thickening NN I-POPU
or CC I-POPU
ulceration NN I-POPU
. . O

Fifty-one CD O
( ( O
64.6 CD O
% NN O
) ) O
of IN O
these DT O
adverse JJ B-OC
events NNS I-OC
occurred VBD O
in IN O
patients NNS O
treated VBN O
with IN O
FLOX NNP B-INTV
and CC O
28 CD O
( ( O
35.4 CD O
% NN O
) ) O
in IN O
those DT O
treated VBN O
with IN O
FL NNP O
( ( O
P NNP O
< NNP O
.01 NNP O
) ) O
. . O

Enteric JJ B-OC
sepsis NN I-OC
( ( I-OC
ES NNP I-OC
) ) I-OC
, , O
characterized VBN O
by IN O
grade NN B-OC
3 CD I-OC
or CC I-OC
greater JJR I-OC
diarrhea NN I-OC
and CC I-OC
grade VBD I-OC
4 CD I-OC
neutropenia NN I-OC
with IN I-OC
or CC I-OC
without IN I-OC
proven JJ I-OC
bacteremia NN I-OC
occurred VBD O
in IN O
22 CD O
patients NNS O
treated VBN O
with IN O
FLOX NNP B-INTV
, , O
versus NN O
8 CD O
in IN O
those DT O
treated VBN O
with IN O
FL NNP B-INTV
( ( O
P NNP O
= NNP O
.01 NNP O
) ) O
. . O

Patients NNPS O
> JJ O
60 CD O
years NNS O
were VBD O
at IN O
higher JJR B-OC
risk NN I-OC
for IN I-OC
BWI NNP I-OC
after IN O
treatment NN O
with IN O
FLOX NNP B-INTV
( ( O
6.7 CD O
% NN O
) ) O
versus NN O
treatment NN O
with IN O
FL NNP B-INTV
( ( O
2.9 CD O
% NN O
, , O
P NNP O
< NNP O
.01 NNP O
) ) O
. . O

Female JJ O
patients NNS O
had VBD O
a DT O
higher JJR B-OC
incidence NN I-OC
of IN I-OC
BWI NNP I-OC
with IN O
FLOX NNP B-INTV
( ( O
9.1 CD O
% NN O
) ) O
than IN O
with IN O
FL NNP O
( ( O
3.9 CD O
% NN O
, , O
P NNP O
< NNP O
.01 NNP O
) ) O
. . O

Severe JJ B-OC
gastrointestinal JJ I-OC
toxicity NN I-OC
usually RB O
occurred VBD O
during IN O
the DT O
third JJ O
or CC O
fourth JJ O
week NN O
on IN O
the DT O
first JJ O
cycle NN O
of IN O
therapy NN O
, , O
required VBN O
hospitalization NN O
, , O
and CC O
was VBD O
managed VBN O
with IN O
fluids NNS O
, , O
antidiarrheals NNS O
, , O
and CC O
antibiotics NNS O
. . O

There EX O
were VBD O
5 CD O
deaths NNS B-OC
( ( O
0.3 CD O
% NN O
) ) O
due JJ O
to TO O
enteropathy VB O
, , O
2 CD O
related VBN O
to TO O
ES NNP O
and CC O
3 CD O
related VBN O
to TO O
both DT O
BWI NNP O
and CC O
ES NNP O
. . O

Seventy-one CD O
percent NN O
of IN O
patients NNS O
resumed VBN O
treatment NN O
with IN O
FL NNP B-INTV
after IN O
recovery NN O
. . O

CONCLUSIONS NNP O
Patients NNPS O
treated VBD O
with IN O
adjuvant JJ O
FL NNP B-INTV
should MD O
be VB O
closely RB O
monitored VBN O
for IN O
diarrhea NN B-OC
and CC O
aggressively RB O
managed VBN O
, , O
especially RB O
if IN O
oxaliplatin VBN O
has VBZ O
been VBN O
added VBN O
to TO O
the DT O
regimen NNS O
. . O

Society NN O
. . O

-DOCSTART- -X- O O

Phase NNP O
II NNP O
study NN O
of IN O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
bevacizumab NN B-INTV
in IN I-INTV
combination NN I-INTV
with IN I-INTV
chemotherapy NN I-INTV
or CC O
erlotinib NN B-INTV
compared VBN O
with IN O
chemotherapy NN B-INTV
alone RB I-INTV
for IN O
treatment NN B-POPU
of IN I-POPU
recurrent NN I-POPU
or CC I-POPU
refractory NN I-POPU
non JJ I-POPU
small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
Bevacizumab NNP B-INTV
, , O
a DT O
humanized JJ O
anti-vascular JJ O
endothelial JJ O
growth NN O
factor NN O
monoclonal JJ O
antibody NN O
, , O
and CC O
erlotinib RB B-INTV
, , O
a DT O
reversible JJ O
, , O
orally RB O
available JJ O
epidermal JJ O
growth NN O
factor NN O
receptor NN O
tyrosine NN O
kinase NN O
inhibitor NN O
, , O
have VBP O
demonstrated VBN O
evidence NN O
of IN O
a DT O
survival JJ O
benefit NN O
in IN O
the DT O
treatment NN O
of IN O
non-small-cell JJ O
lung NN O
cancer NN O
( ( O
NSCLC NNP O
) ) O
. . O

A DT O
single-arm JJ O
phase NN O
I PRP O
and CC O
II NNP O
study NN O
of IN O
bevacizumab NN B-INTV
plus CC I-INTV
erlotinib NN I-INTV
demonstrated VBD O
encouraging JJ O
efficacy NN O
, , O
with IN O
a DT O
favorable JJ O
safety NN O
profile NN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
A NNP O
multicenter NN O
, , O
randomized VBN O
phase NN O
II NNP O
trial NN O
evaluated VBD O
the DT O
safety NN O
of IN O
combining VBG B-INTV
bevacizumab NN I-INTV
with IN I-INTV
either DT I-INTV
chemotherapy NN I-INTV
( ( I-INTV
docetaxel NN I-INTV
or CC I-INTV
pemetrexed NN I-INTV
) ) I-INTV
or CC I-INTV
erlotinib JJ I-INTV
and CC O
preliminarily RB O
assessed VBN O
these DT O
combinations NNS O
versus VBP O
chemotherapy NN B-INTV
alone RB O
, , O
as IN O
measured VBN O
by IN O
progression-free JJ B-OC
survival NN I-OC
( ( I-OC
PFS NNP I-OC
) ) I-OC
. . O

All DT B-POPU
patients NNS I-POPU
had VBD I-POPU
histologically RB I-POPU
confirmed VBN I-POPU
nonsquamous JJ I-POPU
NSCLC NNP I-POPU
that WDT I-POPU
had VBD I-POPU
progressed VBN I-POPU
during IN I-POPU
or CC I-POPU
after IN I-POPU
one CD I-POPU
platinum-based JJ I-POPU
regimen NNS I-POPU
. . O

RESULTS NNP O
One CD B-POPU
hundred VBD I-POPU
twenty NN I-POPU
patients NNS I-POPU
were VBD O
randomly RB O
assigned VBN O
and CC O
treated VBN O
. . O

No DT O
unexpected JJ O
adverse JJ B-OC
events NNS I-OC
were VBD O
noted VBN O
. . O

Fewer JJR O
patients NNS O
( ( O
13 CD O
% NN O
) ) O
in IN O
the DT O
bevacizumab-erlotinib JJ B-INTV
arm NN O
discontinued VBN O
treatment NN O
as IN O
a DT O
result NN B-OC
of IN I-OC
adverse JJ I-OC
events NNS I-OC
than IN O
in IN O
the DT O
chemotherapy NN B-INTV
alone RB O
( ( O
24 CD O
% NN O
) ) O
or CC O
bevacizumab-chemotherapy NN B-INTV
( ( O
28 CD O
% NN O
) ) O
arms NNS O
. . O

The DT O
incidence NN O
of IN O
grade NN B-OC
5 CD I-OC
hemorrhage NN I-OC
in IN O
patients NNS O
receiving VBG O
bevacizumab NN B-INTV
was VBD O
5.1 CD O
% NN O
. . O

Although IN O
not RB O
statistically RB O
significant JJ O
, , O
relative JJ O
to TO O
chemotherapy VB O
alone RB O
, , O
the DT O
risk NN B-OC
of IN I-OC
disease NN I-OC
progression NN I-OC
or CC I-OC
death NN I-OC
was VBD O
0.66 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.38 CD O
to TO O
1.16 CD O
) ) O
among IN O
patients NNS O
treated VBN O
with IN O
bevacizumab-chemotherapy NN B-INTV
and CC O
0.72 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.42 CD O
to TO O
1.23 CD O
) ) O
among IN O
patients NNS O
treated VBN O
with IN O
bevacizumab-erlotinib JJ B-INTV
. . O

One-year JJ B-OC
survival NN I-OC
rate NN I-OC
was VBD O
57.4 CD O
% NN O
for IN O
bevacizumab-erlotinib NN B-INTV
and CC O
53.8 CD O
% NN O
for IN O
bevacizumab-chemotherapy NN B-INTV
compared VBN O
with IN O
33.1 CD O
% NN O
for IN O
chemotherapy NN B-INTV
alone RB O
. . O

CONCLUSION NNP O
Results NNP O
for IN O
PFS NNP B-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
favor NN O
combination NN O
of IN O
bevacizumab NN B-INTV
with IN O
either DT O
chemotherapy NN B-INTV
or CC O
erlotinib NN O
over IN O
chemotherapy NN B-INTV
alone RB O
in IN O
the DT O
second-line JJ O
setting NN O
. . O

No DT O
unexpected JJ O
safety NN B-OC
signals NNS I-OC
were VBD O
noted VBN O
. . O

The DT O
rate NN B-OC
of IN I-OC
fatal JJ I-OC
pulmonary JJ I-OC
hemorrhage NN I-OC
was VBD O
consistent JJ O
with IN O
previous JJ O
bevacizumab NN B-INTV
trials NNS O
. . O

The DT O
toxicity NN B-OC
profile NN I-OC
of IN O
the DT O
bevacizumab-erlotinib JJ B-INTV
combination NN I-INTV
is VBZ O
favorable JJ O
compared VBN O
with IN O
either DT O
chemotherapy-containing JJ B-INTV
group NN O
. . O

-DOCSTART- -X- O O

Letrozole NNP B-INTV
in IN O
the DT O
neoadjuvant JJ O
setting NN O
: : O
the DT O
P024 NNP O
trial NN O
. . O

Neoadjuvant JJ B-INTV
chemotherapy NN I-INTV
trials NNS O
have VBP O
consistently RB O
reported VBN O
lower JJR O
response NN B-OC
rates NNS I-OC
in IN O
hormone NN O
receptor-positive JJ O
( ( O
HR+ NNP O
) ) O
breast NN O
cancer NN O
when WRB O
compared VBN O
with IN O
HR- NNP O
cases NNS O
. . O

Preoperative JJ B-INTV
endocrine NN I-INTV
therapy NN I-INTV
has VBZ O
therefore RB O
become VBN O
a DT O
logical JJ O
alternative NN O
and CC O
has VBZ O
gained VBN O
considerable JJ O
momentum NN O
from IN O
the DT O
finding NN O
that WDT O
aromatase NN B-INTV
inhibitors NNS I-INTV
( ( O
AIs NNP O
) ) O
are VBP O
more RBR O
effective JJ O
than IN O
tamoxifen NN B-INTV
for IN O
HR+ NNP O
breast NN O
cancer NN O
in IN O
both CC O
the DT O
neoadjuvant NN O
and CC O
adjuvant JJ O
settings NNS O
. . O

The DT O
most RBS O
convincing JJ O
neoadjuvant JJ O
trial NN O
to TO O
demonstrate VB O
the DT O
superiority NN O
of IN O
an DT O
AI NNP B-INTV
versus NN O
tamoxifen NN B-INTV
was VBD O
the DT O
P024 NNP O
study NN O
, , O
a DT O
large JJ O
multinational JJ B-POPU
double-blind JJ O
trial NN O
in IN O
postmenopausal JJ B-POPU
women NNS I-POPU
with IN I-POPU
HR+ NNP I-POPU
breast NN I-POPU
cancer NN I-POPU
ineligible JJ I-POPU
for IN I-POPU
breast-conserving JJ I-POPU
surgery NN I-POPU
. . O

The DT O
overall JJ B-OC
response NN I-OC
rate NN I-OC
( ( I-OC
ORR NNP I-OC
) ) I-OC
was VBD O
55 CD O
% NN O
for IN O
letrozole NN B-INTV
and CC O
36 CD O
% NN O
for IN O
tamoxifen NN B-INTV
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

Significantly RB O
more RBR O
letrozole-treated JJ O
patients NNS O
underwent JJ B-OC
breast-conserving JJ B-INTV
surgery NN I-INTV
( ( O
45 CD O
vs. FW O
35 CD O
% NN O
, , O
respectively RB O
; : O
P=0.022 NNP O
) ) O
. . O

In IN O
addition NN O
, , O
ORR NNP B-OC
was VBD O
significantly RB O
higher JJR O
with IN O
letrozole JJR O
than IN O
tamoxifen NN B-INTV
in IN O
the DT O
human JJ O
epidermal JJ O
growth NN O
factor NN O
receptor NN O
HER1/HER2+ NNP O
subgroup NN O
( ( O
P=0.0004 NNP O
) ) O
. . O

The DT O
clinical JJ B-OC
efficacy NN I-OC
of IN O
letrozole NN B-INTV
in IN O
HER2+ NNP O
breast NN O
cancer NN O
was VBD O
confirmed VBN O
by IN O
fluorescent NN O
in IN O
situ JJ O
hybridization NN O
analysis NN O
and CC O
was VBD O
found VBN O
to TO O
be VB O
comparable JJ O
to TO O
that DT O
of IN O
HER2- NNP O
cases NNS O
( ( O
ORR NNP O
71 CD O
% NN O
in IN O
both DT O
subsets NNS O
) ) O
. . O

Biomarker NNP B-OC
studies NNS I-OC
confirmed VBD O
the DT O
superiority NN O
of IN O
letrozole NN B-INTV
in IN O
centrally RB O
assessed VBN O
estrogen NN O
receptor-positive JJ O
( ( O
ER+ NNP O
) ) O
tumors NNS O
and CC O
found VBD O
a DT O
strong JJ O
relationship NN O
with IN O
the DT O
degree NN B-OC
of IN I-OC
ER NNP I-OC
positivity NN I-OC
for IN O
both DT O
agents NNS O
. . O

Interestingly RB O
, , O
letrozole NN B-INTV
was VBD O
effective JJ O
even RB O
in IN O
marginally RB O
ER+ NNP O
tumors NNS O
and CC O
, , O
unlike IN O
tamoxifen NN O
, , O
consistently RB O
reduced VBD O
the DT O
expression NN B-OC
from IN I-OC
estrogen-regulated JJ I-OC
genes NNS I-OC
( ( O
progesterone NN O
receptor NN O
and CC O
trefoil NN O
factor NN O
1 CD O
) ) O
. . O

Furthermore RB O
, , O
when WRB O
analyzed VBN O
by IN O
Ki67 NNP O
immunohistochemistry NN O
, , O
letrozole NN O
was VBD O
significantly RB O
more RBR O
effective JJ O
than IN O
tamoxifen NN O
in IN O
reducing VBG O
tumor NN B-OC
proliferation NN I-OC
( ( O
P=0.0009 NNP O
) ) O
. . O

Thus RB O
, , O
neoadjuvant JJ O
letrozole NN B-INTV
is VBZ O
safe JJ O
and CC O
superior JJ O
to TO O
tamoxifen VB B-INTV
in IN O
the DT O
treatment NN O
of IN O
postmenopausal JJ B-POPU
women NNS I-POPU
with IN I-POPU
HR+ NNP I-POPU
locally RB I-POPU
advanced VBD I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

-DOCSTART- -X- O O

Supportive-expressive JJ B-INTV
group NN I-INTV
therapy NN I-INTV
for IN O
primary JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
: : I-POPU
a DT O
randomized JJ O
prospective JJ O
multicenter NN O
trial NN O
. . O

OBJECTIVE CC O
The DT O
aim NN O
is VBZ O
to TO O
evaluate VB O
the DT O
effectiveness NN O
of IN O
a DT O
manualized JJ B-INTV
12-week JJ I-INTV
supportive-expressive JJ I-INTV
group NN I-INTV
therapy NN I-INTV
program NN I-INTV
among IN O
primary JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
treated VBN I-POPU
in IN I-POPU
community NN I-POPU
settings NNS I-POPU
, , O
to TO O
determine VB O
whether IN O
highly RB B-POPU
distressed JJ I-POPU
patients NNS I-POPU
were VBD O
most RBS O
likely JJ O
to TO O
benefit VB O
and CC O
whether IN O
therapist NN O
's POS O
training NN O
or CC O
experience NN O
was VBD O
related VBN O
to TO O
outcome VB O
. . O

METHOD NNP O
Three CD B-POPU
hundred VBD I-POPU
and CC I-POPU
fifty-three JJ I-POPU
women NNS I-POPU
within IN I-POPU
one CD I-POPU
year NN I-POPU
of IN I-POPU
diagnosis NN I-POPU
with IN I-POPU
primary JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
receive VB I-POPU
supportive-expressive JJ I-POPU
group NN I-POPU
therapy NN I-POPU
or CC I-POPU
to TO I-POPU
an DT I-POPU
education NN I-POPU
control NN I-POPU
condition NN I-POPU
. . O

Participants NNS B-POPU
were VBD I-POPU
recruited VBN I-POPU
from IN I-POPU
two CD I-POPU
academic JJ I-POPU
centers NNS I-POPU
and CC I-POPU
nine CD I-POPU
oncology NN I-POPU
practices NNS I-POPU
, , I-POPU
which WDT I-POPU
were VBD I-POPU
members NNS I-POPU
of IN I-POPU
NCI NNP I-POPU
's POS I-POPU
Community NNP I-POPU
Clinical NNP I-POPU
Oncology NNP I-POPU
Program NNP I-POPU
( ( I-POPU
CCOP NNP I-POPU
) ) I-POPU
and CC I-POPU
were VBD I-POPU
followed VBN I-POPU
over IN I-POPU
2 CD I-POPU
years NNS I-POPU
. . O

RESULTS VB O
A DT O
2x2x19 CD O
analysis NN O
of IN O
variance NN O
was VBD O
conducted VBN O
with IN O
main JJ O
effects NNS B-OC
of IN I-OC
treatment NN I-OC
condition NN I-OC
, , I-OC
cohort NN I-OC
, , I-OC
and CC I-OC
baseline NN I-OC
distress NN I-OC
and CC I-OC
their PRP$ I-OC
interactions NNS I-OC
. . O

There EX O
was VBD O
no DT O
main JJ O
effect NN O
for IN O
treatment NN B-OC
condition NN I-OC
after IN O
removing VBG O
one CD O
subject NN O
with IN O
an DT O
extreme JJ O
score NN O
. . O

Highly NNP B-POPU
distressed JJ I-POPU
women NNS I-POPU
did VBD O
not RB O
derive VB O
a DT O
greater JJR B-OC
benefit NN I-OC
from IN O
treatment NN O
. . O

Therapist VB O
training NN O
and CC O
psychotherapy NN O
experience NN O
were VBD O
not RB O
associated VBN O
with IN O
a DT O
treatment NN O
effect NN O
. . O

CONCLUSIONS VB O
This DT O
study NN O
provides VBZ O
no DT O
evidence NN O
of IN O
reduction NN O
in IN O
distress NN B-OC
as IN O
the DT O
result NN O
of IN O
a DT O
brief JJ B-INTV
supportive-expressive JJ I-INTV
intervention NN I-INTV
for IN O
women NNS B-POPU
with IN I-POPU
primary JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

Future NNP O
studies NNS O
might MD O
productively RB O
focus VB O
on IN O
women NNS B-POPU
with IN I-POPU
higher JJR I-POPU
initial JJ I-POPU
levels NNS I-POPU
of IN I-POPU
distress NN I-POPU
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
menopausal NN O
symptoms NNS O
during IN O
the DT O
first JJ O
year NN O
of IN O
adjuvant JJ O
therapy NN O
with IN O
either DT O
exemestane NN B-INTV
or CC I-INTV
tamoxifen NN I-INTV
in IN O
early JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
report NN O
of IN O
a DT O
Tamoxifen NNP O
Exemestane NNP O
Adjuvant NNP O
Multicenter NNP O
trial NN O
substudy NN O
. . O

PURPOSE NNP O
Hormonal NNP O
breast NN O
cancer NN O
treatment NN O
increases NNS O
menopausal VBP B-OC
symptoms NNS I-OC
in IN O
women NNS B-POPU
. . O

This DT O
study NN O
investigated VBD O
differences NNS O
between IN O
the DT O
symptoms NNS O
associated VBN O
with IN O
either DT O
adjuvant JJ B-INTV
tamoxifen NN I-INTV
or CC I-INTV
exemestane NN I-INTV
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Ten NNP O
common JJ O
symptoms NNS O
were VBD O
assessed VBN O
by IN O
self-report JJ O
questionnaire NN O
administered VBD O
to TO O
1,614 CD B-POPU
consecutive JJ I-POPU
patients NNS I-POPU
at IN O
baseline NN O
and CC O
every DT O
3 CD O
months NNS O
during IN O
the DT O
first JJ O
year NN O
of IN O
a DT O
double-blind NN O
, , O
randomized VBN O
trial NN O
of IN O
postmenopausal JJ B-POPU
women NNS I-POPU
with IN I-POPU
early JJ I-POPU
hormone NN I-POPU
receptor-positive JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

Symptoms NNS O
were VBD O
categorized VBN O
as IN O
none NN O
, , O
mild NN O
, , O
moderate JJ O
, , O
or CC O
severe RB O
. . O

A DT O
hot JJ B-OC
flash NN I-OC
score NN I-OC
was VBD O
calculated VBN O
at IN O
each DT O
time NN O
point NN O
. . O

Symptoms NNS O
were VBD O
analyzed VBN O
by IN O
repeated-measures NNS O
analysis NN O
of IN O
variance NN O
. . O

Each DT O
time NN O
period NN O
was VBD O
tested VBN O
repeatedly RB O
against IN O
the DT O
baseline NN O
; : O
an DT O
overall JJ O
P NNP O
value NN O
was VBD O
assigned VBN O
for IN O
each DT O
reported VBN O
symptom NN O
. . O

RESULTS NNP O
Compliance NNP O
was VBD O
excellent JJ O
, , O
with IN O
7,286 CD O
questionnaires NNS O
analyzed VBN O
. . O

Baseline NNP B-OC
symptom JJ I-OC
prevalence NN O
ranged VBD O
from IN O
2 CD O
% NN O
( ( O
vaginal JJ O
bleeding NN O
) ) O
to TO O
60 CD O
% NN O
to TO O
70 CD O
% NN O
( ( B-OC
bone/muscle NN I-OC
aches NNS I-OC
and CC I-OC
low JJ I-OC
energy NN I-OC
) ) I-OC
. . O

There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
vaginal JJ B-OC
bleeding NN I-OC
, , I-OC
mood NN I-OC
alteration NN I-OC
, , I-OC
or CC I-OC
low JJ I-OC
energy NN I-OC
. . O

Patients NNS B-POPU
receiving VBG I-POPU
tamoxifen NN I-POPU
had VBD O
significantly RB O
more RBR O
vaginal JJ B-OC
discharge NN I-OC
( ( O
P NNP O
< NNP O
.0001 NNP O
) ) O
. . O

Exemestane NN O
patients NNS O
reported VBD O
more RBR O
bone/muscle NN B-OC
aches NNS I-OC
( ( O
P NNP O
< NNP O
.0001 NNP O
) ) O
, , O
vaginal JJ B-OC
dryness NN I-OC
( ( O
P NNP O
= NNP O
.0004 NNP O
) ) O
, , O
and CC O
difficulty NN B-OC
sleeping NN I-OC
( ( O
P NNP O
= NNP O
.03 NNP O
) ) O
. . O

In IN O
both DT O
groups NNS O
, , O
the DT O
hot JJ B-OC
flash NN I-OC
score NN I-OC
peaked VBD O
at IN O
3 CD O
months NNS O
and CC O
decreased JJ O
thereafter NN O
. . O

At IN O
12 CD O
months NNS O
, , O
patients NNS O
receiving VBG O
tamoxifen NN O
had VBD O
a DT O
significantly RB O
higher JJR O
mean JJ B-OC
hot JJ I-OC
flash NN I-OC
score NN I-OC
( ( O
P NNP O
= NNP O
.03 NNP O
) ) O
, , O
with IN O
daily JJ O
hot JJ B-OC
flashes NNS I-OC
increasing VBG O
from IN O
baseline NN O
by IN O
33 CD O
% NN O
compared VBN O
with IN O
a DT O
7 CD O
% NN O
increase NN O
from IN O
baseline NN O
with IN O
exemestane NN O
. . O

CONCLUSION NNP O
At IN O
12 CD O
months NNS O
, , O
exemestane NN O
was VBD O
associated VBN O
with IN O
fewer JJR O
hot JJ B-OC
flashes NNS I-OC
and CC O
less JJR O
vaginal JJ B-OC
discharge NN I-OC
than IN O
tamoxifen NN O
, , O
but CC O
with IN O
more JJR O
vaginal JJ B-OC
dryness NN I-OC
, , I-OC
bone/muscle NN I-OC
aches NNS I-OC
, , I-OC
and CC I-OC
difficulty NN I-OC
sleeping NN I-OC
. . O

Symptoms NNS O
were VBD O
common JJ O
in IN O
both DT O
groups NNS O
. . O

-DOCSTART- -X- O O

Obesity NN O
and CC O
mortality NN O
in IN O
men NNS B-POPU
with IN I-POPU
locally RB I-POPU
advanced JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
: : I-POPU
analysis NN O
of IN O
RTOG NNP O
85-31 JJ O
. . O

BACKGROUND NNP O
Greater NNP O
body NN B-OC
mass NN I-OC
index NN I-OC
( ( I-OC
BMI NNP I-OC
) ) I-OC
is VBZ O
associated VBN O
with IN O
shorter JJR O
time NN O
to TO O
prostate-specific JJ O
antigen NN O
( ( O
PSA NNP O
) ) O
failure NN O
following VBG O
radical JJ B-INTV
prostatectomy NN I-INTV
and CC O
radiation NN B-INTV
therapy NN I-INTV
( ( O
RT NNP O
) ) O
. . O

Whether NNP O
BMI NNP O
is VBZ O
associated VBN O
with IN O
prostate JJ O
cancer-specific JJ O
mortality NN O
( ( O
PCSM NNP O
) ) O
was VBD O
investigated VBN O
in IN O
a DT O
large JJ O
randomized JJ O
trial NN O
of IN O
men NNS B-POPU
treated VBN I-POPU
with IN I-POPU
RT NNP I-POPU
and CC I-POPU
androgen JJ I-POPU
deprivation NN I-POPU
therapy NN I-POPU
( ( I-POPU
ADT NNP I-POPU
) ) I-POPU
for IN I-POPU
locally RB I-POPU
advanced JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

METHODS NNP O
Between NNP B-POPU
1987 CD I-POPU
and CC I-POPU
1992 CD I-POPU
, , I-POPU
945 CD I-POPU
eligible JJ I-POPU
men NNS I-POPU
with IN I-POPU
locally RB I-POPU
advanced JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
were VBD I-POPU
enrolled VBN I-POPU
in IN I-POPU
a DT I-POPU
phase NN I-POPU
3 CD I-POPU
trial NN I-POPU
( ( I-POPU
RTOG NNP I-POPU
85-31 CD I-POPU
) ) I-POPU
and CC O
randomized VBN O
to TO O
RT NNP B-INTV
and CC I-INTV
immediate JJ I-INTV
goserelin NN I-INTV
or CC I-INTV
RT NNP I-INTV
alone RB I-INTV
followed VBD I-INTV
by IN I-INTV
goserelin NN I-INTV
at IN I-INTV
recurrence NN I-INTV
. . O

Height NNP O
and CC O
weight VBN O
data NNS O
were VBD O
available JJ O
at IN O
baseline NN O
for IN B-POPU
788 CD I-POPU
( ( I-POPU
83 CD I-POPU
% NN I-POPU
) ) I-POPU
subjects VBZ I-POPU
. . O

Cox NNP B-INTV
regression NN I-INTV
analyses NNS I-INTV
were VBD O
performed VBN O
to TO O
evaluate VB O
the DT O
relations NNS O
between IN O
BMI NNP B-OC
and CC I-OC
all-cause JJ I-OC
mortality NN I-OC
, , I-OC
PCSM NNP I-OC
, , I-OC
and CC I-OC
nonprostate JJ I-OC
cancer NN I-OC
mortality NN I-OC
. . O

Covariates NNS O
included VBD O
age NN O
, , O
race NN O
, , O
treatment NN O
arm NN O
, , O
history NN O
of IN O
prostatectomy NN O
, , O
nodal JJ O
involvement NN O
, , O
Gleason NNP O
score NN O
, , O
clinical JJ O
stage NN O
, , O
and CC O
BMI NNP O
. . O

RESULTS VB O
The DT O
5-year JJ B-OC
PCSM NNP I-OC
rate NN I-OC
for IN O
men NNS O
with IN O
BMI NNP B-OC
< NNP O
25 CD O
kg/m NN O
( ( O
2 CD O
) ) O
was VBD O
6.5 CD O
% NN O
, , O
compared VBN O
with IN O
13.1 CD O
% NN O
and CC O
12.2 CD O
% NN O
in IN O
men NNS O
with IN O
BMI NNP O
> NNP O
or CC O
=25 VB O
to TO O
< VB O
30 CD O
and CC O
BMI NNP O
> NNP O
or CC O
=30 NNP O
, , O
respectively RB O
( ( O
Gray NNP O
's POS O
P NNP O
= NNP O
.005 NNP O
) ) O
. . O

In IN O
multivariate NN O
analyses NNS O
, , O
greater JJR O
BMI NNP O
was VBD O
significantly RB O
associated VBN O
with IN O
higher JJR B-OC
PCSM NNP I-OC
( ( O
for IN O
BMI NNP O
> NNP O
or CC O
=25 VB O
to TO O
< VB O
30 CD O
, , O
hazard RB O
ratio NN O
[ NNP O
HR NNP O
] NNP O
1.52 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
1.02-2.27 JJ O
, , O
P NNP O
= NNP O
.04 NNP O
; : O
for IN O
BMI NNP O
> NNP O
or CC O
=30 NNP O
, , O
HR NNP O
1.64 CD O
, , O
95 CD O
% NN O
CI NNP O
, , O
1.01-2.66 JJ O
, , O
P NNP O
= NNP O
.04 NNP O
) ) O
. . O

BMI NNP B-OC
was VBD O
not RB O
associated VBN O
with IN O
nonprostate JJ B-OC
cancer NN I-OC
or CC O
all-cause JJ B-OC
mortality NN I-OC
. . O

CONCLUSIONS NNP O
Greater NNP O
baseline NN B-OC
BMI NNP I-OC
is VBZ O
independently RB O
associated VBN O
with IN O
higher JJR O
PCSM NN B-OC
in IN O
men NNS B-POPU
with IN I-POPU
locally RB I-POPU
advanced JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

Further JJ O
studies NNS O
are VBP O
warranted VBN O
to TO O
evaluate VB O
the DT O
mechanism NN O
( ( O
s NN O
) ) O
for IN O
increased VBN O
cancer-specific JJ B-OC
mortality NN I-OC
and CC O
to TO O
assess VB O
whether IN O
weight JJ B-OC
loss NN I-OC
after IN O
prostate JJ O
cancer NN O
diagnosis NN O
alters NNS O
disease VBP O
course NN O
. . O

-DOCSTART- -X- O O

Osteosarcoma NN O
: : O
the DT O
addition NN O
of IN O
muramyl NN B-INTV
tripeptide NN I-INTV
to TO O
chemotherapy VB O
improves NNS O
overall JJ B-OC
survival NN I-OC
-- : I-OC
a DT I-OC
report NN O
from IN O
the DT O
Children NNP B-POPU
's POS I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
. . O

PURPOSE NNP O
To TO O
compare VB O
three-drug JJ O
chemotherapy NN O
with IN O
cisplatin NN B-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
and CC I-INTV
methotrexate NN I-INTV
with IN O
four-drug JJ B-INTV
chemotherapy NN I-INTV
with IN I-INTV
cisplatin NN I-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
methotrexate NN I-INTV
, , I-INTV
and CC I-INTV
ifosfamide NN I-INTV
for IN O
the DT O
treatment NN O
of IN O
osteosarcoma NN O
. . O

To TO O
determine VB O
whether IN O
the DT O
addition NN O
of IN O
muramyl NN B-INTV
tripeptide NN I-INTV
( ( I-INTV
MTP NNP I-INTV
) ) I-INTV
to TO O
chemotherapy VB O
enhances NNS O
event-free JJ B-OC
survival NN I-OC
( ( I-OC
EFS NNP I-OC
) ) I-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
in IN O
newly RB O
diagnosed VBN O
patients NNS O
with IN O
osteosarcoma NN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Six NNP B-POPU
hundred VBD I-POPU
sixty-two JJ I-POPU
patients NNS I-POPU
with IN I-POPU
osteosarcoma NN I-POPU
without IN I-POPU
clinically RB I-POPU
detectable JJ I-POPU
metastatic JJ I-POPU
disease NN I-POPU
and CC I-POPU
whose WP$ I-POPU
disease NN I-POPU
was VBD I-POPU
considered VBN I-POPU
resectable JJ I-POPU
received VBD I-POPU
one CD I-POPU
of IN I-POPU
four CD I-POPU
prospectively RB I-POPU
randomized JJ I-POPU
treatments NNS I-POPU
. . O

All DT O
patients NNS O
received VBD O
identical JJ O
cumulative JJ O
doses NNS O
of IN O
cisplatin NN B-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
and CC I-INTV
methotrexate NN I-INTV
and CC O
underwent JJ O
definitive JJ O
surgical JJ O
resection NN O
of IN O
primary JJ O
tumor NN O
. . O

Patients NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
or CC O
not RB O
to TO O
receive VB B-INTV
ifosfamide JJ I-INTV
and/or NN I-INTV
MTP NNP I-INTV
in IN O
a DT O
2 CD O
x NN O
2 CD O
factorial JJ O
design NN O
. . O

The DT O
primary JJ O
end NN O
points NNS O
for IN O
analysis NN O
were VBD O
EFS NNP B-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
. . O

RESULTS NNP O
In IN O
the DT O
current JJ O
analysis NN O
, , O
there EX O
was VBD O
no DT O
evidence NN O
of IN O
interaction NN O
, , O
and CC O
we PRP O
were VBD O
able JJ O
to TO O
examine VB O
each DT O
intervention NN O
separately RB O
. . O

The DT O
chemotherapy NN O
regimens VBZ O
resulted VBN O
in IN O
similar JJ O
EFS NNP B-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
. . O

There EX O
was VBD O
a DT O
trend NN O
toward IN O
better JJR O
EFS NN B-OC
with IN O
the DT O
addition NN O
of IN O
MTP NNP O
( ( O
P NNP O
= NNP O
.08 NNP O
) ) O
. . O

The DT O
addition NN O
of IN O
MTP NNP O
to TO O
chemotherapy VB O
improved JJ O
6-year JJ B-OC
overall JJ I-OC
survival NN I-OC
from IN O
70 CD O
% NN O
to TO O
78 CD O
% NN O
( ( O
P NNP O
= NNP O
.03 NNP O
) ) O
. . O

The DT O
hazard NN B-OC
ratio NN I-OC
for IN I-OC
overall JJ I-OC
survival NN I-OC
with IN O
the DT O
addition NN O
of IN O
MTP NNP O
was VBD O
0.71 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.52 CD O
to TO O
0.96 CD O
) ) O
. . O

CONCLUSION VB O
The DT O
addition NN O
of IN O
ifosfamide NN O
to TO O
cisplatin VB O
, , O
doxorubicin NN O
, , O
and CC O
methotrexate NN O
did VBD O
not RB O
enhance VB O
EFS NNP B-OC
or CC O
overall JJ B-OC
survival NN I-OC
for IN O
patients NNS O
with IN O
osteosarcoma NN O
. . O

The DT O
addition NN O
of IN O
MTP NNP O
to TO O
chemotherapy VB O
resulted VBN O
in IN O
a DT O
statistically RB O
significant JJ O
improvement NN O
in IN O
overall JJ B-OC
survival NN I-OC
and CC O
a DT O
trend NN O
toward IN O
better JJR O
EFS NNP B-OC
. . O

-DOCSTART- -X- O O

[ VB O
How WRB O
to TO O
treat VB O
the DT O
relapse NN B-OC
of IN I-OC
NSCLC NNP B-POPU
after IN O
surgery NN O
and CC O
chemotherapy NN O
? . O
IFTC NNP O
0702 CD O
randomized VBD O
phase NN O
III NNP O
study NN O
] NNP O
. . O

BACKGROUND NNP O
As IN O
chemotherapy NN O
gains NNS O
wider VBP O
acceptance NN O
for IN O
the DT O
treatment NN O
of IN O
earlier JJR O
stages NNS O
of IN O
NSCLC NNP O
, , O
particularly RB O
in IN O
the DT O
adjuvant NN O
and CC O
neoadjuvant JJ O
setting NN O
, , O
physicians NNS O
face VBP O
a DT O
growing VBG O
population NN O
of IN O
high JJ B-POPU
performance NN I-POPU
status NN I-POPU
patients NNS I-POPU
who WP I-POPU
have VBP I-POPU
relapsed VBN I-POPU
after IN I-POPU
their PRP$ I-POPU
first-line JJ I-POPU
chemotherapy NN I-POPU
. . O

The DT O
type NN O
of IN O
second-line JJ B-INTV
chemotherapy NN I-INTV
after IN O
initial JJ O
adjuvant NN O
or CC O
neoadjuvant JJ O
treatment NN O
with IN O
a DT O
platinum-based JJ B-INTV
regimen NN I-INTV
remains VBZ O
largely RB O
undefined JJ O
. . O

The DT O
current JJ O
study NN O
has VBZ O
been VBN O
designed VBN O
to TO O
compare VB O
the DT O
classical JJ O
mono NN B-INTV
chemotherapy NN I-INTV
docetaxel NN I-INTV
with IN O
a DT O
docetaxel NN B-INTV
cisplatin NN I-INTV
doublet NN I-INTV
. . O

METHODS NNP O
Patients NNPS O
will MD O
be VB O
randomized VBN O
in IN O
2 CD O
arms NNS O
. . O

Arm NN O
: : O
docetaxel NN B-INTV
cisplatin NN I-INTV
( ( O
cycles NNS O
repeated VBN O
every DT O
21 CD O
days NNS O
) ) O
, , O
4 CD O
cycles NNS O
followed VBN O
by IN O
2 CD O
cycles NNS O
of IN O
docetaxel NN O
alone RB O
in IN O
case NN O
of IN O
objective JJ B-OC
response NN I-OC
or CC O
stabilisation NN B-OC
. . O

Arm NN O
B NN O
: : O
docetaxel NN B-INTV
alone RB I-INTV
( ( O
cycles NNS O
repeated VBN O
every DT O
21 CD O
days NNS O
) ) O
, , O
4 CD O
cycles NNS O
followed VBN O
by IN O
2 CD O
cycles NNS O
of IN O
docetaxel NN O
alone RB O
in IN O
case NN O
of IN O
objective JJ B-OC
response NN I-OC
or CC O
stabilisation NN B-OC
. . O

EXPECTED NNP O
RESULTS NNP O
300 CD B-POPU
patients NNS I-POPU
will MD I-POPU
be VB I-POPU
randomized VBN I-POPU
with IN O
a DT O
statistical JJ O
hypothesis NN O
of IN O
a DT O
progression NN B-OC
free JJ I-OC
survival NN I-OC
of IN O
3 CD O
months NNS O
in IN O
the DT O
control NN O
arm NN O
and CC O
of IN O
4.5 CD O
months NNS O
in IN O
the DT O
experimental JJ O
arm NN O
. . O

-DOCSTART- -X- O O

Preliminary JJ O
evaluation NN O
of IN O
psychoeducational JJ B-INTV
support NN I-INTV
interventions NNS I-INTV
on IN O
quality NN B-OC
of IN I-OC
life NN I-OC
in IN O
rural JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
survivors NNS I-POPU
after IN I-POPU
primary JJ I-POPU
treatment NN I-POPU
. . O

Although IN O
most JJS O
cancer NN B-POPU
survivors NNS I-POPU
are VBP O
at IN O
risk NN O
for IN O
being VBG O
lost VBN O
in IN O
the DT O
transition NN O
from IN O
treatment NN O
to TO O
survivorship VB O
, , O
rural JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
survivors NNS I-POPU
face VBP O
special JJ O
challenges NNS O
that WDT O
might MD O
place VB O
them PRP O
at IN O
particular JJ O
risk NN O
. . O

This DT O
small-scale JJ O
preliminary JJ O
study NN O
had VBD O
2 CD O
specific JJ O
aims NNS O
: : O
( ( O
aim IN O
1 CD O
) ) O
establish VB O
the DT O
feasibility NN O
of IN O
rural JJ O
breast NN O
cancer NN O
survivors NNS O
participation VBP O
in IN O
a DT O
longitudinal JJ B-INTV
quality NN I-INTV
of IN I-INTV
life NN I-INTV
( ( I-INTV
QOL NNP I-INTV
) ) I-INTV
intervention NN I-INTV
trial NN O
and CC O
( ( O
aim VB O
2 CD O
) ) O
determine VB O
the DT O
effects NNS O
of IN O
the DT O
Breast NNP B-INTV
Cancer NNP I-INTV
Education NNP I-INTV
Intervention NNP I-INTV
( ( I-INTV
BCEI NNP I-INTV
) ) I-INTV
on IN O
overall JJ B-OC
QOL NNP I-OC
. . O

Fifty-three JJ B-POPU
rural JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
survivors NNS I-POPU
were VBD O
randomized VBN O
to TO O
either DT O
an DT O
experimental JJ O
( ( O
n JJ O
= NNP O
27 CD O
) ) O
or CC O
a DT O
wait-control JJ O
arm NN O
( ( O
n JJ O
= NNP O
26 CD O
) ) O
. . O

Participants NNS O
in IN O
the DT O
experimental JJ O
arm NN O
received VBD O
the DT O
BCEI NNP O
consisting NN O
of IN O
3 CD B-INTV
face-to-face JJ I-INTV
education NN I-INTV
and CC I-INTV
support NN I-INTV
sessions NNS I-INTV
and CC O
2 CD O
face-to-face NN O
and CC O
3 CD O
telephone NN B-INTV
follow-up JJ I-INTV
sessions NNS I-INTV
, , O
along IN O
with IN O
supplemental JJ O
written VBN O
and CC O
audiotape JJ O
materials NNS O
over IN O
a DT O
6-month JJ O
period NN O
. . O

Breast NNP B-INTV
Cancer NNP I-INTV
Education NNP I-INTV
Intervention NNP I-INTV
modules NNS I-INTV
and CC I-INTV
interventions NNS I-INTV
are VBP O
organized VBN O
within IN O
a DT O
QOL NNP O
framework NN O
. . O

To TO O
address VB O
the DT O
possible JJ O
effects NNS O
of IN O
attention NN O
, , O
wait-control JJ O
participants NNS O
received VBD O
3 CD O
face-to-face JJ O
sessions NNS O
and CC O
3 CD O
telephone NN O
sessions NNS O
during IN O
the DT O
first JJ O
6 CD O
months NNS O
of IN O
participation NN O
in IN O
the DT O
study NN O
, , O
but CC O
not RB O
the DT O
BCEI NNP B-INTV
intervention NN I-INTV
. . O

Research NNP O
questions NNS O
addressing VBG O
aim NN O
1 CD O
were VBD O
as IN O
follows VBZ O
: : O
( ( O
a DT O
) ) O
can MD O
rural VB O
breast NN O
cancer NN O
survivors NNS O
be VB O
recruited VBN O
into IN O
a DT O
longitudinal JJ O
intervention NN O
trial NN O
, , O
and CC O
( ( O
b NN O
) ) O
can MD O
their PRP$ O
participation NN O
be VB O
retained VBN O
. . O

Research NNP O
questions NNS O
for IN O
aim NN O
2 CD O
were VBD O
as IN O
follows VBZ O
: : O
( ( O
a DT O
) ) O
do VBP O
participants NNS O
who WP O
received VBD O
the DT O
BCEI NNP O
show NN O
improvement NN O
in IN O
overall JJ B-OC
QOL NNP I-OC
, , O
and CC O
( ( O
b NN O
) ) O
is VBZ O
the DT O
QOL NNP B-OC
improvement NN I-OC
sustained VBD O
over IN O
time NN O
. . O

Data NNS O
were VBD O
analyzed VBN O
using VBG O
repeated-measures JJ O
general JJ O
linear NN O
mixed JJ O
models NNS O
. . O

Results NNS O
demonstrated VBD O
the DT O
ability NN O
to TO O
recruit VB O
and CC O
retain VB O
53 CD O
rural JJ O
breast NN O
cancer NN O
survivors NNS O
, , O
that IN O
the DT O
experimental JJ O
arm NN O
showed VBD O
improvement NN O
in IN O
overall JJ B-OC
QOL NNP I-OC
( ( O
P NNP O
= NNP O
.013 NNP O
) ) O
, , O
and CC O
that IN O
there EX O
were VBD O
significant JJ O
differences NNS O
in IN O
overall JJ B-OC
QOL NNP I-OC
between IN O
the DT O
experimental JJ O
and CC O
wait-control JJ O
groups NNS O
at IN O
both DT O
months NNS O
3 CD O
and CC O
6 CD O
. . O

Thus RB O
, , O
it PRP O
appears VBZ O
that IN O
at IN O
least JJS O
some DT O
rural JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
survivors NNS I-POPU
can MD O
and CC O
will MD O
participate VB O
in IN O
a DT O
larger JJR O
trial NN O
and CC O
will MD O
maintain VB O
their PRP$ O
participation NN O
and CC O
that IN O
those DT O
that WDT O
do VBP O
participate VB O
experience NN O
significant JJ O
QOL NNP B-OC
benefit NN O
. . O

-DOCSTART- -X- O O

A DT O
randomized JJ O
trial NN O
of IN O
external JJ B-INTV
beam NN I-INTV
radiotherapy NN I-INTV
versus NN O
cryoablation NN B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
localized JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
: : I-POPU
quality NN O
of IN O
life NN O
outcomes NNS O
. . O

BACKGROUND VB O
A DT O
recent JJ O
randomized JJ O
trial NN O
to TO O
compare VB O
external JJ B-INTV
beam NN I-INTV
radiation NN I-INTV
therapy NN I-INTV
( ( I-INTV
EBRT NNP I-INTV
) ) I-INTV
to TO O
cryoablation NN O
for IN O
localized JJ O
disease NN O
showed VBD O
cryoablation NN O
to TO O
be VB O
noninferior JJ O
to TO O
external JJ B-INTV
beam NN I-INTV
EBRT NNP I-INTV
in IN O
disease NN O
progression NN O
and CC O
overall JJ O
and CC O
disease-specific JJ O
survival NN O
. . O

We PRP O
report VBP O
on IN O
the DT O
quality NN B-OC
of IN I-OC
life NN I-OC
( ( I-OC
QOL NNP I-OC
) ) I-OC
outcomes VBZ O
for IN O
this DT O
trial NN O
. . O

METHODS NN O
From IN B-POPU
December NNP I-POPU
1997 CD I-POPU
through IN I-POPU
February NNP I-POPU
2003 CD I-POPU
, , I-POPU
244 CD I-POPU
men NNS I-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
localized JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
cryoablation NN B-INTV
or CC I-INTV
EBRT NNP I-INTV
( ( O
median JJ O
dose NN O
68 CD O
Gy NNP O
) ) O
. . O

All DT O
patients NNS O
received VBD O
neoadjuvant JJ B-INTV
antiandrogen NN I-INTV
therapy NN O
. . O

Patients NNS O
completed VBD O
the DT O
EORTC NNP O
QLQ NNP O
C30 NNP O
and CC O
the DT O
Prostate NNP O
Cancer NNP O
Index NNP O
( ( O
PCI NNP O
) ) O
before IN O
treatment NN O
and CC O
at IN O
1.5 CD O
, , O
3 CD O
, , O
6 CD O
, , O
12 CD O
, , O
18 CD O
, , O
24 CD O
, , O
and CC O
36 CD O
months NNS O
post-treatment JJ O
. . O

RESULTS NNP O
Regardless NNP O
of IN O
treatment NN O
arm NN O
, , O
participants NNS O
reported VBD O
high JJ O
levels NNS O
of IN O
QOL NNP B-OC
with IN O
few JJ O
exceptions NNS O
. . O

cryoablation NN B-OC
was VBD O
associated VBN O
with IN O
more RBR O
acute JJ B-OC
urinary JJ I-OC
dysfunction NN I-OC
( ( O
mean JJ O
PCI NNP O
urinary JJ O
function NN O
cryoablation=69.4 NN O
; : O
mean JJ O
EBRT=90.7 NNP O
; : O
P NNP O
< NNP O
.001 NNP O
) ) O
, , O
which WDT O
resolved VBD O
over IN O
time NN O
. . O

No DT B-OC
late JJ I-OC
arising NN I-OC
QOL NNP I-OC
issues NNS I-OC
were VBD O
observed VBN O
. . O

Both DT O
EBRT NNP B-INTV
and CC O
cryoablation NN B-INTV
participants NNS O
reported VBD O
decreases NNS B-OC
in IN I-OC
sexual JJ I-OC
function NN I-OC
at IN O
3 CD O
months NNS O
with IN O
the DT O
cryoablation NN O
patients NNS O
reporting VBG O
poorer NN O
functioning NN O
( ( O
mean JJ O
cryoablation=7.2 NN O
: : O
mean JJ O
EBRT=32.9 NNP O
; : O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

Mean JJ B-OC
sexual JJ I-OC
function NN I-OC
score NN I-OC
was VBD O
15 CD O
points NNS O
lower JJR O
at IN O
3 CD O
years NNS O
for IN O
the DT O
cryoablation NN B-INTV
group NN O
and CC O
13 CD O
% NN O
more JJR O
of IN O
the DT O
cryoablation NN B-INTV
men NNS O
said VBD O
that IN O
sexuality NN O
was VBD O
a DT O
moderate JJ O
or CC O
big JJ O
problem NN O
. . O

CONCLUSIONS NNP O
In IN O
this DT O
randomized JJ O
trial NN O
, , O
no DT O
long-term JJ O
QOL NNP B-OC
advantage NN O
for IN O
either DT O
treatment NN O
was VBD O
apparent JJ O
with IN O
the DT O
exception NN O
of IN O
poorer JJR O
sexual JJ B-OC
function NN I-OC
reported VBN O
by IN O
those DT O
treated VBN O
with IN O
cryoablation NN B-INTV
. . O

Men NN O
who WP O
wish VBZ O
to TO O
increase VB O
their PRP$ O
odds NNS O
of IN O
retaining VBG O
sexual JJ B-OC
function NN I-OC
might MD O
be VB O
counseled VBN O
to TO O
choose VB O
EBRT NNP B-INTV
over IN O
cryoablation NN B-INTV
. . O

-DOCSTART- -X- O O

A DT O
comparison NN O
of IN O
a DT O
spiritually RB B-INTV
based VBN I-INTV
and CC I-INTV
non-spiritually RB I-INTV
based VBN I-INTV
educational JJ I-INTV
intervention NN I-INTV
for IN O
informed JJ O
decision NN O
making NN O
for IN O
prostate NN O
cancer NN O
screening VBG O
among IN O
church-attending JJ B-POPU
African-American JJ I-POPU
men NNS I-POPU
. . O

INTRODUCTION NNP O
Health NNP B-INTV
communication NN I-INTV
interventions NNS I-INTV
have VBP O
been VBN O
modestly RB O
effective JJ O
for IN O
increasing VBG O
informed JJ O
decision NN O
making NN O
for IN O
prostate NN O
cancer NN O
screening VBG O
among IN B-POPU
African-American JJ I-POPU
men NNS I-POPU
; : I-POPU
however RB O
, , O
knowledge NN O
and CC O
informed JJ O
decision NN O
making NN O
is VBZ O
still RB O
questionable JJ O
even RB O
with IN O
screening VBG O
. . O

Church-based JJ O
programs NNS O
may MD O
be VB O
more RBR O
effective JJ O
if IN O
they PRP O
are VBP O
spiritually RB O
based VBN O
in IN O
nature NN O
. . O

OBJECTIVE CC O
The DT O
aims NNS O
of IN O
the DT O
present JJ O
study NN O
were VBD O
to TO O
implement VB O
and CC O
provide VB O
an DT O
initial JJ O
evaluation NN O
of IN O
a DT O
spiritually RB O
based VBN O
prostate NN O
cancer NN O
screening VBG O
informed JJ O
decision NN O
making VBG O
intervention NN O
for IN O
African-American JJ B-POPU
men NNS I-POPU
who WP I-POPU
attend VBP I-POPU
church NN I-POPU
, , O
and CC O
determine VB O
its PRP$ O
efficacy NN O
for IN O
increasing VBG O
informed JJ O
decision NN O
making NN O
. . O

DESIGN NNP O
AND CC O
METHOD NNP O
Churches NNP B-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
either CC O
the DT O
spiritually RB B-INTV
based VBN I-INTV
or CC I-INTV
the DT I-INTV
non-spiritual JJ I-INTV
intervention NN I-INTV
. . O

Trained NNP O
community NN O
health NN O
advisors NNS O
, , O
who WP O
were VBD O
African-American JJ O
male JJ O
church NN O
members NNS O
, , O
led VBD O
an DT O
educational JJ B-INTV
session NN I-INTV
and CC O
distributed VBD B-INTV
educational JJ I-INTV
print NN I-INTV
materials NNS I-INTV
. . O

Participants NNS O
completed VBD O
baseline NN O
and CC O
immediate JJ O
follow-up JJ O
surveys NNS O
to TO O
assess VB O
the DT O
intervention NN O
impact NN O
on IN O
study NN O
outcomes NNS O
. . O

RESULTS VB O
The DT O
spiritually RB O
based VBN O
intervention NN O
appeared VBD O
to TO O
be VB O
more RBR O
effective JJ O
in IN O
areas NNS O
such JJ O
as IN O
knowledge NN O
, , O
and CC O
men NNS O
read VBP O
more JJR O
of IN O
their PRP$ O
materials NNS B-OC
in IN O
the DT O
spiritually RB O
based VBN O
group NN O
than IN O
in IN O
the DT O
non-spiritual JJ O
group NN O
. . O

CONCLUSIONS NNP O
Further NNP O
examination NN O
of IN O
the DT O
efficacy NN B-OC
of IN O
the DT O
spiritually RB O
based VBN O
approach NN O
to TO O
health NN O
communication NN O
is VBZ O
warranted VBN O
. . O

-DOCSTART- -X- O O

Weekly JJ O
docetaxel NN B-INTV
with IN O
or CC O
without IN O
gemcitabine JJ B-INTV
as IN O
second-line JJ B-INTV
chemotherapy NN I-INTV
in IN O
paclitaxel-pretreated JJ B-POPU
patients NNS I-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
randomized JJ O
phase NN O
II NNP O
study NN O
conducted VBN O
by IN O
the DT O
Hellenic NNP O
Co-Operative NNP O
Oncology NNP O
Group NNP O
. . O

OBJECTIVE CC O
A DT O
randomized JJ O
phase NN O
II NNP O
trial NN O
was VBD O
conducted VBN O
to TO O
test VB O
whether IN O
the DT O
addition NN O
of IN O
gemcitabine NN B-INTV
to TO O
weekly VB O
docetaxel NN B-INTV
could MD O
improve VB O
the DT O
objective JJ B-OC
response NN I-OC
rate NN I-OC
and CC I-OC
survival NN I-OC
outcomes NNS I-OC
as IN O
second-line JJ O
chemotherapy NN O
in IN O
patients NNS B-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
who WP I-POPU
have VBP I-POPU
failed VBN I-POPU
a DT I-POPU
paclitaxel-containing JJ I-POPU
regimen NN I-POPU
. . O

METHODS JJ O
Patients NNPS O
were VBD O
randomized VBN O
to TO O
receive VB O
either DT O
weekly JJ O
docetaxel NN B-INTV
40 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
( ( O
group NN O
A NNP O
, , O
n JJ O
= NNP O
34 CD O
) ) O
or CC O
the DT O
combination NN O
of IN O
weekly JJ O
docetaxel NN B-INTV
35 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
with IN I-INTV
gemcitabine NN I-INTV
600 CD O
mg/m NN O
( ( O
2 CD O
) ) O
( ( O
group NN O
B NNP O
, , O
n JJ O
= NNP O
41 CD O
) ) O
. . O

Three CD O
consecutive JJ O
weekly JJ O
infusions NNS O
followed VBN O
by IN O
a DT O
1-week JJ O
rest NN O
period NN O
represented VBD O
1 CD O
chemotherapy NN B-INTV
cycle NN O
. . O

RESULTS VB O
The DT O
objective JJ B-OC
response NN I-OC
rate NN I-OC
was VBD O
18 CD O
% NN O
and CC O
27.5 CD O
% NN O
in IN O
group NN O
A NNP O
and CC O
B NNP O
, , O
respectively RB O
( ( O
p JJ O
= NNP O
0.413 CD O
) ) O
. . O

No DT O
statistically RB O
significant JJ O
differences NNS O
were VBD O
demonstrated VBN O
in IN O
terms NNS O
of IN O
median JJ B-OC
overall JJ I-OC
survival NN I-OC
and CC I-OC
time NN I-OC
to TO I-OC
disease VB I-OC
progression NN I-OC
. . O

The DT O
rate NN B-OC
and CC I-OC
grade NN I-OC
3 CD I-OC
and CC I-OC
4 CD I-OC
neutropenia NNS I-OC
were VBD O
higher JJR O
in IN O
group NN O
B NNP O
( ( O
23 CD O
vs. FW O
3 CD O
% NN O
) ) O
. . O

CONCLUSIONS VB O
The DT O
weekly JJ O
administration NN O
of IN O
docetaxel NN B-INTV
and CC O
gemcitabine NN B-INTV
did VBD O
not RB O
result VB O
in IN O
superior JJ O
clinical JJ B-OC
outcomes NNS I-OC
over IN O
weekly JJ O
docetaxel NN O
. . O

-DOCSTART- -X- O O

Conjugated VBN O
equine JJ O
estrogen NN O
influence NN O
on IN O
mammographic JJ B-OC
density NN I-OC
in IN O
postmenopausal JJ B-POPU
women NNS I-POPU
in IN I-POPU
a DT I-POPU
substudy NN I-POPU
of IN I-POPU
the DT I-POPU
women NNS I-POPU
's POS I-POPU
health NN I-POPU
initiative NN I-POPU
randomized VBN I-POPU
trial NN I-POPU
. . O

PURPOSE NNP O
Increased VBD O
mammographic JJ B-OC
density NN I-OC
is VBZ O
associated VBN O
with IN O
increased JJ O
breast NN O
cancer NN O
risk NN O
and CC O
reduced JJ O
sensitivity NN O
of IN O
screening VBG O
mammography NN O
and CC O
is VBZ O
related VBN O
to TO O
hormone VB O
exposure NN O
. . O

However RB O
, , O
the DT O
effects NNS O
of IN O
conjugated JJ B-INTV
equine NN I-INTV
estrogens NNS I-INTV
( ( I-INTV
CEEs NNP I-INTV
) ) I-INTV
alone RB O
on IN O
mammographic JJ B-OC
density NN I-OC
in IN O
diverse JJ B-POPU
racial/ethnic JJ I-POPU
populations NNS I-POPU
are VBP O
not RB O
established VBN O
. . O

We PRP O
examined VBD O
the DT O
effect NN O
of IN O
CEE NNP O
alone RB O
on IN O
mammographic JJ B-OC
density NN I-OC
in IN O
a DT O
subsample NN B-POPU
of IN I-POPU
the DT I-POPU
Women NNP I-POPU
's POS I-POPU
Health NNP I-POPU
Initiative NNP I-POPU
( ( I-POPU
WHI NNP I-POPU
) ) I-POPU
clinical JJ I-POPU
trial NN I-POPU
participants NNS I-POPU
. . O

PATIENTS NNS O
AND CC O
METHODS NNP O
In IN O
the DT O
WHI NNP O
trial NN O
, , O
women NNS B-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
daily VB B-INTV
CEE NNP I-INTV
0.625 CD I-INTV
mg NN I-INTV
or CC I-INTV
placebo NN I-INTV
. . O

The DT O
effect NN O
of IN O
CEE NNP O
on IN O
mammographic JJ B-OC
percent NN I-OC
density NN I-OC
was VBD O
determined VBN O
over IN O
1 CD O
and CC O
2 CD O
years NNS O
in IN O
a DT O
stratified JJ O
random JJ B-POPU
sample NN I-POPU
of IN I-POPU
435 CD I-POPU
racially RB I-POPU
and CC I-POPU
ethnically RB I-POPU
diverse JJ I-POPU
participants NNS I-POPU
from IN I-POPU
15 CD I-POPU
of IN I-POPU
40 CD I-POPU
WHI NNP I-POPU
clinics NNS I-POPU
. . O

RESULTS NNP O
Use NNP O
of IN O
CEE NNP O
resulted VBD O
in IN O
mean JJ O
increase NN O
in IN O
mammographic JJ B-OC
percent NN I-OC
density NN I-OC
of IN O
1.6 CD O
percentage NN O
points NNS O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.8 CD O
to TO O
2.4 CD O
) ) O
at IN O
year NN O
1 CD O
compared VBN O
with IN O
a DT O
mean JJ O
decrease NN O
of IN O
1.0 CD O
percentage NN O
point NN O
( ( O
95 CD O
% NN O
CI NNP O
, , O
-1.7 NNP O
to TO O
-0.4 VB O
) ) O
in IN O
the DT O
placebo NN O
group NN O
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

The DT O
effect NN O
persisted VBD O
for IN O
2 CD O
years NNS O
, , O
with IN O
a DT O
mean JJ O
increase NN O
of IN O
1.7 CD O
percentage NN O
points NNS O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.7 CD O
to TO O
2.7 CD O
) ) O
versus NN O
a DT O
mean JJ O
decrease NN O
of IN O
1.2 CD O
percentage NN O
points NNS O
( ( O
95 CD O
% NN O
CI NNP O
, , O
-1.8 NNP O
to TO O
-0.5 VB O
; : O
P NNP O
< NNP O
.001 NNP O
) ) O
in IN O
the DT O
hormone NN O
and CC O
placebo NN O
groups NNS O
, , O
respectively RB O
. . O

These DT O
effects NNS O
were VBD O
greater JJR O
in IN O
women NNS B-POPU
age NN I-POPU
60 CD I-POPU
to TO I-POPU
79 CD I-POPU
years NNS I-POPU
( ( O
P NNP O
= NNP O
.03 NNP O
for IN O
interaction NN O
across IN O
age NN O
) ) O
. . O

CONCLUSION NNP O
Use NNP O
of IN O
CEE NNP O
results NNS O
in IN O
a DT O
modest JJ O
but CC O
statistically RB O
significant JJ O
increase NN O
in IN O
mammographic JJ B-OC
density NN I-OC
that WDT O
is VBZ O
sustained VBN O
over IN O
at IN O
least JJS O
a DT O
2-year JJ O
period NN O
. . O

The DT O
clinical JJ O
significance NN O
of IN O
the DT O
CEE NNP O
effect NN O
on IN O
mammographic JJ B-OC
density NN I-OC
remains VBZ O
to TO O
be VB O
determined VBN O
. . O

-DOCSTART- -X- O O

First-line JJ B-INTV
cisplatin NN I-INTV
with IN I-INTV
docetaxel NN I-INTV
or CC I-INTV
vinorelbine NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
quality NN B-POPU
of IN I-POPU
life NN I-POPU
directed VBN I-POPU
phase NN I-POPU
II NNP I-POPU
randomized VBD I-POPU
trial NN I-POPU
of IN I-POPU
Gruppo NNP I-POPU
Oncologico NNP I-POPU
Italia NNP I-POPU
Meridionale NNP I-POPU
. . O

BACKGROUND NNP O
Quality NNP B-OC
of IN I-OC
life NN I-OC
( ( I-OC
QoL NNP I-OC
) ) I-OC
has VBZ O
gained VBN O
greater JJR O
importance NN O
in IN O
the DT O
management NN O
of IN O
metastatic JJ B-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
due JJ O
to TO O
the DT O
palliative JJ O
nature NN O
of IN O
treatment NN O
. . O

Docetaxel NNP B-INTV
( ( I-INTV
DCT NNP I-INTV
) ) I-INTV
and CC I-INTV
cisplatin NN I-INTV
( ( I-INTV
CDDP NNP I-INTV
) ) I-INTV
doublet NN I-INTV
has VBZ O
been VBN O
reported VBN O
to TO O
be VB O
associated VBN O
to TO O
a DT O
better JJR O
QoL NNP O
than IN O
the DT O
weekly JJ O
vinorelbine NN B-INTV
( ( I-INTV
VNR NNP I-INTV
) ) I-INTV
and CC I-INTV
CDDP NNP I-INTV
regimen NNS O
. . O

Recently RB O
a DT O
newer NN O
more RBR O
tolerated JJ O
schedule NN O
of IN O
the DT O
VNR/CDDP NNP B-INTV
regimen NN O
has VBZ O
been VBN O
published VBN O
and CC O
is VBZ O
widely RB O
employed VBN O
in IN O
medical JJ O
practice NN O
. . O

The DT O
impact NN O
of IN O
these DT O
regimens NNS O
on IN O
patients NNS O
' POS O
QoL NNP O
as RB O
well RB O
as IN O
symptoms NNS B-OC
control NN I-OC
and CC I-OC
type NN I-OC
and CC O
grading VBG O
chemo-related JJ O
side-effects NNS B-OC
has VBZ O
been VBN O
compared VBN O
prospectically RB O
. . O

METHODS NNP O
Patients NNPS B-POPU
received VBD O
CDDP NNP B-INTV
75 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
plus CC I-INTV
DCT NNP I-INTV
75 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
on IN O
day NN O
1 CD O
every DT O
weeks NNS O
( ( O
arm IN O
A NNP O
) ) O
or CC O
CDDP $ B-INTV
80 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
on IN I-INTV
day NN I-INTV
1 CD I-INTV
plus CC I-INTV
VNR NNP I-INTV
30 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
day NN O
1 CD O
and CC O
8 CD O
every DT O
3 CD O
weeks NNS O
( ( O
arm NN O
B NNP O
) ) O
. . O

G-CSF NNP B-INTV
and/or JJ I-INTV
EPO NNP I-INTV
were VBD O
employed VBN O
as IN O
needed VBN O
. . O

Health-related JJ B-OC
QoL NNP I-OC
was VBD O
assessed VBN O
at IN O
entry NN O
and CC O
after IN O
every DT O
cycle NN O
by IN O
the DT O
EORTC-QLQ-C30 NNP O
and CC O
LC13 NNP B-OC
questionnaires NNS I-OC
, , I-OC
toxicity NN I-OC
by IN O
the DT O
NCI-NCCN NNP O
CTC NNP O
vs NN O
2 CD O
, , O
and CC O
intent-to-treat JJ O
objective JJ B-OC
response NN I-OC
by IN O
the DT O
Recist NNP O
criteria NNS O
. . O

RESULTS VB O
The DT O
QoL NNP B-OC
questionnaires NNS I-OC
were VBD O
completed VBN O
by IN O
37 CD B-POPU
pts NNS I-POPU
( ( I-POPU
88 CD I-POPU
% NN I-POPU
) ) I-POPU
in IN I-POPU
the DT I-POPU
DCT/CDDP NNP I-POPU
arm NN I-POPU
and CC O
39 CD B-POPU
pts NNS I-POPU
( ( I-POPU
87 CD I-POPU
% NN I-POPU
) ) I-POPU
in IN I-POPU
the DT I-POPU
VNR/CDDP NNP I-POPU
one NN I-POPU
. . O

Baseline JJ O
mean JJ O
scores NNS O
and CC O
rates NNS O
at IN O
which WDT O
pts NNS O
failed VBD O
to TO O
complete VB O
QoL NNP O
assessment NN O
were VBD O
similar JJ O
in IN O
the DT O
two CD O
arms NNS O
. . O

Global NNP B-OC
health NN I-OC
status NN I-OC
of IN O
the DT O
EORTC NNP B-OC
QLQ-C30 NNP I-OC
scale NN I-OC
and CC O
specific JJ B-OC
symptoms NNS I-OC
control NN I-OC
( ( O
LC13 NNP O
module NN O
) ) O
improved VBD O
during IN O
treatment NN O
without IN O
any DT O
statistically RB O
significant JJ O
difference NN O
between IN O
the DT O
two CD O
arms NNS O
. . O

Emotional JJ B-OC
functioning NN I-OC
remained VBD O
stable JJ O
in IN O
both DT O
groups NNS O
during IN O
treatment NN O
, , O
whereas JJ O
physical JJ B-OC
and CC I-OC
role NN I-OC
improved VBN O
slightly RB O
. . O

In IN O
the DT O
DCT/CDDP NNP B-INTV
arm NN O
14 CD O
pts NNS O
( ( O
33 CD O
% NN O
; : O
95 CD O
% NN O
CL NNP O
24-40 CD O
% NN O
) ) O
had VBD O
PR NNP O
, , O
and CC O
10 CD O
( ( O
24 CD O
% NN O
) ) O
SD NNP O
for IN O
a DT O
57 CD O
% NN O
TGCR NNP O
. . O

In IN O
the DT O
VNR/CDDP NNP B-INTV
arm NN O
12 CD O
pts NNS O
( ( O
27 CD O
% NN O
) ) O
achieved VBD O
PR NNP B-OC
, , O
18 CD O
( ( O
41 CD O
% NN O
) ) O
SD VBZ O
a DT O
68 CD O
% NN O
TGCR NNP O
. . O

Differences NNS O
were VBD O
not RB O
statistically RB O
significant JJ O
. . O

Median JJ B-OC
time-to-progression NN I-OC
was VBD O
4.2 CD O
months NNS O
in IN O
the DT O
DCT/CDDP NNP B-INTV
arm NN O
and CC O
4.5 CD O
months NNS O
in IN O
the DT O
VNR/CDDP NNP B-INTV
one CD O
, , O
and CC O
median JJ B-OC
overall JJ I-OC
survival NN I-OC
was VBD O
12.1 CD O
( ( O
range VB O
1-26+ JJ O
months NNS O
) ) O
and CC O
12.5 CD O
months NNS O
( ( O
range VB O
1-28+ JJ O
months NNS O
) ) O
for IN O
DCT/CDDP NNP B-INTV
and CC O
VNR/CDDP NNP B-INTV
arms NNS O
, , O
respectively RB O
. . O

Febrile NNP B-OC
neutropenia JJ I-OC
rate NN I-OC
was VBD O
higher RBR O
in IN O
the DT O
VNR/CDDP NNP B-INTV
arm NN O
( ( O
p=0.02 NN O
) ) O
as RB O
well RB O
as IN O
G3-4 NNP O
anemia NN B-OC
( ( O
p=0.005 NN O
) ) O
and CC O
G-CSF/EPO NNP O
use NN O
( ( O
p=0.019 NN O
) ) O
. . O

CONCLUSIONS NNP O
Global NNP B-OC
and CC I-OC
specific JJ I-OC
health-related JJ I-OC
QoL NNP I-OC
data NNS O
similar JJ O
in IN O
both DT O
treatment NN O
groups NNS O
with IN O
no DT O
statistically RB O
significant JJ O
difference NN O
. . O

Efficacy NN B-OC
measures NNS I-OC
, , I-OC
overall JJ I-OC
response NN I-OC
rate NN I-OC
, , I-OC
time-to-progression NN I-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
were VBD O
equivalent JJ O
in IN O
both DT O
arms NNS O
. . O

However RB O
, , O
severe JJ B-OC
anemia NN I-OC
and CC I-OC
febrile JJ I-OC
neutropenia NN I-OC
are VBP O
statistically RB O
more RBR O
frequent JJ O
in IN O
the DT O
VNR/CDDP NNP B-INTV
arm NN O
than IN O
in IN O
the DT O
DCT/CDDP NNP B-INTV
one NN O
. . O

These DT O
data NNS O
should MD O
be VB O
considered VBN O
in IN O
treatment NN O
decision-making NN O
for IN O
pts NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
non-small-cell JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
and CC O
for IN O
the DT O
design NN O
of IN O
future JJ O
trials NNS O
with IN O
chemotherapy NN O
plus CC O
biologics NNS O
. . O

-DOCSTART- -X- O O

Conservative JJ O
surgery NN O
with IN O
and CC O
without IN O
radiotherapy NN O
in IN O
elderly JJ B-POPU
patients NNS I-POPU
with IN I-POPU
early-stage JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
prospective JJ O
randomised VBN O
multicentre JJ O
trial NN O
. . O

Breast NNP B-INTV
conserving VBG I-INTV
therapy NN I-INTV
( ( I-INTV
BCT NNP I-INTV
) ) I-INTV
including VBG O
postoperative JJ O
irradiation NN O
of IN O
the DT O
remaining VBG O
breast NN O
tissue NN O
is VBZ O
generally RB O
accepted VBN O
as IN O
the DT O
best JJS O
treatment NN O
for IN O
the DT O
majority NN O
of IN O
patients NNS B-POPU
with IN I-POPU
early-stage JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

The DT O
question NN O
is VBZ O
whether IN O
there EX O
is VBZ O
a DT O
necessity NN O
for IN O
irradiating VBG O
all DT O
patients NNS O
. . O

Between JJ B-POPU
2001 CD I-POPU
and CC I-POPU
2005 CD I-POPU
, , I-POPU
749 CD I-POPU
women NNS I-POPU
aged VBN I-POPU
55-75 JJ I-POPU
years NNS I-POPU
with IN I-POPU
infiltrating VBG I-POPU
breast NN I-POPU
carcinoma NN I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
breast VB B-INTV
conservative JJ I-INTV
surgery NN I-INTV
, , I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
radiotherapy NN I-INTV
( ( O
RT NNP O
) ) O
, , O
to TO O
evaluate VB O
the DT O
incidence NN B-OC
of IN I-OC
in-breast JJ I-OC
recurrence NN I-OC
( ( I-OC
IBR NNP I-OC
) ) I-OC
. . O

After IN O
5 CD O
years NNS O
of IN O
median JJ O
follow-up NN O
, , O
the DT O
cumulative JJ B-OC
incidence NN I-OC
of IN I-OC
IBR NNP I-OC
was VBD O
2.5 CD O
% NN O
in IN O
the DT O
surgery-only JJ O
arm NN O
and CC O
0.7 CD O
% NN O
in IN O
the DT O
surgery NN O
plus CC O
RT NNP O
arm NN O
. . O

There EX O
are VBP O
no DT B-OC
differences NNS I-OC
in IN O
terms NNS O
of IN O
overall JJ B-OC
survival NN I-OC
and CC I-OC
distant JJ I-OC
disease-free JJ I-OC
survival NN I-OC
. . O

The DT O
preliminary JJ O
evaluation NN O
suggests VBZ O
that IN O
breast NN O
irradiation NN O
after IN O
conservative JJ O
surgery NN O
can MD O
be VB O
avoided VBN O
without IN O
exposing VBG O
these DT O
patients NNS O
to TO O
an DT O
increased VBN O
risk NN B-OC
of IN I-OC
distant-disease JJ I-OC
recurrence NN I-OC
. . O

Prolonged VBN O
follow-up NN O
will MD O
further RBR O
clarify VB O
the DT O
possible JJ O
risks NNS O
and CC O
late JJ O
sequelae NN O
potentially RB O
induced VBN O
by IN O
breast NN O
RT NNP O
. . O

-DOCSTART- -X- O O

Acupuncture NNP B-INTV
versus NN I-INTV
venlafaxine NN I-INTV
for IN O
the DT O
management NN O
of IN O
vasomotor NN B-OC
symptoms NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
hormone JJ I-POPU
receptor-positive JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
randomized NN O
controlled VBN O
trial NN O
. . O

PURPOSE NNP O
Vasomotor NNP B-OC
symptoms NNS I-OC
are VBP O
common JJ O
adverse JJ O
effects NNS O
of IN O
antiestrogen NN B-INTV
hormone NN I-INTV
treatment NN I-INTV
in IN O
conventional JJ O
breast NN O
cancer NN O
care NN O
. . O

Hormone CD B-INTV
replacement NN I-INTV
therapy NN I-INTV
is VBZ O
contraindicated VBN O
in IN O
patients NNS B-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
. . O

Venlafaxine NNP B-INTV
( ( I-INTV
Effexor NNP I-INTV
) ) I-INTV
, , O
the DT O
therapy NN O
of IN O
choice NN O
for IN O
these DT O
symptoms NNS O
, , O
has VBZ O
numerous JJ O
adverse JJ O
effects NNS O
. . O

Recent JJ O
studies NNS O
suggest VBP O
acupuncture NN B-INTV
may MD O
be VB O
effective JJ O
in IN O
reducing VBG O
vasomotor NN B-OC
symptoms NNS I-OC
in IN O
menopausal JJ B-POPU
women NNS I-POPU
. . O

This DT O
randomized VBD O
controlled JJ O
trial NN O
tested VBD O
whether IN O
acupuncture NN B-INTV
reduces NNS O
vasomotor NN B-OC
symptoms NNS I-OC
and CC O
produces VBZ O
fewer JJR O
adverse JJ O
effects NNS O
than IN O
venlafaxine NN B-INTV
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Fifty NNP B-POPU
patients NNS I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
12 CD O
weeks NNS O
of IN O
acupuncture NN B-INTV
( ( O
n JJ O
= NNP O
25 CD O
) ) O
or CC O
venlafaxine NN B-INTV
( ( O
n JJ O
= NNP O
25 CD O
) ) O
treatment NN O
. . O

Health NNP B-OC
outcomes NNS I-OC
were VBD O
measured VBN O
for IN O
up RB O
to TO O
1 CD O
year NN O
post-treatment NN O
. . O

RESULTS NNP O
Both NNP O
groups NNS O
exhibited VBD O
significant JJ O
decreases NNS O
in IN O
hot JJ B-OC
flashes NNS I-OC
, , I-OC
depressive NN I-OC
symptoms NNS I-OC
, , I-OC
and CC I-OC
other JJ I-OC
quality-of-life NN I-OC
symptoms NNS I-OC
, , O
including VBG O
significant JJ B-OC
improvements NNS I-OC
in IN I-OC
mental JJ I-OC
health NN I-OC
from IN O
pre- JJ O
to TO O
post-treatment JJ O
. . O

These DT O
changes NNS O
were VBD O
similar JJ O
in IN O
both DT O
groups NNS O
, , O
indicating VBG O
that IN O
acupuncture NN B-INTV
was VBD O
as RB O
effective JJ O
as IN O
venlafaxine NN B-INTV
. . O

By IN O
2 CD O
weeks NNS O
post-treatment JJ O
, , O
the DT O
venlafaxine NN B-INTV
group NN O
experienced VBD O
significant JJ O
increases NNS O
in IN O
hot JJ B-OC
flashes NNS I-OC
, , O
whereas NNS O
hot JJ O
flashes NNS O
in IN O
the DT O
acupuncture NN B-INTV
group NN O
remained VBD O
at IN O
low JJ O
levels NNS O
. . O

The DT O
venlafaxine NN B-INTV
group NN O
experienced VBD O
18 CD O
incidences NNS O
of IN O
adverse JJ O
effects NNS O
( ( O
eg NN O
, , O
nausea NN B-OC
, , I-OC
dry JJ I-OC
mouth NN I-OC
, , I-OC
dizziness NN I-OC
, , I-OC
anxiety NN I-OC
) ) I-OC
, , O
whereas IN O
the DT O
acupuncture NN B-INTV
group NN O
experienced VBD O
no DT O
negative JJ O
adverse JJ O
effects NNS O
. . O

Acupuncture NN B-INTV
had VBD O
the DT O
additional JJ O
benefit NN O
of IN O
increased JJ O
sex NN B-OC
drive NN I-OC
in IN O
some DT O
women NNS O
, , O
and CC O
most JJS O
reported VBD O
an DT O
improvement NN O
in IN O
their PRP$ O
energy NN B-OC
, , I-OC
clarity NN I-OC
of IN I-OC
thought NN I-OC
, , I-OC
and CC I-OC
sense NN I-OC
of IN I-OC
well-being NN I-OC
. . O

CONCLUSION NNP O
Acupuncture NNP B-INTV
appears VBZ O
to TO O
be VB O
equivalent JJ O
to TO O
drug NN O
therapy NN O
in IN O
these DT O
patients NNS O
. . O

It PRP O
is VBZ O
a DT O
safe JJ O
, , O
effective JJ O
and CC O
durable JJ O
treatment NN O
for IN O
vasomotor NN O
symptoms NNS O
secondary JJ O
to TO O
long-term JJ O
antiestrogen NN B-INTV
hormone NN I-INTV
use NN O
in IN O
patients NNS B-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
. . O

-DOCSTART- -X- O O

Epirubicin NNP B-INTV
and CC I-INTV
cyclophosphamide VB I-INTV
versus NN O
epirubicin NN B-INTV
and CC I-INTV
docetaxel NN I-INTV
as IN O
first-line JJ O
therapy NN O
for IN O
women NNS B-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
final JJ O
results NNS O
of IN O
a DT O
randomised JJ O
phase NN O
III NNP O
trial NN O
. . O

BACKGROUND VB O
This DT O
randomised JJ O
phase NN O
III NNP O
trial NN O
was VBD O
carried VBN O
out IN O
to TO O
compare VB O
the DT O
efficacy NN O
and CC O
safety NN O
of IN O
epirubicin NN B-INTV
and CC I-INTV
cyclophosphamide NN I-INTV
( ( I-INTV
EC NNP I-INTV
) ) I-INTV
with IN I-INTV
epirubicin NN I-INTV
and CC I-INTV
docetaxel NN I-INTV
( ( I-INTV
Taxotere NNP I-INTV
) ) I-INTV
( ( I-INTV
ED NNP I-INTV
) ) I-INTV
as IN O
first-line JJ O
chemotherapy NN O
for IN O
metastatic JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Patients NNP B-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
240 CD I-POPU
) ) I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO O
receive VB O
either DT O
ED NNP B-INTV
( ( I-INTV
epirubicin JJ I-INTV
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
and CC B-INTV
docetaxel $ I-INTV
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
or CC O
EC NNP B-INTV
( ( I-INTV
epirubicin VBP I-INTV
90 CD O
mg/m NN O
( ( O
2 CD O
) ) O
and CC O
cyclophosphamide $ B-INTV
600 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
objective JJ B-OC
response NN I-OC
rate NN I-OC
( ( I-OC
ORR NNP I-OC
) ) I-OC
. . O

Secondary JJ O
end NN O
points NNS O
were VBD O
progression-free JJ B-OC
survival NN I-OC
( ( I-OC
PFS NNP I-OC
) ) I-OC
, , I-OC
overall JJ I-OC
survival NN I-OC
( ( I-OC
OS NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
safety NN I-OC
. . O

RESULTS NNP O
ORR NNP B-OC
for IN O
patients NNS O
randomly RB O
assigned VBN O
to TO O
receive VB O
EC NNP B-INTV
and CC O
ED NNP B-INTV
were VBD O
42 CD O
% NN O
and CC O
47 CD O
% NN O
, , O
respectively RB O
( ( O
P NNP O
= NNP O
0.63 CD O
) ) O
. . O

Median JJ B-OC
PFS NNP I-OC
[ NNP O
10.1 CD O
versus NN O
10.3 CD O
months NNS O
; : O
hazard VBN O
ratio NN O
( ( O
HR NNP O
) ) O
0.98 CD O
; : O
log-rank JJ O
P NNP O
= NNP O
0.38 CD O
] NN O
and CC O
OS NNP B-OC
( ( O
19.9 CD O
versus NN O
30.0 CD O
months NNS O
; : O
HR NNP O
0.663 CD O
; : O
log-rank JJ O
P NNP O
= NNP O
0.21 CD O
) ) O
were VBD O
comparable JJ O
in IN O
both DT O
arms NNS O
. . O

Although IN O
grade JJ B-OC
3/4 CD I-OC
leucopenia NN I-OC
occurred VBD O
more RBR O
frequently RB O
with IN O
ED NNP B-INTV
( ( O
81 CD O
% NN O
versus IN O
73 CD O
% NN O
; : O
P NNP O
= NNP O
0.01 CD O
) ) O
, , O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
the DT O
incidence NN O
of IN O
febrile JJ B-OC
neutropenia NN I-OC
and CC I-OC
grade VBD I-OC
3/4 CD I-OC
infections NNS I-OC
. . O

Grade VB B-OC
3/4 CD I-OC
non-haematologic JJ I-OC
toxicity NN I-OC
was VBD O
infrequent JJ O
in IN O
both DT O
arms NNS O
. . O

Congestive JJ B-OC
heart NN I-OC
failure NN I-OC
was VBD O
observed VBN O
in IN O
one CD O
patient NN O
in IN O
each DT O
arm NN O
. . O

CONCLUSION NN O
In IN O
this DT O
randomised JJ O
trial NN O
, , O
no DT O
differences NNS O
in IN O
the DT O
efficacy NN O
study VBD O
end JJ O
points NNS O
were VBD O
observed VBN O
between IN O
the DT O
two CD O
treatment NN O
arms NNS O
. . O

-DOCSTART- -X- O O

Pazopanib NNP B-INTV
in IN O
locally RB B-POPU
advanced JJ I-POPU
or CC I-POPU
metastatic JJ I-POPU
renal NN I-POPU
cell NN I-POPU
carcinoma NN I-POPU
: : I-POPU
results NNS O
of IN O
a DT O
randomized JJ O
phase NN O
III NNP O
trial NN O
. . O

PURPOSE NNP O
Pazopanib NNP B-INTV
is VBZ O
an DT O
oral JJ B-INTV
angiogenesis NN I-INTV
inhibitor NN I-INTV
targeting VBG O
vascular JJ O
endothelial JJ O
growth NN O
factor NN O
receptor NN O
, , O
platelet-derived JJ O
growth NN O
factor NN O
receptor NN O
, , O
and CC O
c-Kit NN O
. . O

This DT O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
phase NN O
III NNP O
study NN O
evaluated VBD O
efficacy NN O
and CC O
safety NN O
of IN O
pazopanib JJ B-INTV
monotherapy NN I-INTV
in IN O
treatment-naive JJ B-POPU
and CC I-POPU
cytokine-pretreated JJ I-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
renal JJ I-POPU
cell NN I-POPU
carcinoma NN I-POPU
( ( I-POPU
RCC NNP I-POPU
) ) I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Adult NNP B-POPU
patients NNS I-POPU
with IN I-POPU
measurable JJ I-POPU
, , I-POPU
locally RB I-POPU
advanced JJ I-POPU
, , I-POPU
and/or JJ I-POPU
metastatic JJ I-POPU
RCC NNP I-POPU
were VBD O
randomly RB O
assigned VBN O
2:1 CD O
to TO O
receive VB B-INTV
oral JJ I-INTV
pazopanib NN I-INTV
or CC I-INTV
placebo NN I-INTV
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
progression-free JJ B-OC
survival NN I-OC
( ( I-OC
PFS NNP I-OC
) ) I-OC
. . O

Secondary JJ O
end NN O
points NNS O
included VBD O
overall JJ B-OC
survival NN I-OC
, , I-OC
tumor NN I-OC
response NN I-OC
rate NN I-OC
( ( I-OC
Response NNP I-OC
Evaluation NNP I-OC
Criteria NNP I-OC
in IN I-OC
Solid NNP I-OC
Tumors NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
safety NN I-OC
. . O

Radiographic JJ O
assessments NNS O
of IN O
tumors NNS O
were VBD O
independently RB O
reviewed VBN O
. . O

Results NNS O
Of IN B-POPU
435 CD I-POPU
patients NNS I-POPU
enrolled VBD I-POPU
, , I-POPU
233 CD I-POPU
were VBD I-POPU
treatment NN I-POPU
naive JJ I-POPU
( ( I-POPU
54 CD I-POPU
% NN I-POPU
) ) I-POPU
and CC I-POPU
202 CD I-POPU
were VBD I-POPU
cytokine NN I-POPU
pretreated VBN I-POPU
( ( I-POPU
46 CD I-POPU
% NN I-POPU
) ) I-POPU
. . O

PFS NNP B-OC
was VBD O
significantly RB O
prolonged VBN O
with IN O
pazopanib NNS B-INTV
compared VBN O
with IN O
placebo NN B-INTV
in IN O
the DT O
overall JJ O
study NN O
population NN O
( ( O
median JJ O
, , O
PFS NNP O
9.2 CD O
v NN O
4.2 CD O
months NNS O
; : O
hazard PRP$ O
ratio NN O
[ NNP O
HR NNP O
] NNP O
, , O
0.46 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.34 CD O
to TO O
0.62 CD O
; : O
P NNP O
< NNP O
.0001 NNP O
) ) O
, , O
the DT O
treatment-naive JJ B-INTV
subpopulation NN O
( ( O
median JJ O
PFS NNP O
11.1 CD O
v NN O
2.8 CD O
months NNS O
; : O
HR NNP O
, , O
0.40 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.27 CD O
to TO O
0.60 CD O
; : O
P NNP O
< NNP O
.0001 NNP O
) ) O
, , O
and CC O
the DT O
cytokine-pretreated JJ O
subpopulation NN O
( ( O
median JJ O
PFS NNP O
, , O
7.4 CD O
v NN O
4.2 CD O
months NNS O
; : O
HR NNP O
, , O
0.54 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.35 CD O
to TO O
0.84 CD O
; : O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

The DT O
objective JJ B-OC
response NN I-OC
rate NN I-OC
was VBD O
30 CD O
% NN O
with IN O
pazopanib NN B-INTV
compared VBN O
with IN O
3 CD O
% NN O
with IN O
placebo NN B-INTV
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

The DT O
median JJ B-OC
duration NN I-OC
of IN I-OC
response NN I-OC
was VBD O
longer JJR O
than IN O
1 CD O
year NN O
. . O

The DT O
most RBS O
common JJ O
adverse JJ O
events NNS O
were VBD O
diarrhea RB B-OC
, , I-OC
hypertension NN I-OC
, , I-OC
hair NN I-OC
color NN I-OC
changes NNS I-OC
, , I-OC
nausea NN I-OC
, , I-OC
anorexia NN I-OC
, , I-OC
and CC I-OC
vomiting VBG I-OC
. . O

There EX O
was VBD O
no DT O
evidence NN O
of IN O
clinically RB O
important JJ O
differences NNS O
in IN O
quality NN O
of IN O
life NN O
for IN O
pazopanib JJ B-INTV
versus NN I-INTV
placebo NN I-INTV
. . O

CONCLUSION NNP O
Pazopanib NNP B-INTV
demonstrated VBD O
significant JJ O
improvement NN O
in IN O
PFS NNP O
and CC O
tumor NN O
response NN O
compared VBN O
with IN O
placebo NN B-INTV
in IN O
treatment-naive JJ B-POPU
and CC I-POPU
cytokine-pretreated JJ I-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
and/or NNS I-POPU
metastatic JJ I-POPU
RCC NNP I-POPU
. . O

-DOCSTART- -X- O O

Helping VBG O
women NNS O
make VBP O
choices NNS O
about IN O
mammography NN O
screening NN O
: : O
an DT O
online NN O
randomized VBN O
trial NN O
of IN O
a DT O
decision NN O
aid NN O
for IN O
40-year-old JJ B-POPU
women NNS I-POPU
. . O

OBJECTIVE NNP O
To TO O
evaluate VB O
the DT O
effect NN O
of IN O
a DT O
decision NN B-INTV
aid NN I-INTV
( ( I-INTV
DA NNP I-INTV
) ) I-INTV
on IN O
women NNS O
's POS O
knowledge NN O
of IN O
the DT O
benefits NNS O
and CC O
harms NNS O
of IN O
screening VBG O
and CC O
on IN O
their PRP$ O
ability NN O
to TO O
make VB O
an DT O
informed JJ O
decision NN O
. . O

METHODS NNP O
An DT O
online NN O
randomized VBN O
controlled VBN O
trial NN O
among IN O
321 CD B-POPU
women NNS I-POPU
aged VBN I-POPU
38-45 CD I-POPU
years NNS I-POPU
was VBD I-POPU
conducted VBN I-POPU
. . O

Participants NNS O
were VBD O
randomized VBN O
to TO O
either DT O
immediate JJ B-INTV
or CC I-INTV
delayed JJ I-INTV
access NN I-INTV
to TO I-INTV
the DT I-INTV
online NN I-INTV
DA NNP I-INTV
which WDT O
( ( O
i NN O
) ) O
explained VBD O
the DT O
benefits NNS O
and CC O
harms NNS O
, , O
( ( O
ii NN O
) ) O
included VBD O
a DT O
values NNS O
clarification NN O
exercise NN O
and CC O
a DT O
worksheet NN O
to TO O
support VB O
decision NN O
making NN O
. . O

The DT O
primary JJ O
outcome NN O
, , O
knowledge NN B-OC
of IN I-OC
benefits NNS I-OC
and CC I-OC
harms NNS I-OC
of IN I-OC
screening NN I-OC
, , I-OC
and CC I-OC
secondary JJ I-OC
outcomes NNS I-OC
, , I-OC
informed VBN I-OC
choice NN I-OC
( ( I-OC
composite JJ I-OC
of IN I-OC
knowledge NN I-OC
, , I-OC
values NNS I-OC
and CC I-OC
intention NN I-OC
) ) I-OC
, , I-OC
anxiety NN I-OC
and CC I-OC
acceptability NN I-OC
of IN I-OC
the DT I-OC
DA NNP I-OC
were VBD O
measured VBN O
using VBG O
online JJ O
questionnaires NNS O
. . O

RESULTS NNP O
Women NNP B-POPU
in IN I-POPU
the DT I-POPU
intervention NN I-POPU
group NN I-POPU
were VBD O
more RBR O
knowledgeable JJ B-OC
( ( O
mean VB O
score NN O
out IN O
of IN O
10 CD O
, , O
7.35 CD O
vs NN O
6.27 CD O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
and CC O
were VBD O
more RBR O
likely JJ O
to TO O
have VB O
made VBN B-OC
a DT I-OC
decision NN I-OC
( ( O
82 CD O
% NN O
vs JJ O
61 CD O
% NN O
p NN O
< NNP O
0.001 CD O
) ) O
. . O

Of IN O
those DT O
who WP O
made VBD O
a DT O
decision NN O
, , O
women NNS O
in IN O
the DT O
intervention NN O
group NN O
were VBD O
less RBR O
likely JJ O
to TO O
start VB B-OC
screening VBG I-OC
now RB I-OC
( ( O
52 CD O
% NN O
vs JJ O
65 CD O
% NN O
p=0.05 NN O
) ) O
. . O

There EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
the DT O
proportion NN B-OC
of IN I-OC
women NNS I-OC
who WP I-OC
made VBD I-OC
an DT I-OC
informed JJ I-OC
choice NN I-OC
( ( O
71 CD O
% NN O
intervention NN O
group NN O
vs VBD O
64 CD O
% NN O
control NN B-INTV
group NN O
, , O
p=0.24 NN O
) ) O
. . O

The DT O
DA NNP O
was VBD O
helpful JJ O
, , O
balanced JJ O
and CC O
clear JJ O
, , O
and CC O
did VBD O
not RB O
make VB O
women NNS O
anxious JJ B-OC
. . O

CONCLUSIONS VB O
The DT O
DA NNP O
increased VBD O
knowledge NN B-OC
and CC O
reduced JJ O
indecision NN B-OC
, , O
without IN O
increasing VBG O
feelings NNS B-OC
of IN I-OC
anxiety NN I-OC
. . O

PRACTICE NNP O
IMPLICATIONS NNP O
This DT O
decision NN O
aid NN O
is VBZ O
easy JJ O
to TO O
access NN O
online NN O
and CC O
could MD O
be VB O
an DT O
inexpensive JJ O
way NN O
of IN O
supporting VBG O
women NNS O
aged VBN O
40 CD O
who WP O
are VBP O
considering VBG O
whether IN O
to TO O
start VB O
screening VBG O
now RB O
, , O
or CC O
wait VBP O
until IN O
they PRP O
are VBP O
50 CD O
. . O

The DT O
results NNS O
of IN O
this DT O
study NN O
demonstrate VB O
the DT O
potential NN O
of IN O
DAs NNP O
to TO O
help VB O
inform VB O
women NNS O
about IN O
both DT O
the DT O
benefits NNS O
and CC O
risks NNS O
of IN O
screening VBG O
at IN O
this DT O
age NN O
and CC O
to TO O
support VB O
women NNS O
and CC O
clinicians NNS O
in IN O
this DT O
decision NN O
making VBG O
process NN O
. . O

-DOCSTART- -X- O O

The DT O
development NN O
of IN O
a DT O
web- JJ B-INTV
and CC I-INTV
a DT I-INTV
print-based JJ I-INTV
decision NN I-INTV
aid NN I-INTV
for IN O
prostate NN B-POPU
cancer NN I-POPU
screening VBG B-OC
. . O

BACKGROUND NNP O
Whether NNP O
early JJ O
detection NN O
and CC O
treatment NN O
of IN O
prostate NN O
cancer NN O
( ( O
PCa NNP O
) ) O
will MD O
reduce VB O
disease-related JJ B-OC
mortality NN I-OC
remains VBZ O
uncertain JJ O
. . O

As IN O
a DT O
result NN O
, , O
tools NNS O
are VBP O
needed VBN O
to TO O
facilitate VB O
informed JJ O
decision NN B-OC
making NN I-OC
. . O

While IN O
there EX O
have VBP O
been VBN O
several JJ O
decision NN O
aids NNS O
( ( O
DAs NNP O
) ) O
developed VBD O
and CC O
tested VBD O
, , O
very RB O
few JJ O
have VBP O
included VBN O
an DT O
exercise NN O
to TO O
help VB O
men NNS O
clarify VB O
their PRP$ O
values NNS B-OC
and CC I-OC
preferences NNS I-OC
about IN O
PCa NNP O
screening NN O
. . O

Further NNP O
, , O
only RB O
one CD O
DA NNP O
has VBZ O
utilized VBN O
an DT O
interactive JJ O
web-based JJ O
format NN O
, , O
which WDT O
allows VBZ O
for IN O
an DT O
expansion NN O
and CC O
customization NN O
of IN O
the DT O
material NN O
. . O

We PRP O
describe VBP O
the DT O
development NN O
of IN O
two CD O
DAs NNP O
, , O
a DT O
booklet NN B-INTV
and CC O
an DT O
interactive JJ B-INTV
website NN I-INTV
, , O
each DT O
with IN O
a DT O
values NNS O
clarification NN O
component NN O
and CC O
designed VBN O
for IN O
use NN O
in IN O
diverse JJ O
settings NNS O
. . O

METHODS NNP O
We PRP O
conducted VBD O
two CD O
feasibility NN O
studies NNS O
to TO O
assess VB O
men NNS B-POPU
's POS I-POPU
( ( I-POPU
45-70 CD I-POPU
years NNS I-POPU
) ) I-POPU
Internet NNP I-POPU
access NN I-POPU
and CC I-POPU
their PRP$ I-POPU
willingness NN I-POPU
to TO I-POPU
use VB I-POPU
a DT I-POPU
web- JJ I-POPU
vs. FW I-POPU
a DT I-POPU
print-based JJ I-POPU
tool NN I-POPU
. . O

The DT O
booklet NN O
was VBD O
adapted VBN O
from IN O
two CD O
previous JJ O
versions NNS O
evaluated VBN O
in IN O
randomized VBN B-INTV
controlled JJ I-INTV
trials NNS I-INTV
( ( I-INTV
RCTs NNP I-INTV
) ) I-INTV
and CC O
the DT O
website NN B-INTV
was VBD O
created VBN O
to TO O
closely RB O
match VB O
the DT O
content NN O
of IN O
the DT O
revised JJ O
booklet NN O
. . O

Usability NNP B-OC
testing NN I-OC
was VBD O
conducted VBN O
to TO O
obtain VB O
feedback NN O
regarding VBG O
draft JJ O
versions NNS O
of IN O
the DT O
materials NNS O
. . O

The DT O
tools NNS O
were VBD O
also RB O
reviewed VBN O
by IN O
a DT O
plain NN O
language NN O
expert NN O
and CC O
the DT O
interdisciplinary JJ O
research NN O
team NN O
. . O

Feedback NN O
on IN O
the DT O
content NN O
and CC O
presentation NN O
led VBD O
to TO O
iterative JJ O
modifications NNS O
of IN O
the DT O
tools NNS O
. . O

RESULTS VB O
The DT O
feasibility NN O
studies NNS O
confirmed VBD O
that IN O
the DT O
Internet NNP B-OC
was VBD O
a DT O
viable JJ O
medium NN O
, , O
as IN O
the DT O
majority NN O
of IN O
men NNS O
used VBN B-OC
a DT I-OC
computer NN I-OC
, , O
had VBD O
access NN B-OC
to TO I-OC
the DT I-OC
Internet NNP I-OC
, , O
and CC O
Internet NNP B-OC
use NN I-OC
increased VBD O
over IN O
time NN O
. . O

Feedback NN O
from IN O
the DT O
usability NN O
testing VBG O
on IN O
the DT O
length NN B-OC
, , I-OC
presentation NN I-OC
, , I-OC
and CC I-OC
content NN I-OC
of IN I-OC
the DT I-OC
materials NNS I-OC
was VBD O
incorporated VBN O
into IN O
the DT O
final JJ O
versions NNS O
of IN O
the DT O
booklet NN O
and CC O
website NN O
. . O

Both CC O
the DT O
feasibility NN B-OC
studies NNS I-OC
and CC I-OC
the DT I-OC
usability NN I-OC
testing VBG I-OC
highlighted VBD O
the DT O
need NN O
to TO O
address VB O
men NNS B-POPU
's POS I-POPU
informed VBN I-POPU
decision NN I-POPU
making VBG I-POPU
regarding VBG O
screening NN O
. . O

CONCLUSIONS NNP O
Informed NNP O
decision NN O
making VBG O
for IN O
PCa NNP O
screening NN O
is VBZ O
crucial JJ O
at IN O
present JJ O
and CC O
may MD O
be VB O
important JJ O
for IN O
some DT O
time NN O
, , O
particularly RB O
if IN O
a DT O
definitive JJ O
recommendation NN O
either DT O
for IN O
or CC O
against IN O
screening VBG O
does VBZ O
not RB O
emerge VB O
from IN O
ongoing VBG O
prostate NN O
cancer NN O
screening VBG O
trials NNS O
. . O

We PRP O
have VBP O
detailed VBN O
our PRP$ O
efforts NNS O
at IN O
developing VBG O
print- JJ O
and CC O
web-based JJ O
DAs NNP O
to TO O
assist VB O
men NNS O
in IN O
determining VBG O
how WRB O
to TO O
best VB O
meet VB O
their PRP$ O
PCa NNP O
screening NN O
preferences NNS O
. . O

Following VBG O
completion NN O
of IN O
our PRP$ O
ongoing JJ O
RCT NNP O
designed VBN O
to TO O
test VB O
these DT O
materials NNS O
, , O
our PRP$ O
goal NN O
will MD O
be VB O
to TO O
develop VB O
a DT O
dissemination NN B-OC
project NN I-OC
for IN O
the DT O
more RBR O
effective JJ O
tool NN O
. . O

TRIAL NNP O
REGISTRATION NNP O
NCT00623090 NNP O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
on IN O
disseminated JJ O
tumour NN O
cells NNS O
in IN O
women NNS B-POPU
with IN I-POPU
locally RB I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
an DT O
open JJ O
label NN O
, , O
randomised VBN O
, , O
phase VB O
2 CD O
trial NN O
. . O

BACKGROUND NNP O
Treatment NNP O
with IN O
bisphosphonates NNS B-INTV
decreases NNS O
bone VBP O
loss NN O
and CC O
can MD O
increase VB O
disease-free JJ O
survival NN O
in IN O
patients NNS B-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
. . O

The DT O
aim NN O
of IN O
our PRP$ O
study NN O
was VBD O
to TO O
assess VB O
the DT O
effect NN O
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
on IN O
clearance NN O
of IN O
disseminated JJ B-OC
tumour NN I-OC
cells NNS I-OC
( ( I-OC
DTCs NNP I-OC
) ) I-OC
from IN O
the DT O
bone NN O
marrow NN O
in IN O
women NNS B-POPU
undergoing VBG I-POPU
neoadjuvant JJ I-POPU
chemotherapy NN I-POPU
for IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

METHODS NNP O
Patients NNPS O
were VBD O
recruited VBN O
for IN O
this DT O
open-label JJ B-POPU
, , I-POPU
phase VB I-POPU
2 CD I-POPU
randomised JJ I-POPU
trial NN I-POPU
between IN I-POPU
March NNP I-POPU
17 CD I-POPU
, , I-POPU
2003 CD I-POPU
, , I-POPU
and CC I-POPU
May NNP I-POPU
19 CD I-POPU
, , I-POPU
2006 CD I-POPU
, , I-POPU
at IN I-POPU
a DT I-POPU
single JJ I-POPU
centre NN I-POPU
. . O

Eligible JJ B-POPU
patients NNS I-POPU
had VBD I-POPU
clinical JJ I-POPU
stage NN I-POPU
II-III NNP I-POPU
( ( I-POPU
> CD I-POPU
or CC I-POPU
= VB I-POPU
T2 NNP I-POPU
and/or JJ I-POPU
> NN I-POPU
or CC I-POPU
= VB I-POPU
N1 NNP I-POPU
) ) I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
breast NN I-POPU
cancer NN I-POPU
, , I-POPU
Eastern NNP I-POPU
Cooperative NNP I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
performance NN I-POPU
status NN I-POPU
of IN I-POPU
0 CD I-POPU
or CC I-POPU
1 CD I-POPU
, , I-POPU
and CC I-POPU
normal JJ I-POPU
cardiac NN I-POPU
, , I-POPU
renal JJ I-POPU
, , I-POPU
and CC I-POPU
liver JJ I-POPU
function NN I-POPU
. . O

120 CD B-POPU
women NNS I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
, , O
using VBG O
allocation NN O
concealment NN O
, , O
to TO O
receive VB O
4 CD B-INTV
mg NN I-INTV
zoledronic JJ I-INTV
acid NN I-INTV
intravenously RB I-INTV
every DT I-INTV
3 CD O
weeks NNS O
( ( O
n=60 NN O
) ) O
, , O
or CC O
no DT B-INTV
zoledronic JJ I-INTV
acid NN I-INTV
( ( O
n=60 JJ O
) ) O
, , O
for IN O
1 CD O
year NN O
concomitant NN O
with IN O
four CD B-INTV
cycles NNS I-INTV
of IN I-INTV
neoadjuvant JJ I-INTV
epirubicin NN I-INTV
( ( O
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
plus CC B-INTV
docetaxel JJ I-INTV
( ( O
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
and CC B-INTV
two CD I-INTV
cycles NNS I-INTV
of IN I-INTV
adjuvant JJ I-INTV
epirubicin JJ I-INTV
plus CC I-INTV
docetaxel JJ I-INTV
. . O

The DT O
primary JJ O
endpoint NN O
was VBD O
the DT O
number NN O
of IN O
patients NNS O
with IN O
detectable JJ B-OC
DTCs NNP I-OC
at IN O
3 CD O
months NNS O
. . O

Final NNP O
analysis NN O
was VBD O
done VBN O
1 CD O
year NN O
after IN O
the DT O
last JJ O
patient NN O
was VBD O
enrolled VBN O
. . O

Analyses NNS O
were VBD O
done VBN O
for IN O
all DT O
patients NNS O
with IN O
available JJ O
data NNS O
at IN O
3 CD O
months NNS O
. . O

This DT O
study NN O
is VBZ O
registered VBN O
with IN O
ClinicalTrials.gov NNP O
, , O
number NN O
NCT00242203 NNP O
. . O

FINDINGS NNP O
Of IN O
the DT O
120 CD B-POPU
patients NNS I-POPU
initially RB I-POPU
enrolled VBD I-POPU
, , I-POPU
one CD I-POPU
withdrew NN I-POPU
after IN I-POPU
signing VBG I-POPU
consent NN I-POPU
and CC I-POPU
one CD I-POPU
patient NN I-POPU
's POS I-POPU
baseline NN I-POPU
bone NN I-POPU
marrow NN I-POPU
was VBD I-POPU
not RB I-POPU
available JJ I-POPU
. . O

Both DT O
of IN O
these DT O
patients NNS O
were VBD O
in IN O
the DT O
control NN O
group NN O
. . O

At IN O
3 CD O
months NNS O
, , O
109 CD B-POPU
bone-marrow NN I-POPU
samples NNS I-POPU
were VBD I-POPU
available JJ I-POPU
for IN O
analysis NN O
. . O

In IN O
the DT O
zoledronic JJ O
acid NN O
group NN O
, , O
bone NN O
marrow NN O
was VBD O
not RB O
collected VBN O
from IN O
one CD O
patient NN O
because IN O
of IN O
disease NN O
progression NN O
, , O
one CD O
patient NN O
was VBD O
taken VBN O
off RP O
study NN O
because IN O
of IN O
severe JJ O
diarrhoea NN O
, , O
and CC O
two CD O
patients NNS O
had VBD O
not RB O
consented VBN O
at IN O
the DT O
time NN O
of IN O
surgery NN O
. . O

In IN O
the DT O
control NN O
group NN O
, , O
bone NN O
marrow NN O
was VBD O
not RB O
collected VBN O
from IN O
two CD O
patients NNS O
because IN O
of IN O
disease NN O
progression NN O
, , O
one CD O
patient NN O
withdrew VBD O
consent NN O
, , O
and CC O
three CD O
patients NNS O
were VBD O
not RB O
consented VBN O
at IN O
the DT O
time NN O
of IN O
surgery NN O
. . O

At IN O
baseline NN O
, , O
DTCs NNP O
were VBD O
detected VBN O
in IN O
26 CD O
of IN O
60 CD O
patients NNS O
in IN O
the DT O
zoledronic JJ B-INTV
acid NN I-INTV
group NN O
and CC O
28 CD O
of IN O
58 CD O
patients NNS O
in IN O
the DT O
control NN O
group NN O
. . O

At IN O
3 CD O
months NNS O
, , O
17 CD O
of IN O
56 CD O
patients NNS O
receiving VBG O
zoledronic JJ O
acid NN O
versus IN O
25 CD O
of IN O
53 CD O
patients NNS O
who WP O
did VBD O
not RB O
receive VB O
zoledronic JJ O
acid NN O
had VBD O
detectable JJ O
DTCs NNP O
( ( O
p=0.054 NN O
) ) O
. . O

The DT O
most RBS O
common JJ O
grade NN O
3-4 JJ O
toxicities NNS O
were VBD O
infection NN O
( ( O
five CD O
of IN O
60 CD O
patients NNS O
in IN O
the DT O
zoledronic JJ O
acid NN O
group NN O
and CC O
six CD O
of IN O
59 CD O
in IN O
the DT O
control NN O
group NN O
) ) O
and CC O
thrombosis NN O
( ( O
five CD O
of IN O
60 CD O
in IN O
the DT O
zoledronic JJ O
acid NN O
and CC O
two CD O
of IN O
59 CD O
in IN O
the DT O
control NN O
group NN O
) ) O
. . O

There EX O
was VBD O
one CD O
documented JJ O
case NN O
of IN O
osteonecrosis NN B-OC
in IN O
the DT O
zoledronic JJ O
acid NN O
group NN O
. . O

INTERPRETATION NNP O
Zoledronic NNP B-INTV
acid NN I-INTV
administered VBD O
with IN O
chemotherapy NN O
resulted VBN O
in IN O
a DT O
decreased JJ O
proportion NN O
of IN O
patients NNS O
with IN O
DTCs NNP O
detected VBD O
in IN O
the DT O
bone NN O
marrow NN O
at IN O
the DT O
time NN O
of IN O
surgery NN O
. . O

Our PRP$ O
study NN O
supports VBZ O
the DT O
hypothesis NN O
that IN O
the DT O
antimetastatic JJ O
effects NNS O
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
may MD O
be VB O
through IN O
effects NNS O
on IN O
DTCs NNP O
. . O

FUNDING NN O
Novartis NN O
Pharmaceuticals NNP O
and CC O
Pfizer NNP O
Inc NNP O
. . O

-DOCSTART- -X- O O

Acute NNP B-OC
and CC I-OC
late JJ I-OC
toxicity NN I-OC
in IN O
a DT O
randomized JJ O
trial NN O
of IN O
conventional JJ B-INTV
versus NN O
hypofractionated VBD B-INTV
three-dimensional JJ I-INTV
conformal JJ I-INTV
radiotherapy NN I-INTV
for IN O
prostate NN B-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
To TO O
compare VB O
the DT O
toxicity NN O
between IN O
hypofractionation NN B-INTV
vs. FW I-INTV
conventional JJ I-INTV
fractionation NN I-INTV
schedules NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
high-risk JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

METHODS NNP O
AND CC O
MATERIALS NNP O
Between NNP B-POPU
January NNP I-POPU
2003 CD I-POPU
and CC I-POPU
December NNP I-POPU
2007 CD I-POPU
, , I-POPU
168 CD I-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
either RB O
hypofractionated VBN B-INTV
( ( O
62 CD O
Gy NNP O
in IN O
20 CD O
fractions NNS O
within IN O
5 CD O
weeks NNS O
, , O
4 CD O
fractions/wk NN O
) ) O
or CC B-INTV
conventionally RB I-INTV
fractionated VBN I-INTV
( ( O
80 CD O
Gy NNP O
in IN O
40 CD O
fractions NNS O
within IN O
8 CD O
weeks NNS O
) ) O
three-dimensional JJ B-INTV
conformal JJ I-INTV
radiotherapy NN I-INTV
to TO O
the DT O
prostate NN O
and CC O
seminal JJ O
vesicles NNS O
. . O

All DT B-POPU
patients NNS I-POPU
had VBD I-POPU
undergone RP I-POPU
a DT I-POPU
9-month JJ I-POPU
course NN I-POPU
of IN I-POPU
total JJ I-POPU
androgen NN I-POPU
deprivation NN I-POPU
, , I-POPU
with IN I-POPU
radiotherapy NN I-POPU
starting VBG I-POPU
2 CD I-POPU
months NNS I-POPU
after IN I-POPU
initiation NN I-POPU
of IN I-POPU
the DT I-POPU
total JJ I-POPU
androgen NN I-POPU
deprivation NN I-POPU
. . O

RESULTS VB O
The DT O
median JJ O
follow-up NN O
was VBD O
32 CD O
and CC O
35 CD O
months NNS O
in IN O
the DT O
hypofractionation NN O
and CC O
conventional JJ O
fractionation NN O
arms NNS O
, , O
respectively RB O
. . O

For IN O
the DT O
patients NNS O
developing VBG O
acute JJ O
toxicity NN O
, , O
no DT O
difference NN O
between IN O
the DT O
two CD O
fractionation NN O
groups NNS O
was VBD O
found VBN O
in IN O
either DT O
severity NN B-OC
or CC I-OC
duration NN I-OC
of IN I-OC
gastrointestinal JJ I-OC
or CC I-OC
genitourinary JJ I-OC
toxicity NN I-OC
. . O

Also RB O
, , O
no DT O
difference NN O
was VBD O
found VBN O
in IN O
the DT O
incidence NN O
and CC O
severity NN B-OC
of IN I-OC
late JJ I-OC
gastrointestinal NN I-OC
and CC I-OC
genitourinary JJ I-OC
toxicity NN I-OC
between IN O
the DT O
two CD O
treatment NN O
schedules NNS O
, , O
with IN O
a DT O
3-year JJ O
rate NN O
of IN O
Grade NNP O
2 CD O
or CC O
greater JJR O
toxicity NN O
of IN O
17 CD O
% NN O
and CC O
16 CD O
% NN O
for IN O
the DT O
hypofractionation NN O
arm NN O
and CC O
14 CD O
% NN O
and CC O
11 CD O
% NN O
for IN O
the DT O
conventional JJ O
fractionation NN O
arm NN O
, , O
respectively RB O
. . O

A DT O
statistically RB O
significant JJ O
correlation NN O
between IN O
acute NN B-OC
and CC I-OC
late JJ I-OC
gastrointestinal JJ I-OC
toxicity NN I-OC
was VBD O
found VBN O
only RB O
in IN O
the DT O
conventional JJ O
fractionation NN O
group NN O
. . O

CONCLUSION NNP O
Our PRP$ O
findings NNS O
suggest VBP O
that IN O
the DT O
hypofractionation NN B-INTV
regimen NNS O
used VBN O
in IN O
our PRP$ O
study NN O
is VBZ O
safe JJ O
, , O
with IN O
only RB O
a DT O
slight NN O
, , O
nonsignificant JJ O
increase NN O
in IN O
tolerable JJ B-OC
and CC I-OC
temporary JJ I-OC
acute NN I-OC
toxicity NN I-OC
compared VBN O
with IN O
the DT O
conventional JJ O
fractionation NN O
schedule NN O
. . O

The DT O
severity NN O
and CC O
frequency NN O
of IN O
late JJ O
complications NNS O
was VBD O
equivalent JJ O
between IN O
the DT O
two CD O
treatment NN O
groups NNS O
. . O

-DOCSTART- -X- O O

Biomarkers NNS O
of IN O
dietary JJ B-INTV
exposure NN I-INTV
are VBP O
associated VBN O
with IN O
lower JJR O
risk NN O
of IN O
breast NN B-POPU
fibroadenomas NN I-POPU
in IN I-POPU
Chinese JJ I-POPU
women NNS I-POPU
. . O

Fibroadenomas NNP O
are VBP O
the DT O
most RBS O
common JJ O
benign NN O
breast JJ O
condition NN O
among IN O
women NNS O
and CC O
account NN O
for IN O
up IN O
to TO O
50 CD O
% NN O
of IN O
all DT O
breast NN O
biopsies NNS O
being VBG O
performed VBN O
. . O

Although IN O
considered VBN O
a DT O
benign JJ O
condition NN O
, , O
fibroadenomas JJ O
utilize VBP O
substantial JJ O
resources NNS O
for IN O
management NN O
and CC O
treatment NN O
to TO O
rule VB O
out RP O
potential JJ O
malignancies NNS O
. . O

Dietary JJ B-INTV
factors NNS I-INTV
may MD O
influence VB O
benign JJ O
fibrocystic JJ O
breast NN O
conditions NNS O
, , O
but CC O
little JJ O
is VBZ O
known VBN O
of IN O
their PRP$ O
association NN O
with IN O
fibroadenomas NN O
. . O

We PRP O
examined VBD O
possible JJ O
associations NNS O
between IN O
a DT O
broad JJ O
spectrum NN O
of IN O
circulating VBG O
biomarkers NNS B-OC
of IN I-OC
dietary JJ I-OC
intake NN I-OC
and CC O
risk NN O
of IN O
fibroadenomas NN O
. . O

Participants NNS B-POPU
were VBD I-POPU
women NNS I-POPU
in IN I-POPU
a DT I-POPU
breast NN I-POPU
self-examination NN I-POPU
trial NN I-POPU
in IN I-POPU
Shanghai NNP I-POPU
, , I-POPU
China NNP I-POPU
who WP I-POPU
were VBD I-POPU
diagnosed VBN I-POPU
with IN I-POPU
fibroadenomas NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
258 CD I-POPU
) ) I-POPU
and CC I-POPU
1035 CD I-POPU
controls NNS I-POPU
. . O

Conditional NNP B-OC
logistic JJ I-OC
regression NN I-OC
was VBD O
used VBN O
to TO O
estimate VB B-OC
adjusted VBN I-OC
odds NNS I-OC
ratios NNS I-OC
( ( I-OC
OR NNP I-OC
) ) I-OC
and CC O
95 CD B-OC
% NN I-OC
CI NNP I-OC
. . O

Isoflavone NNP B-OC
concentrations NNS I-OC
were VBD O
inversely RB O
associated VBN O
with IN O
risk NN B-OC
of IN I-OC
fibroadenomas NN I-OC
. . O

Adjusted VBN B-OC
OR NNP I-OC
( ( I-OC
95 CD I-OC
% NN I-OC
CI NNP I-OC
) ) I-OC
for IN O
the DT O
highest JJS O
versus NN O
the DT O
lowest JJS O
quartile NN O
of IN O
plasma JJ O
concentration NN O
were VBD O
0.36 CD O
( ( O
0.16-0.79 CD O
; : O
P-trend NNP O
< NNP O
0.001 CD O
) ) O
for IN O
daidzein NN B-INTV
and CC O
0.39 CD O
( ( O
0.19-0.84 CD O
; : O
P-trend NNP O
= NNP O
0.010 CD O
) ) O
for IN O
genistein NN B-INTV
. . O

We PRP O
also RB O
observed VBD O
inverse JJ B-OC
associations NNS I-OC
between IN O
higher JJR O
percentages NNS B-OC
of IN I-OC
the DT I-OC
RBC NNP I-OC
( ( I-OC
n-3 JJ I-OC
) ) I-OC
fatty JJ I-OC
acids NNS I-OC
, , I-OC
eicosapentaenoic JJ I-OC
acid NN I-OC
( ( I-OC
EPA NNP I-OC
) ) I-OC
( ( O
[ $ O
0.38 CD O
( ( O
0.19-0.77 JJ O
) ) O
; : O
P-trend JJ O
= NN O
0.007 CD O
] NN O
and CC O
docosapentaenoic NN B-OC
acid NN I-OC
( ( I-OC
DPA NNP I-OC
) ) I-OC
[ VBZ O
0.32 CD O
( ( O
0.15-0.70 JJ O
) ) O
; : O
P-trend JJ O
= NN O
0.024 CD O
] NN O
, , O
and CC O
fibroadenoma NN O
risk NN O
. . O

Circulating VBG O
concentrations NNS O
of IN O
carotenoids NNS B-OC
, , I-OC
vitamin FW I-OC
C NNP I-OC
, , I-OC
retinol NN I-OC
, , I-OC
and CC I-OC
ferritin NNS I-OC
were VBD O
not RB O
associated VBN O
with IN O
fibroadenoma NN O
risk NN O
. . O

The DT O
inverse JJ B-OC
associations NNS I-OC
between IN O
plasma NN B-OC
isoflavone NN I-OC
concentrations NNS I-OC
and CC O
RBC NNP B-OC
EPA NNP I-OC
and CC I-OC
DPA NNP I-OC
and CC O
fibroadenoma NN B-OC
risk NN I-OC
suggest VBP O
that IN O
higher JJR O
intakes NNS O
of IN O
soy JJ B-INTV
foods NNS I-INTV
and CC I-INTV
fatty JJ I-INTV
fish NN I-INTV
may MD O
lower VB O
the DT O
risk NN B-OC
of IN I-OC
fibroadenomas NN I-OC
. . O

-DOCSTART- -X- O O

[ JJ B-INTV
Pleural NNP I-INTV
tent NN I-INTV
after IN O
upper JJ B-POPU
lobectomy NN I-POPU
-- : I-POPU
randomized VBD I-POPU
study NN O
of IN O
it PRP O
's VBZ O
efficacy NN O
and CC O
duration NN O
of IN O
the DT O
effect NN O
] NNP O
. . O

UNLABELLED IN O
The DT O
aim NN O
of IN O
our PRP$ O
study NN O
is VBZ O
to TO O
evaluate VB O
the DT O
safety NN B-OC
, , I-OC
efficacy NN I-OC
and CC I-OC
also RB I-OC
the DT I-OC
maximum JJ I-OC
duration NN I-OC
of IN I-OC
effect NN I-OC
of IN I-OC
the DT I-OC
pleural JJ B-INTV
tent NN I-INTV
in IN O
reducing VBG O
the DT O
incidence NN O
of IN O
air NN O
leak NN O
after IN O
upper JJ O
lobectomy NN O
. . O

METHODS NNP O
Sixty NNP B-POPU
patients NNS I-POPU
who WP I-POPU
underwent VBP I-POPU
upper JJ I-POPU
lobectomy NN I-POPU
were VBD O
prospectively RB O
randomized VBN O
into IN O
two CD O
groups NNS O
: : O
30 CD B-POPU
patients NNS I-POPU
had VBD O
creation NN B-INTV
of IN I-INTV
pleural JJ I-INTV
tent NN I-INTV
( ( O
group NN O
1 CD O
) ) O
and CC O
30 CD O
did VBD B-INTV
not RB I-INTV
( ( O
group NN O
2 CD O
) ) O
. . O

The DT O
preoperative JJ O
, , O
operative JJ O
, , O
and CC O
postoperative JJ O
characteristics NNS O
of IN O
both DT O
groups NNS O
were VBD O
compared VBN O
. . O

Then RB O
multivariate JJ O
analyses NNS O
were VBD O
used VBN O
to TO O
identify VB O
factors NNS O
predictive CD O
of IN O
prolonged JJ O
air NN O
leaks NNS O
and CC O
their PRP$ O
duration NN O
. . O

The DT O
reduction NN O
of IN O
incidences NNS B-OC
of IN I-OC
air NN I-OC
leak NN I-OC
in IN O
the DT O
two CD O
groups NNS O
was VBD O
subsequently RB O
compared VBN O
during IN O
successive JJ O
postoperative JJ O
periods NNS O
. . O

RESULTS NNP O
Demographic NNP O
and CC O
clinical JJ O
profiles NNS O
of IN O
both DT O
groups NNS O
were VBD O
not RB O
statistically RB O
different JJ O
. . O

The DT O
tented JJ O
patients NNS O
had VBD O
statistically RB O
significant JJ O
reduction NN O
of IN O
mean JJ B-OC
duration NN I-OC
of IN I-OC
air NN I-OC
leak NN I-OC
in IN O
days NNS O
( ( O
4.9 CD O
+/- JJ O
1.79 CD O
vs JJ O
8.2 CD O
+/- JJ O
4.2 CD O
) ) O
, , O
the DT O
number NN B-OC
of IN I-OC
days NNS I-OC
of IN I-OC
a DT I-OC
chest NN I-OC
tube NN I-OC
duration NN I-OC
( ( O
7.3 CD O
+/- JJ O
1.14 CD O
vs JJ O
12.46 CD O
+/- JJ O
3.6 CD O
) ) O
, , O
the DT O
length NN B-OC
of IN I-OC
postoperative JJ I-OC
in-hospital JJ I-OC
stay NN I-OC
in IN I-OC
days NNS I-OC
( ( O
9.4 CD O
+/- JJ O
1.86 CD O
vs JJ O
13.6 CD O
+/- JJ O
2.49 CD O
) ) O
, , O
and CC O
the DT O
hospital NN B-OC
stay NN I-OC
cost NN I-OC
per IN I-OC
patient NN I-OC
( ( O
leva NN O
, , O
3840 CD O
+/- JJ O
298 CD O
vs JJ O
5160 CD O
+/- JJ O
3890 CD O
) ) O
. . O

Logistic JJ O
regression NN O
analyses NNS O
showed VBD O
that IN O
no DT O
having VBG O
creation NN O
a DT O
pleural JJ B-INTV
tent NN I-INTV
procedure NN O
was VBD O
the DT O
most RBS O
significant JJ O
predictive JJ O
factor NN O
of IN O
the DT O
occurrence NN B-OC
and CC I-OC
duration NN I-OC
of IN I-OC
prolonged JJ I-OC
air NN I-OC
leaks NNS I-OC
. . O

A DT O
greater JJR O
reduction NN O
in IN O
the DT O
duration NN B-OC
of IN I-OC
air NN I-OC
leaks NNS I-OC
was VBD O
observed VBN O
before IN O
postoperative JJ O
day NN O
4 CD O
in IN O
group NN O
1 CD O
, , O
and CC O
logistic JJ O
regression NN O
analysis NN O
showed VBD O
that IN O
having VBG O
a DT O
pleural JJ O
tent NN O
procedure NN O
was VBD O
the DT O
most RBS O
significant JJ O
predictive JJ O
factor NN O
of IN O
air NN B-OC
leaks NNS I-OC
that WDT O
persisted VBD O
for IN O
less JJR O
than IN O
4 CD O
days NNS O
. . O

CONCLUSIONS NNP O
Pleural NNP O
tent NN O
creation NN O
after IN O
upper JJ O
lobectomy NN O
is VBZ O
a DT O
simple JJ B-OC
and CC I-OC
safe JJ I-OC
procedure NN I-OC
that WDT O
reduces VBZ O
the DT O
duration NN B-OC
of IN I-OC
air NN I-OC
leaks NNS I-OC
and CC O
the DT O
hospital NN B-OC
stay NN I-OC
costs NNS I-OC
. . O

The DT O
benefit NN O
from IN O
that DT O
procedure NN O
is VBZ O
achieved VBN O
before IN O
postoperative JJ O
day NN O
4 CD O
. . O

-DOCSTART- -X- O O

Evaluation NN O
of IN O
the DT O
effect NN O
of IN O
topical JJ B-INTV
agents NNS I-INTV
on IN O
radiation-induced JJ B-POPU
skin NN I-POPU
disease NN I-POPU
by IN O
reflectance NN O
spectrophotometry NN O
. . O

OBJECTIVES NNP O
Radiotherapy NNP O
may MD O
cause VB O
severe JJ O
skin NN O
changes NNS O
that WDT O
significantly RB O
interfere VBZ O
with IN O
the DT O
patient NN O
's POS O
quality NN O
of IN O
life NN O
and CC O
reduce VB O
radiotherapy NN O
effectiveness NN O
. . O

Many JJ O
skin NN O
care NN O
instructions NNS O
and CC O
various JJ O
topical JJ O
agents NNS O
are VBP O
recommended VBN O
to TO O
help VB O
patients NNS O
in IN O
the DT O
management NN O
of IN O
radiation NN O
skin NN O
reactions NNS O
, , O
but CC O
evidence NN O
to TO O
support VB O
the DT O
value NN O
of IN O
the DT O
topical JJ O
treatments NNS O
of IN O
the DT O
irradiated JJ O
skin NN O
is VBZ O
lacking VBG O
. . O

In IN O
the DT O
present JJ O
study NN O
we PRP O
investigated VBD O
the DT O
effects NNS O
of IN O
topical JJ B-INTV
agents NNS I-INTV
used VBN O
as IN O
supportive JJ O
care NN O
to TO O
minimise VB O
radiation-induced JJ B-OC
skin NN I-OC
disease NN I-OC
using VBG O
an DT O
instrumental JJ O
method NN O
. . O

METHODS NNP O
Subjects NNPS B-POPU
who WP I-POPU
were VBD I-POPU
undergoing VBG I-POPU
a DT I-POPU
planned JJ I-POPU
course NN I-POPU
of IN I-POPU
radiation NN I-POPU
therapy NN I-POPU
after IN I-POPU
breast-conserving JJ I-POPU
surgery NN I-POPU
were VBD O
randomised VBN O
to TO O
treatment NN O
( ( O
using VBG O
one CD O
of IN O
two CD O
topical JJ B-INTV
agents NNS I-INTV
) ) I-INTV
or CC I-INTV
non-treatment JJ I-INTV
( ( I-INTV
control NN I-INTV
) ) I-INTV
groups NNS O
and CC O
monitored VBD O
over IN O
8 CD O
weeks NNS O
. . O

The DT O
intensity NN B-OC
of IN I-OC
skin NN I-OC
erythema NN I-OC
was VBD O
evaluated VBN O
once RB O
per IN O
week NN O
by IN O
non-invasive JJ O
instrumental JJ O
reflectance NN O
spectrophotometry NN O
in IN O
comparison NN O
with IN O
a DT O
visual JJ O
scoring NN O
system NN O
. . O

KEY NNP O
FINDINGS NNP O
Examination NNP O
of IN O
the DT O
erythema JJ B-OC
time NN I-OC
course NN I-OC
by IN O
a DT O
sensitive JJ O
spectrophotometric JJ O
reflectance NN O
method NN O
showed VBD O
a DT O
significant JJ O
increase NN O
of IN O
skin JJ B-OC
reactions NNS I-OC
in IN O
the DT O
non-treated JJ O
group NN O
after IN O
the DT O
second JJ O
week NN O
of IN O
treatment NN O
and CC O
maximal JJ O
alterations NNS O
between IN O
the DT O
fourth JJ O
and CC O
sixth JJ O
week NN O
. . O

CONCLUSIONS NN O
From IN O
the DT O
results NNS O
obtained VBD O
, , O
we PRP O
observed VBD O
that DT O
application NN O
of IN O
topical JJ B-INTV
agents NNS I-INTV
used VBN O
in IN O
radio-induced JJ O
skin JJ O
disease NN O
were VBD O
able JJ O
to TO O
significantly RB O
reduce VB O
the DT O
erythema NN B-OC
extent NN O
compared VBN O
to TO O
the DT O
non-treated JJ O
group NN O
. . O

-DOCSTART- -X- O O

[ VB O
A NNP O
prospective JJ O
randomized VBN O
study NN O
of IN O
the DT O
radiotherapy NN B-INTV
volume NN I-INTV
for IN O
limited-stage JJ O
small JJ O
cell NN O
lung NN O
cancer NN O
: : O
a DT O
preliminary JJ O
report NN O
] NNP O
. . O

BACKGROUND NNP O
AND NNP O
OBJECTIVE NNP O
Controversies NNP O
exists VBZ O
with IN O
regard NN O
to TO O
target VB O
volumes NNS O
as RB O
far RB O
as IN O
thoracic JJ B-INTV
radiotherapy NN I-INTV
( ( I-INTV
TRT NNP I-INTV
) ) I-INTV
is VBZ O
concerned VBN O
in IN O
the DT O
multimodality NN O
treatment NN O
for IN O
limited-stage NN B-POPU
small JJ I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
LSCLC NNP I-POPU
) ) I-POPU
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
prospectively RB O
compare VB O
the DT O
local JJ O
control NN O
rate NN O
, , O
toxicity NN O
profiles NNS O
, , O
and CC O
overall JJ O
survival NN O
( ( O
OS NNP O
) ) O
between IN O
patients NNS O
received VBN O
different JJ B-INTV
target NN I-INTV
volumes NNS I-INTV
irradiation VBP I-INTV
after IN I-INTV
induction NN I-INTV
chemotherapy NN I-INTV
. . O

METHODS NNP O
LSCLC NNP B-POPU
patients NNS I-POPU
received VBD O
2 CD O
cycles NNS O
of IN O
etoposide NN B-INTV
and CC I-INTV
cisplatin NN I-INTV
( ( I-INTV
EP NNP I-INTV
) ) I-INTV
induction NN I-INTV
chemotherapy NN I-INTV
and CC O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
TRT NNP B-INTV
to TO O
either VB O
the DT O
post- NN O
or CC O
pre-chemotherapy JJ O
tumor NN O
extent NN O
( ( O
GTV-T NNP O
) ) O
as IN O
study NN O
arm NN O
and CC O
control NN O
arm NN O
, , O
CTV-N NNP O
included VBD O
the DT O
positive JJ O
nodal JJ O
drainage NN O
area NN O
for IN O
both DT O
arms NNS O
. . O

One CD O
to TO O
2 CD O
weeks NNS O
after IN O
induction NN B-POPU
chemotherapy NN I-POPU
, , B-INTV
45 CD I-INTV
Gy/30 NNP I-INTV
Fx/19 NNP I-INTV
d NN I-INTV
TRT NNP I-INTV
was VBD O
administered VBN O
concurrently RB O
with IN O
the DT O
third JJ O
cycle NN O
of IN O
EP NNP B-INTV
regimen NNS I-INTV
. . O

After IN O
that DT O
, , O
additional JJ O
3 CD O
cycles NNS O
of IN O
EP NNP B-INTV
consolidation NN O
were VBD O
administered VBN O
. . O

Prophylactic JJ B-INTV
cranial JJ I-INTV
irradiation NN I-INTV
( ( I-INTV
PCI NNP I-INTV
) ) I-INTV
was VBD O
administered VBN O
to TO O
patients NNS O
with IN O
a DT O
complete JJ O
response NN O
. . O

RESULTS NNP O
Thirty-seven JJ B-POPU
and CC I-POPU
40 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
study VB I-POPU
arm NN I-POPU
and CC I-POPU
control NN I-POPU
arm NN I-POPU
. . O

The DT O
local JJ B-OC
recurrence NN I-OC
rates NNS I-OC
were VBD O
32.4 CD O
% NN O
and CC O
28.2 CD O
% NN O
respectively RB O
( ( O
P NNP O
= NNP O
0.80 CD O
) ) O
; : O
the DT O
isolated JJ O
nodal JJ B-OC
failure NN I-OC
( ( I-OC
INF NNP I-OC
) ) I-OC
rates NNS O
were VBD O
3.0 CD O
% NN O
and CC O
2.6 CD O
% NN O
respectively RB O
( ( O
P NNP O
= NNP O
0.91 CD O
) ) O
; : O
all DT O
INF NNP O
sites NNS O
were VBD O
in IN O
the DT O
ipsilateral JJ O
supraclavicular JJ O
fossa NN O
. . O

Medastinal NNP B-OC
N3 NNP I-OC
disease NN I-OC
was VBD O
the DT O
risk NN O
factor NN O
for IN O
INF NNP O
( ( O
P NNP O
= NNP O
0.02 CD O
, , O
OR NNP O
= VBZ O
14.13 CD O
, , O
95 CD O
% NN O
CI NNP O
: : O
1.47-136.13 JJ O
) ) O
. . O

During IN O
radiotherapy NN O
, , O
grade NN B-OC
I PRP I-OC
, , I-OC
II NNP I-OC
weight VBD I-OC
loss NN I-OC
was VBD O
observed VBN O
in IN O
29.4 CD O
% NN O
, , O
5.9 CD O
% NN O
and CC O
56.4 CD O
% NN O
, , O
7.7 CD O
% NN O
patients NNS O
respectively RB O
( ( O
P NNP O
= NNP O
0.04 CD O
) ) O
. . O

Grade VBN B-OC
0-I JJ I-OC
and CC I-OC
II-III JJ I-OC
late JJ I-OC
pulmonary JJ I-OC
injury NN I-OC
was VBD O
developed VBN O
in IN O
97.1 CD O
% NN O
, , O
2.9 CD O
% NN O
and CC O
86.4 CD O
% NN O
, , O
15.4 CD O
% NN O
patients NNS O
respectively RB O
( ( O
P NNP O
= NNP O
0.07 CD O
) ) O
. . O

Median JJ B-OC
survival JJ I-OC
time NN I-OC
was VBD O
22.1 CD O
months NNS O
and CC O
26.9 CD O
months NNS O
respectively RB O
. . O

The DT O
1 CD B-OC
to TO I-OC
3-year JJ I-OC
OS NNP I-OC
were VBD O
77.9 CD O
% NN O
, , O
44.4 CD O
% NN O
, , O
37.3 CD O
% NN O
and CC O
75.8 CD O
% NN O
, , O
56.3 CD O
% NN O
, , O
41.7 CD O
% NN O
respectively RB O
( ( O
P NNP O
= NNP O
0.79 CD O
) ) O
. . O

CONCLUSIONS VB O
The DT O
preliminary JJ O
results NNS O
of IN O
this DT O
study NN O
indicate VBP O
that WDT O
irradiant VBP O
the DT O
post-chemotherapy JJ O
tumor NN O
extent NN O
( ( O
GTV-T NNP O
) ) O
and CC O
positive JJ O
nodal JJ O
drainage NN O
area NN O
did VBD O
not RB O
decrease VB O
local JJ O
control NN O
and CC O
overall JJ O
survival NN O
while IN O
radiation NN O
toxicity NN O
was VBD O
reduced VBN O
. . O

But CC O
the DT O
current JJ O
sample NN O
size NN O
has VBZ O
not RB O
met VBN O
designed VBN O
requirements NNS O
, , O
and CC O
further JJ O
investigation NN O
is VBZ O
warranted VBN O
before IN O
final JJ O
conclusions NNS O
could MD O
be VB O
drawn VBN O
. . O

-DOCSTART- -X- O O

Anti-angiogenic JJ O
effect NN O
of IN O
tamoxifen NN B-INTV
combined VBN I-INTV
with IN I-INTV
epirubicin NN I-INTV
in IN O
breast NN B-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

Vascular JJ O
endothelial JJ O
growth NN O
factor NN O
A NNP O
( ( O
VEGF-A NNP O
) ) O
and CC O
vascular JJ O
endothelial JJ O
growth NN O
factor NN O
receptor NN O
2 CD O
( ( O
VEGFR2 NNP O
) ) O
are VBP O
the DT O
key JJ O
factors NNS O
mediating VBG O
neo-vascularization NN O
. . O

They PRP O
are VBP O
often RB O
coexpressed VBN O
in IN O
breast NN O
cancer NN O
. . O

Sex NNP O
steroids NNS O
may MD O
stimulate VB O
angiogenesis NN O
via IN O
the DT O
estrogen NN O
receptor NN O
( ( O
ER NNP O
) ) O
pathway RB O
. . O

We PRP O
investigated VBD O
to TO O
compare VB O
the DT O
effects NNS O
of IN O
the DT O
addition NN O
of IN O
tamoxifen NN B-INTV
to TO I-INTV
epirubicin VB I-INTV
versus NN I-INTV
epirubicin FW I-INTV
alone RB I-INTV
on IN O
VEGF NNP O
and CC O
VEGFR2 NNP O
expression NN O
in IN O
breast NN O
cancer NN O
patients NNS O
. . O

The DT O
expression NN O
of IN O
VEGF NNP B-OC
and CC I-OC
VEGFR2 NNP I-OC
was VBD O
assessed VBN O
on IN O
tissue NN O
microarray NN O
by IN O
immunohistochemistry NN O
at IN O
baseline JJ O
conditions NNS O
and CC O
after IN O
treatments NNS O
in IN O
the DT O
case NN O
of IN O
191 CD B-POPU
patients NNS I-POPU
with IN I-POPU
T2-4 NNP I-POPU
N0-1 NNP I-POPU
breast NN I-POPU
cancer NN I-POPU
enrolled VBN I-POPU
in IN I-POPU
a DT I-POPU
randomized JJ I-POPU
trial NN I-POPU
comparing VBG O
four CD O
cycles NNS O
of IN O
single JJ O
agent NN O
epirubicin NN O
versus NN O
epirubicin NN O
plus CC O
tamoxifen NN O
as IN O
primary JJ O
systemic JJ O
treatment NN O
. . O

Epirubicin NNP O
alone RB O
failed VBD O
to TO O
induce VB O
changes NNS B-OC
in IN I-OC
VEGF NNP I-OC
expression NN I-OC
( ( O
P NNP O
= NNP O
0.54 CD O
) ) O
, , O
while IN O
the DT O
addition NN O
of IN O
tamoxifen NN B-INTV
to TO I-INTV
epirubicin VB I-INTV
resulted VBN O
in IN O
a DT O
significant JJ O
reduction NN O
in IN O
VEGF NNP B-OC
expression NN I-OC
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

As IN O
a DT O
consequence NN O
, , O
baseline NN B-OC
VEGF NNP I-OC
had VBD O
a DT O
negative JJ O
prognostic JJ O
role NN O
in IN O
patients NNS O
who WP O
received VBD O
epirubicin JJ O
alone RB O
but CC O
not RB O
in IN O
patients NNS O
receiving VBG O
epirubicin JJ B-INTV
plus CC I-INTV
tamoxifen JJ I-INTV
( ( O
interaction JJ O
test NN O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

VEGFR2 NNP B-OC
expression NN I-OC
increased VBD O
at IN O
residual JJ O
tumor NN O
histology NN O
in IN O
both DT O
treatment NN O
arms NNS O
, , O
with IN O
a DT O
lesser JJR O
extent NN O
in IN O
patients NNS O
receiving VBG O
tamoxifen JJ B-INTV
plus CC I-INTV
epirubicin JJ I-INTV
. . O

Decrease NNP O
in IN O
VEGFR2 NNP B-OC
expression NN I-OC
was VBD O
significantly RB O
associated VBN O
with IN O
response NN B-OC
rate NN I-OC
( ( O
P NNP O
= NNP O
0.02 CD O
) ) O
. . O

The DT O
addition NN B-INTV
of IN I-INTV
tamoxifen NN I-INTV
to TO I-INTV
epirubicin VB I-INTV
resulted VBN O
in IN O
a DT O
suppression NN B-OC
of IN I-OC
a DT I-OC
key JJ I-OC
angiogenic JJ I-OC
pathway NN I-OC
. . O

These DT O
data NNS O
suggest VBP O
a DT O
potential JJ O
synergism NN O
of IN O
these DT O
two CD O
drugs NNS O
. . O

-DOCSTART- -X- O O

Reversal NNP O
of IN O
skeletal JJ O
effects NNS B-OC
of IN O
endocrine NN B-INTV
treatments NNS I-INTV
in IN O
the DT O
Intergroup NNP O
Exemestane NNP O
Study NNP O
. . O

The DT O
adjuvant JJ O
use NN O
of IN O
aromatase NN B-INTV
inhibitors NNS I-INTV
in IN O
breast NN O
cancer NN O
is VBZ O
associated VBN O
with IN O
adverse JJ O
effects NNS O
on IN O
bone NN O
health NN O
. . O

We PRP O
previously RB O
reported VBD O
a DT O
decline NN O
in IN O
bone JJ O
mineral JJ O
density NN O
( ( O
BMD NNP O
) ) O
following VBG O
the DT O
switch NN O
from IN O
tamoxifen NN B-INTV
to TO O
exemestane VB B-INTV
in IN O
the DT O
Intergroup NNP O
Exemestane NNP O
Study NNP O
( ( O
IES NNP O
) ) O
. . O

Here RB O
we PRP O
report VBP O
effects NNS O
of IN O
endocrine JJ B-INTV
treatment NN I-INTV
withdrawal NN O
on IN O
BMD NNP O
, , O
bone NN O
turnover NN O
markers NNS O
( ( O
BTM NNP O
) ) O
and CC O
fracture JJ O
rates NNS O
. . O

4,724 CD B-POPU
patients NNS I-POPU
took VBD I-POPU
part NN I-POPU
in IN I-POPU
IES NNP I-POPU
, , I-POPU
and CC I-POPU
206 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
included VBN I-POPU
in IN I-POPU
a DT I-POPU
bone NN I-POPU
sub-study NN I-POPU
. . O

BMD NNP O
and CC O
BTM NNP O
were VBD O
assessed VBN O
pre-randomization NN O
, , O
during IN O
and CC O
after IN O
the DT O
end NN O
of IN O
treatment NN O
( ( O
EOT NNP O
) ) O
. . O

To TO O
evaluate VB O
treatment NN O
withdrawal NN O
effects NNS O
, , O
12- JJ O
and CC O
24-month JJ O
post NN O
EOT NNP O
BMD NNP O
results NNS O
are VBP O
available JJ O
for IN O
122 CD O
and CC O
126 CD O
patients NNS O
, , O
respectively RB O
. . O

Similar JJ O
patient NN O
numbers NNS O
had VBD O
BTM NNP O
measured VBD O
post NN O
EOT NNP O
. . O

Following VBG O
treatment NN O
withdrawal NN O
, , O
the DT O
differences NNS O
in IN O
BMD NNP O
observed VBD O
between IN O
the DT O
two CD O
endocrine NN O
strategies NNS O
were VBD O
partially RB O
reversed VBN O
. . O

At IN O
24 CD O
months NNS O
from IN O
EOT NNP O
, , O
spine JJ B-OC
BMD NNP I-OC
increased VBN I-OC
by IN O
1.53 CD O
% NN O
( ( O
95 CD O
% NN O
CI NNP O
0.63-2.43 CD O
; : O
p CC O
= VB O
0.001 CD O
) ) O
after IN O
stopping VBG O
exemestane NN O
and CC O
fell VBD O
by IN O
1.93 CD O
% NN O
( ( O
95 CD O
% NN O
CI NNP O
-2.91 NNP O
to TO O
0.95 CD O
; : O
p NN O
= VBZ O
0.0002 CD O
) ) O
following VBG O
tamoxifen NN B-INTV
withdrawal NN O
. . O

A DT O
similar JJ O
pattern NN O
of IN O
changes NNS O
was VBD O
observed VBN O
at IN O
the DT O
hip NN O
. . O

At IN O
2 CD O
years NNS O
post RB O
EOT NNP O
, , O
BMD NNP B-OC
changes NNS I-OC
from IN I-OC
baseline NN I-OC
were VBD O
similar JJ O
with IN O
both DT O
treatment NN O
strategies NNS O
. . O

Corresponding VBG O
inverse JJ B-OC
changes NNS I-OC
in IN I-OC
BTM NNP I-OC
were VBD O
seen VBN O
, , O
with IN O
an DT O
increase NN O
following VBG O
tamoxifen JJ O
withdrawal NN O
and CC O
a DT O
reduction NN O
after IN O
exemestane NN O
. . O

A DT O
higher JJR O
number NN B-OC
of IN I-OC
fractures NNS I-OC
occurred VBD I-OC
during IN O
exemestane NN B-INTV
treatment NN O
, , O
but CC O
fracture NN B-OC
rates NNS I-OC
were VBD O
similar JJ O
after IN O
treatment NN O
withdrawal NN O
. . O

With IN O
the DT O
switch NN O
strategy NN O
used VBN O
in IN O
IES NNP O
, , O
the DT O
on IN O
treatment NN O
adverse JJ B-OC
bone NN I-OC
effects NNS I-OC
of IN O
exemestane NN B-INTV
are VBP O
reversed VBN O
. . O

Ongoing VBG O
monitoring NN O
of IN O
BMD NNP O
is VBZ O
therefore RB O
not RB O
routinely RB O
required VBN O
. . O

-DOCSTART- -X- O O

Cardiovascular JJ O
safety NN O
of IN O
degarelix NN B-INTV
: : I-INTV
results NNS O
from IN O
a DT O
12-month JJ O
, , O
comparative JJ O
, , O
randomized VBN O
, , O
open JJ O
label NN O
, , O
parallel JJ O
group NN O
phase NN O
III NNP O
trial NN O
in IN O
patients NNS B-POPU
with IN I-POPU
prostate JJ I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
We PRP O
assessed VBD O
the DT O
cardiovascular JJ O
safety NN O
profile NN O
of IN O
degarelix NN B-INTV
, , O
a DT O
new JJ O
gonadotropin-releasing JJ B-INTV
hormone NN I-INTV
antagonist NN I-INTV
. . O

MATERIALS NNP O
AND CC O
METHODS NNP O
This DT O
is VBZ O
the DT O
first JJ O
report NN O
to TO O
our PRP$ O
knowledge NN O
on IN O
cardiovascular JJ O
safety NN O
data NNS O
from IN O
a DT O
completed VBN O
1-year JJ O
randomized NNS O
controlled VBD O
trial NN O
of IN O
leuprolide JJ B-INTV
acetate NN I-INTV
vs NN I-INTV
degarelix NN I-INTV
. . O

Outcomes CC O
considered VBN O
in IN O
these DT O
analyses NNS O
included VBD O
the DT O
QT NNP B-OC
interval NN I-OC
by IN I-OC
central JJ I-OC
reading NN I-OC
and CC I-OC
analysis NN I-OC
, , I-OC
and CC I-OC
cardiovascular JJ I-OC
adverse JJ I-OC
events NNS I-OC
. . O

On IN O
multivariate NN O
analyses NNS O
relationships VBP O
between IN O
selected VBN O
baseline NN O
factors NNS O
and CC O
cardiovascular JJ B-OC
events NNS I-OC
were VBD O
evaluated VBN O
. . O

RESULTS VB O
There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
between IN O
treatment NN O
groups NNS O
for IN O
mean JJ O
change NN O
in IN O
Fridericia NNP O
's POS O
correction NN O
of IN O
QT NNP O
during IN O
the DT O
trial NN O
. . O

Markedly RB B-OC
abnormal JJ I-OC
Fridericia NNP I-OC
's POS I-OC
correction NN I-OC
of IN I-OC
QT NNP I-OC
values NNS I-OC
( ( O
500 CD O
milliseconds NNS O
or CC O
greater JJR O
) ) O
were VBD O
observed VBN O
in IN O
only RB O
a DT O
small JJ O
number NN O
of IN O
subjects NNS O
by IN O
treatment NN O
group NN O
, , O
that WDT O
is VBZ O
2 CD O
( ( O
less JJR O
than IN O
1 CD O
% NN O
) ) O
in IN O
the DT O
pooled JJ O
degarelix NN B-INTV
group NN O
and CC O
2 CD O
( ( O
1 CD O
% NN O
) ) O
in IN O
the DT O
leuprolide NN B-INTV
group NN O
. . O

Supraventricular JJ B-OC
arrhythmias NN I-OC
were VBD O
the DT O
most RBS O
common JJ O
type NN O
of IN O
arrhythmias NN O
, , O
affecting VBG O
2 CD O
% NN O
of IN O
subjects NNS O
in IN O
the DT O
pooled JJ O
degarelix NN B-INTV
group NN O
and CC O
4 CD O
% NN O
in IN O
the DT O
leuprolide NN B-INTV
group NN O
. . O

Other JJ B-OC
arrhythmias JJ I-OC
occurred VBN O
in IN O
1 CD O
% NN O
or CC O
less JJR O
of IN O
subjects NNS O
by IN O
treatment NN O
group NN O
. . O

The DT O
most RBS O
frequently RB O
reported VBD O
cardiac JJ O
disorder NN O
was VBD O
ischemic JJ B-OC
heart NN I-OC
disease NN I-OC
, , O
which WDT O
occurred VBD O
in IN O
4 CD O
% NN O
of IN O
subjects NNS O
treated VBN O
with IN O
degarelix NN B-INTV
and CC O
10 CD O
% NN O
of IN O
those DT O
on IN O
leuprolide NN B-INTV
. . O

Cox NNP O
proportional JJ O
hazard NN O
ratio NN O
estimates NNS O
for IN O
selected VBN O
baseline NN O
covariates NNS O
showed VBD O
a DT O
significantly RB O
increased VBN O
risk NN O
of IN O
cardiovascular JJ O
events NNS O
by IN O
age NN O
( ( O
p=0.0459 NN O
) ) O
and CC O
systolic JJ O
blood NN O
pressure NN O
( ( O
p=0.0061 NN O
) ) O
. . O

CONCLUSIONS NNP O
In IN O
men NNS B-POPU
with IN I-POPU
prostate NN I-POPU
cancer NN I-POPU
degarelix NN B-INTV
and CC O
leuprolide NN B-INTV
have VBP O
similar JJ O
cardiovascular JJ O
safety NN O
profiles NNS O
. . O

These DT O
observations NNS O
suggest VBP O
that IN O
the DT O
cardiovascular JJ O
events NNS O
associated VBN O
with IN O
both DT O
agents NNS O
result VBP O
from IN O
hypogonadism NN O
rather RB O
than IN O
a DT O
direct JJ O
drug NN O
effect NN O
. . O

-DOCSTART- -X- O O

Detection NN B-OC
rates NNS I-OC
of IN I-OC
cancer NN I-OC
, , I-OC
high JJ B-INTV
grade NN I-INTV
PIN NNP I-INTV
and CC I-INTV
atypical JJ I-INTV
lesions NNS I-INTV
suspicious JJ B-OC
for IN I-OC
cancer NN I-OC
in IN O
the DT O
European NNP B-POPU
Randomized NNP I-POPU
Study NNP I-POPU
of IN I-POPU
Screening NNP I-POPU
for IN I-POPU
Prostate NNP I-POPU
Cancer NNP I-POPU
. . O

THE NNP O
AIM NNP O
OF IN O
THE NNP O
STUDY NNP O
This DT O
article NN O
presents VBZ O
the DT O
incidence NN O
of IN O
prostate NN O
cancer NN O
, , O
isolated VBN O
high JJ O
grade NN O
prostatic JJ O
intraepithelial JJ O
neoplasia NN O
( ( O
PIN NNP O
) ) O
and CC O
atypical JJ O
lesions NNS O
suspicious JJ O
for IN O
prostate NN O
cancer NN O
( ( O
LSPC NNP O
) ) O
during IN O
subsequent JJ O
screening VBG B-INTV
rounds NNS I-INTV
in IN O
the DT O
centres NNS O
of IN O
five CD O
of IN O
the DT O
countries NNS O
participating VBG B-POPU
in IN I-POPU
the DT I-POPU
European NNP I-POPU
Randomized NNP I-POPU
Study NNP I-POPU
of IN I-POPU
Screening NNP I-POPU
for IN I-POPU
Prostate NNP I-POPU
Cancer NNP I-POPU
( ( I-POPU
ERSPC NNP I-POPU
) ) I-POPU
. . O

The DT O
incidence NN O
and CC O
predictive JJ O
value NN O
of IN O
high JJ O
grade NN O
PIN NNP O
and CC O
LSPC NNP O
for IN O
prostate NN O
cancer NN O
in IN O
subsequent JJ O
biopsy NN B-INTV
following VBG O
these DT O
diagnoses NNS O
were VBD O
evaluated VBN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Study NNP O
group NN O
consisted VBD O
of IN O
56,653 CD B-POPU
screened JJ I-POPU
men NNS I-POPU
in IN I-POPU
the DT I-POPU
ERSPC NNP I-POPU
centres NNS I-POPU
of IN I-POPU
Finland NNP I-POPU
, , I-POPU
Italy NNP I-POPU
, , I-POPU
Netherlands NNP I-POPU
, , I-POPU
Sweden NNP I-POPU
and CC I-POPU
Switzerland NNP I-POPU
, , I-POPU
who WP I-POPU
underwent VBD I-POPU
3-7 JJ I-POPU
screening NN I-POPU
rounds NNS I-POPU
at IN I-POPU
2-4 JJ I-POPU
year NN I-POPU
interval NN I-POPU
. . O

Data NNP B-POPU
for IN I-POPU
prostate NN I-POPU
cancer NN I-POPU
were VBD I-POPU
obtained VBN I-POPU
from IN I-POPU
the DT I-POPU
ERSPC NNP I-POPU
central JJ I-POPU
database NN I-POPU
. . O

Data NNP B-POPU
for IN I-POPU
high JJ I-POPU
grade NN I-POPU
PIN NNP I-POPU
and CC I-POPU
LSPC NNP I-POPU
were VBD I-POPU
gathered VBN I-POPU
from IN I-POPU
each DT I-POPU
ERSPC NNP I-POPU
centre NN I-POPU
. . O

Detection NNP B-OC
rates NNS I-OC
of IN O
subsequent JJ B-OC
prostate NN I-OC
cancer NN I-OC
in IN O
the DT O
first JJ O
re-biopsy NN O
after IN O
these DT O
diagnoses NNS O
were VBD O
determined VBN O
. . O

RESULTS VB O
The DT O
average JJ B-OC
cancer NN I-OC
detection NN I-OC
rate NN I-OC
was VBD O
3.5 CD O
% NN O
, , O
3.2 CD O
% NN O
and CC O
3.5 CD O
% NN O
for IN O
the DT O
completed VBN O
rounds NNS O
1 CD O
, , O
2 CD O
and CC O
3 CD O
, , O
respectively RB O
, , O
in IN O
all DT O
five CD O
centres NNS O
. . O

Incidence NN B-OC
of IN I-OC
high JJ I-OC
grade NN I-OC
PIN NNP I-OC
increased VBD O
from IN O
1.5 CD O
% NN O
in IN O
the DT O
first JJ O
round NN O
to TO O
5.0 CD O
% NN O
in IN O
the DT O
third JJ O
round NN O
, , O
varying VBG O
among IN O
centres NNS O
in IN O
the DT O
first JJ O
round NN O
between IN O
0.8 CD O
% NN O
and CC O
7.6 CD O
% NN O
. . O

The DT O
cancer NN B-OC
detection NN I-OC
rate NN I-OC
in IN O
the DT O
first JJ O
re-biopsy NN O
after IN O
the DT O
diagnosis NN O
of IN O
high JJ O
grade NN O
PIN NNP O
was VBD O
12.9 CD O
% NN O
. . O

Incidence NN B-OC
of IN I-OC
LSPC NNP I-OC
was VBD O
2.4 CD O
% NN O
, , O
2.7 CD O
% NN O
, , O
2.2 CD O
% NN O
and CC O
2.6 CD O
% NN O
in IN O
the DT O
first JJ O
, , O
second JJ O
, , O
third JJ O
and CC O
fourth JJ O
round NN O
, , O
respectively RB O
. . O

The DT O
cancer NN B-OC
detection NN I-OC
rate NN I-OC
at IN O
the DT O
first JJ O
re-biopsy NN O
after IN O
the DT O
diagnosis NN O
of IN O
LSPC NNP O
was VBD O
in IN O
average JJ O
33.8 CD O
% NN O
. . O

CONCLUSIONS NNP O
Cancer NNP B-OC
detection NN I-OC
rate NN I-OC
was VBD O
stable JJ O
during IN O
the DT O
three CD O
screening VBG B-INTV
rounds NNS O
. . O

The DT O
wide JJ O
variation NN O
in IN O
frequency NN O
in IN O
particular JJ O
of IN O
high JJ O
grade NN O
PIN NNP O
among IN O
the DT O
ERSPC NNP O
centres VBZ O
suggests VBZ O
a DT O
considerable JJ O
inter-observer JJ O
variation NN O
. . O

The DT O
average JJ O
comparatively RB O
low JJ O
detection NN B-OC
rate NN I-OC
of IN O
isolated JJ O
high JJ O
grade NN O
PIN NNP O
in IN O
the DT O
first JJ O
screening NN O
round NN O
may MD O
be VB O
screening-related JJ O
, , O
while IN O
its PRP$ O
consistent JJ O
increase NN O
during IN O
three CD O
screening VBG O
rounds NNS O
could MD O
be VB O
the DT O
consequence NN O
of IN O
a.o NN O
. . O

previous JJ O
screening NN O
and CC O
ageing NN O
of IN O
the DT O
population NN O
. . O

The DT O
observed JJ O
low JJ B-OC
risk NN I-OC
of IN I-OC
prostate NN I-OC
cancer NN I-OC
after IN O
isolated VBN O
high JJ O
grade NN O
PIN NNP O
in IN O
this DT O
screening NN O
setting NN O
is VBZ O
in IN O
line NN O
with IN O
the DT O
current JJ O
recommendation NN O
to TO O
abstain VB O
from IN O
early JJ O
repeat NN O
biopsies NNS O
after IN O
this DT O
diagnosis NN O
. . O

The DT O
association NN O
of IN O
LSPC NNP O
with IN O
high JJ O
incidence NN O
of IN O
prostate NN O
cancer NN O
in IN O
re-biopsies NNS O
confirms NNS O
the DT O
need NN O
for IN O
early JJ O
repeat NN O
biopsies NNS O
and CC O
follow-up NN O
of IN O
these DT O
men NNS B-POPU
. . O

The DT O
low JJ O
percentage NN O
of IN O
LSPC NNP O
( ( O
< VB O
3 CD O
% NN O
of IN O
biopsies NNS O
) ) O
throughout IN O
all DT O
rounds NNS O
is VBZ O
reassuring VBG O
as IN O
it PRP O
limits VBZ O
the DT O
biopsy NN O
burden NN O
in IN O
a DT O
screening NN O
setting NN O
. . O

-DOCSTART- -X- O O

Lead-time NN O
in IN O
the DT O
European NNP O
Randomised VBD O
Study NNP O
of IN O
Screening NNP O
for IN O
Prostate NNP B-POPU
Cancer NNP I-POPU
. . O

BACKGROUND NNP O
Lead-time NNP O
is VBZ O
defined VBN O
as IN O
the DT O
time NN O
by IN O
which WDT O
screening VBG O
advances VBZ O
the DT O
diagnosis NN O
compared VBN O
with IN O
absence NN O
of IN O
screening VBG O
. . O

A DT O
sufficiently RB O
long JJ O
lead-time JJ O
needs NNS O
to TO O
be VB O
achieved VBN O
so RB O
that IN O
cancer NN O
can MD O
be VB O
detected VBN O
while IN O
still RB O
curable JJ O
. . O

A DT O
very RB O
short JJ O
lead-time NN O
may MD O
indicate VB O
poor JJ O
sensitivity NN O
of IN O
the DT O
screening JJ O
test NN O
, , O
while IN O
a DT O
very RB O
long JJ O
lead-time JJ O
suggests NNS O
overdiagnosis NN O
. . O

MATERIAL NNP O
AND NNP O
METHODS NNP O
In IN O
the DT O
first JJ O
screening NN O
round NN O
, , O
a DT B-POPU
total NN I-POPU
of IN I-POPU
56,294 CD I-POPU
men NNS I-POPU
aged VBN I-POPU
55-74 CD I-POPU
years NNS I-POPU
were VBD I-POPU
screened VBN I-POPU
with IN I-POPU
serum NN I-POPU
prostate NN I-POPU
specific JJ I-POPU
antigen NN I-POPU
( ( I-POPU
PSA NNP I-POPU
) ) I-POPU
in IN I-POPU
five CD I-POPU
countries NNS I-POPU
of IN I-POPU
the DT I-POPU
European NNP I-POPU
Randomised VBD I-POPU
Study NNP I-POPU
of IN I-POPU
Screening NNP I-POPU
for IN I-POPU
Prostate NNP I-POPU
Cancer NNP I-POPU
( ( I-POPU
ERSPC NNP I-POPU
) ) I-POPU
with IN I-POPU
an DT I-POPU
overall JJ I-POPU
detection NN I-POPU
rate NN I-POPU
( ( I-POPU
prevalence NN I-POPU
) ) I-POPU
of IN I-POPU
2.8 CD I-POPU
% NN I-POPU
( ( I-POPU
1972 CD I-POPU
prostate NN I-POPU
cancers NNS I-POPU
) ) I-POPU
. . O

Prostate NNP B-POPU
cancer NN I-POPU
incidence NN I-POPU
among IN I-POPU
92,142 CD I-POPU
men NNS I-POPU
randomly RB I-POPU
allocated VBN I-POPU
to TO I-POPU
the DT I-POPU
control NN I-POPU
arm NN I-POPU
of IN I-POPU
the DT I-POPU
trial NN I-POPU
was VBD I-POPU
also RB I-POPU
assessed VBN I-POPU
. . O

Lead-time NNP B-OC
was VBD O
estimated VBN O
as IN O
the DT O
time NN O
required VBN O
to TO O
accumulate VB O
a DT O
similar JJ O
cumulative JJ O
risk NN O
of IN O
prostate NN O
cancer NN O
in IN O
the DT O
control NN O
arm NN O
to TO O
the DT O
detection NN O
rate NN O
in IN O
the DT O
intervention NN O
arm NN O
, , O
i.e NN O
. . O

from IN O
the DT O
ratio NN O
of IN O
detection NN O
rate NN O
( ( O
prevalence NN O
of IN O
screen-detected JJ O
cases NNS O
) ) O
and CC O
expected VBN O
incidence NN O
( ( O
cumulative JJ O
risk NN O
) ) O
. . O

RESULTS NNP O
Using VBG O
a DT O
serum JJ O
PSA NNP O
cut-off NN O
of IN O
4 CD O
ng/ml NNS O
, , O
the DT O
mean JJ B-OC
lead-time NN I-OC
in IN O
the DT O
whole NN O
study NN O
population NN O
was VBD O
estimated VBN O
as IN O
6.8 CD O
years NNS O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
( ( O
95 CD O
% NN O
CI NNP O
) ) O
7.9-8.4 NN O
) ) O
. . O

It PRP O
was VBD O
8 CD O
years NNS O
in IN O
The DT O
Netherlands NNP B-POPU
, , O
6 CD O
in IN O
Sweden NNP B-POPU
and CC I-POPU
Finland NNP I-POPU
, , O
5 CD O
in IN O
Italy NNP B-POPU
and CC O
4 CD O
in IN O
Belgium NNP B-POPU
. . O

The DT O
mean JJ B-OC
lead-time NN I-OC
was VBD O
similar JJ O
, , O
6-7 JJ O
years NNS O
, , O
at IN O
ages NNS O
50-64 CD O
years NNS O
, , O
but CC O
close RB O
to TO O
8 CD O
years NNS O
among IN O
men NNS O
aged VBN O
65-74 CD O
years NNS O
. . O

A DT O
lower JJR O
PSA NNP B-OC
cut-off JJ I-OC
level NN I-OC
of IN O
3 CD O
ng/ml NNS O
used VBN O
in IN O
Sweden NNP O
and CC O
The DT O
Netherlands NNP O
prolonged VBD O
the DT O
mean JJ O
lead-time JJ O
by IN O
approximately RB O
1 CD O
year NN O
. . O

Lead-time NNP B-OC
based VBN I-OC
on IN I-OC
advanced JJ I-OC
prostate NN I-OC
cancer NN I-OC
only RB O
was VBD O
slightly RB O
shorter JJR O
, , O
mean JJ O
5.3 CD O
years NNS O
( ( O
95 CD O
% NN O
CI NNP O
4.6-6.0 CD O
) ) O
. . O

The DT O
lead-time NN B-OC
for IN I-OC
the DT I-OC
second JJ I-OC
screening NN I-OC
round NN I-OC
was VBD O
slightly RB O
shorter JJR O
than IN O
that DT O
for IN O
the DT O
first JJ O
( ( O
5.9 CD O
, , O
95 CD O
% NN O
CI NNP O
5.4-6.4 CD O
) ) O
, , O
reflecting VBG O
a DT O
similar JJ O
relation NN O
between IN O
detection NN O
rate NN O
and CC O
control NN O
group NN O
incidence NN O
. . O

CONCLUSION VB O
The DT O
lead-time NN O
for IN O
prostate NN O
cancer NN O
found VBD O
in IN O
ERSPC NNP O
substantially RB O
exceeded VBD O
that IN O
found NN O
for IN O
breast NN O
, , O
cervical JJ O
and CC O
colorectal JJ O
cancer NN O
screening NN O
. . O

One CD O
round NN O
of IN O
prostate NN O
cancer NN O
screening VBG O
can MD O
advance VB O
clinical JJ O
diagnosis NN O
by IN O
4-8 JJ O
years NNS O
. . O

Overdiagnosis NN O
or CC O
detection NN O
of IN O
non-progressive JJ O
tumours NNS O
may MD O
contribute VB O
substantially RB O
to TO O
the DT O
lead-time NN B-OC
. . O

-DOCSTART- -X- O O

Denosumab NNP B-INTV
compared VBN O
with IN O
zoledronic JJ B-INTV
acid NN I-INTV
for IN O
the DT O
treatment NN O
of IN O
bone NN O
metastases NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
randomized JJ O
, , O
double-blind JJ O
study NN O
. . O

PURPOSE VB O
This DT O
randomized VBN O
study NN O
compared VBN O
denosumab NN B-INTV
, , O
a DT O
fully RB O
human JJ O
monoclonal JJ O
antibody NN O
against IN O
receptor NN O
activator NN O
of IN O
nuclear JJ O
factor NN O
κ NN O
B NNP O
( ( O
RANK NNP O
) ) O
ligand NN O
, , O
with IN B-INTV
zoledronic JJ I-INTV
acid NN I-INTV
in IN O
delaying VBG O
or CC O
preventing VBG O
skeletal-related JJ O
events NNS O
( ( O
SREs NNP O
) ) O
in IN B-POPU
patients NNS I-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
with IN I-POPU
bone NN I-POPU
metastases NNS I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Patients NNPS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB B-INTV
either RB I-INTV
subcutaneous JJ I-INTV
denosumab NN I-INTV
120 CD I-INTV
mg NN I-INTV
and CC I-INTV
intravenous JJ I-INTV
placebo NN B-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
1,026 CD I-POPU
) ) I-POPU
or CC B-INTV
intravenous JJ I-INTV
zoledronic JJ I-INTV
acid NN I-INTV
4 CD I-INTV
mg NN I-INTV
adjusted VBN I-INTV
for IN I-INTV
creatinine JJ I-INTV
clearance NN I-INTV
and CC I-INTV
subcutaneous JJ I-INTV
placebo NN B-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
1,020 CD I-POPU
) ) I-POPU
every DT O
4 CD O
weeks NNS O
. . O

All DT O
patients NNS O
were VBD O
strongly RB O
recommended VBN O
to TO O
take VB O
daily JJ B-INTV
calcium NN I-INTV
and CC I-INTV
vitamin NN I-INTV
D NNP I-INTV
supplements NNS O
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
time NN O
to TO B-OC
first VB I-OC
on-study JJ I-OC
SRE NNP I-OC
( ( I-OC
defined VBN I-OC
as IN I-OC
pathologic JJ I-OC
fracture NN I-OC
, , I-OC
radiation NN I-OC
or CC I-OC
surgery NN I-OC
to TO I-OC
bone VB I-OC
, , I-OC
or CC I-OC
spinal JJ I-OC
cord NN I-OC
compression NN I-OC
) ) I-OC
. . O

RESULTS NNP B-INTV
Denosumab NNP I-INTV
was VBD O
superior JJ O
to TO B-INTV
zoledronic JJ I-INTV
acid NN I-INTV
in IN B-OC
delaying VBG I-OC
time NN I-OC
to TO I-OC
first VB I-OC
on-study JJ I-OC
SRE NNP I-OC
( ( O
hazard NN O
ratio NN O
, , O
0.82 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.71 CD O
to TO O
0.95 CD O
; : O
P NNP O
= NNP O
.01 NNP O
superiority NN O
) ) O
and CC B-OC
time NN I-OC
to TO I-OC
first RB I-OC
and CC I-OC
subsequent JJ I-OC
( ( I-OC
multiple JJ I-OC
) ) I-OC
on-study NN I-OC
SREs NNP I-OC
( ( O
rate NN O
ratio NN O
, , O
0.77 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.66 CD O
to TO O
0.89 CD O
; : O
P NNP O
= NNP O
.001 NNP O
) ) O
. . O

Reduction NN B-OC
in IN I-OC
bone NN I-OC
turnover NN I-OC
markers NNS I-OC
was VBD O
greater JJR O
with IN O
denosumab NN O
. . O

Overall JJ B-OC
survival NN I-OC
, , I-OC
disease NN I-OC
progression NN I-OC
, , I-OC
and CC I-OC
rates NNS I-OC
of IN I-OC
adverse JJ I-OC
events NNS I-OC
( ( I-OC
AEs NNP I-OC
) ) I-OC
and CC I-OC
serious JJ I-OC
AEs NNP I-OC
were VBD O
similar JJ O
between IN O
groups NNS O
. . O

An DT B-OC
excess NN I-OC
of IN I-OC
renal JJ I-OC
AEs NNP I-OC
and CC I-OC
acute-phase JJ I-OC
reactions NNS I-OC
occurred VBD O
with IN O
zoledronic JJ O
acid NN B-OC
; : I-OC
hypocalcemia NN I-OC
occurred VBD O
more RBR O
frequently RB O
with IN B-INTV
denosumab NN I-INTV
. . O

Osteonecrosis NN B-OC
of IN I-OC
the DT I-OC
jaw NN I-OC
occurred VBD O
infrequently RB O
( ( O
2.0 CD O
% NN O
, , O
denosumab NN B-INTV
; : I-INTV
1.4 CD O
% NN O
, , O
zoledronic JJ B-INTV
acid NN I-INTV
; : I-INTV
P NNP O
= NNP O
.39 NNP O
) ) O
. . O

CONCLUSION NNP B-INTV
Denosumab NNP I-INTV
was VBD O
superior JJ O
to TO B-INTV
zoledronic JJ I-INTV
acid NN I-INTV
in IN O
delaying VBG O
or CC O
preventing VBG O
SREs NNP O
in IN B-POPU
patients NNS I-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
metastatic NN I-POPU
to TO I-POPU
bone NN I-POPU
and CC O
was VBD O
generally RB O
well RB O
tolerated VBN O
. . O

With IN O
the DT O
convenience NN O
of IN O
a DT O
subcutaneous JJ O
injection NN O
and CC O
no DT O
requirement NN O
for IN O
renal JJ O
monitoring NN O
, , O
denosumab JJ B-INTV
represents VBZ O
a DT O
potential JJ O
treatment NN O
option NN O
for IN B-POPU
patients NNS I-POPU
with IN I-POPU
bone NN I-POPU
metastases NNS I-POPU
. . O

-DOCSTART- -X- O O

Phase NNP O
III NNP O
trial NN O
of IN O
gemcitabine NN B-INTV
plus CC I-INTV
docetaxel JJ I-INTV
versus NN O
capecitabine NN B-INTV
plus CC I-INTV
docetaxel NN I-INTV
with IN O
planned VBN O
crossover NN O
to TO O
the DT O
alternate NN O
single JJ O
agent NN O
in IN O
metastatic JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

BACKGROUND NNP O
Safety NNP B-OC
and CC I-OC
efficacy NN I-OC
of IN O
gemcitabine JJ B-INTV
plus CC I-INTV
docetaxel JJ I-INTV
( ( I-INTV
GD NNP I-INTV
) ) I-INTV
and CC O
capecitabine JJ B-INTV
plus CC I-INTV
docetaxel JJ I-INTV
( ( I-INTV
CD NN I-INTV
) ) I-INTV
were VBD O
compared VBN O
in IN O
patients NNS B-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
, , I-POPU
where WRB I-POPU
the DT I-POPU
alternate NN I-POPU
crossover NN I-POPU
monotherapy NN I-POPU
( ( I-POPU
GD→C NNP I-POPU
or CC I-POPU
CD→G NNP I-POPU
) ) I-POPU
was VBD I-POPU
predetermined VBN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Patients NNPS O
were VBD O
randomly RB O
assigned VBN O
to TO O
3-week JJ O
cycles NNS O
of IN O
either DT B-INTV
gemcitabine NN I-INTV
1000 CD O
mg/m NN O
( ( O
2 CD O
) ) O
on IN O
days NNS O
1 CD O
and CC O
8 CD O
plus CC B-INTV
docetaxel JJ I-INTV
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
on IN O
day NN O
1 CD B-INTV
or CC I-INTV
capecitabine VB I-INTV
1000 CD O
mg/m NN O
( ( O
2 CD O
) ) O
twice RB O
daily RB O
on IN O
days NNS O
1-14 JJ B-INTV
plus JJ I-INTV
docetaxel NN I-INTV
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
day NN O
1 CD O
. . O

Upon IN O
progression NN O
, , O
patients NNS O
received VBD B-INTV
crossover JJ I-INTV
monotherapy NN I-INTV
. . O

Primary JJ O
end NN O
point NN O
was VBD B-OC
time NN I-OC
to TO I-OC
progression NN I-OC
( ( I-OC
TtP NNP I-OC
) ) I-OC
. . O

Secondary JJ O
end NN O
points NNS O
evaluated VBD B-OC
overall JJ I-OC
response NN I-OC
rate NN I-OC
( ( I-OC
ORR NNP I-OC
) ) I-OC
, , I-OC
overall JJ I-OC
survival NN I-OC
( ( I-OC
OS NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
adverse JJ I-OC
events NNS I-OC
( ( I-OC
AEs NNP I-OC
) ) I-OC
. . O

RESULTS NNP B-POPU
Despite IN I-POPU
over-accrual JJ I-POPU
of IN I-POPU
475 CD I-POPU
patients NNS I-POPU
, , I-POPU
the DT I-POPU
trial NN I-POPU
matured VBD I-POPU
with IN I-POPU
only RB I-POPU
324 CD I-POPU
of IN I-POPU
385 CD I-POPU
planned JJ I-POPU
TtP NNP I-POPU
events NNS I-POPU
due JJ I-POPU
to TO I-POPU
patient JJ I-POPU
discontinuations NNS I-POPU
. . O

Human NNP O
epidermal JJ O
growth NN O
factor NN O
receptor NN O
2 CD O
status NN O
was VBD O
not RB O
captured VBN O
in IN O
this DT O
study NN O
. . O

More JJR B-INTV
CD NN O
patients NNS O
( ( O
28 CD O
% NN O
) ) O
discontinued VBD O
due JJ O
to TO O
AEs NNP O
than IN B-INTV
GD NNP O
patients NNS O
( ( O
18.0 CD O
% NN O
, , O
P NNP O
= NNP O
0.009 CD B-OC
) ) I-OC
. . O

TtP NNP O
[ NNP O
hazard NN O
ratio NN O
( ( O
HR NNP O
) ) O
= VBD O
1.101 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
( ( O
CI NNP O
) ) O
0.885-1.370 NN O
, , O
P NNP O
= VBZ O
0.387 CD O
] NN O
and CC B-OC
OS NNP O
( ( O
HR NNP O
= NNP O
1.031 CD O
, , O
95 CD O
% NN O
CI NNP O
0.830-1.280 NN O
, , O
P NNP O
= NNP O
0.785 CD O
) ) O
were VBD O
not RB O
significantly RB O
different JJ O
comparing VBG B-INTV
GD NNP O
and CC B-INTV
CD NNP B-OC
. . O

ORR NNP O
was VBD O
not RB O
statistically RB O
different JJ O
( ( O
P NNP O
= NNP O
0.239 CD O
) ) O
comparing VBG O
GD NNP O
( ( O
72 CD O
of IN O
207 CD O
, , O
34.8 CD O
% NN O
) ) O
and CC O
CD NNP O
( ( O
78 CD O
of IN O
191 CD O
, , O
40.8 CD B-OC
% NN I-OC
) ) I-OC
. . O

TtP NNP B-OC
, , I-OC
OS NNP I-OC
, , I-OC
and CC I-OC
ORR NNP O
were VBD O
not RB O
significantly RB O
different JJ O
comparing VBG O
crossover NN O
groups NNS B-INTV
. . O

GD NNP O
caused VBD O
greater JJR B-OC
fatigue NN I-OC
, , I-OC
hepatotoxicity NN I-OC
, , I-OC
neutropenia NN I-OC
, , I-OC
and CC I-OC
thrombocytopenia NNS I-OC
but CC I-OC
not RB I-OC
febrile JJ I-OC
neutropenia NN B-INTV
; : I-INTV
CD NN O
caused VBD O
more JJR B-OC
hand-foot JJ I-OC
syndrome NN I-OC
, , I-OC
gastrointestinal JJ I-OC
toxicity NN I-OC
, , I-OC
and CC I-OC
mucositis NN I-OC
. . O

CONCLUSIONS NNP B-INTV
GD NNP O
and CC B-INTV
CD NNP O
produced VBD O
similar JJ B-OC
efficacy NN I-OC
and CC I-OC
toxicity NN I-OC
profiles NNS O
consistent JJ O
with IN O
prior JJ O
clinical JJ O
experience NN O
. . O

-DOCSTART- -X- O O

Inhibin NNP O
A NNP O
is VBZ O
down-regulated JJ O
during IN O
chemotherapy NN B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
. . O

BACKGROUND NNP O
Inhibins NNP O
are VBP O
dimeric JJ O
glycoproteins NNS O
, , O
composed VBN O
of IN O
an DT O
alpha-subunit JJ O
( ( O
INH-α NNP O
) ) O
and CC O
one CD O
of IN O
two CD O
possible JJ O
beta-subunits NNS O
( ( O
βA CD O
or CC O
βB NNP O
) ) O
, , O
with IN O
substantial JJ O
roles NNS O
in IN O
human JJ O
reproduction NN O
and CC O
in IN O
endocrine-responsive JJ O
tumours NNS O
. . O

Aims NNS O
of IN O
this DT O
study NN O
were VBD O
to TO O
determine VB O
the DT O
serological JJ O
measurement NN O
of IN B-OC
inhibin NN I-OC
A NNP I-OC
( ( B-POPU
α-βA JJ I-POPU
) ) I-POPU
in IN I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
during IN I-POPU
chemotherapy NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
A NNP O
series NN B-POPU
of IN I-POPU
30 CD I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
who WP I-POPU
underwent VBP I-POPU
standardised VBN I-POPU
chemotherapy NN I-POPU
were VBD O
prospectively RB O
evaluated VBN O
before IN B-INTV
chemotherapeutic JJ I-INTV
treatment NN I-INTV
as RB O
well RB O
as IN O
four CD O
weeks NNS O
after IN B-INTV
chemotherapy NN I-INTV
and CC O
two CD O
years NNS O
after IN B-INTV
chemotherapy NN I-INTV
for IN O
the DT O
serological JJ O
expression NN O
of IN O
inhibin NN O
A NNP O
. . O

For IN O
statistical JJ O
analysis NN B-OC
the DT I-OC
Wilcoxon NNP I-OC
rank NN I-OC
sum NN I-OC
test NN O
was VBD O
used VBN O
for IN O
paired JJ O
samples NNS O
. . O

Statistical JJ O
significance NN O
was VBD O
assumed VBN O
at IN O
p NN O
< $ O
0.05 CD O
. . O

RESULTS VB B-OC
The DT I-OC
concentration NN I-OC
of IN I-OC
inhibin NN I-OC
A NNP O
showed VBD O
a DT O
significant JJ O
decrease NN O
between IN O
data NNS O
obtained VBN O
before IN B-INTV
chemotherapy NN I-INTV
and CC O
after IN B-INTV
chemotherapy NN I-INTV
( ( O
p JJ O
< NNP O
0.005 CD O
) ) O
and CC O
two-year JJ O
follow-up NN O
( ( O
p JJ O
< NNP O
0.001 CD O
) ) O
. . O

Interestingly RB O
, , O
there EX O
were VBD O
no DT O
differences NNS B-OC
in IN I-OC
inhibin NN I-OC
A NNP I-OC
concentrations NNS I-OC
between IN O
the DT O
four-week JJ O
and CC O
two-year JJ O
follow-up NN O
( ( O
p=0.744 NN O
) ) O
. . O

DISCUSSION NNP B-INTV
Chemotherapy NNP I-INTV
significantly RB O
decreases VBZ O
inhibin VB O
A DT O
concentration NN O
during IN O
chemotherapy NN O
. . O

This DT O
might MD O
reflect VB O
a DT O
suppression NN O
of IN O
ovarian JJ O
function NN O
, , O
being VBG O
also RB O
a DT O
marker NN O
for IN O
chemotherapy-induced JJ O
amenorrhoea NN O
. . O

Moreover RB O
, , O
it PRP O
has VBZ O
been VBN O
suggested VBN O
that IN O
inhibin VBZ O
A DT O
might MD O
be VB O
a DT O
tumour JJ O
marker NN O
for IN O
breast NN O
cancer NN O
, , O
and CC O
therefore RB O
a DT O
sudden JJ O
increase NN O
in IN O
its PRP$ O
concentration NN O
might MD O
be VB O
indicative JJ O
of IN O
breast NN O
cancer NN O
recurrence NN O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
different JJ O
approaches NNS O
for IN O
assessment NN O
of IN O
HER2 NNP O
expression NN O
on IN O
protein NN O
and CC O
mRNA JJ O
level NN O
: : O
prediction NN O
of IN O
chemotherapy NN B-INTV
response NN O
in IN O
the DT O
neoadjuvant JJ O
GeparTrio NNP O
trial NN O
( ( O
NCT00544765 NNP O
) ) O
. . O

Human NNP B-INTV
epidermal JJ I-INTV
growth NN I-INTV
factor NN I-INTV
receptor NN I-INTV
2 CD I-INTV
( ( O
HER2 NNP O
) ) O
testing NN O
is VBZ O
an DT O
essential JJ O
part NN O
of IN O
pathological JJ O
assessment NN O
in IN O
breast NN B-POPU
cancer NN I-POPU
patients NNS I-POPU
, , O
as IN O
HER2 NNP O
provides VBZ O
not RB O
only RB O
prognostic JJ O
but CC O
also RB O
predictive JJ O
information NN O
on IN O
response NN O
to TO O
targeted VBN O
therapy NN O
. . O

So RB O
far RB O
, , O
HER2 NNP O
test JJS O
accuracy NN O
of IN O
immunohistochemistry/in JJ O
situ-hybridization NN O
techniques NNS O
is VBZ O
still RB O
under IN O
debate NN O
, , O
and CC O
more RBR O
reliable JJ O
and CC O
robust JJ O
technologies NNS O
are VBP O
needed VBN O
. . O

To TO O
address VB O
this DT O
issue NN O
and CC O
to TO O
evaluate VB O
the DT O
predictive JJ O
value NN O
of IN O
HER2 NNP O
on IN O
chemotherapy NN B-INTV
, , O
we PRP O
investigated VBD B-POPU
a DT I-POPU
cohort NN I-POPU
of IN I-POPU
278 CD I-POPU
patients NNS I-POPU
from IN I-POPU
the DT I-POPU
GeparTrio NNP I-POPU
trial NN I-POPU
, , O
a DT O
prospective JJ O
neoadjuvant JJ O
anthracycline/taxane-based JJ O
multicenter NN O
study NN O
. . O

In IN O
the DT O
GeparTrio NNP O
trial NN O
, , O
patients NNS O
were VBD O
not RB O
treated VBN O
with IN O
any DT O
anti-HER2 JJ B-INTV
therapy NN I-INTV
, , O
as IN O
this DT O
was VBD O
not RB O
standard JJ O
therapy NN O
at IN O
this DT O
time NN O
. . O

The DT O
HER2 NNP B-OC
status NN I-OC
was VBD O
analyzed VBN O
by IN O
three CD O
different JJ O
approaches NNS O
: : O
local JJ B-INTV
and CC I-INTV
central JJ I-INTV
evaluation NN I-INTV
using VBG I-INTV
immunohistochemistry NN I-INTV
combined VBN I-INTV
with IN I-INTV
in IN I-INTV
situ-hybridization NN I-INTV
as RB O
well RB O
as IN O
evaluation NN B-INTV
of IN I-INTV
HER2 NNP I-INTV
mRNA FW I-INTV
expression NN I-INTV
using VBG I-INTV
kinetic JJ I-INTV
RT-PCR JJ I-INTV
from IN I-INTV
formalin-fixed JJ I-INTV
, , I-INTV
paraffin-embedded JJ I-INTV
( ( I-INTV
FFPE NNP I-INTV
) ) I-INTV
tissue NN I-INTV
samples NNS I-INTV
using VBG O
a DT O
predefined VBN O
cutoff NN O
. . O

HER2 NNP B-OC
overexpression/amplification NN I-OC
was VBD O
observed VBN O
in IN O
37.3 CD O
% NN O
( ( O
91/244 CD O
) ) O
and CC O
17.9 CD O
% NN O
( ( O
41/229 CD O
) ) O
of IN O
the DT O
informative JJ O
samples NNS O
in IN O
the DT O
local JJ O
and CC O
central JJ O
evaluations NNS O
, , O
respectively RB O
. . O

Positive JJ B-OC
HER2 NNP I-OC
mRNA NN I-OC
levels NNS I-OC
were VBD O
found VBN O
in IN O
19.8 CD O
% NN O
( ( O
55/278 CD O
) ) O
. . O

We PRP O
observed VBD O
a DT O
highly RB O
significant JJ O
correlation NN B-OC
between IN I-OC
central JJ I-OC
HER2 NNP I-OC
expression NN I-OC
and CC I-OC
HER2 NNP I-OC
status NN I-OC
measured VBN I-OC
by IN I-OC
kinetic JJ I-OC
RT-PCR NNP I-OC
( ( O
r VB O
= RB O
0.856 CD O
, , O
P NNP O
< NNP O
0.0001 CD O
) ) O
and CC O
an DT O
overall JJ O
agreement NN O
of IN O
95.6 CD O
% NN O
( ( O
κ JJ O
statistic NN O
, , O
0.862 CD O
, , O
CI NNP O
0.77-0.94 NN O
) ) O
. . O

Further NNP O
, , O
central JJ B-OC
HER2 NNP I-OC
as RB I-OC
well RB I-OC
as IN I-OC
HER2 NNP I-OC
mRNA FW I-OC
expression NN I-OC
were VBD I-OC
predictors NNS I-OC
for IN I-OC
a DT I-OC
pathological JJ I-OC
complete JJ I-OC
response NN I-OC
after IN I-OC
neoadjuvant JJ I-OC
anthracycline/taxane-based JJ I-OC
primary JJ B-INTV
chemotherapy NN I-INTV
in IN O
a DT O
univariate JJ O
binary JJ O
logistic JJ O
regression NN O
analysis NN O
( ( O
OR CC O
3.29 CD O
, , O
P NNP O
= NNP O
0.002 CD O
; : O
OR CC O
2.65 CD O
, , O
P NNP O
= NNP O
0.004 CD O
) ) O
. . O

The DT B-OC
predictive JJ I-OC
value NN I-OC
could MD O
be VB O
confirmed VBN O
for IN O
the DT B-OC
central JJ I-OC
HER2 NNP I-OC
status NN I-OC
by IN O
multivariate NN O
analysis NN O
( ( O
OR CC O
3.04 CD O
, , O
P NNP O
= NNP O
0.027 CD O
) ) O
. . O

The DT B-OC
locally RB I-OC
assessed VBN I-OC
HER2 NNP I-OC
status NN I-OC
was VBD I-OC
not RB I-OC
predictive JJ I-OC
of IN I-OC
response NN I-OC
to TO I-OC
chemotherapy NN I-OC
. . O

Our PRP$ O
results NNS O
suggest VBP O
that IN O
standardized JJ O
methods NNS O
are VBP O
preferable JJ O
for IN O
evaluation NN O
of IN O
HER2 NNP O
status NN O
. . O

The DT O
kinetic JJ O
RT-PCR NNP O
from IN O
FFPE NNP O
tissue NN O
might MD O
be VB O
an DT O
additional JJ O
approach NN O
for IN O
assessment NN O
of IN O
this DT O
important JJ O
prognostic NN O
and CC O
predictive JJ O
parameter NN O
but CC O
has VBZ O
to TO O
be VB O
confirmed VBN O
by IN O
other JJ O
studies NNS O
. . O

-DOCSTART- -X- O O

Gefitinib NNP B-INTV
or CC I-INTV
placebo NN I-INTV
in IN O
combination NN O
with IN O
tamoxifen NN O
in IN O
patients NNS B-POPU
with IN I-POPU
hormone JJ I-POPU
receptor-positive JJ I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
randomized JJ O
phase NN O
II NNP O
study NN O
. . O

PURPOSE NNP O
Increased VBD O
growth NN O
factor NN O
signaling VBG O
may MD O
contribute VB O
to TO O
tamoxifen VB O
resistance NN O
. . O

This DT O
randomized JJ O
phase NN O
II NNP O
trial NN O
assessed VBD O
tamoxifen JJ B-INTV
plus CC I-INTV
placebo NN I-INTV
or CC O
the DT O
epidermal JJ O
growth NN O
factor NN O
receptor NN O
inhibitor NN O
gefitinib NN O
in IN O
estrogen NN O
receptor NN O
( ( O
ER NNP O
) ) O
-positive VBP O
metastatic JJ O
breast NN O
cancer NN O
. . O

EXPERIMENTAL NNP O
DESIGN NNP O
Patients NNPS B-POPU
with IN I-POPU
newly RB I-POPU
metastatic JJ I-POPU
disease NN I-POPU
or CC I-POPU
recurred VBN I-POPU
after IN I-POPU
adjuvant JJ I-POPU
tamoxifen NN I-POPU
( ( I-POPU
stratum JJ I-POPU
1 CD I-POPU
) ) I-POPU
, , I-POPU
or CC I-POPU
recurred VBD I-POPU
during/after NN I-POPU
adjuvant JJ I-POPU
aromatase NN I-POPU
inhibitor NN I-POPU
( ( I-POPU
AI NNP I-POPU
) ) I-POPU
or CC I-POPU
after IN I-POPU
failed VBN I-POPU
first-line NN I-POPU
AI NNP I-POPU
( ( I-POPU
stratum JJ I-POPU
2 CD I-POPU
) ) I-POPU
, , I-POPU
were VBD I-POPU
eligible JJ I-POPU
. . O

Primary JJ O
variables NNS O
were VBD O
progression-free JJ B-OC
survival NN I-OC
( ( O
PFS NNP O
; : O
stratum VBZ O
1 CD O
) ) O
and CC O
clinical JJ B-OC
benefit NN I-OC
rate NN I-OC
( ( O
CBR NNP O
; : O
stratum VBZ O
2 CD O
) ) O
. . O

A DT O
5 CD O
% NN O
or CC O
more JJR O
improvement NN O
in IN O
response NN O
variables NNS O
with IN O
gefitinib NN B-INTV
was VBD O
considered VBN O
to TO O
warrant VB O
further JJ O
investigation NN O
. . O

Outcome NNP O
was VBD O
correlated VBN O
with IN O
biomarkers NNS O
measured VBN O
on IN O
the DT O
primary JJ O
tumor NN O
. . O

RESULTS NNP O
In IN O
stratum JJ O
1 CD O
( ( O
n JJ O
= NNP O
206 CD O
) ) O
, , O
the DT O
PFS NNP B-OC
HR NNP I-OC
( ( B-INTV
gefitinib NN I-INTV
: : I-INTV
placebo NN I-INTV
) ) I-INTV
was VBD O
0.84 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.59-1.18 NNP O
; : O
median JJ B-OC
PFS NNP I-OC
10.9 CD O
versus NN O
8.8 CD O
months NNS O
) ) O
. . O

In IN O
the DT O
stratum NN O
1 CD O
endocrine JJ O
therapy-naïve JJ O
subset NN O
( ( O
n JJ O
= NNP O
158 CD O
) ) O
the DT B-OC
HR NNP I-OC
was VBD O
0.78 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.52-1.15 NNP O
) ) O
, , O
and CC O
the DT O
prior JJ O
endocrine-treated JJ O
subgroup NN O
( ( O
n JJ O
= NNP O
48 CD O
) ) O
1.47 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.63-3.45 NN O
) ) O
. . O

In IN O
stratum NN O
1 CD O
, , O
CBRs NNP B-OC
were VBD O
50.5 CD O
% NN O
with IN B-INTV
gefitinib NN I-INTV
and CC O
45.5 CD O
% NN O
with IN B-INTV
placebo NN I-INTV
. . O

In IN O
stratum NN O
2 CD O
( ( O
n JJ O
= NNP O
84 CD O
) ) O
, , O
CBRs NNP B-OC
were VBD O
29.2 CD O
% NN O
with IN B-INTV
gefitinib NN I-INTV
and CC O
31.4 CD O
% NN O
with IN B-INTV
placebo NN I-INTV
. . O

Biomarker NNP O
analysis NN O
suggested VBD O
that IN O
in IN O
stratum NN O
1 CD O
there EX O
was VBD O
greater JJR O
benefit NN O
with IN O
gefitinib NN O
in IN O
patients NNS O
who WP O
were VBD O
ER-negative JJ O
or CC O
had VBD O
lower JJR O
levels NNS O
of IN O
ER NNP O
protein NN O
. . O

CONCLUSIONS NNP O
In IN O
stratum NN O
1 CD O
, , O
the DT O
improved JJ O
PFS NNP O
with IN B-INTV
gefitinib JJ I-INTV
plus CC I-INTV
tamoxifen JJ I-INTV
met VBD O
the DT O
protocol NN O
criteria NNS O
to TO O
warrant VB O
further JJ O
investigation NN O
of IN O
this DT O
strategy NN O
. . O

In IN O
stratum NN O
2 CD O
, , O
there EX O
was VBD O
a DT O
numerical JJ O
disadvantage NN O
for IN B-INTV
gefitinib NN I-INTV
; : I-INTV
additional JJ O
investigation NN O
after IN O
AI NNP O
therapy NN O
is VBZ O
not RB O
warranted VBN O
. . O

Studies NNS O
of IN O
predictive JJ O
biomarkers NNS O
are VBP O
needed VBN O
to TO O
subset VB B-POPU
appropriate JJ I-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Sequential JJ O
alternate JJ O
administration NN O
of IN O
tamoxifen NN B-INTV
and CC O
medroxyprogesterone NN B-INTV
acetate NN I-INTV
in IN O
advanced JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
clinical-biological JJ O
randomized NN O
study NN O
. . O

From IN B-POPU
January NNP I-POPU
1985 CD I-POPU
to TO I-POPU
September NNP I-POPU
1988 CD I-POPU
, , I-POPU
60 CD I-POPU
women NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
were VBD I-POPU
randomized VBN I-POPU
in IN I-POPU
two CD I-POPU
arms NNS I-POPU
to TO B-INTV
receive VB I-INTV
: : I-INTV
A DT I-INTV
) ) I-INTV
tamoxifen NN I-INTV
( ( I-INTV
TAM NNP I-INTV
) ) I-INTV
( ( I-INTV
20 CD I-INTV
mg/die NN I-INTV
) ) I-INTV
until IN I-INTV
progression NN I-INTV
or CC I-INTV
B NNP I-INTV
) ) I-INTV
TAM NNP I-INTV
( ( I-INTV
20 CD I-INTV
mg/die NN I-INTV
for IN I-INTV
14 CD I-INTV
days NNS I-INTV
) ) I-INTV
then RB I-INTV
medroxyprogesterone NN I-INTV
acetate NN I-INTV
( ( I-INTV
MPA NNP I-INTV
) ) I-INTV
( ( I-INTV
1500 CD I-INTV
mg/die NN I-INTV
p.o NN I-INTV
. . O

for IN B-INTV
14 CD I-INTV
days NNS I-INTV
) ) I-INTV
followed VBN I-INTV
by IN I-INTV
7 CD I-INTV
days NNS I-INTV
of IN I-INTV
wash-out NN I-INTV
before IN I-INTV
repeating VBG I-INTV
the DT I-INTV
TAM/MPA NNP I-INTV
treatment NN I-INTV
. . O

All DT B-POPU
patients NNS I-POPU
were VBD I-POPU
post-menopausal JJ I-POPU
, , I-POPU
previously RB I-POPU
untreated VBN I-POPU
with IN I-POPU
hormone NN I-POPU
therapy NN I-POPU
, , I-POPU
and CC I-POPU
with IN I-POPU
tumor NN I-POPU
receptor NN I-POPU
status NN I-POPU
determined VBD I-POPU
immediately RB I-POPU
before IN I-POPU
randomization NN I-POPU
; : I-POPU
all DT I-POPU
had VBD I-POPU
objectively RB I-POPU
evaluable JJ I-POPU
lesions NNS I-POPU
. . O

In IN O
order NN O
to TO O
verify VB O
hormone NN B-OC
receptor NN I-OC
variations NNS I-OC
due JJ O
to TO O
the DT O
antiestrogen NN O
, , O
when WRB B-INTV
possible JJ I-INTV
a DT I-INTV
second JJ I-INTV
biopsy NN I-INTV
was VBD I-INTV
performed VBN I-INTV
after IN I-INTV
the DT I-INTV
initial JJ I-INTV
14 CD I-INTV
day NN I-INTV
cycle NN I-INTV
of IN I-INTV
TAM NNP I-INTV
. . O

Thirty-one NN B-POPU
and CC I-POPU
29 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
included VBN I-POPU
respectively RB I-POPU
in IN I-POPU
arms NNS I-POPU
A NNP I-POPU
and CC I-POPU
B NNP I-POPU
. . O

Objective JJ B-OC
regression NN I-OC
( ( O
CR NNP O
+ NNP O
PR NNP O
) ) O
was VBD O
observed VBN O
in IN O
58 CD O
% NN O
of IN O
group NN O
A NNP O
and CC O
75 CD O
% NN O
of IN O
group NN O
B NNP O
, , O
with IN O
CR NNP O
in IN O
11 CD O
% NN O
and CC O
23 CD O
% NN O
, , O
respectively RB O
. . O

Differences NNS O
were VBD O
not RB O
statistically RB O
significant JJ O
. . O

Median JJ B-OC
time NN I-OC
to TO I-OC
progression NN I-OC
was VBD O
12 CD O
months NNS O
for IN O
group NN O
A NNP O
and CC O
9 CD O
for IN O
group NN O
B NNP O
. . O

Overall NNP B-OC
survival NN I-OC
has VBZ O
not RB O
yet RB O
been VBN O
reached VBN O
in IN O
group NN O
A NNP O
while IN O
it PRP O
was VBD O
34 CD O
months NNS O
for IN O
patients NNS O
of IN O
group NN O
B. NNP O
Metrorrhagia NNP B-OC
was VBD O
observed VBN O
in IN O
two CD O
cases NNS O
of IN O
group NN O
A NNP O
and CC O
in IN O
6 CD O
of IN O
group NN O
B NNP O
, , O
and CC O
thrombophlebitis NN O
in IN O
1 CD O
and CC O
3 CD O
cases NNS O
, , O
respectively RB O
. . O

The DT O
second JJ O
biopsy NN O
confirmed VBD O
a DT O
clear JJ O
increase NN O
of IN O
PgR NNP B-OC
content NN I-OC
in IN O
8/11 CD O
cases NNS O
( ( O
75 CD O
% NN O
) ) O
. . O

Plasma NNP B-OC
level JJ I-OC
variations NNS I-OC
of IN I-OC
TAM NNP I-OC
, , I-OC
N-desmethyl NNP I-OC
TAM NNP I-OC
and CC I-OC
MPA NNP I-OC
were VBD O
checked VBN O
at IN O
various JJ O
intervals NNS O
on IN O
3 CD O
patients NNS O
of IN O
group NN O
B NNP O
, , O
and CC O
confirmed VBD O
that IN O
our PRP$ O
schedule NN O
is VBZ O
able JJ O
to TO O
produce VB O
a DT O
drug NN O
wash-out NN O
period NN O
for IN O
tumor NN O
cells NNS O
. . O

In IN O
conclusion NN O
, , O
our PRP$ O
study NN O
demonstrated VBD O
that IN O
while IN O
the DT O
manipulation NN O
of IN O
hormone NN O
receptors NNS O
seems VBZ O
possible JJ O
, , O
results NNS O
indicating VBG O
better JJR O
overall JJ O
survival NN O
and CC O
time NN O
to TO O
progression NN O
were VBD O
not RB O
obtained VBN O
with IN O
alternate JJ O
sequential JJ O
TAM-MPA NNP O
therapy NN O
. . O

-DOCSTART- -X- O O

Noninfiltrative JJ B-INTV
anesthesia NN I-INTV
for IN O
transrectal JJ B-POPU
prostate NN I-POPU
biopsy NN I-POPU
: : I-POPU
a DT O
randomized JJ O
prospective JJ O
study NN O
comparing VBG O
lidocaine-prilocaine JJ B-INTV
cream NN I-INTV
and CC O
lidocaine-ketorolac JJ B-INTV
gel NN I-INTV
. . O

OBJECTIVES NNP O
Periprostatic NNP O
nerve NN O
block NN O
( ( O
PPNB NNP O
) ) O
is VBZ O
the DT O
standard JJ O
anesthesia NN B-INTV
for IN O
ultrasound NN O
( ( O
US NNP O
) ) O
guided VBD O
transrectal JJ B-POPU
prostate NN I-POPU
biopsy NN I-POPU
( ( I-POPU
TPB NNP I-POPU
) ) I-POPU
, , O
but CC O
periprostatic JJ O
infiltration NN O
itself PRP O
constitutes VBZ O
a DT O
major JJ O
, , O
though RB O
often RB O
neglected VBN O
, , O
source NN O
of IN O
discomfort NN O
even RB O
in IN O
patients NNS B-POPU
receiving VBG I-POPU
perianal-intrarectal JJ I-POPU
lidocaine-prilocaine NN I-POPU
( ( I-POPU
PILP NNP I-POPU
) ) I-POPU
cream NN I-POPU
before IN I-POPU
PPNB NNP I-POPU
. . O

Noninfiltrative NNP B-INTV
anesthesia NN I-INTV
therefore NN O
represents VBZ O
an DT O
attractive JJ O
alternative NN O
to TO O
periprostatic JJ O
infiltration NN O
. . O

With IN O
this DT O
in IN O
mind NN O
, , O
we PRP O
aimed VBD O
to TO O
determine VB O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
perianal-intrarectal JJ B-INTV
( ( I-INTV
PI NNP I-INTV
) ) I-INTV
lidocaine NN I-INTV
gel NN I-INTV
, , I-INTV
lidocaine-ketorolac JJ I-INTV
gel NN I-INTV
, , O
and CC O
lidocaine-prilocaine JJ B-INTV
cream NN I-INTV
in IN O
relieving VBG B-OC
pain NN I-OC
during IN O
TPB NNP O
. . O

MATERIALS NNP O
AND CC O
METHODS NNP O
Three NNP B-POPU
hundred VBD I-POPU
consecutive JJ I-POPU
patients NNS I-POPU
scheduled VBN I-POPU
for IN I-POPU
US-guided JJ I-POPU
TPB NNP I-POPU
were VBD O
randomized VBN O
1:1:1 CD O
to TO O
receive VB O
PI NNP B-INTV
administration NN O
of IN O
5 CD O
g JJ O
2.5 CD O
% NN O
lidocaine JJ B-INTV
gel NN I-INTV
10 CD O
minutes NNS O
before IN O
TPB NNP O
( ( O
Group NNP O
1 CD O
) ) O
, , O
or CC O
a DT O
mixture NN O
of IN O
5 CD B-INTV
g JJ I-INTV
2.5 CD I-INTV
% NN I-INTV
lidocaine JJ I-INTV
gel NN I-INTV
and CC I-INTV
0.3 CD I-INTV
% NN I-INTV
ketorolac NN I-INTV
tromethamine JJ I-INTV
solution NN I-INTV
1 CD I-INTV
hour NN I-INTV
before IN I-INTV
TPB NNP I-INTV
( ( O
Group NNP O
2 CD O
) ) O
, , O
or CC O
5 CD B-INTV
g JJ I-INTV
2.5 CD I-INTV
% NN I-INTV
lidocaine NN I-INTV
and CC I-INTV
2.5 CD I-INTV
% NN I-INTV
prilocaine NN I-INTV
cream NN I-INTV
20 CD I-INTV
minutes NNS I-INTV
before IN I-INTV
TPB NNP I-INTV
( ( O
Group NNP O
3 CD O
) ) O
. . O

The DT O
0-to-10 JJ B-OC
points NNS I-OC
visual JJ I-OC
analogue JJ I-OC
scale NN I-OC
( ( I-OC
VAS NNP I-OC
) ) I-OC
was VBD O
used VBN O
for IN O
assessing VBG O
pain NN O
at IN O
probe NN O
insertion NN O
and CC O
movements NNS O
( ( O
VAS-1 NNP O
) ) O
, , O
at IN O
prostate NN O
sampling NN O
( ( O
VAS-2 NNP O
) ) O
, , O
and CC O
maximal JJ O
procedural JJ O
pain NN O
( ( O
MPP NNP O
) ) O
. . O

Complications NNS O
occurring VBG O
up RB O
to TO O
20 CD O
days NNS O
after IN O
the DT O
procedure NN O
were VBD O
also RB O
recorded VBN O
. . O

RESULTS VB O
Four NNP O
( ( O
1.3 CD O
% NN O
) ) O
patients NNS O
were VBD O
excluded VBN O
because IN O
of IN O
unbearable JJ B-OC
pain NN I-OC
during IN O
the DT O
procedure NN O
, , O
leaving VBG O
Group NNP O
1 CD O
with IN O
98 CD O
patients NNS O
, , O
Group NNP O
2 CD O
with IN O
99 CD O
, , O
and CC O
Group NNP O
3 CD O
with IN O
99 CD O
; : O
the DT O
3 CD O
groups NNS O
were VBD O
comparable JJ O
for IN O
patients NNS O
' POS O
age NN O
, , O
serum NN B-OC
PSA NNP I-OC
, , I-OC
prostate NN I-OC
volume NN I-OC
, , I-OC
and CC I-OC
cancer NN I-OC
detection NN I-OC
rate NN I-OC
. . O

The DT O
addition NN O
of IN O
either DT O
ketorolac NN B-INTV
or CC O
prilocaine NN B-INTV
to TO I-INTV
lidocaine VB I-INTV
significantly RB O
( ( O
P NNP O
< NNP O
0.0001 CD O
) ) O
reduced VBD O
probe-related JJ O
, , O
sampling-related JJ O
, , O
and CC O
maximal JJ O
procedural JJ B-OC
pain NN I-OC
. . O

Compared VBN O
with IN O
lidocaine-prilocaine JJ B-INTV
, , I-INTV
lidocaine-ketorolac JJ I-INTV
was VBD O
less RBR O
effective JJ O
in IN O
relieving VBG O
probe-related JJ B-OC
pain NN I-OC
( ( O
mean JJ O
VAS-1 NNP O
: : O
1.47 CD O
± $ O
1.30 CD O
vs. FW O
0.39 CD O
± $ O
0.65 CD O
; : O
P NNP O
< NNP O
0.0001 CD O
) ) O
but CC O
more RBR O
effective JJ O
in IN O
relieving VBG B-OC
sampling-related JJ I-OC
pain NN I-OC
( ( O
mean JJ O
VAS-2 NNP O
: : O
0.76 CD O
± $ O
0.94 CD O
vs. FW O
1.54 CD O
± $ O
1.02 CD O
; : O
P NNP O
< NNP O
0.0001 CD O
) ) O
; : O
there EX O
was VBD O
no DT O
difference NN O
in IN O
MPP NNP O
( ( O
mean JJ O
1.82 CD O
± $ O
1.21 CD O
vs. FW O
1.67 CD O
± $ O
0.95 CD O
) ) O
, , O
probably RB O
due JJ O
to TO O
such JJ O
different JJ O
efficacy NN O
on IN O
the DT B-OC
two CD I-OC
pain NN I-OC
sources NNS I-OC
. . O

Complications NNS O
were VBD O
similar JJ O
in IN O
the DT O
3 CD O
groups NNS O
. . O

CONCLUSIONS NNP B-INTV
Lidocaine-prilocaine JJ I-INTV
cream NN O
was VBD O
most RBS O
effective JJ O
on IN O
probe-related JJ B-OC
pain NN O
, , O
whereas IN B-INTV
lidocaine-ketorolac JJ I-INTV
gel NN O
was VBD O
most RBS O
effective JJ O
on IN O
sampling-related JJ O
pain NN O
. . O

These DT O
noninfiltrative JJ O
anesthetics NNS O
were VBD O
safe JJ O
, , O
easy JJ O
to TO O
administer VB O
, , O
and CC O
well RB O
accepted VBN O
by IN O
patients NNS O
; : O
the DT O
possibility NN O
to TO O
combine VB O
them PRP O
to TO O
further JJ O
improve VB B-OC
pain NN I-OC
control NN I-OC
during IN O
TPB NNP O
deserves VBZ O
further JJ O
well-designed JJ O
studies NNS O
. . O

-DOCSTART- -X- O O

A DT O
randomized VBN O
study NN O
on IN O
hormone-resistant JJ B-POPU
prostatic JJ I-POPU
cancer NN I-POPU
: : I-POPU
estramustine JJ B-INTV
phosphate NN I-INTV
versus NN O
low JJ B-INTV
dose JJ I-INTV
epirubicin NN I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
medroxyprogesterone JJ I-INTV
acetate NN I-INTV
. . O

A DT O
Norwegian JJ O
multicenter NN O
study NN O
. . O

A DT O
prospective JJ O
randomized NN O
study NN O
has VBZ O
been VBN O
carried VBN O
out RP O
in IN O
order NN O
to TO O
compare VB O
three CD O
different JJ O
treatment NN O
modalities NNS O
for IN O
symptomatic JJ B-POPU
metastatic JJ I-POPU
hormone-resistant JJ I-POPU
prostatic JJ I-POPU
cancer NN I-POPU
. . O

A DT O
total NN B-POPU
of IN I-POPU
79 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
included VBN I-POPU
. . O

One CD O
group NN O
was VBD O
treated VBN B-INTV
with IN I-INTV
estramustine JJ I-INTV
phosphate NN I-INTV
, , I-INTV
another DT I-INTV
with IN I-INTV
Epirubicin NNP I-INTV
plus CC I-INTV
Medroxyprogesterone NNP I-INTV
acetate NN I-INTV
( ( I-INTV
MPA NNP I-INTV
) ) I-INTV
, , I-INTV
while IN I-INTV
the DT I-INTV
third JJ I-INTV
arm NN I-INTV
consisted VBD I-INTV
of IN I-INTV
Epirubicin NNP I-INTV
plus CC I-INTV
placebo NN I-INTV
. . O

Best JJS B-OC
palliation NN I-OC
was VBD O
obtained VBN O
by IN O
the DT O
combination NN O
of IN O
Epirubicin NNP B-INTV
and CC I-INTV
MPA NNP I-INTV
. . O

This DT O
combination NN O
also RB O
seemed VBD O
to TO O
be VB O
associated VBN O
with IN O
the DT O
longest JJS O
response NN O
duration NN O
. . O

-DOCSTART- -X- O O

National NNP O
Surgical NNP O
Adjuvant NNP O
Breast NNP O
and CC O
Bowel NNP O
Project NNP O
's POS O
Breast NNP O
Cancer NNP O
Prevention NNP O
Trial NNP O
. . O

The DT O
Breast NNP O
Cancer NNP O
Prevention NNP O
Trial NNP O
is VBZ O
the DT O
largest JJS O
breast NN O
cancer NN O
prevention NN O
study NN O
ever RB O
undertaken RB O
. . O

Administered VBN O
by IN O
the DT O
National NNP O
Surgical NNP O
Adjuvant NNP O
Breast NNP O
and CC O
Bowel NNP O
Project NNP O
, , O
it PRP O
is VBZ O
the DT O
first JJ O
trial NN O
seeking VBG O
to TO O
demonstrate VB O
whether IN O
a DT O
drug NN O
, , O
tamoxifen NN B-POPU
, , O
can MD O
prevent VB B-POPU
breast NN I-POPU
cancer NN I-POPU
in IN I-POPU
high-risk JJ I-POPU
women NNS I-POPU
. . O

The DT O
objectives NNS O
of IN O
this DT O
trial NN O
are VBP O
to TO O
determine VB O
whether IN O
tamoxifen NN B-INTV
is VBZ O
effective JJ O
in IN O
1 CD O
) ) O
reducing VBG B-OC
the DT I-OC
incidence NN I-OC
of IN I-OC
invasive JJ I-OC
breast NN I-OC
cancer NN I-OC
, , I-OC
2 CD I-OC
) ) I-OC
reducing VBG I-OC
breast NN I-OC
cancer NN I-OC
mortality NN I-OC
, , I-OC
3 CD I-OC
) ) I-OC
reducing VBG I-OC
deaths NNS I-OC
from IN I-OC
cardiovascular JJ I-OC
disease NN I-OC
, , I-OC
and CC I-OC
4 CD I-OC
) ) I-OC
reducing VBG I-OC
bone NN I-OC
fractures NNS I-OC
. . O

In IN O
addition NN O
, , O
the DT O
study NN O
will MD O
evaluate VB O
side NN B-OC
effects NNS I-OC
, , I-OC
toxicity NN I-OC
, , I-OC
and CC I-OC
the DT I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
of IN O
all DT O
study NN O
participants NNS O
. . O

-DOCSTART- -X- O O

Intraperitoneal NNP B-INTV
distribution NN I-INTV
imaging VBG I-INTV
prior RB O
to TO O
chromic VB O
phosphate NN O
( ( O
P-32 NNP O
) ) O
therapy NN O
in IN O
ovarian JJ B-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

This DT O
study NN O
addressed VBD O
the DT O
technique NN O
of IN O
intraperitoneal JJ B-INTV
distribution NN I-INTV
imaging NN I-INTV
( ( I-INTV
IDI NNP I-INTV
) ) I-INTV
. . O

A DT O
literature NN O
search NN O
( ( O
MEDLINE NNP O
database NN O
) ) O
revealed VBD O
wide JJ O
variations NNS O
in IN O
IDI NNP B-INTV
techniques NNS O
without IN O
a DT O
basis NN O
for IN O
comparison NN O
. . O

From IN O
April NNP O
1990 CD O
to TO O
September NNP O
1992 CD O
, , O
the DT O
authors NNS O
studied VBD O
8 CD B-POPU
patients NNS I-POPU
( ( I-POPU
age NN I-POPU
43-65 CD I-POPU
years NNS I-POPU
) ) I-POPU
with IN I-POPU
ovarian JJ I-POPU
cancer NN I-POPU
. . O

A DT O
total NN O
of IN O
1000 CD O
ml NN O
of IN O
normal JJ B-INTV
saline NN I-INTV
and CC I-INTV
1 CD I-INTV
mCi NN I-INTV
of IN I-INTV
Tc-99m NNP I-INTV
SC NNP I-INTV
was VBD O
infused VBN O
intraperitoneally RB O
for IN O
IDI NNP B-INTV
. . O

In IN O
one CD O
patient NN O
loculation NN B-OC
was VBD O
observed VBN O
, , O
but CC O
only RB O
250 CD O
ml NNS O
of IN O
normal JJ B-INTV
saline NN I-INTV
was VBD O
infused VBN O
with IN O
Tc-99m NNP B-INTV
SC NNP I-INTV
. . O

A NNP O
repeat NN O
study NN O
using VBG O
our PRP$ O
standard NN O
technique NN O
rendered VBD O
free JJ B-OC
intraperitoneal NN I-OC
distribution NN I-OC
in IN O
this DT O
patient NN O
, , O
as RB O
well RB O
as IN O
in IN O
the DT O
other JJ O
seven CD O
cases NNS O
. . O

Some DT O
investigators NNS O
recommend VBP O
low JJ O
volumes NNS O
, , O
but CC O
in IN O
our PRP$ O
experience NN O
this DT O
produced VBD O
the DT O
finding NN O
of IN O
pseudoloculation NN B-OC
, , O
which WDT O
could MD O
change VB O
treatment NN O
inappropriately RB O
. . O

Although IN O
the DT O
number NN O
of IN O
patients NNS O
studied VBN O
at IN O
our PRP$ O
institution NN O
was VBD O
small JJ O
, , O
administration NN O
of IN O
1 CD O
liter NN O
intraperitoneally RB O
provided VBD O
consistent JJ O
IDI NNP B-OC
results NNS O
. . O

-DOCSTART- -X- O O

Granulocyte-macrophage JJ B-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
( ( I-INTV
GM-CSF NNP I-INTV
) ) I-INTV
allows VBZ O
acceleration NN O
and CC O
dose JJ O
intensity NN O
increase NN O
of IN O
CEF NNP B-INTV
chemotherapy NN I-INTV
: : I-INTV
a DT O
randomised JJ O
study NN O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

A DT O
randomised JJ O
study NN O
was VBD O
conducted VBN O
in IN O
62 CD B-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
to TO O
assess VB O
whether IN O
granulocyte-macrophage JJ O
colony-stimulating JJ O
factor NN O
( ( B-INTV
GM-CSF NNP I-INTV
) ) I-INTV
would MD O
yield VB O
an DT O
increase NN O
in IN O
the DT O
dose JJ O
intensity NN O
of IN O
a DT O
standard-dose JJ B-INTV
CEF NNP I-INTV
regimen NNS I-INTV
through IN O
an DT O
acceleration NN O
of IN O
chemotherapy JJ B-INTV
administration NN O
. . O

Patients NNS O
received VBD O
CEF NNP B-INTV
( ( I-INTV
cyclophosphamide VB I-INTV
600 CD I-INTV
mg JJ I-INTV
m-2 NN I-INTV
, , I-INTV
epidoxorubicin VBZ I-INTV
60 CD I-INTV
mg NN I-INTV
m-2 NN I-INTV
and CC I-INTV
fluorouracil NN I-INTV
600 CD I-INTV
mg JJ I-INTV
m-2 NN I-INTV
) ) I-INTV
i.v NN O
. . O

on IN O
day NN O
1 CD O
or CC O
the DT O
same JJ O
chemotherapy NN B-INTV
, , O
plus CC O
GM-CSF NNP B-INTV
10 CD O
micrograms NNS O
kg-1 JJ O
s.c. NNS O
starting VBG O
from IN O
day NN O
4 CD O
, , O
repeated VBN O
as RB O
soon RB O
as IN O
haematopoietic JJ O
recovery NN O
from IN O
nadir NN O
occurred VBD O
. . O

Patients NNS O
in IN O
the DT O
CEF NNP B-INTV
+ NNP I-INTV
GM-CSF NNP I-INTV
group NN O
received VBD O
chemotherapy NN O
at IN O
a DT O
median JJ O
interval NN O
of IN O
16 CD O
days NNS O
compared VBN O
with IN O
20 CD O
days NNS O
in IN O
the DT O
control NN O
group NN O
. . O

This DT O
led VBD O
to TO O
a DT O
significant JJ O
increase NN O
( ( O
P NNP O
= NNP O
0.02 CD O
) ) O
in IN O
the DT O
dose JJ O
intensity NN O
actually RB O
administered VBN O
in IN O
the DT O
third JJ O
, , O
fourth JJ O
and CC O
sixth JJ O
cycles NNS O
: : O
+28 CD O
% NN O
, , O
+25 CD O
% NN O
, , O
+20 CD O
% NN O
respectively RB O
. . O

Non-haematological JJ B-OC
toxicity NN I-OC
was VBD O
mild JJ O
. . O

GM-CSF NNP B-INTV
had VBD O
to TO O
be VB O
reduced VBN O
or CC O
suspended VBN O
in IN O
50 CD O
% NN O
of IN O
patients NNS O
because IN O
of IN O
toxicity NN B-OC
. . O

Haematological JJ B-OC
toxicity NN I-OC
, , O
mainly RB O
cumulative JJ B-OC
anaemia NN I-OC
and CC I-OC
thrombocytopenia NN I-OC
, , O
was VBD O
manageable JJ O
. . O

An DT O
increase NN O
in IN O
response NN B-OC
rate NN I-OC
for IN O
patients NNS O
with IN O
measurable JJ B-OC
disease NN I-OC
, , O
of IN O
borderline JJ O
statistical JJ O
significance NN O
( ( O
P NNP O
= NNP O
0.088 CD O
, , O
P NNP O
for IN O
trend NN O
= NNP O
0.018 CD O
) ) O
, , O
from IN O
42 CD O
% NN O
in IN O
the DT O
CEF NNP B-INTV
group NN O
to TO O
69 CD O
% NN O
in IN O
the DT O
CEF NNP B-INTV
+ NNP I-INTV
GM-CSF NNP I-INTV
group NN O
, , O
was VBD O
observed VBN O
. . O

This DT O
randomised JJ O
trial NN O
indicates VBZ O
that IN O
GM-CSF NNP B-INTV
is VBZ O
useful JJ O
for IN O
chemotherapy NN O
acceleration NN O
. . O

Accelerated NNP O
CEF NNP B-INTV
+ NNP I-INTV
GM-CSF NNP I-INTV
is VBZ O
a DT O
moderately RB O
dose-intensive JJ O
regimen NNS O
that WDT O
can MD O
be VB O
administered VBN O
in IN O
an DT O
outpatient NN O
clinic NN O
and CC O
is VBZ O
associated VBN O
with IN O
a DT O
high JJ O
objective JJ O
response NN O
. . O

-DOCSTART- -X- O O

Continuous JJ B-INTV
chemotherapy NN I-INTV
in IN O
responsive JJ O
metastatic JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
role NN O
for IN O
tumour NN O
markers NNS O
? . O
A DT O
biochemical JJ O
response NN O
index NN O
comprising VBG O
ESR NNP O
, , O
CEA NNP O
and CC O
CA NNP O
15.3 CD O
was VBD O
evaluated VBN O
in IN O
67 CD B-POPU
patients NNS I-POPU
with IN I-POPU
systemic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
treated VBN I-POPU
by IN I-POPU
chemotherapy NN I-POPU
; : I-POPU
55 CD I-POPU
were VBD I-POPU
assessable JJ I-POPU
by IN I-POPU
UICC NNP I-POPU
criteria NNS I-POPU
and CC I-POPU
the DT I-POPU
response NN I-POPU
index NN I-POPU
( ( I-POPU
96 CD I-POPU
% NN I-POPU
of IN I-POPU
all DT I-POPU
UICC NNP I-POPU
assessable JJ I-POPU
patients NNS I-POPU
) ) I-POPU
. . O

Marker NNP O
changes NNS O
at IN O
2 CD O
and CC O
4 CD O
months NNS O
showed VBD O
a DT O
highly RB O
significant JJ O
correlation NN O
with IN O
the DT O
UICC NNP O
assessed VBD O
response NN O
at IN O
3 CD O
and CC O
6 CD O
months NNS O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
; : O
sensitivity $ O
100 CD O
% NN O
, , O
specificity NN O
87 CD O
% NN O
; : O
positive JJ O
predictive JJ O
value NN O
85 CD O
% NN O
; : O
negative JJ O
predictive JJ O
value NN O
100 CD O
% NN O
. . O

This DT O
index NN O
was VBD O
then RB O
used VBN O
to TO O
select VB O
out RP O
truly RB O
responsive JJ O
patients NNS B-POPU
and CC O
to TO O
prospectively RB O
direct VB O
their PRP$ O
chemotherapy NN B-INTV
. . O

Twenty-six JJ O
responding NN O
( ( O
biochemical/clinical JJ O
) ) O
patients NNS O
were VBD O
randomised VBN O
to TO O
discontinue VB B-INTV
cytotoxics NNS I-INTV
after IN I-INTV
6 CD I-INTV
months NNS I-INTV
and CC I-INTV
move VB I-INTV
to TO I-INTV
maintenance VB I-INTV
hormones NNS I-INTV
( ( O
n JJ O
= NNP O
13 CD O
) ) O
or CC O
continue VB B-INTV
chemotherapy NN I-INTV
whilst IN O
the DT O
biochemical JJ O
markers NNS O
kept VBD O
falling VBG O
or CC O
remained VBN O
within IN O
the DT O
normal JJ O
range NN O
. . O

Biochemical JJ O
progression NN O
prompted VBD O
a DT O
change NN O
of IN O
chemotherapy NN O
. . O

Continuous JJ B-INTV
chemotherapy NN I-INTV
in IN O
biochemically RB O
defined JJ O
responders NNS O
was VBD O
associated VBN O
with IN O
a DT O
significant JJ O
lengthening NN B-OC
of IN I-OC
remission NN I-OC
duration NN I-OC
and CC I-OC
an DT I-OC
improved JJ I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
and CC I-OC
survival NN I-OC
. . O

We PRP O
are VBP O
now RB O
using VBG O
the DT O
index NN O
to TO O
routinely RB O
direct JJ O
chemotherapy NN O
and CC O
select VB O
out RP O
true JJ O
responders NNS O
for IN O
maintenance NN O
chemotherapy NN O
. . O

-DOCSTART- -X- O O

Radiation-induced JJ O
brachial JJ O
plexopathy NN O
: : O
neurological JJ O
follow-up NN O
in IN O
161 CD B-POPU
recurrence-free JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

PURPOSE VB O
The DT O
purpose NN O
was VBD O
to TO O
assess VB B-OC
the DT I-OC
incidence NN I-OC
and CC I-OC
clinical JJ I-OC
manifestations NNS I-OC
of IN O
radiation-induced JJ O
brachial JJ O
plexopathy NN O
in IN O
breast NN B-POPU
cancer NN I-POPU
patients NNS I-POPU
, , I-POPU
treated VBD I-POPU
according VBG I-POPU
to TO I-POPU
the DT I-POPU
Danish JJ I-POPU
Breast NNP I-POPU
Cancer NNP I-POPU
Cooperative NNP I-POPU
Group NNP I-POPU
protocols VBZ I-POPU
. . O

METHODS NNP O
AND CC O
MATERIALS NNP O
One NNP B-POPU
hundred CD I-POPU
and CC I-POPU
sixty-one JJ I-POPU
recurrence-free JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
were VBD I-POPU
examined VBN I-POPU
for IN I-POPU
radiation-induced JJ I-POPU
brachial JJ I-POPU
plexopathy NN I-POPU
after IN I-POPU
a DT I-POPU
median JJ I-POPU
follow-up JJ I-POPU
period NN I-POPU
of IN I-POPU
50 CD I-POPU
months NNS I-POPU
( ( I-POPU
13-99 JJ I-POPU
months NNS I-POPU
) ) I-POPU
. . O

After IN O
total JJ O
mastectomy NN O
and CC O
axillary JJ O
node NN O
sampling NN O
, , O
high-risk JJ B-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
adjuvant VB B-INTV
therapy NN I-INTV
. . O

One CD O
hundred VBD O
twenty-eight JJ O
patients NNS O
were VBD O
treated VBN O
with IN O
postoperative JJ B-INTV
radiotherapy NN I-INTV
with IN I-INTV
50 CD I-INTV
Gy NNP I-INTV
in IN O
25 CD O
daily JJ O
fractions NNS O
over IN O
5 CD O
weeks NNS O
. . O

In IN O
addition NN O
, , O
82 CD O
of IN O
these DT O
patients NNS O
received VBD O
cytotoxic JJ B-INTV
therapy NN I-INTV
( ( I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
methotrexate NN I-INTV
, , I-INTV
and CC I-INTV
5-fluorouracil JJ I-INTV
) ) I-INTV
and CC O
46 CD O
received VBD O
tamoxifen NN B-INTV
. . O

RESULTS NNP O
Five CD O
percent NN O
and CC O
9 CD O
% NN O
of IN O
the DT O
patients NNS O
receiving VBG O
radiotherapy NN O
had VBD O
disabling NN B-OC
and CC I-OC
mild JJ I-OC
radiation-induced JJ I-OC
brachial NN I-OC
plexopathy NN I-OC
, , O
respectively RB O
. . O

Radiation-induced JJ B-OC
brachial JJ I-OC
plexopathy NN I-OC
was VBD O
more RBR O
frequent JJ O
in IN O
patients NNS O
receiving VBG O
cytotoxic JJ O
therapy NN O
( ( O
p JJ O
= NNP O
0.04 CD O
) ) O
and CC O
in IN O
younger JJR O
patients NNS O
( ( O
p JJ O
= NNP O
0.04 CD O
) ) O
. . O

The DT O
clinical JJ O
manifestations NNS O
were VBD O
paraesthesia JJ B-OC
( ( O
100 CD O
% NN O
) ) O
, , O
hypaesthesia NN B-OC
( ( O
74 CD O
% NN O
) ) O
, , O
weakness NN B-OC
( ( O
58 CD O
% NN O
) ) O
, , O
decreased VBN B-OC
muscle NN I-OC
stretch NN I-OC
reflexes NNS I-OC
( ( O
47 CD O
% NN O
) ) O
, , O
and CC O
pain NN B-OC
( ( O
47 CD O
% NN O
) ) O
. . O

CONCLUSION VB O
The DT O
brachial JJ O
plexus NN O
is VBZ O
more RBR O
vulnerable JJ O
to TO O
large JJ O
fraction NN O
size NN O
. . O

Fractions NNS O
of IN O
2 CD O
Gy NNP O
or CC O
less JJR O
are VBP O
advisable JJ O
. . O

Cytotoxic NNP B-INTV
therapy NN I-INTV
adds VBZ O
to TO O
the DT O
damaging JJ O
effect NN O
of IN O
radiotherapy NN O
. . O

Peripheral JJ O
nerves NNS O
in IN O
younger JJR B-POPU
patients NNS I-POPU
seems VBZ O
more RBR O
vulnerable JJ O
. . O

Radiation-induced JJ O
brachial JJ O
plexopathy NN O
occurs VBZ O
mainly RB O
as IN O
diffuse NN O
damage NN O
to TO O
the DT O
brachial JJ O
plexus NN O
. . O

-DOCSTART- -X- O O

The DT O
sequencing NN O
of IN O
chemotherapy NN B-INTV
and CC O
radiation NN B-INTV
therapy NN I-INTV
after IN O
conservative JJ B-POPU
surgery NN I-POPU
for IN I-POPU
early-stage JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

BACKGROUND NNP O
Patients NNPS B-POPU
with IN I-POPU
early-stage JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
who WP I-POPU
are VBP I-POPU
at IN I-POPU
substantial JJ I-POPU
risk NN I-POPU
for IN I-POPU
systemic JJ I-POPU
metastases NNS I-POPU
are VBP O
increasingly RB O
treated VBN O
with IN O
breast-conserving JJ B-INTV
therapy NN I-INTV
and CC I-INTV
adjuvant JJ I-INTV
chemotherapy NN I-INTV
. . O

However RB O
, , O
the DT O
optimal JJ O
sequencing NN O
of IN O
chemotherapy NN B-INTV
and CC I-INTV
radiation NN I-INTV
therapy NN I-INTV
is VBZ O
not RB O
clear JJ O
. . O

METHODS NNP O
Two CD B-POPU
hundred VBD I-POPU
forty-four JJ I-POPU
patients NNS I-POPU
with IN I-POPU
stage NN I-POPU
I PRP I-POPU
or CC I-POPU
II NNP I-POPU
breast NN I-POPU
cancer NN I-POPU
who WP I-POPU
were VBD I-POPU
at IN I-POPU
substantial JJ I-POPU
risk NN I-POPU
for IN I-POPU
distant JJ I-POPU
metastases NNS I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
a DT O
12-week JJ B-INTV
course NN I-INTV
of IN I-INTV
chemotherapy NN I-INTV
either CC I-INTV
before IN I-INTV
or CC I-INTV
after IN I-INTV
radiation NN I-INTV
therapy NN I-INTV
. . O

All DT B-POPU
had VBD I-POPU
had VBN I-POPU
breast-conserving JJ I-POPU
surgery NN I-POPU
. . O

The DT O
median JJ O
length NN O
of IN O
follow-up NN O
in IN O
surviving VBG O
patients NNS O
was VBD O
58 CD O
months NNS O
( ( O
range NN O
, , O
10 CD O
to TO O
124 CD O
) ) O
. . O

RESULTS VB O
The DT O
five-year JJ B-OC
actuarial JJ I-OC
rates NNS I-OC
of IN I-OC
cancer NN I-OC
recurrence NN I-OC
at IN O
any DT O
site NN O
and CC O
of IN O
distant JJ O
metastases NNS O
in IN O
the DT O
radiotherapy-first JJ B-INTV
group NN O
and CC O
the DT O
chemotherapy-first JJ B-INTV
group NN O
were VBD O
38 CD O
percent NN O
and CC O
31 CD O
percent NN O
( ( O
P NNP O
= NNP O
0.17 CD O
) ) O
and CC O
36 CD O
percent NN O
and CC O
25 CD O
percent NN O
( ( O
P NNP O
= NNP O
0.05 CD O
) ) O
, , O
respectively RB O
. . O

Overall JJ B-OC
survival NN I-OC
was VBD O
73 CD O
percent NN O
and CC O
81 CD O
percent NN O
( ( O
P NNP O
= NNP O
0.11 CD O
) ) O
, , O
respectively RB O
. . O

The DT O
five-year JJ B-OC
crude NN I-OC
rates NNS I-OC
of IN I-OC
first JJ I-OC
recurrence NN I-OC
according VBG O
to TO O
site NN O
in IN O
the DT O
radiotherapy-first JJ B-INTV
and CC I-INTV
chemotherapy-first JJ I-INTV
groups NNS O
, , O
respectively RB O
, , O
were VBD O
5 CD O
percent NN O
and CC O
14 CD O
percent NN O
for IN O
local JJ O
recurrence NN O
and CC O
32 CD O
percent NN O
and CC O
20 CD O
percent NN O
for IN O
distant NN O
or CC O
regional JJ O
recurrence NN O
or CC O
both DT O
. . O

This DT O
difference NN O
in IN O
the DT O
pattern NN B-OC
of IN I-OC
recurrence NN I-OC
was VBD O
of IN O
borderline JJ O
statistical JJ O
significance NN O
( ( O
P NNP O
= NNP O
0.07 CD O
) ) O
. . O

CONCLUSIONS VB O
This DT O
study NN O
suggests VBZ O
that IN O
for IN O
patients NNS B-POPU
ar VBP I-POPU
substantial JJ I-POPU
risk NN I-POPU
for IN I-POPU
systemic JJ I-POPU
metastases NNS I-POPU
, , O
it PRP O
is VBZ O
preferable JJ O
to TO O
give VB O
a DT O
12-week JJ O
course NN O
of IN O
chemotherapy NN B-INTV
followed VBN O
by IN O
radiation NN B-INTV
therapy NN I-INTV
, , O
rather RB O
than IN O
radiation NN B-INTV
therapy NN I-INTV
followed VBN I-INTV
by IN I-INTV
chemotherapy NN I-INTV
. . O

-DOCSTART- -X- O O

Fadrozole NNP B-INTV
HCL NNP I-INTV
( ( I-INTV
CGS-16949A NNP I-INTV
) ) I-INTV
versus NN O
megestrol NN B-INTV
acetate VBP I-INTV
treatment NN O
of IN O
postmenopausal NN B-POPU
patients NNS I-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
carcinoma NN I-POPU
: : I-POPU
results NNS O
of IN O
two CD O
randomized JJ O
double JJ O
blind NN O
controlled VBD O
multiinstitutional JJ O
trials NNS O
. . O

BACKGROUND NNP O
Breast NNP B-POPU
cancer NN I-POPU
patients NNS I-POPU
with IN I-POPU
prior JJ I-POPU
response NN I-POPU
to TO I-POPU
endocrine VB I-POPU
therapy NN I-POPU
achieve VB O
subsequent JJ O
benefit NN O
from IN O
additional JJ O
endocrine NN O
therapies NNS O
. . O

The DT O
efficacy NN O
and CC O
safety NN O
of IN O
an DT O
aromatase NN O
inhibitor NN O
, , O
fadrozole JJ B-INTV
HCL NNP I-INTV
, , O
were VBD O
compared VBN O
with IN O
megestrol NN O
acetate NN O
in IN O
post NN B-POPU
menopausal NN I-POPU
patients NNS I-POPU
who WP I-POPU
had VBD I-POPU
disease NN I-POPU
progression NN I-POPU
after IN I-POPU
receiving VBG I-POPU
antiestrogen NN I-POPU
therapy NN I-POPU
either DT I-POPU
for IN I-POPU
metastatic JJ I-POPU
disease NN I-POPU
or CC I-POPU
as IN I-POPU
adjuvant JJ I-POPU
therapy NN I-POPU
. . O

METHODS NNP O
In IN B-POPU
2 CD I-POPU
multiinstitutional JJ I-POPU
prospective JJ I-POPU
trials NNS I-POPU
, , I-POPU
683 CD I-POPU
postmenopausal NN I-POPU
patients NNS I-POPU
were VBD O
randomized VBN B-INTV
to TO I-INTV
receive VB I-INTV
either DT I-INTV
fadrozole JJ I-INTV
HCL NNP I-INTV
, , I-INTV
1 CD I-INTV
mg NN I-INTV
twice RB I-INTV
daily RB I-INTV
, , I-INTV
or CC I-INTV
megestrol NN I-INTV
acetate NN I-INTV
, , I-INTV
40 CD I-INTV
mg NN I-INTV
4 CD I-INTV
times NNS I-INTV
daily RB I-INTV
, , I-INTV
in IN I-INTV
a DT I-INTV
double JJ I-INTV
blind NN I-INTV
fashion NN I-INTV
after IN I-INTV
progression NN I-INTV
on IN I-INTV
first-line JJ I-INTV
hormonal JJ I-INTV
therapy NN I-INTV
. . O

Objective JJ B-OC
response NN I-OC
rates NNS I-OC
, , I-OC
time NN I-OC
to TO I-OC
progression NN I-OC
, , I-OC
survival NN I-OC
and CC I-OC
safety NN I-OC
of IN O
the DT O
two CD O
regimens NNS O
were VBD O
compared VBN O
. . O

RESULTS NNP O
Results NNP O
of IN O
intent-to-treat JJ O
analyses NNS O
are VBP O
presented VBN O
in IN O
this DT O
study NN O
. . O

No DT O
significant JJ O
differences NNS O
were VBD O
detected VBN O
between IN O
the DT O
two CD O
treatment NN O
groups NNS O
in IN O
time NN B-OC
to TO I-OC
progression NN I-OC
, , I-OC
objective JJ I-OC
response NN I-OC
rates NNS I-OC
, , I-OC
duration NN I-OC
of IN I-OC
response NN I-OC
, , I-OC
and CC I-OC
survival NN I-OC
in IN O
either DT O
trial NN O
. . O

There EX O
were VBD O
no DT O
clinically RB O
meaningful JJ O
differences NNS O
between IN O
the DT O
treatment NN O
groups NNS O
in IN O
the DT O
incidence NN O
and CC O
severity NN O
of IN O
adverse JJ B-OC
experiences NNS I-OC
, , O
except IN O
that DT O
weight NN B-OC
gain NN I-OC
, , I-OC
fluid JJ I-OC
retention NN I-OC
, , I-OC
and CC I-OC
dyspnea NN I-OC
were VBD O
observed VBN O
in IN O
more JJR O
patients NNS O
in IN O
the DT O
megestrol NN O
acetate NN O
group NN O
compared VBN O
with IN O
those DT O
receiving VBG O
fadrozole JJ O
HCL NNP O
, , O
whereas JJ O
nausea NN B-OC
and CC I-OC
vomiting NN I-OC
were VBD O
observed VBN O
in IN O
more JJR O
patients NNS O
in IN O
the DT O
fadrozole JJ O
HCL NNP O
group NN O
compared VBN O
with IN O
those DT O
receiving VBG O
megestrol NN O
acetate NN O
. . O

CONCLUSIONS NNP O
Fadrozole NNP B-INTV
HCL NNP I-INTV
was VBD O
as RB O
efficacious JJ B-OC
as IN O
megestrol NN O
acetate NN O
in IN O
postmenopausal NN B-POPU
patients NNS I-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
carcinoma NN I-POPU
after IN O
one CD O
hormonal JJ O
therapy NN O
. . O

Adverse JJ O
experiences NNS O
were VBD O
mild JJ O
with IN O
both DT O
therapies NNS O
, , O
but CC O
megestrol NN O
acetate NN O
was VBD O
associated VBN O
wiht PDT O
a DT O
higher JJR O
frequency NN O
of IN O
weight NN B-OC
gain NN I-OC
, , I-OC
fluid JJ I-OC
retention NN I-OC
and CC I-OC
dyspnea NN I-OC
, , O
whereas JJ O
fadrozole NN B-INTV
HCL NNP I-INTV
was VBD O
associated VBN O
with IN O
a DT O
higher JJR O
frequency NN O
of IN O
nausea NN B-OC
and CC I-OC
vomiting NN I-OC
. . O

-DOCSTART- -X- O O

[ JJ O
Effectiveness NNP O
of IN O
adjuvant JJ B-INTV
hormone NN I-INTV
therapy NN I-INTV
in IN O
breast NN O
cancer NN O
] NNP O
. . O

A NNP O
third JJ O
series NN O
of IN O
randomized JJ O
tests NNS O
was VBD O
undertaken VBN O
to TO O
evaluate VB B-OC
the DT O
efficacy NN B-OC
of IN O
postoperative JJ O
adjuvant JJ B-INTV
hormone NN I-INTV
therapy NN I-INTV
( ( I-INTV
tamoxifen NN I-INTV
, , I-INTV
diethylstilbestrol NN I-INTV
, , I-INTV
orimethen VBP I-INTV
amino JJ I-INTV
glutethymide NN I-INTV
) ) I-INTV
in IN O
breast NN B-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

Tamoxifen NNP B-INTV
was VBD O
studied VBN O
in IN O
176 CD B-POPU
patients NNS I-POPU
with IN I-POPU
T1-2N0M0 NNP I-POPU
tumors NNS I-POPU
. . O

Five-year JJ B-OC
recurrence-free JJ I-OC
survival NN I-OC
was VBD O
registered VBN O
in IN O
85.2 CD O
% NN O
of IN O
menopausal NN O
patients NNS O
treated VBN O
with IN O
tamoxifen JJ B-INTV
versus NN O
71.1 CD O
% NN O
in IN O
control NN O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

Five-year JJ B-OC
recurrence-free JJ I-OC
survival NN I-OC
in IN O
menopausal NN O
females NNS O
with IN O
breast NN O
tumors NNS O
, , O
stage NN O
IIb NNP O
, , O
was VBD O
71.1 CD O
% NN O
among IN O
those DT O
treated VBN O
with IN O
diethylstilbestrol NN O
and CC O
as RB O
low JJ O
as IN O
57.4 CD O
% NN O
in IN O
the DT O
tamoxifen NN B-INTV
group NN O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

Untoward NNP B-OC
side-effect JJ I-OC
incidence NN I-OC
was VBD O
much JJ B-OC
higher JJR I-OC
in IN O
the DT O
diethylstilbestrol NN O
group NN O
( ( O
30.4 CD O
% NN O
) ) O
as IN O
compared VBN O
with IN O
tamoxifen NN B-INTV
( ( O
3.5 CD O
% NN O
) ) O
. . O

No DT O
significant JJ O
difference NN O
was VBD O
found VBN O
for IN O
the DT O
relationship NN O
between IN O
orimethen NN B-INTV
and CC O
tamoxifen JJ B-INTV
treatment NN O
with IN O
respect NN O
to TO O
5-year JJ B-OC
survival NN I-OC
and CC I-OC
recurrence-free JJ I-OC
survival NN I-OC
. . O

-DOCSTART- -X- O O

Randomized VBN O
trial NN O
comparing VBG O
induction NN B-INTV
chemotherapy NN I-INTV
versus NN O
induction NN B-INTV
chemotherapy NN I-INTV
followed VBN I-INTV
by IN I-INTV
maintenance NN I-INTV
chemotherapy NN I-INTV
in IN O
small-cell JJ B-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

European JJ O
Lung NNP O
Cancer NNP O
Working NNP O
Party NNP O
. . O

PURPOSE NNP O
AND CC O
METHODS NNP O
The DT O
European NNP O
Lung NNP O
Cancer NNP O
Working NNP O
Party NNP O
( ( O
ELCWP NNP O
) ) O
performed VBD O
a DT O
randomized JJ O
trial NN O
with IN O
the DT O
primary JJ O
end NN O
point NN O
to TO O
determine VB O
if IN O
maintenance NN O
chemotherapy NN O
with IN O
12 CD O
courses NNS O
of IN O
etoposide NN B-INTV
( ( O
120 CD O
mg/m2 NN O
on IN O
days NNS O
1 CD O
and CC O
3 CD O
) ) O
and CC O
vindesine NN B-INTV
( ( O
3 CD O
mg/m2 NN O
on IN O
day NN O
3 CD O
) ) O
could MD O
improve VB O
progression-free JJ B-OC
survival NN I-OC
in IN O
small-cell JJ B-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
SCLC NNP I-POPU
) ) I-POPU
patients NNS I-POPU
who WP I-POPU
responded VBD I-POPU
to TO I-POPU
six CD I-POPU
courses NNS I-POPU
of IN I-POPU
induction NN I-POPU
chemotherapy NN I-POPU
with IN I-POPU
ifosfamide NN I-POPU
, , I-POPU
etoposide RB I-POPU
, , I-POPU
and CC I-POPU
an DT I-POPU
anthracycline NN I-POPU
( ( I-POPU
doxorubicin NN I-POPU
or CC I-POPU
epirubicin NN I-POPU
) ) I-POPU
. . O

RESULTS NNP O
Among IN B-POPU
235 CD I-POPU
eligible JJ I-POPU
patients NNS I-POPU
initially RB I-POPU
registered VBD I-POPU
, , I-POPU
91 CD I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
receive VB I-POPU
maintenance NN I-POPU
therapy NN I-POPU
, , I-POPU
including VBG I-POPU
seven CD I-POPU
patients NNS I-POPU
who WP I-POPU
were VBD I-POPU
no RB I-POPU
longer RBR I-POPU
responding VBG I-POPU
. . O

Among IN O
84 CD O
randomized JJ O
responders NNS O
, , O
progression-free JJ B-OC
survival NN I-OC
was VBD O
significantly RB O
improved VBN O
( ( O
P NNP O
= NNP O
.003 NNP O
) ) O
by IN O
maintenance NN O
therapy NN O
, , O
with IN O
median JJ O
durations NNS O
( ( O
maintenance NN O
v IN O
follow-up JJ O
) ) O
of IN O
25 CD O
versus NNS O
12 CD O
weeks NNS O
after IN O
the DT O
second JJ O
randomization NN O
, , O
but CC O
survival NN B-OC
was VBD O
not RB O
significantly RB O
increased VBN O
( ( O
P NNP O
= NNP O
.10 NNP O
) ) O
, , O
with IN O
median JJ O
durations NNS O
of IN O
48 CD O
and CC O
38 CD O
weeks NNS O
. . O

However RB O
, , O
in IN O
a DT O
multi-variate JJ O
analysis NN O
that WDT O
took VBD O
into IN O
account NN B-OC
disease NN I-OC
extent NN I-OC
, , I-OC
maintenance NN I-OC
therapy NN I-OC
, , I-OC
Karnofsky NNP I-OC
performance NN I-OC
status NN I-OC
( ( I-OC
PS NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
absolute JJ I-OC
dose-intensity NN I-OC
( ( I-OC
ADI NNP I-OC
) ) I-OC
of IN I-OC
anthracycline NN I-OC
given VBN O
during IN O
induction NN O
, , O
limited JJ B-OC
disease NN I-OC
( ( I-OC
LD NNP I-OC
) ) I-OC
and CC I-OC
maintenance NN I-OC
were VBD O
found VBN O
to TO O
be VB O
independent JJ O
positive JJ O
predictors NNS O
of IN O
survival NN B-OC
. . O

CONCLUSION NNP O
We PRP O
conclude VBP O
that DT O
maintenance NN O
chemotherapy NN O
in IN O
responding VBG O
patients NNS O
is VBZ O
beneficial JJ O
in IN O
SCLC NNP O
. . O

-DOCSTART- -X- O O

[ JJ O
Clinical NNP O
early JJ O
phase NN O
II NNP O
study NN O
of IN O
bicalutamide NN B-INTV
( ( I-INTV
Casodex NNP I-INTV
) ) I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
prostatic JJ I-POPU
cancer NN I-POPU
] NN I-POPU
. . O

To TO O
investigate VB O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
bicalutamide NN B-INTV
( ( O
Casodex NNP O
) ) O
with IN O
its PRP$ O
clinically NN O
recommended VBD O
dose NN O
, , O
the DT O
randomized VBN O
early JJ O
phase NN O
II NNP O
study NN O
was VBD O
performed VBN O
in IN O
124 CD B-POPU
patients NNS I-POPU
with IN I-POPU
prostatic JJ I-POPU
cancer NN I-POPU
( ( I-POPU
stage NN I-POPU
C NNP I-POPU
, , I-POPU
D NNP I-POPU
) ) I-POPU
. . O

The DT O
patients NNS O
were VBD O
given VBN O
50 CD B-INTV
, , I-INTV
80 CD I-INTV
or CC I-INTV
100 CD I-INTV
mg NN I-INTV
of IN I-INTV
bicalutamide NN I-INTV
orally RB O
once RB O
a DT O
day NN O
in IN O
fixed JJ O
doses NNS O
for IN O
12 CD O
weeks NNS O
; : O
122 CD O
patients NNS O
were VBD O
eligible JJ O
for IN O
evaluation NN O
. . O

The DT O
overall JJ B-OC
response NN I-OC
rate NN I-OC
was VBD O
50.0 CD O
% NN O
( ( O
20/40 CD O
) ) O
, , O
61.0 CD O
% NN O
( ( O
25/41 CD O
) ) O
and CC O
53.7 CD O
% NN O
( ( O
22/41 CD O
) ) O
in IN O
the DT O
50 CD O
mg NN O
, , O
80 CD O
mg NN O
and CC O
100 CD O
mg NN O
groups NNS O
, , O
respectively RB O
. . O

The DT O
response NN B-OC
rate NN I-OC
in IN I-OC
prostate NN I-OC
lesion NN I-OC
, , I-OC
bone NN I-OC
and CC I-OC
lymph NN I-OC
node NN I-OC
metastases NNS I-OC
was VBD O
slightly RB O
higher JJR O
in IN O
the DT O
80 CD O
mg NN O
group NN O
than IN O
in IN O
the DT O
50 CD O
mg NN O
and CC O
100 CD O
mg NN O
groups NNS O
. . O

The DT O
proportion NN B-OC
of IN I-OC
patients NNS I-OC
showing VBG I-OC
a DT I-OC
response NN I-OC
with IN I-OC
regard NN I-OC
to TO I-OC
serum VB I-OC
PSA NNP I-OC
( ( I-OC
CR NNP I-OC
and CC I-OC
PR NNP I-OC
) ) I-OC
was VBD O
84.2 CD O
, , O
92.7 CD O
and CC O
97.6 CD O
% NN O
in IN O
the DT O
50 CD O
, , O
80 CD O
and CC O
100 CD O
mg NN O
groups NNS O
, , O
respectively RB O
. . O

The DT O
incidence NN B-OC
of IN I-OC
adverse JJ I-OC
reactions NNS I-OC
was VBD O
65.0 CD O
, , O
61.0 CD O
and CC O
61.0 CD O
% NN O
in IN O
the DT O
50 CD O
, , O
80 CD O
and CC O
100 CD O
mg NN O
groups NNS O
, , O
respectively RB O
, , O
and CC O
there EX O
was VBD O
no DT B-OC
significant JJ I-OC
difference NN I-OC
in IN O
overall JJ B-OC
safety NN I-OC
rating NN I-OC
in IN O
the DT O
three CD O
groups NNS O
. . O

Frequent JJ B-OC
adverse JJ I-OC
reactions NNS I-OC
were VBD O
gynecomastia JJ B-OC
and CC I-OC
breast NN I-OC
pain NN I-OC
. . O

Only RB O
one CD O
patient NN O
in IN O
the DT O
80 CD O
mg NN O
group NN O
was VBD O
withdrawn VBN B-OC
due JJ I-OC
to TO I-OC
shortness VB I-OC
of IN I-OC
breath NN I-OC
. . O

Serum NNP B-OC
concentrations NNS I-OC
of IN I-OC
LH NNP I-OC
, , I-OC
testosterone NN I-OC
and CC I-OC
estradiol NN I-OC
increased VBD I-OC
significantly RB I-OC
after IN O
treatment NN O
. . O

Bicalutamide NNP B-INTV
was VBD O
concluded VBN O
to TO O
be VB O
effective JJ O
and CC O
well RB O
tolerated VBN O
in IN O
patients NNS B-POPU
with IN I-POPU
prostatic JJ I-POPU
cancer NN I-POPU
, , O
and CC O
its PRP$ O
recommended VBD O
dose NN O
was VBD O
80 CD O
mg NN O
once RB O
daily RB O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
analgesic JJ O
effect NN O
of IN O
locally RB O
and CC O
systemically RB O
administered VBN O
ketorolac NN B-INTV
in IN O
mastectomy JJ B-POPU
patients NNS I-POPU
. . O

BACKGROUND NNP O
Ketorolac NNP B-INTV
is VBZ O
a DT O
parenteral JJ O
nonsteroidal JJ O
antiinflammatory JJ O
drug NN O
( ( O
NSAID NNP O
) ) O
. . O

Two CD O
features NNS O
have VBP O
limited VBN O
its PRP$ O
clinical JJ O
utility NN O
: : O
tendency NN O
to TO O
elicit VB O
kidney NN O
failure NN O
and CC O
inability NN O
to TO O
produce VB O
complete JJ O
analgesia NN O
. . O

Because IN O
most JJS O
NSAIDs NNP B-INTV
are VBP O
weak JJ O
acids NNS O
( ( O
pKa IN O
3-5 NNP O
) ) O
and CC O
become VBN O
concentrated JJ O
in IN O
acidic JJ O
tissues NNS O
, , O
such JJ O
as IN O
injured JJ O
and CC O
inflamed JJ O
tissues NNS O
, , O
we PRP O
hypothesized VBD O
that IN O
local JJ O
administration NN O
may MD O
enhance VB O
its PRP$ O
analgesic JJ O
efficacy NN O
while IN O
lowering VBG O
the DT O
potential NN O
for IN O
systemic JJ O
complications NNS O
. . O

METHODS NNP O
We PRP O
conducted VBD O
a DT O
randomized VBN O
, , O
placebo-controlled JJ B-INTV
study NN O
of IN O
60 CD B-POPU
group NN I-POPU
I-II NNP I-POPU
( ( I-POPU
American JJ I-POPU
Society NNP I-POPU
of IN I-POPU
Anesthesiology NNP I-POPU
criteria NNS I-POPU
) ) I-POPU
mastectomy NN I-POPU
patients NNS I-POPU
, , I-POPU
20 CD I-POPU
in IN I-POPU
each DT I-POPU
group NN I-POPU
. . O

Near IN O
the DT O
end NN O
of IN O
surgery NN O
and CC O
every DT O
6 CD O
h NN O
postoperatively RB O
, , O
20 CD O
ml NN O
of IN O
the DT O
study NN O
solution NN O
containing VBG O
normal JJ B-INTV
saline NN I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
30 CD I-INTV
mg NN I-INTV
of IN I-INTV
ketorolac NN I-INTV
were VBD O
administered VBN O
simultaneously RB O
either CC O
via IN O
a DT O
Jackson-Pratt JJ O
drain NN O
or CC O
intravenously RB O
in IN O
a DT O
double-blind JJ O
fashion NN O
. . O

The DT O
quality NN B-OC
of IN I-OC
pain NN I-OC
control NN I-OC
, , I-OC
the DT I-OC
amount NN I-OC
and CC I-OC
character NN I-OC
of IN I-OC
the DT I-OC
drain NN I-OC
fluid NN I-OC
, , I-OC
incidence NN I-OC
of IN I-OC
nausea NN I-OC
and CC I-OC
vomiting NN I-OC
, , I-OC
length NN I-OC
of IN I-OC
stay NN I-OC
in IN I-OC
the DT I-OC
postoperative JJ I-OC
care NN I-OC
unit NN I-OC
, , I-OC
and CC I-OC
amount NN I-OC
of IN I-OC
morphine NN I-OC
used VBN O
for IN O
treatment NN O
of IN O
break-through JJ O
pain NN O
were VBD O
recorded VBN O
. . O

RESULTS NNP O
Intraoperative NNP O
administration NN O
of IN O
ketorolac NN B-INTV
resulted VBD O
in IN O
better JJR O
quality NN B-OC
of IN I-OC
pain NN I-OC
control NN I-OC
in IN O
the DT O
immediate JJ O
postoperative JJ O
period NN O
regardless NN O
of IN O
route NN O
of IN O
administration NN O
. . O

The DT O
incidence NN B-OC
of IN I-OC
nausea NN I-OC
was VBD O
significantly RB O
higher JJR O
in IN O
the DT O
placebo NN O
group NN O
, , O
and CC O
drain NN B-OC
output NN I-OC
in IN O
the DT O
ketorolac NN B-INTV
groups NNS O
did VBD O
not RB O
exceed VB O
the DT O
output NN O
in IN O
the DT O
placebo NN B-INTV
group NN O
. . O

CONCLUSION NNP O
Analgesic NNP O
of IN O
the DT O
locally RB O
administered VBN O
ketorolac NN B-INTV
is VBZ O
equally RB O
effective JJ B-OC
to TO O
the DT O
efficacy NN B-OC
of IN O
ketorolac NN B-INTV
administered VBN O
intravenously RB O
. . O

-DOCSTART- -X- O O

Levels NNS O
of IN O
recombinant JJ B-INTV
human JJ I-INTV
granulocyte NN I-INTV
colony-stimulating NN I-INTV
factor NN I-INTV
in IN O
serum NN O
are VBP O
inversely RB O
correlated VBN O
with IN O
circulating VBG O
neutrophil JJ O
counts NNS O
. . O

Recombinant NNP B-INTV
human JJ I-INTV
granulocyte NN I-INTV
colony-stimulating NN I-INTV
factor NN I-INTV
( ( I-INTV
rhG-CSF NN I-INTV
) ) I-INTV
is VBZ O
effective JJ O
in IN O
countering VBG O
chemotherapy-induced JJ O
neutropenia NN O
. . O

However RB O
, , O
serum JJ B-OC
rhG-CSF NN B-INTV
levels NNS B-OC
can MD O
not RB O
be VB O
maintained VBN O
throughout IN O
the DT O
course NN O
of IN O
rhG-CSF JJ B-INTV
therapy NN I-INTV
. . O

The DT O
drop NN O
in IN O
serum JJ B-OC
rhG-CSF JJ B-INTV
levels NNS B-OC
may MD O
vary VB O
with IN O
the DT O
duration NN O
of IN O
rhG-CSF JJ B-INTV
administration NN O
or CC O
with IN O
the DT O
circulating VBG O
neutrophil JJ O
counts NNS O
. . O

We PRP O
investigated VBD O
the DT O
relationship NN O
between IN O
serum JJ B-OC
G-CSF NNP I-OC
levels NNS I-OC
and CC O
circulating VBG B-OC
neutrophil JJ I-OC
counts NNS I-OC
and CC O
the DT O
pharmacokinetics NNS O
of IN O
rhG-CSF NN O
for IN O
patients NNS B-POPU
with IN I-POPU
lung NN I-POPU
cancer NN I-POPU
who WP I-POPU
had VBD I-POPU
been VBN I-POPU
treated VBN I-POPU
with IN I-POPU
myelosuppressive JJ I-POPU
chemotherapy NN I-POPU
and CC I-POPU
then RB I-POPU
with IN I-POPU
subcutaneous JJ I-POPU
rhG-CSF NN I-POPU
( ( I-POPU
lenograstim NN I-POPU
, , I-POPU
2 CD I-POPU
micrograms NNS I-POPU
per IN I-POPU
kg NN I-POPU
of IN I-POPU
body NN I-POPU
weight JJ I-POPU
per IN I-POPU
day NN I-POPU
) ) I-POPU
. . O

Twelve CD B-POPU
patients NNS I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO O
four CD O
groups NNS O
with IN O
different JJ O
rhG-CSF JJ B-INTV
therapy NN I-INTV
schedules NNS I-INTV
. . O

Serum NNP B-OC
G-CSF JJ I-OC
levels NNS I-OC
were VBD O
measured VBN O
by IN O
an DT O
enzyme JJ O
immunoassay NN O
method NN O
. . O

Serum NNP B-OC
G-CSF NNP I-OC
levels NNS I-OC
during IN O
the DT O
rhG-CSF JJ B-INTV
therapy NN I-INTV
greatly RB O
exceeded VBD O
endogenous JJ B-OC
G-CSF NNP I-OC
levels NNS I-OC
and CC O
were VBD O
mainly RB O
due JJ O
to TO O
the DT O
presence NN O
of IN O
exogenous JJ O
rhG-CSF NN B-INTV
rather RB O
than IN O
increased VBN O
levels NNS O
of IN O
endogenous JJ O
G-CSF NNP O
. . O

Despite IN O
the DT O
duration NN O
of IN O
rhG-CSF JJ B-INTV
administration NN O
, , O
serum JJ B-OC
G-CSF NNP I-OC
levels NNS I-OC
during IN O
rhG-CSF JJ B-INTV
therapy NN I-INTV
were VBD O
inversely RB O
correlated VBN O
with IN O
circulating VBG O
neutrophil JJ O
counts NNS O
( ( O
r2 VB O
= RB O
0.73 CD O
, , O
P NNP O
< NNP O
0.0001 CD O
) ) O
. . O

The DT O
value NN O
for IN O
the DT O
area NN O
under IN O
the DT O
concentration-time JJ B-OC
curve NN I-OC
of IN O
rhG-CSF NN B-INTV
on IN O
the DT O
day NN O
of IN O
neutrophilia NN O
was VBD O
lower JJR O
than IN O
that DT O
on IN O
the DT O
day NN O
of IN O
neutropenia NN O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

Our PRP$ O
results NNS O
suggest VBP O
that IN O
the DT O
fall NN O
in IN O
serum JJ B-OC
G-CSF NNP I-OC
levels NNS I-OC
during IN O
rhG-CSF JJ B-INTV
therapy NN I-INTV
may MD O
result VB O
from IN O
increased VBN O
clearance NN O
and/or NN O
decreased VBD O
absorption NN O
of IN O
rhG-CSF NN B-INTV
, , O
two CD O
processes NNS O
related VBN O
to TO O
circulating VBG O
neutrophil JJ O
counts NNS O
. . O

-DOCSTART- -X- O O

The DT O
impact NN O
of IN O
a DT O
psychological JJ B-INTV
intervention NN I-INTV
on IN O
quality NN B-OC
of IN I-OC
life NN I-OC
in IN O
non-metastatic JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
whether IN O
psychological JJ B-INTV
intervention NN I-INTV
had VBD O
a DT O
beneficial JJ O
effect NN O
on IN O
the DT O
quality NN B-OC
of IN I-OC
life NN I-OC
and CC I-OC
behaviour NN I-OC
of IN O
women NNS B-POPU
diagnosed VBN I-POPU
with IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

36 CD B-POPU
consecutive JJ I-POPU
patients NNS I-POPU
with IN I-POPU
non-metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
assigned VBD I-POPU
to TO I-POPU
surgery VB I-POPU
and CC I-POPU
systemic VB I-POPU
chemotherapy NN I-POPU
were VBD O
randomised VBN O
to TO O
receive VB O
either DT O
psychological JJ B-INTV
intervention NN I-INTV
( ( I-INTV
weekly JJ I-INTV
cognitive VBP I-INTV
individual JJ I-INTV
psychotherapy NN I-INTV
and CC I-INTV
bimonthly JJ I-INTV
family NN I-INTV
counselling VBG I-INTV
) ) I-INTV
or CC O
standard JJ B-INTV
follow-up NN I-INTV
. . O

Personality NNP B-OC
( ( I-OC
16-PF JJ I-OC
and CC I-OC
IIQ NNP I-OC
) ) I-OC
, , I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
( ( I-OC
FLIC NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
depression NN I-OC
( ( I-OC
BDI NNP I-OC
) ) I-OC
scores NNS I-OC
were VBD O
the DT O
endpoints NNS O
for IN O
this DT O
study NN O
, , O
and CC O
the DT O
questionnaires NNS O
were VBD O
completed VBN O
by IN O
the DT O
patients NNS O
at IN O
diagnosis NN O
, , O
and CC O
up RB O
to TO O
9 CD O
months NNS O
after IN O
diagnosis NN O
. . O

Cognitive JJ O
psychotherapy NN O
and CC O
family NN O
counselling NN O
improved VBD O
both DT O
depression NN B-OC
and CC I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
indexes NNS I-OC
compared VBN O
with IN O
the DT O
control NN O
group NN O
. . O

Better NNP O
emotional JJ B-OC
coping NN I-OC
behaviours NNS I-OC
were VBD O
also RB O
revealed VBN O
by IN O
some DT O
changes NNS O
in IN O
personality NN O
traits NNS O
in IN O
the DT O
intervention NN O
group NN O
. . O

-DOCSTART- -X- O O

The DT O
management NN O
of IN O
dermoid JJ B-POPU
cysts NNS I-POPU
-- : I-POPU
a DT I-POPU
comparative JJ O
study NN O
of IN O
laparoscopy NN B-INTV
and CC O
laparotomy NN B-INTV
. . O

The DT O
aim NN O
of IN O
our PRP$ O
study NN O
was VBD O
to TO O
compare VB O
laparoscopy NN B-INTV
with IN O
laparotomy NN B-INTV
for IN O
the DT O
removal NN O
of IN O
ovarian JJ B-POPU
dermoid NN I-POPU
cysts NNS I-POPU
. . O

Thirty-eight JJ B-POPU
women NNS I-POPU
with IN I-POPU
benign JJ I-POPU
ovarian JJ I-POPU
dermoid NN I-POPU
cyst NN I-POPU
were VBD O
allocated VBN O
for IN O
either DT O
laparoscopy NN B-INTV
( ( O
18 CD O
patients NNS O
) ) O
or CC O
laparotomy NN B-INTV
( ( O
20 CD O
patients NNS O
) ) O
. . O

The DT O
two CD O
groups NNS O
were VBD O
compared VBN O
for IN O
operative JJ O
and CC O
hospitalization NN O
times NNS O
and CC O
postoperative JJ O
course NN O
. . O

Operating NN B-OC
time NN I-OC
was VBD O
longer RB O
( ( O
93.6 CD O
+/- JJ O
23.8 CD O
min NN O
) ) O
and CC O
hospitalization NN B-OC
time NN I-OC
significantly RB O
shorter JJR O
( ( O
22.4 CD O
+/- JJ O
6.6 CD O
h NN O
) ) O
in IN O
the DT O
laparoscopy NN O
group NN O
. . O

No DT O
complications NNS B-OC
were VBD O
reported VBN O
in IN O
either DT O
group NN O
. . O

We PRP O
conclude VBP O
that IN O
operative JJ B-INTV
laparoscopy NN I-INTV
is VBZ O
a DT O
safe JJ B-OC
procedure NN O
for IN O
the DT O
removal NN O
of IN O
dermoid JJ B-POPU
ovarian JJ I-POPU
cysts NNS I-POPU
and CC O
is VBZ O
as RB O
effective JJ B-OC
as IN O
laparotomy NN B-INTV
. . O

-DOCSTART- -X- O O

Outcome NNP B-POPU
assessment NN I-POPU
for IN I-POPU
clinical JJ I-POPU
trials NNS I-POPU
: : I-POPU
how WRB O
many JJ O
adjudicators NNS B-POPU
do VBP O
we PRP O
need VB O
? . O
Canadian JJ O
Lung NNP O
Oncology NNP O
Group NNP O
. . O

Considerable JJ O
effort NN O
is VBZ O
often RB O
expended VBN O
to TO O
adjudicate VB O
outcomes NNS O
in IN O
clinical JJ O
trials NNS O
, , O
but CC O
little JJ O
has VBZ O
been VBN O
written VBN O
on IN O
the DT O
administration NN O
of IN O
the DT O
adjudication NN O
process NN O
and CC O
its PRP$ O
possible JJ O
impact NN O
on IN O
study NN O
results NNS O
. . O

As IN O
a DT O
case NN O
study NN O
, , O
we PRP O
describe VBP O
the DT O
function NN B-OC
and CC I-OC
performance NN I-OC
of IN I-OC
an DT I-OC
adjudication NN B-POPU
committee NN I-POPU
in IN I-POPU
a DT I-POPU
large JJ I-POPU
randomized JJ I-POPU
trial NN I-POPU
of IN O
two CD O
diagnostic JJ O
approaches NNS O
to TO O
potentially RB B-POPU
operable JJ I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

Up IN B-POPU
to TO I-POPU
five CD I-POPU
independent JJ I-POPU
adjudicators NNS I-POPU
independently RB O
determined VBD O
two CD O
primary JJ O
outcomes NNS O
: : O
tumor NN B-OC
status NN I-OC
at IN I-OC
death NN I-OC
or CC I-OC
at IN I-OC
final JJ I-OC
follow-up NN I-OC
and CC I-OC
the DT I-OC
cause NN I-OC
of IN I-OC
death NN I-OC
. . O

Patients NNS B-POPU
for IN O
whom WP O
there EX O
was VBD O
any DT O
disagreement NN O
were VBD O
discussed VBN O
in IN O
committee NN O
until IN O
a DT O
consensus NN O
was VBD O
achieved VBN O
. . O

We PRP O
describe VBP O
the DT O
pattern NN O
of IN O
agreement NN O
among IN O
the DT O
adjudicators NNS O
and CC O
with IN O
the DT O
final JJ O
consensus NN O
result NN O
. . O

Additionally RB O
, , O
we PRP O
model VBP O
the DT O
adjudication NN O
process NN O
and CC O
predict VBP O
the DT O
results NNS O
if IN O
a DT O
smaller JJR O
committee NN O
had VBD O
been VBN O
used VBN O
. . O

We PRP O
found VBD O
that IN O
reducing VBG O
the DT O
number NN B-OC
of IN I-OC
adjudicators NNS I-OC
from IN O
five CD O
to TO O
two CD O
or CC O
three CD O
would MD O
probably RB O
have VB O
changed VBN O
the DT O
consensus NN O
outcome NN O
in IN O
less JJR O
than IN O
10 CD O
% NN O
of IN O
cases NNS O
. . O

Correspondingly RB O
, , O
the DT O
effect NN O
on IN O
the DT O
final JJ O
study NN O
results NNS O
( ( O
comparing VBG O
primary JJ O
outcomes NNS O
in IN O
both DT O
randomized JJ O
arms NNS O
) ) O
would MD O
have VB O
been VBN O
altered VBN O
very RB O
little JJ O
. . O

Even RB O
using VBG O
a DT O
single JJ O
adjudicator NN O
would MD O
not RB O
have VB O
affected VBN O
the DT O
results NNS O
substantially RB O
. . O

About IN O
90 CD O
minutes NNS O
of IN O
person-time JJ O
per IN O
patient NN B-POPU
was VBD O
required VBN O
for IN O
activities NNS O
directly RB O
related VBN O
to TO O
the DT O
adjudication NN B-INTV
process NN I-INTV
, , O
or CC O
approximately RB O
6 CD O
months NNS O
of IN O
full JJ O
time NN O
work NN O
for IN O
the DT O
entire JJ O
study NN O
. . O

This DT O
level NN O
of IN O
effort NN O
could MD O
be VB O
substantially RB O
reduced VBN O
by IN O
using VBG O
fewer JJR O
adjudicators NNS O
with IN O
little JJ O
impact NN O
on IN O
the DT O
results NNS O
. . O

Thus RB O
, , O
we PRP O
suggest VBP O
that IN O
when WRB O
high JJ O
observer NN O
agreement NN O
is VBZ O
demonstrated VBN O
or CC O
anticipated VBN O
, , O
adjudication NN O
committees NNS O
should MD O
consist VB O
of IN O
no DT O
more RBR O
than IN O
three CD O
members NNS O
. . O

Further JJ O
work NN O
is VBZ O
needed VBN O
to TO O
evaluate VB O
if IN O
smaller JJR O
committees NNS O
are VBP O
adequate JJ O
to TO O
detect VB O
small JJ O
but CC O
important JJ O
treatment NN O
effects NNS O
or CC O
if IN O
they PRP O
compromise VBP O
validity NN O
when WRB O
the DT O
level NN O
of IN O
adjudicator NN O
agreement NN O
is VBZ O
lower JJR O
. . O

-DOCSTART- -X- O O

Incidence NN O
and CC O
clinical JJ O
significance NN O
of IN O
false-negative JJ B-POPU
sextant JJ I-POPU
prostate NN I-POPU
biopsies NNS I-POPU
. . O

PURPOSE NNP O
Since IN O
most JJS O
patients NNS O
do VBP O
not RB O
undergo VB O
repeat NN O
sextant JJ O
prostate NN O
biopsies NNS O
after IN O
a DT O
biopsy NN O
is VBZ O
positive JJ O
for IN O
prostate NN O
cancer NN O
, , O
the DT O
true JJ O
incidence NN O
of IN O
false-negative JJ O
biopsies NNS O
is VBZ O
not RB O
well RB O
defined VBN O
. . O

We PRP O
assess VBP O
the DT O
incidence NN O
and CC O
clinical JJ O
significance NN O
of IN O
false-negative JJ B-POPU
sextant JJ I-POPU
prostate NN I-POPU
biopsies NNS I-POPU
in IN I-POPU
patients NNS I-POPU
undergoing VBG I-POPU
radical JJ I-POPU
prostatectomy NN I-POPU
. . O

MATERIALS NNP O
AND NNP O
METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
118 CD I-POPU
patients NNS I-POPU
with IN I-POPU
biopsy NN I-POPU
proved VBN I-POPU
prostate JJ I-POPU
cancer NN I-POPU
underwent JJ O
repeat NN B-INTV
sextant JJ I-INTV
prostate NN I-INTV
biopsy NN I-INTV
before IN O
enrollment NN O
in IN O
a DT O
prospective JJ O
randomized VBN O
trial NN O
of IN O
radical JJ B-INTV
prostatectomy NN I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
neoadjuvant JJ I-INTV
hormonal JJ I-INTV
therapy NN I-INTV
. . O

Clinical JJ O
parameters NNS O
were VBD O
assessed VBN O
to TO O
determine VB O
potential JJ O
sources NNS O
of IN O
bias NN O
. . O

Pathological JJ O
parameters NNS O
and CC O
prostate NN B-OC
specific JJ I-OC
antigen NN I-OC
relapse-free JJ I-OC
survival NN I-OC
rates NNS I-OC
were VBD O
compared VBN O
to TO O
determine VB O
the DT O
clinical JJ O
significance NN O
of IN O
false-negative JJ O
biopsies NNS O
. . O

RESULTS NNP O
Of IN O
the DT O
118 CD B-POPU
patients NNS I-POPU
27 CD O
( ( O
23 CD O
% NN O
) ) O
had VBD O
a DT O
negative JJ O
repeat NN O
sextant JJ O
biopsy NN O
. . O

Except IN O
for IN O
initial JJ O
clinical JJ O
stage NN O
, , O
no DT O
differences NNS O
were VBD O
noted VBN O
in IN O
the DT O
clinical JJ B-OC
or CC I-OC
pathological JJ I-OC
parameters NNS I-OC
, , O
or CC O
prostate VB B-OC
specific JJ I-OC
antigen NN I-OC
relapse NN I-OC
rates NNS I-OC
in IN O
patients NNS O
with IN O
negative JJ O
versus NN O
positive JJ O
repeat NN O
biopsies NNS O
. . O

CONCLUSIONS NNP O
Our PRP$ O
findings NNS O
suggest VBP O
that IN O
this DT O
23 CD O
% NN O
incidence NN O
of IN O
false-negative JJ O
biopsies NNS O
represents VBZ O
significant JJ O
cancer NN O
. . O

This DT O
relatively RB O
high JJ O
incidence NN O
is VBZ O
important JJ O
to TO O
consider VB O
in IN O
treatment NN O
modalities NNS O
in IN O
which WDT O
prostate VBP O
biopsy NN O
may MD O
be VB O
performed VBN O
to TO O
determine VB O
response NN O
to TO O
therapy NN O
. . O

-DOCSTART- -X- O O

Impact NN O
of IN O
surgical JJ B-INTV
staging NN I-INTV
in IN O
evaluating VBG O
the DT O
radiotherapeutic JJ O
outcome NN O
in IN O
RTOG NNP O
# # O
77-06 NNP O
, , O
a DT O
phase NN O
III NNP O
study NN O
for IN O
T1BN0M0 NNP O
( ( O
A2 NNP O
) ) O
and CC O
T2N0M0 NNP O
( ( O
B NNP O
) ) O
prostate NN O
carcinoma NN O
. . O

PURPOSE NNP O
To TO O
evaluate VB O
survival NN O
and CC O
time NN O
to TO O
metastatic JJ O
disease NN O
in IN O
patients NNS B-POPU
treated VBN I-POPU
for IN I-POPU
localized JJ I-POPU
prostatic JJ I-POPU
carcinoma NN I-POPU
in IN I-POPU
a DT I-POPU
Phase NNP I-POPU
III NNP I-POPU
radiotherapy NN I-POPU
( ( I-POPU
RT NNP I-POPU
) ) I-POPU
protocol NN I-POPU
, , I-POPU
Radiation NNP I-POPU
Therapy NNP I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
( ( I-POPU
RTOG NNP I-POPU
) ) I-POPU
77-06 NN I-POPU
. . O

Patients NNS B-POPU
with IN I-POPU
T18N0M0 NNP I-POPU
( ( I-POPU
A2 NNP I-POPU
) ) I-POPU
or CC I-POPU
T2N0M0 NNP I-POPU
( ( I-POPU
B NNP I-POPU
) ) I-POPU
disease NN I-POPU
after IN I-POPU
lymphangiogram NN I-POPU
( ( I-POPU
LAG NNP I-POPU
) ) I-POPU
or CC I-POPU
staging VBG I-POPU
laparotomy NN I-POPU
( ( I-POPU
SL NNP I-POPU
) ) I-POPU
were VBD I-POPU
randomized VBN I-POPU
between IN I-POPU
prophylactic JJ I-POPU
radiation NN I-POPU
to TO I-POPU
the DT I-POPU
pelvic JJ I-POPU
lymph NN I-POPU
nodes NNS I-POPU
and CC I-POPU
prostatic JJ I-POPU
bed NN I-POPU
vs. FW I-POPU
prostatic JJ I-POPU
bed NN I-POPU
alone RB I-POPU
. . O

The DT O
outcome NN O
of IN O
both DT O
treatment NN O
arms NNS O
, , O
as RB O
well RB O
as IN O
a DT O
comparison NN O
of IN O
the DT O
LAG NNP O
group NN O
, , O
to TO O
that DT O
of IN O
the DT O
SL NNP O
group NN O
, , O
are VBP O
updated VBN O
. . O

METHODS NNP O
AND NNP O
MATERIALS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
449 CD I-POPU
eligible JJ I-POPU
males NNS I-POPU
were VBD I-POPU
entered VBN I-POPU
into IN I-POPU
RTOG NNP I-POPU
protocol NN I-POPU
7706 CD I-POPU
between IN I-POPU
1978 CD I-POPU
and CC I-POPU
1983 CD I-POPU
. . O

Lymph NNP O
node IN O
staging VBG O
was VBD O
mandatory JJ O
but CC O
at IN O
the DT O
physician NN O
's POS O
discretion NN O
; : O
117 CD B-POPU
( ( I-POPU
26 CD I-POPU
% NN I-POPU
) ) I-POPU
patients NNS I-POPU
had VBD I-POPU
SL NNP I-POPU
, , I-POPU
while IN I-POPU
332 CD I-POPU
( ( I-POPU
74 CD I-POPU
% NN I-POPU
) ) I-POPU
had VBD I-POPU
LAG NNP I-POPU
. . O

Follow-up NNP O
was VBD O
a DT O
median NN O
of IN O
12 CD O
years NNS O
and CC O
a DT O
maximum NN O
of IN O
16 CD O
years NNS O
. . O

For IN O
those DT O
randomized VBN O
to TO O
receive VB O
prophylactic JJ O
pelvic NNS O
lymph VBP O
nodal JJ O
irradiation NN O
, , O
45 CD O
Gy NNP O
of IN O
megavoltage NN O
RT NNP O
was VBD O
delivered VBN O
via IN O
multiple JJ O
portals NNS O
in IN O
4.5-5 JJ O
weeks NNS O
, , O
while IN O
all DT O
patients NNS O
received VBD O
65 CD O
Gy NNP O
in IN O
6.5-8 JJ O
weeks NNS O
to TO O
the DT O
prostatic JJ O
bed NN O
. . O

RESULTS NNP O
There EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
survival JJ B-OC
whether IN O
treatment NN O
was VBD O
administered VBN O
to TO O
the DT O
prostate NN O
or CC O
prostate NN O
and CC O
pelvic JJ O
lymph NN O
nodes NNS O
. . O

The DT O
SL NNP O
group NN O
had VBD O
greater JJR O
12-year JJ B-OC
survival NN I-OC
than IN O
the DT O
LAG NNP O
group NN O
( ( O
48 CD O
% NN O
vs. FW O
38 CD O
% NN O
, , O
p NN O
= NNP O
0.02 CD O
) ) O
. . O

Disease-free JJ B-OC
survival NN I-OC
was VBD O
statistically RB O
significant JJ O
, , O
with IN O
38 CD O
% NN O
for IN O
the DT O
SL NNP O
group NN O
vs. FW O
26 CD O
% NN O
for IN O
the DT O
LAG NNP O
group NN O
( ( O
p JJ O
= NNP O
0.003 CD O
) ) O
. . O

Bone NNP B-OC
metastasis NN I-OC
was VBD O
less JJR O
common JJ O
in IN O
the DT O
SL NNP O
group NN O
( ( O
14 CD O
% NN O
) ) O
than IN O
the DT O
LAG NNP O
group NN O
( ( O
27 CD O
% NN O
) ) O
( ( O
p JJ O
= NNP O
0.003 CD O
) ) O
. . O

CONCLUSION NN O
At IN O
12-year JJ O
median JJ O
follow-up NN O
, , O
there EX O
still RB O
was VBD O
no DT O
survival JJ O
difference NN O
in IN O
those DT O
patients NNS O
treated VBD O
prophylactically RB O
to TO O
the DT O
pelvic JJ O
nodes NNS O
and CC O
prostatic JJ O
bed NN O
vs. IN O
the DT O
prostatic JJ O
bed NN O
alone RB O
. . O

Those DT O
patients NNS O
not RB O
surgically RB O
staged VBN O
with IN O
only RB O
LAG NNP O
for IN O
lymph JJ O
node JJ O
evaluation NN O
were VBD O
less RBR O
accurately RB O
staged VBN O
, , O
as IN O
reflected VBN O
by IN O
a DT O
statistically RB O
significant JJ O
reduced VBN O
survival NN O
and CC O
earlier JJR O
metastases NNS O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
prostate-specific JJ B-INTV
antigen NN I-INTV
corrected VBN I-INTV
for IN I-INTV
total JJ I-INTV
prostate NN I-INTV
volume NN I-INTV
and CC I-INTV
transition NN I-INTV
zone NN I-INTV
volume NN I-INTV
in IN O
a DT O
population-based JJ B-POPU
screening NN I-POPU
study NN I-POPU
. . O

OBJECTIVES NNP O
To TO O
compare VB O
the DT O
discriminatory JJ O
potential NN O
between IN O
prostate NN B-POPU
cancer NN I-POPU
and CC I-POPU
benign JJ I-POPU
conditions NNS I-POPU
of IN I-POPU
the DT I-POPU
prostate NN I-POPU
in IN O
a DT O
population-based JJ O
screening NN B-INTV
study NN I-INTV
, , I-INTV
of IN I-INTV
serum JJ I-INTV
prostate-specific JJ I-INTV
antigen NN I-INTV
levels NNS I-INTV
( ( I-INTV
PSA NNP I-INTV
) ) I-INTV
and CC I-INTV
PSA NNP I-INTV
corrected VBD I-INTV
for IN I-INTV
both DT I-INTV
the DT I-INTV
total JJ I-INTV
prostate NN I-INTV
volume NN I-INTV
( ( I-INTV
PSA-D NNP I-INTV
) ) I-INTV
and CC I-INTV
the DT I-INTV
transition NN I-INTV
zone NN I-INTV
volume NN I-INTV
( ( I-INTV
PSA-T NNP I-INTV
) ) I-INTV
. . O

METHODS NNP O
In IN O
a DT O
randomized JJ O
population-based JJ O
screening NN O
study NN O
( ( B-POPU
Rotterdam NNP I-POPU
section NN I-POPU
of IN I-POPU
the DT I-POPU
European NNP I-POPU
Randomized NNP I-POPU
Study NNP I-POPU
of IN I-POPU
Screening NNP I-POPU
for IN I-POPU
Prostate NNP I-POPU
Cancer NNP I-POPU
) ) I-POPU
, , O
in IN O
which WDT O
10,865 CD B-POPU
men NNS I-POPU
have VBP I-POPU
been VBN I-POPU
screened VBN I-POPU
, , O
the DT O
biopsy NN B-POPU
results NNS I-POPU
of IN I-POPU
1202 CD I-POPU
men NNS I-POPU
with IN I-POPU
PSA NNP I-POPU
levels NNS I-POPU
of IN I-POPU
4 CD I-POPU
ng/mL NNS I-POPU
or CC I-POPU
more JJR I-POPU
were VBD O
evaluated VBN O
. . O

Planimetric NNP B-INTV
and CC I-INTV
prolate VB I-INTV
ellipsoid JJ I-INTV
volumes NNS I-INTV
of IN I-INTV
the DT I-INTV
total JJ I-INTV
prostate NN I-INTV
as RB I-INTV
well RB I-INTV
as IN I-INTV
of IN I-INTV
the DT I-INTV
transition NN I-INTV
zone NN I-INTV
were VBD I-INTV
measured VBN I-INTV
. . O

The DT O
measured JJ O
volumes NNS O
were VBD O
compared VBN O
with IN O
the DT O
volumes NNS B-INTV
of IN I-INTV
57 CD I-INTV
radical JJ I-INTV
prostatectomy NN I-INTV
specimens NNS I-INTV
through IN O
Spearman NNP O
's POS O
rank NN O
correlation NN O
coefficient NN O
and CC O
agreement NN O
tests NNS O
. . O

A DT O
receiver NN O
operating VBG O
characteristic JJ O
( ( O
ROC NNP O
) ) O
curve VBP O
analysis NN O
was VBD O
done VBN O
of IN O
sensitivity NN O
and CC O
specificity NN O
of IN O
biopsy NN O
indications NNS O
through IN O
PSA NNP B-INTV
and CC I-INTV
PSA NNP I-INTV
corrected VBD I-INTV
for IN I-INTV
the DT I-INTV
volumes NNS I-INTV
measured VBN I-INTV
with IN O
transrectal JJ O
ultrasound NN O
. . O

RESULTS NNP O
In IN O
the DT O
1202 CD B-POPU
men NNS I-POPU
studied VBD I-POPU
, , I-POPU
361 CD I-POPU
cases NNS I-POPU
of IN I-POPU
prostate NN I-POPU
cancer NN I-POPU
were VBD O
diagnosed VBN O
. . O

Both DT O
PSA-D NNP O
and CC O
PSA-T NNP O
showed VBD O
a DT O
significantly RB O
higher JJR O
area NN B-OC
under IN I-OC
the DT I-OC
ROC NNP I-OC
curve NN I-OC
( ( O
0.77 CD O
and CC O
0.79 CD O
, , O
respectively RB O
) ) O
than IN O
PSA NNP O
alone RB O
( ( O
area NN O
0.65 CD O
) ) O
. . O

There EX O
was VBD O
no DT O
significant JJ O
difference NN O
between IN O
PSA-D NNP O
and CC O
PSA-T NNP O
. . O

The DT O
use NN O
of IN O
a DT O
PSA-D NNP O
threshold JJ O
value NN O
of IN O
0 CD O
. . O

10 CD O
ng/mL/cc NN O
would MD O
have VB O
avoided VBN O
28 CD O
% NN O
of IN O
biopsies NNS O
at IN O
the DT O
cost NN O
of IN O
10 CD O
% NN O
of IN O
detectable JJ O
cancers NNS O
. . O

A DT O
PSA-D JJ O
threshold NN O
of IN O
0.15 CD O
ng/mL/cc NNS O
would MD O
have VB O
avoided VBN O
73.8 CD O
% NN O
of IN O
biopsies NNS O
at IN O
the DT O
cost NN O
of IN O
not RB O
diagnosing VBG O
43.8 CD O
% NN O
of IN O
detectable JJ O
cancers NNS O
. . O

CONCLUSIONS VB O
The DT O
planimetrically RB O
obtained JJ O
prostate NN O
volume NN O
showed VBD O
a DT O
more RBR O
favorable JJ O
agreement NN O
with IN O
the DT O
radical JJ O
prostatectomy NN O
volume NN O
than IN O
the DT O
prolate JJ O
ellipsoid NN O
volume NN O
. . O

The DT O
discriminatory JJ O
potential NN O
of IN O
the DT O
corrected VBN O
PSA NNP B-OC
value NN I-OC
is VBZ O
better JJR O
at IN O
predicting VBG O
the DT O
results NNS O
of IN O
needle JJ O
biopsy NN O
of IN O
the DT O
prostate NN O
when WRB O
compared VBN O
with IN O
PSA NNP O
alone RB O
. . O

The DT O
use NN O
of IN O
the DT O
transition NN B-INTV
zone NN I-INTV
volume NN I-INTV
for IN O
this DT O
correction NN O
results NNS O
in IN O
a DT O
higher JJR O
discriminatory JJ O
potential NN O
when WRB O
compared VBN O
to TO O
the DT O
use NN O
of IN O
the DT O
total JJ B-INTV
prostate NN I-INTV
volume NN I-INTV
; : I-INTV
however RB O
, , O
the DT O
observed JJ O
difference NN O
was VBD O
not RB O
statistically RB O
significant JJ O
. . O

-DOCSTART- -X- O O

A DT O
double JJ O
blind NN O
randomized VBD O
study NN O
of IN O
oral JJ O
clodronate NN B-INTV
in IN O
the DT O
treatment NN O
of IN O
bone NN B-POPU
metastases NNS I-POPU
from IN I-POPU
tumors NNS I-POPU
poorly RB I-POPU
responsive VBP I-POPU
to TO I-POPU
chemotherapy VB I-POPU
. . O

Bisphosphonates NNS B-INTV
are VBP O
used VBN O
in IN O
oncology NN O
as IN O
a DT O
means NN O
of IN O
decreasing VBG O
complications NNS O
due JJ O
to TO O
bone VB B-POPU
metastases NNS I-POPU
, , O
in IN O
association NN O
with IN O
anticancer NN O
treatment NN O
, , O
especially RB O
in IN O
patients NNS O
with IN O
breast NN O
cancer NN O
, , O
prostate NN O
cancer NN O
and CC O
myeloma NN O
. . O

Little JJ O
is VBZ O
known VBN O
about IN O
the DT O
effects NNS O
of IN O
bisphosphonates NNS B-INTV
on IN O
bone NN O
metastases NNS O
from IN O
other JJ O
tumors NNS O
and CC O
in IN O
particular JJ O
from IN O
tumors NNS O
for IN O
which WDT O
no DT O
effective JJ O
treatment NN O
is VBZ O
available JJ O
. . O

We PRP O
conducted VBD O
a DT O
randomized VBN O
, , O
double-blind JJ O
placebo-controlled JJ B-INTV
trial NN O
of IN O
oral JJ B-INTV
clodronate NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
bone NN I-POPU
metastases NNS I-POPU
from IN I-POPU
tumors NNS I-POPU
poorly RB I-POPU
responsive VBP I-POPU
to TO I-POPU
chemotherapy VB I-POPU
, , O
with IN O
the DT O
aims NNS O
of IN O
evaluating VBG O
the DT O
effects NNS B-OC
of IN I-OC
this DT I-OC
drug NN I-OC
on IN I-OC
symptoms NNS I-OC
control NN I-OC
and CC I-OC
bone NN I-OC
metastases NNS I-OC
evolution NN I-OC
. . O

Sixty-six JJ B-POPU
patients NNS I-POPU
with IN I-POPU
poorly JJ I-POPU
responsive JJ I-POPU
tumors NNS I-POPU
such JJ I-POPU
as IN I-POPU
non-small JJ I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
NSCLC NNP I-POPU
) ) I-POPU
, , I-POPU
bladder NN I-POPU
cancer NN I-POPU
, , I-POPU
gastrointestinal JJ I-POPU
cancers NNS I-POPU
, , I-POPU
kidney NN I-POPU
cancer NN I-POPU
, , I-POPU
melanoma NN I-POPU
and CC I-POPU
metastatic JJ I-POPU
carcinoma NN I-POPU
of IN I-POPU
unknown JJ I-POPU
origin NN I-POPU
entered VBD I-POPU
the DT I-POPU
study NN I-POPU
. . O

Patients NNS B-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
receive VB I-POPU
either DT I-POPU
clodronate NN I-POPU
1,600 CD I-POPU
mg/day NN I-POPU
for IN I-POPU
one CD I-POPU
year NN I-POPU
or CC I-POPU
identical JJ I-POPU
placebo-containing JJ I-POPU
tablets NNS I-POPU
. . O

Various JJ B-INTV
parameters NNS I-INTV
such JJ I-INTV
as IN I-INTV
Karnofsky NNP I-INTV
performance NN I-INTV
status NN I-INTV
, , I-INTV
pain NN I-INTV
score NN I-INTV
( ( I-INTV
measured VBN I-INTV
by IN I-INTV
a DT I-INTV
visual-analogue JJ I-INTV
scale NN I-INTV
) ) I-INTV
and CC I-INTV
analgesic JJ I-INTV
requirement NN I-INTV
were VBD I-INTV
recorded VBN I-INTV
at IN I-INTV
monthly JJ I-INTV
intervals NNS I-INTV
. . O

Of IN B-POPU
the DT I-POPU
66 CD I-POPU
patients NNS I-POPU
enrolled VBD I-POPU
, , I-POPU
9 CD I-POPU
were VBD I-POPU
observed VBN I-POPU
for IN I-POPU
one CD I-POPU
month NN I-POPU
or CC I-POPU
less JJR I-POPU
; : I-POPU
7 CD I-POPU
were VBD I-POPU
followed VBN I-POPU
for IN I-POPU
two CD I-POPU
months NNS I-POPU
; : I-POPU
only RB I-POPU
50 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
followed VBN I-POPU
for IN I-POPU
more JJR I-POPU
than IN I-POPU
2 CD I-POPU
months NNS I-POPU
and CC I-POPU
could MD I-POPU
be VB I-POPU
adequately RB I-POPU
evaluated VBN I-POPU
. . O

At IN O
3 CD O
months NNS O
both DT O
clodronate NN B-INTV
and CC O
placebo-treated JJ B-INTV
patients NNS O
had VBD O
a DT O
decrease NN B-OC
in IN I-OC
Karnofsky NNP I-OC
performance NN I-OC
status NN I-OC
, , O
with IN O
the DT O
decrease NN O
being VBG O
more RBR O
evident JJ O
in IN O
the DT O
placebo NN O
group NN O
. . O

Mean NNP B-OC
pain NN I-OC
scores NNS I-OC
showed VBD O
an DT O
increase NN B-OC
of IN I-OC
pain NN I-OC
in IN O
patients NNS O
receiving VBG O
placebo NN B-INTV
and CC O
a DT O
decrease NN O
of IN O
pain NN O
in IN O
patients NNS O
receiving VBG O
clodronate NN B-INTV
, , O
although IN O
the DT O
difference NN O
failed VBD O
to TO O
be VB O
statistically RB O
significant JJ O
. . O

Analgesics NNPS B-OC
requirement NN I-OC
increased VBN O
in IN O
both DT O
groups NNS O
, , O
but CC O
significantly RB O
more RBR O
in IN O
patients NNS O
receiving VBG O
placebo NN B-INTV
( ( O
p JJ O
= NNP O
0.042 CD O
) ) O
, , O
in IN O
whom WP O
increase NN O
in IN O
opioid JJ O
requirements NNS O
was VBD O
particularly RB O
evident JJ O
. . O

Toxicity NNP B-OC
was VBD I-OC
low JJ I-OC
, , O
with IN O
occasional JJ B-OC
gastroenteric JJ I-OC
discomfort NN I-OC
in IN O
both DT O
groups NNS O
. . O

The DT O
main JJ O
problem NN O
of IN O
this DT O
study NN O
was VBD O
the DT O
difficulty NN O
in IN O
recruiting VBG O
an DT O
adequate JJ O
number NN O
of IN O
patients NNS O
and CC O
following VBG O
them PRP O
for IN O
a DT O
sufficient JJ O
period NN O
of IN O
time NN O
: : O
general JJ O
conditions NNS O
rapidly RB O
deteriorated VBD O
in IN O
many JJ O
patients NNS O
, , O
and CC O
approximately RB O
25 CD O
% NN O
of IN O
the DT O
66 CD O
enrolled NNS O
were VBD O
not RB O
considered VBN O
evaluable JJ O
; : O
few JJ O
patients NNS O
survived VBD O
for IN O
the DT O
length NN O
of IN O
the DT O
study NN O
, , O
one CD O
year NN O
. . O

This DT O
might MD O
partly RB O
account VB O
for IN O
the DT O
lack NN O
of IN O
significance NN O
of IN O
some DT O
of IN O
the DT O
parameters NNS O
under IN O
study NN O
. . O

With IN O
these DT O
limits NNS O
, , O
oral JJ O
clodronate NN O
demonstrated VBD O
some DT O
efficacy NN O
in IN O
symptom NN O
control NN O
and CC O
in IN O
reducing VBG O
the DT O
need NN O
for IN O
analgesics NNS O
. . O

-DOCSTART- -X- O O

Pelvic JJ O
lymphocysts NNS O
following VBG O
retroperitoneal JJ O
lymphadenectomy NN O
: : O
retroperitoneal NN B-INTV
partial JJ I-INTV
" NNP I-INTV
no-closure NN I-INTV
" NN I-INTV
for IN O
ovarian JJ O
and CC O
endometrial JJ O
cancers NNS O
. . O

BACKGROUND NNP O
AND NNP O
OBJECTIVES NNP O
Pelvic NNP O
lymphocysts NNS O
have VBP O
been VBN O
reported VBN O
mainly RB O
following VBG O
pelvic JJ O
lymphadenectomy NN O
for IN O
cervical JJ O
cancer NN O
. . O

We PRP O
attempted VBD O
to TO O
assess VB O
whether IN O
retroperitoneal JJ B-INTV
partial JJ I-INTV
" NN I-INTV
no-closure JJ I-INTV
" NN I-INTV
reduces VBZ O
the DT O
incidence NN O
of IN O
lymphocyst JJ B-OC
formation NN I-OC
following VBG O
retroperitoneal JJ O
lymphadenectomy NN O
. . O

METHODS NNP O
Sixty-one JJ B-POPU
patients NNS I-POPU
with IN I-POPU
ovarian JJ I-POPU
cancer NN I-POPU
or CC I-POPU
endometrial JJ I-POPU
cancer NN I-POPU
who WP I-POPU
underwent JJ I-POPU
retroperitoneal NN I-POPU
lymph NN I-POPU
node JJ I-POPU
resection NN I-POPU
were VBD O
assigned VBN O
at IN O
random NN O
to TO O
a DT O
retroperitoneal JJ B-INTV
partial JJ I-INTV
" NN I-INTV
no-closure JJ I-INTV
" NNP I-INTV
group NN I-INTV
or CC I-INTV
a DT I-INTV
" JJ I-INTV
closure NN I-INTV
" NNP I-INTV
group NN I-INTV
. . O

The DT O
incidence NN O
of IN O
lymphocysts NNS B-OC
in IN O
the DT O
two CD O
groups NNS O
as IN O
determined JJ O
using VBG O
ultrasonography NN O
was VBD O
compared VBN O
. . O

RESULTS JJ O
Lymphocysts NNS B-OC
appeared VBD O
in IN O
23/61 CD O
patients NNS O
( ( O
38 CD O
% NN O
) ) O
in IN O
total JJ O
. . O

In IN O
the DT O
" JJ O
closure NN O
" NNP O
group NN O
, , O
the DT O
incidence NN O
was VBD O
52 CD O
% NN O
( ( O
16/31 CD O
) ) O
, , O
but CC O
in IN O
the DT O
" JJ O
no-closure JJ O
" NN O
group NN O
it PRP O
was VBD O
only RB O
23 CD O
% NN O
( ( O
7/30 CD O
) ) O
; : O
the DT O
incidence NN O
in IN O
the DT O
" JJ O
no-closure JJ O
" NN O
group NN O
was VBD O
significantly RB O
lower JJR O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

The DT O
incidence NN O
of IN O
postoperative JJ B-OC
fever NN I-OC
was VBD O
17 CD O
% NN O
( ( O
5/30 CD O
) ) O
in IN O
the DT O
" JJ O
no-closure JJ O
" NN O
group NN O
, , O
which WDT O
was VBD O
lower JJR O
than IN O
that DT O
in IN O
the DT O
" JJ O
closure NN O
" NNP O
group NN O
( ( O
42 CD O
% NN O
, , O
13/31 CD O
) ) O
, , O
but CC O
not RB O
significantly RB O
so RB O
( ( O
P NNP O
< NNP O
0.1 CD O
) ) O
. . O

No DT O
patients NNS O
in IN O
the DT O
" JJ O
no-closure JJ O
" NNP O
group NN O
required VBD O
surgical JJ O
procedures NNS O
such JJ O
as IN O
needle JJ O
aspiration NN O
or CC O
cyst NN O
drainage NN O
. . O

CONCLUSIONS NNP O
Retroperitoneal NNP B-INTV
partial JJ I-INTV
" NNP I-INTV
no-closure NN I-INTV
" NN I-INTV
appears VBZ O
to TO O
be VB O
a DT O
useful JJ O
procedure NN O
for IN O
reducing VBG O
the DT O
incidence NN O
of IN O
pelvic JJ B-OC
lymphocysts NNS I-OC
associated VBN O
with IN O
retroperitoneal JJ B-INTV
lymphadenectomy NN I-INTV
. . O

-DOCSTART- -X- O O

Therapy NNP B-OC
effect NN I-OC
of IN O
either CC O
paclitaxel NN B-INTV
or CC I-INTV
cyclophosphamide JJ I-INTV
combination NN I-INTV
treatment NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
epithelial JJ I-POPU
ovarian JJ I-POPU
cancer NN I-POPU
and CC I-POPU
relation NN I-POPU
to TO I-POPU
TP53 NNP I-POPU
gene NN I-POPU
status NN I-POPU
. . O

Cell NNP O
death NN O
after IN O
treatment NN O
with IN O
chemotherapy NN B-INTV
is VBZ O
exerted VBN O
by IN O
activation NN O
of IN O
apoptosis NN O
, , O
and CC O
the DT O
p53 NN O
protein NN O
has VBZ O
been VBN O
shown VBN O
to TO O
actively RB O
participate VB O
in IN O
this DT O
process NN O
. . O

This DT O
recent JJ O
focus NN O
on IN O
TP53 NNP B-OC
status NN I-OC
as IN O
a DT O
possible JJ O
determinant NN O
of IN O
cancer NN O
therapy NN O
response NN O
has VBZ O
raised VBN O
the DT O
question NN O
of IN O
whether IN O
or CC O
not RB O
mutations NNS O
in IN O
the DT O
TP53 NNP O
gene NN O
have VBP O
an DT O
influence NN O
on IN O
paclitaxel NN B-INTV
therapy NN I-INTV
. . O

The DT O
TP53 NNP B-OC
status NN I-OC
has VBZ O
been VBN O
analysed VBN O
at IN O
the DT O
DNA NNP O
level NN O
in IN O
tumours NNS O
from IN O
45 CD B-POPU
ovarian JJ I-POPU
cancer NN I-POPU
patients NNS I-POPU
randomized VBN I-POPU
to TO I-POPU
treatment NN I-POPU
with IN O
paclitaxel NN B-INTV
and CC I-INTV
cisplatin NN I-INTV
or CC I-INTV
cyclophosphamide NN I-INTV
and CC I-INTV
cisplatin NN I-INTV
. . O

Therapy NNP B-OC
response NN I-OC
was VBD O
obtained VBN O
for IN O
38 CD B-POPU
patients NNS I-POPU
with IN I-POPU
clinically RB I-POPU
evaluable JJ I-POPU
disease NN I-POPU
after IN I-POPU
initial JJ I-POPU
surgery NN I-POPU
. . O

The DT O
positive JJ B-OC
response NN I-OC
rate NN I-OC
to TO O
the DT O
paclitaxel/cisplatin NN B-INTV
therapy NN I-INTV
was VBD O
85 CD O
% NN O
vs JJ O
61 CD O
% NN O
for IN O
the DT O
patients NNS O
who WP O
received VBD O
the DT O
cyclophosphamide/cisplatin JJ B-INTV
regimen NNS O
. . O

A DT O
significant JJ O
difference NN O
in IN O
relapse-free JJ B-OC
survival NN I-OC
in IN O
favour NN O
of IN O
paclitaxel/cisplatin NN B-INTV
chemotherapy NN I-INTV
was VBD O
found VBN O
( ( O
P NNP O
= NNP O
0.001 CD O
) ) O
. . O

A DT O
total NN O
of IN O
33 CD O
tumour NN O
samples NNS O
( ( O
73 CD O
% NN O
) ) O
had VBD O
detectable JJ O
sequence NN B-OC
alterations NNS I-OC
in IN I-OC
the DT I-OC
TP53 NNP I-OC
gene NN I-OC
. . O

When WRB O
relapse-free JJ B-OC
survival NN I-OC
was VBD O
estimated VBN O
for IN O
all DT O
patients NNS O
with IN O
TP53 NNP B-OC
alterations NNS I-OC
in IN O
their PRP$ O
tumours NNS O
, , O
a DT O
significant JJ O
better RBR O
outcome NN O
for IN O
the DT O
paclitaxel/cisplatin NN B-INTV
group NN O
was VBD O
found VBN O
compared VBN O
with IN O
the DT O
patient NN O
group NN O
receiving VBG O
cyclophosphamide NN B-INTV
and CC O
cisplatin NN B-INTV
therapy NN I-INTV
( ( O
P NNP O
= NNP O
0.002 CD O
) ) O
. . O

We PRP O
did VBD O
not RB O
observe VB O
an DT O
association NN O
between IN O
TP53 NNP B-OC
tumour NN I-OC
status NN I-OC
and CC O
prognosis NN B-OC
for IN O
patients NNS O
who WP O
received VBD O
paclitaxel/cisplatin JJ B-INTV
combination NN O
treatment NN O
, , O
indicating VBG O
that IN O
the DT O
effect NN O
of IN O
this DT O
therapy NN O
is VBZ O
not RB O
influenced VBN O
by IN O
this DT O
parameter NN O
. . O

-DOCSTART- -X- O O

Ten-year JJ O
results NNS O
of IN O
a DT O
randomised JJ O
trial NN O
comparing VBG O
cisplatin NN B-INTV
with IN I-INTV
cisplatin NN I-INTV
and CC I-INTV
cyclophosphamide NN I-INTV
in IN O
advanced JJ B-POPU
, , I-POPU
suboptimally RB I-POPU
debulked JJ I-POPU
ovarian JJ I-POPU
cancer NN I-POPU
. . O

176 CD B-POPU
eligible JJ I-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
suboptimally RB I-POPU
operated JJ I-POPU
ovarian JJ I-POPU
carcinoma NN I-POPU
were VBD O
randomly RB O
allocated VBN O
to TO O
receive VB O
either DT O
cisplatin NN B-INTV
75 CD I-INTV
mg/m2 NN I-INTV
or CC I-INTV
cisplatin NN I-INTV
50 CD I-INTV
mg/m2 NN I-INTV
and CC I-INTV
cyclophosphamide VB I-INTV
500 CD I-INTV
mg/m2 NN I-INTV
( ( O
CP NNP O
) ) O
every DT O
28 CD O
days NNS O
for IN O
six CD O
courses NNS O
. . O

The DT O
overall JJ B-OC
clinical JJ I-OC
response NN I-OC
rates NNS I-OC
( ( I-OC
complete JJ I-OC
response NN O
plus CC O
partial JJ O
response NN O
) ) O
were VBD O
52 CD O
and CC O
63 CD O
% NN O
for IN O
CP NNP B-INTV
and CC I-INTV
cisplatin NN I-INTV
, , O
respectively RB O
( ( O
non-significant JJ O
) ) O
. . O

Including VBG O
results NNS O
obtained VBN O
by IN O
second-look JJ O
laparotomy NN O
, , O
we PRP O
did VBD O
not RB O
observe VB O
a DT O
statistically RB O
significant JJ O
difference NN O
in IN O
response NN O
rates NNS O
in IN O
the DT O
two CD O
treatment NN O
groups NNS O
. . O

Median JJ B-OC
progression-free JJ I-OC
survival NN I-OC
was VBD O
10 CD O
and CC O
11.9 CD O
months NNS O
for IN O
CP NNP B-INTV
and CC I-INTV
cisplatin NN I-INTV
, , O
respectively RB O
( ( O
non-significant JJ O
) ) O
. . O

No DT O
significant JJ O
difference NN O
was VBD O
observed VBN O
in IN O
overall JJ B-OC
survival NN I-OC
, , O
with IN O
a DT O
median NN O
of IN O
19.4 CD O
and CC O
21.5 CD O
months NNS O
for IN O
CP NNP B-INTV
and CC I-INTV
cisplatin NN I-INTV
, , O
respectively RB O
. . O

Thirty-seven JJ B-POPU
platinum-resistant JJ I-POPU
and CC I-POPU
27 CD I-POPU
platinum-sensitive JJ I-POPU
tumours NNS I-POPU
were VBD O
treated VBN O
with IN O
carboplatin NN B-INTV
or CC I-INTV
cisplatin NN I-INTV
as IN O
second-line JJ O
therapy NN O
. . O

Response JJ B-OC
rates NNS I-OC
to TO O
platinum VB O
second-line JJ O
therapy NN O
were VBD O
6 CD O
and CC O
50 CD O
% NN O
for IN O
resistant NN O
and CC O
sensitive JJ O
tumours NNS O
, , O
respectively RB O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

This DT O
difference NN O
in IN O
response NN B-OC
rate NN I-OC
was VBD O
also RB O
confirmed VBN O
by IN O
survival NN O
analysis NN O
. . O

Patients NNS B-POPU
with IN I-POPU
platinum-sensitive JJ I-POPU
tumours NNS I-POPU
survived VBD O
longer RBR O
when WRB O
they PRP O
were VBD O
treated VBN O
with IN O
platinum-containing JJ B-INTV
chemotherapy NN I-INTV
( ( O
P NNP O
= NNP O
0.005 CD O
) ) O
. . O

Median JJ B-OC
survival NN I-OC
was VBD O
22.8 CD O
and CC O
8.5 CD O
months NNS O
after IN O
initiation NN O
of IN O
second-line JJ O
treatment NN O
for IN O
the DT O
platinum-containing JJ B-INTV
and CC O
platinum-free JJ B-INTV
regimens NNS O
, , O
respectively RB O
. . O

In IN O
summary JJ O
, , O
we PRP O
observed VBD O
in IN O
suboptimally RB B-POPU
operated JJ I-POPU
ovarian JJ I-POPU
carcinoma NN I-POPU
patients NNS I-POPU
similar JJ O
response NN B-OC
rates NNS I-OC
, , I-OC
progression-free JJ I-OC
interval NN I-OC
, , I-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
for IN O
equitoxic JJ O
cisplatin NN B-INTV
and CC I-INTV
CP NNP I-INTV
. . O

However RB O
, , O
the DT O
doses NNS O
of IN O
cisplatin NN B-INTV
and CC I-INTV
cyclophosphamide NN I-INTV
chosen NNS O
were VBD O
substantially RB O
lower JJR O
than IN O
current JJ O
standard JJ O
doses NNS O
of IN O
CP NNP B-INTV
. . O

Our PRP$ O
study NN O
demonstrates VBZ O
, , O
therefore RB O
, , O
that IN O
a DT O
suboptimal JJ O
dose NN O
of IN O
CP NNP B-INTV
is VBZ O
as RB O
effective JJ O
as IN O
optimal JJ O
dose JJ O
monotherapy NN O
cisplatin NN B-INTV
. . O

Patients NNS B-POPU
with IN I-POPU
recurrences NNS I-POPU
considered VBN I-POPU
as IN I-POPU
platinum-sensitive JJ I-POPU
had VBD O
a DT O
significantly RB O
higher JJR O
response NN B-OC
rate NN I-OC
and CC O
improved VBN O
survival NN B-OC
when WRB O
retreated VBN O
with IN O
platinum-containing JJ B-INTV
therapy NN I-INTV
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
soy JJ B-INTV
intake NN O
on IN O
sex NN B-OC
hormone NN I-OC
metabolism NN I-OC
in IN O
premenopausal JJ B-POPU
women NNS I-POPU
. . O

Studies NNS O
suggest VBP O
that IN O
phytoestrogens NNS O
in IN O
soy JJ B-INTV
products NNS O
may MD O
impart VB O
hormonal JJ B-OC
effects NNS I-OC
that WDT O
protect VBP O
women NNS O
against IN O
breast NN O
cancer NN O
. . O

Limited VBN O
research NN O
suggests VBZ O
that IN O
intake NN O
of IN O
soy NN B-INTV
products NNS O
high JJ O
in IN O
isoflavonoid JJ O
phytoestrogens NNS O
affects VBZ O
sex NN B-OC
hormone NN I-OC
metabolism NN I-OC
, , O
but CC O
it PRP O
is VBZ O
unknown JJ O
whether IN O
phytoestrogens NNS O
in IN O
soy NNS B-INTV
have VBP O
any DT O
effect NN O
on IN O
menstrual JJ B-OC
function NN I-OC
or CC I-OC
serum VB I-OC
sex NN I-OC
hormones NNS I-OC
in IN O
women NNS O
on IN O
common JJ O
hormone NN O
therapies NNS O
, , O
such JJ O
as IN O
oral JJ O
contraceptives NNS O
( ( O
OC NNP O
) ) O
. . O

We PRP O
studied VBD O
the DT O
effects NNS O
of IN O
soy NN B-INTV
in IN O
36 CD B-POPU
premenopausal JJ I-POPU
women NNS I-POPU
, , I-POPU
20 CD I-POPU
of IN I-POPU
whom WP I-POPU
used VBD I-POPU
OC NNP I-POPU
. . O

Subjects NNS O
consumed VBD O
their PRP$ O
normal JJ B-INTV
diet NNS I-INTV
for IN O
two CD O
menstrual JJ O
cycles NNS O
and CC O
added VBD O
a DT O
soy JJ B-INTV
beverage NN I-INTV
containing VBG O
20 CD O
g NN O
of IN O
protein NN O
and CC O
38 CD O
mg NN O
of IN O
total JJ O
isoflavones NNS O
to TO O
their PRP$ O
usual JJ O
diet NN O
for IN O
another DT O
two CD O
menstrual JJ O
cycles NNS O
. . O

No DT O
significant JJ O
differences NNS O
were VBD O
observed VBN O
in IN O
serum NN B-OC
estrone NN I-OC
, , I-OC
estradiol NN I-OC
, , I-OC
sex NN I-OC
hormone-binding JJ I-OC
globulin NN I-OC
, , I-OC
dehydroepiandrosterone NN I-OC
sulfate NN I-OC
, , I-OC
prolactin NN I-OC
, , I-OC
or CC I-OC
progesterone NN I-OC
concentrations NNS I-OC
with IN O
soy JJ B-INTV
feeding NN O
in IN O
the DT O
non-OC JJ O
or CC O
the DT O
OC NNP O
group NN O
. . O

No DT O
changes NNS O
in IN O
menstrual JJ B-OC
cycle NN I-OC
length NN I-OC
or CC I-OC
the DT I-OC
urinary JJ I-OC
estrogen NN I-OC
metabolite NNS I-OC
ratio NN I-OC
of IN I-OC
2-hydroxyestrone CD I-OC
to TO I-OC
16 CD I-OC
alpha-hydroxyestrone NN I-OC
were VBD O
seen VBN O
with IN O
soy JJ O
feeding NN O
in IN O
the DT O
non-OC JJ O
or CC O
the DT O
OC NNP O
group NN O
. . O

Levels NNP O
of IN O
urinary JJ B-OC
estrogen NN I-OC
metabolites NNS I-OC
were VBD O
significantly RB O
different JJ O
between IN O
the DT O
non-OC JJ O
and CC O
the DT O
OC NNP O
group NN O
. . O

Thus RB O
soy JJ B-INTV
consumption NN O
had VBD O
no DT O
significant JJ O
effect NN O
on IN O
the DT O
menstrual JJ B-OC
cycle NN I-OC
, , I-OC
serum JJ I-OC
sex NN I-OC
hormones NNS I-OC
, , I-OC
or CC I-OC
urinary JJ I-OC
estrogen NN I-OC
metabolite NN I-OC
ratio NN I-OC
in IN O
premenopausal NN B-POPU
OC NNP I-POPU
or CC I-POPU
non-OC JJ I-POPU
users NNS I-POPU
. . O

-DOCSTART- -X- O O

Recurrent JJ B-POPU
epithelial JJ I-POPU
ovarian JJ I-POPU
carcinoma NN I-POPU
: : I-POPU
a DT O
randomized JJ O
phase NN O
III NNP O
study NN O
of IN O
pegylated VBN B-INTV
liposomal JJ I-INTV
doxorubicin NN I-INTV
versus NN O
topotecan JJ B-INTV
. . O

PURPOSE NNP O
To TO O
compare VB O
the DT O
efficacy NN B-OC
and CC O
safety NN B-OC
of IN O
pegylated JJ B-INTV
liposomal JJ I-INTV
doxorubicin NN I-INTV
( ( I-INTV
PLD NNP I-INTV
) ) I-INTV
and CC O
topotecan JJ B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
epithelial JJ I-POPU
ovarian JJ I-POPU
carcinoma NN I-POPU
that WDT I-POPU
recurred VBD I-POPU
after IN I-POPU
or CC I-POPU
did VBD I-POPU
n't RB I-POPU
respond VB I-POPU
to TO I-POPU
first-line JJ I-POPU
, , I-POPU
platinum-based JJ I-POPU
chemotherapy NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Patients NNPS B-POPU
with IN I-POPU
measurable JJ I-POPU
and CC I-POPU
assessable JJ I-POPU
disease NN I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
either DT O
PLD NNP B-INTV
50 CD O
mg/m NN O
( ( O
2 CD O
) ) O
as IN O
a DT O
1-hour JJ O
infusion NN O
every DT O
4 CD O
weeks NNS O
or CC O
topotecan JJ B-INTV
1.5 CD O
mg/m NN O
( ( O
2 CD O
) ) O
/d NN O
for IN O
5 CD O
consecutive JJ O
days NNS O
every DT O
3 CD O
weeks NNS O
. . O

Patients NNS O
were VBD O
stratified VBN O
prospectively RB O
for IN O
platinum NN O
sensitivity NN O
and CC O
for IN O
the DT O
presence NN O
or CC O
absence NN O
of IN O
bulky JJ O
disease NN O
. . O

RESULTS VB O
A DT B-POPU
total NN I-POPU
of IN I-POPU
474 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
treated VBN I-POPU
( ( O
239 CD O
PLD NNP B-INTV
and CC O
235 CD O
topotecan JJ B-INTV
) ) I-INTV
. . O

They PRP O
comprised VBD O
the DT O
intent-to-treat JJ O
population NN O
. . O

The DT O
overall JJ B-OC
progression-free JJ I-OC
survival NN I-OC
rates NNS I-OC
were VBD O
similar JJ O
between IN O
the DT O
two CD O
arms NNS O
( ( O
P NNP O
=.095 NNP O
) ) O
. . O

The DT O
overall JJ B-OC
response NN I-OC
rates NNS I-OC
for IN O
PLD NNP B-INTV
and CC O
topotecan JJ B-INTV
were VBD O
19.7 CD O
% NN O
and CC O
17.0 CD O
% NN O
, , O
respectively RB O
( ( O
P NNP O
=.390 NNP O
) ) O
. . O

Median JJ B-OC
overall JJ I-OC
survival NN I-OC
times NNS I-OC
were VBD O
60 CD O
weeks NNS O
for IN O
PLD NNP B-INTV
and CC O
56.7 CD O
weeks NNS O
for IN O
topotecan JJ B-INTV
. . O

Data NNP O
analyzed VBD O
in IN O
platinum-sensitive JJ O
patients NNS O
demonstrated VBD O
a DT O
statistically RB O
significant JJ O
benefit NN O
from IN O
PLD NNP B-INTV
for IN O
progression-free JJ O
survival NN O
( ( O
P NNP O
=.037 NNP O
) ) O
, , O
with IN O
medians NNS O
of IN O
28.9 CD O
for IN O
PLD NNP B-INTV
versus FW O
23.3 CD O
weeks NNS O
for IN O
topotecan JJ B-INTV
. . O

For IN O
overall JJ B-OC
survival NN I-OC
, , O
PLD NNP B-INTV
was VBD O
significantly RB O
superior JJ O
to TO O
topotecan VB B-INTV
( ( O
P NNP O
=.008 NNP O
) ) O
, , O
with IN O
a DT O
median NN O
of IN O
108 CD O
weeks NNS O
versus RB O
71.1 CD O
weeks NNS O
. . O

The DT O
platinum-refractory JJ O
subgroup NN O
demonstrated VBD O
a DT O
nonstatistically RB O
significant JJ O
survival JJ B-OC
trend NN O
in IN O
favor NN O
of IN O
topotecan JJ B-INTV
( ( O
P NNP O
=.455 NNP O
) ) O
. . O

Severe JJ B-OC
hematologic JJ I-OC
toxicity NN I-OC
was VBD O
more RBR O
common JJ O
with IN O
topotecan JJ B-INTV
and CC O
was VBD O
more RBR O
likely JJ O
to TO O
be VB O
associated VBN O
with IN O
dosage NN O
modification NN O
, , O
or CC O
growth NN O
factor NN O
or CC O
blood NN O
product NN O
utilization NN O
. . O

CONCLUSION VB O
The DT O
comparable JJ O
efficacy NN B-OC
, , I-OC
favorable JJ I-OC
safety NN I-OC
profile NN I-OC
, , O
and CC O
convenient NN B-OC
dosing VBG I-OC
support NN O
the DT O
role NN O
of IN O
PLD NNP B-INTV
as IN O
a DT O
valuable JJ O
treatment NN O
option NN O
in IN O
this DT O
patient JJ O
population NN O
. . O

-DOCSTART- -X- O O

Long-term JJ B-OC
survival NN I-OC
in IN O
a DT O
phase NN O
III NNP O
, , O
randomised VBD O
study NN O
of IN O
topotecan JJ B-INTV
versus NN O
paclitaxel NN B-INTV
in IN O
advanced JJ B-POPU
epithelial JJ I-POPU
ovarian JJ I-POPU
carcinoma NN I-POPU
. . O

BACKGROUND IN O
We PRP O
have VBP O
continued VBN O
to TO O
monitor VB O
the DT O
survival NN B-OC
of IN O
patients NNS O
randomised VBN O
in IN O
a DT O
previously RB O
reported VBN O
multicentre JJ O
phase NN O
III NNP O
study NN O
of IN O
topotecan JJ B-INTV
versus NN O
paclitaxel NN B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
epithelial JJ I-POPU
ovarian JJ I-POPU
cancer NN I-POPU
who WP I-POPU
had VBD I-POPU
failed VBN I-POPU
one CD I-POPU
prior JJ I-POPU
platinum-based JJ I-POPU
regimen NNS I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Patients NNPS B-POPU
with IN I-POPU
bidimensionally RB I-POPU
measurable JJ I-POPU
disease NN I-POPU
were VBD O
randomised VBN O
to TO O
topotecan VB B-INTV
( ( O
1.5 CD O
mg/m NN O
( ( O
2 CD O
) ) O
/day NN O
for IN O
5 CD O
days NNS O
) ) O
or CC O
paclitaxel NN B-INTV
( ( O
175 CD O
mg/m NN O
( ( O
2 CD O
) ) O
/day NN O
as IN O
a DT O
3-h JJ O
infusion NN O
) ) O
every DT O
21 CD O
days NNS O
. . O

Patients NNS O
were VBD O
eligible JJ O
for IN O
treatment NN O
with IN O
the DT O
alternate NN O
therapy NN O
at IN O
third JJ O
line NN O
. . O

The DT B-OC
European JJ I-OC
Organisation NNP I-OC
for IN I-OC
Research NNP I-OC
and CC I-OC
Treatment NNP I-OC
of IN I-OC
Cancer NNP I-OC
Quality NNP I-OC
of IN I-OC
Life NNP I-OC
( ( I-OC
EORTC NNP I-OC
QOL NNP I-OC
) ) I-OC
-C30 VBP I-OC
questionnaire NN I-OC
was VBD O
also RB O
used VBN O
to TO O
measure VB O
eight CD O
symptoms NNS O
at IN O
baseline NN O
and CC O
during IN O
each DT O
course NN O
( ( B-OC
pain NN I-OC
, , I-OC
anorexia NN I-OC
, , I-OC
diarrhoea NN I-OC
, , I-OC
fatigue NN I-OC
, , I-OC
nausea NN I-OC
and CC I-OC
vomiting NN I-OC
, , I-OC
dyspnea NN I-OC
, , I-OC
constipation NN I-OC
and CC I-OC
insomnia NN I-OC
) ) I-OC
. . O

RESULTS VB O
A DT B-POPU
total NN I-POPU
of IN I-POPU
226 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
evaluable JJ I-POPU
for IN I-POPU
response NN I-POPU
. . O

Demographic JJ O
characteristics NNS O
were VBD O
similar JJ O
in IN O
both DT O
treatment NN O
groups NNS O
, , O
as IN O
were VBD O
results NNS O
of IN O
the DT O
EORTC NNP B-OC
QOL-30 NNP I-OC
questionnaire NN I-OC
. . O

For IN O
the DT O
topotecan JJ B-INTV
group NN O
, , O
median JJ O
time NN O
to TO O
progression NN B-OC
was VBD O
18.9 CD O
weeks NNS O
( ( O
range NN O
< RB O
1 CD O
to TO O
92.6+ CD O
weeks NNS O
; : O
25 CD O
% NN O
censored VBN O
) ) O
, , O
and CC O
, , O
for IN O
paclitaxel NN B-INTV
, , O
14.7 CD O
weeks NNS O
( ( O
range NN O
< RB O
1 CD O
to TO O
137.3+ CD O
weeks NNS O
; : O
12.3 CD O
% NN O
censored VBN O
) ) O
; : O
P NNP O
= VBD O
0.076 CD O
. . O

At IN O
4 CD O
years NNS O
post-randomisation NN O
, , O
median JJ B-OC
survival NN I-OC
in IN O
the DT O
topotecan JJ B-INTV
group NN O
was VBD O
63.0 CD O
weeks NNS O
( ( O
range NN O
< RB O
1 CD O
to TO O
238.4+ CD O
weeks NNS O
; : O
20.5 CD O
% NN O
censored VBN O
) ) O
and CC O
, , O
for IN O
paclitaxel NN B-INTV
, , O
53.0 CD O
weeks NNS O
( ( O
range NN O
< RB O
1 CD O
to TO O
226.3+ CD O
weeks NNS O
; : O
12.3 CD O
% NN O
censored VBN O
) ) O
; : O
P NNP O
= VBD O
0.44 CD O
. . O

CONCLUSION NNP O
Topotecan NNP B-INTV
continues VBZ O
to TO O
demonstrate VB O
comparable JJ O
efficacy NN B-OC
and CC O
survival NN B-OC
to TO O
paclitaxel VB B-INTV
with IN O
manageable JJ O
and CC O
non-cumulative JJ O
haematological JJ B-OC
toxicity NN I-OC
. . O

Non-haematological JJ B-OC
toxicity NN I-OC
was VBD O
generally RB O
mild VBN O
for IN O
both DT O
groups NNS O
. . O

The DT O
long-term JJ B-OC
survival NN I-OC
rate NN I-OC
indicates VBZ O
substantial JJ O
therapeutic JJ O
benefit NN O
for IN O
this DT O
group NN O
of IN O
patients NNS O
receiving VBG O
topotecan JJ B-INTV
at IN O
relapse NN O
of IN O
ovarian JJ B-POPU
cancer NN I-POPU
. . O

-DOCSTART- -X- O O

Feasibility NN B-OC
of IN O
two CD O
dose-dense JJ O
FEC NNP B-INTV
regimens VBZ O
with IN O
growth NN O
factor NN O
support NN O
for IN O
adjuvant JJ O
therapy NN O
in IN O
patients NNS B-POPU
with IN I-POPU
early JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
results NNS O
from IN O
a DT O
randomised JJ O
study NN O
of IN O
the DT O
Central NNP O
European NNP B-POPU
Cooperative NNP O
Oncology NNP O
Group NNP O
( ( O
CECOG NNP O
) ) O
. . O

Addition NN O
of IN O
epirubicin NN B-INTV
to TO O
adjuvant VB O
chemotherapy NN O
can MD O
provide VB O
important JJ O
benefits NNS O
for IN O
patients NNS B-POPU
with IN I-POPU
early JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
, , O
but CC O
the DT O
optimal JJ O
dose NN O
remains VBZ O
unclear JJ O
. . O

Further JJ O
improvements NNS O
can MD O
be VB O
achieved VBN O
with IN O
dose-dense JJ O
regimens NNS O
, , O
but CC O
densification NN O
of IN O
fluorouracil/epirubicin/cyclophosphamide NN B-INTV
( ( I-INTV
FEC NNP I-INTV
) ) I-INTV
has VBZ O
proved VBN O
difficult JJ O
, , O
with IN O
FEC NNP B-INTV
( ( I-INTV
60 CD I-INTV
) ) I-INTV
providing VBG O
little JJ O
benefit NN O
over IN O
standard JJ O
chemotherapy NN O
and CC O
FEC NNP B-INTV
( ( I-INTV
100 CD I-INTV
) ) I-INTV
associated VBN O
with IN O
toxicity NN O
. . O

We PRP O
investigated VBD O
the DT O
feasibility NN B-OC
of IN O
two CD O
intermediate JJ O
dose-dense JJ O
FEC NNP B-INTV
regimens NNS O
. . O

Patients NNS O
were VBD O
randomised VBN O
to TO O
six CD O
cycles NNS O
of IN O
FEC NNP B-INTV
( ( I-INTV
75 CD I-INTV
) ) I-INTV
or CC O
FEC NNP B-INTV
( ( I-INTV
90 CD I-INTV
) ) I-INTV
, , O
with IN O
all DT O
three CD O
drugs NNS O
given VBN O
on IN O
day NN O
1 CD O
of IN O
each DT O
14-day JJ O
cycle NN O
. . O

Patients NNS O
also RB O
received VBD O
pegfilgrastim JJ B-INTV
6 CD O
mg NN O
as IN O
a DT O
single JJ O
subcutaneous JJ O
injection NN O
on IN O
day NN O
2 CD O
of IN O
each DT O
cycle NN O
. . O

The DT O
primary JJ O
efficacy NN B-OC
endpoint NN O
was VBD O
the DT O
proportion NN B-OC
of IN I-OC
subjects NNS I-OC
receiving VBG I-OC
> NN I-OC
or CC I-OC
=85 CD I-OC
% NN I-OC
relative JJ I-OC
dose JJ I-OC
intensity NN I-OC
and CC O
was VBD O
achieved VBN O
by IN O
96 CD O
% NN O
and CC O
88 CD O
% NN O
of IN O
patients NNS O
in IN O
the DT O
FEC NNP B-INTV
( ( I-INTV
75 CD I-INTV
) ) I-INTV
and CC O
FEC NNP B-INTV
( ( I-INTV
90 CD I-INTV
) ) I-INTV
arms NNS O
, , O
respectively RB O
. . O

Of IN O
147 CD O
FEC NNP B-INTV
( ( I-INTV
75 CD I-INTV
) ) I-INTV
infusions NNS O
, , O
4.1 CD O
% NN O
were VBD O
delayed VBN O
, , O
while IN O
9.8 CD O
% NN O
of IN O
143 CD O
FEC NNP B-INTV
( ( I-INTV
90 CD I-INTV
) ) I-INTV
infusions NNS O
were VBD O
delayed VBN O
. . O

The DT O
most RBS O
common JJ O
reasons NNS O
for IN O
delay NN O
were VBD O
adverse JJ B-OC
events NNS I-OC
and CC O
personal/logistical JJ O
reasons NNS O
. . O

One CD O
dose JJ O
reduction NN O
occurred VBD O
during IN O
the DT O
study NN O
( ( B-INTV
FEC NNP I-INTV
( ( I-INTV
90 CD I-INTV
) ) I-INTV
) ) I-INTV
, , O
related VBN O
to TO O
diarrhoea VB B-OC
. . O

Grade VB O
3-4 JJ O
haematological JJ B-OC
toxicities NNS I-OC
were VBD O
reported VBN O
in IN O
two CD O
patients NNS O
in IN O
the DT O
FEC NNP B-INTV
( ( I-INTV
90 CD I-INTV
) ) I-INTV
arm NN O
. . O

There EX O
were VBD O
no DT O
incidences NNS O
of IN O
febrile JJ B-OC
neutropenia NN I-OC
during IN O
the DT O
study NN O
. . O

The DT O
most RBS O
common JJ O
adverse JJ B-OC
events NNS I-OC
were VBD O
increases NNS B-OC
in IN I-OC
liver NN I-OC
enzymes NNS I-OC
and CC I-OC
gastrointestinal JJ I-OC
events NNS I-OC
; : I-OC
no DT O
event NN O
resulted VBD O
in IN O
discontinuation NN O
. . O

Only RB O
one CD O
patient NN O
( ( B-INTV
FEC NNP I-INTV
( ( I-INTV
90 CD I-INTV
) ) I-INTV
) ) I-INTV
experienced VBD O
serious JJ B-OC
adverse JJ I-OC
events NNS I-OC
( ( I-OC
vomiting VBG I-OC
and CC I-OC
throat VB I-OC
oedema NN I-OC
) ) I-OC
. . O

In IN O
conclusion NN O
, , O
dose-dense JJ O
FEC NNP B-INTV
( ( I-INTV
75 CD I-INTV
) ) O
and CC O
FEC NNP B-INTV
( ( I-INTV
90 CD I-INTV
) ) I-INTV
are VBP O
feasible JJ B-OC
with IN O
pegfilgrastim JJ B-INTV
support NN O
. . O

These DT O
regimens NNS O
are VBP O
associated VBN O
with IN O
a DT O
very RB O
low JJ O
risk NN O
of IN O
Grade NNP O
3-4 JJ O
toxicity NN O
. . O

-DOCSTART- -X- O O

The DT O
effect NN O
of IN O
weight NN B-INTV
training NN I-INTV
on IN O
bone JJ B-OC
mineral JJ I-OC
density NN I-OC
and CC I-OC
bone NN I-OC
turnover NN I-OC
in IN O
postmenopausal JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
survivors NNS I-POPU
with IN I-POPU
bone JJ I-POPU
loss NN I-POPU
: : I-POPU
a DT O
24-month JJ O
randomized NN O
controlled VBD O
trial NN O
. . O

SUMMARY VB O
This DT O
study NN O
examined VBD O
whether IN O
24 CD O
months NNS O
of IN O
weight JJ B-INTV
training NN I-INTV
exercises NNS I-INTV
enhanced VBD O
the DT O
effectiveness NN B-OC
of IN O
risedronate NN O
, , O
calcium NN O
, , O
and CC O
vitamin NN O
D NNP O
in IN O
maintaining VBG O
or CC O
improving VBG O
bone JJ B-OC
mineral JJ I-OC
density NN I-OC
( ( I-OC
BMD NNP I-OC
) ) I-OC
in IN O
223 CD B-POPU
postmenopausal NN I-POPU
breast NN I-POPU
cancer NN I-POPU
survivors NNS I-POPU
. . O

Subjects NNS O
who WP O
were VBD O
> NNP O
or CC O
=50 CD O
% NN O
adherent NN O
to TO O
exercise VB O
had VBN O
no DT O
improvement NN O
in IN O
BMD NNP B-OC
but CC O
were VBD O
less RBR O
likely JJ O
to TO O
lose VB O
BMD NNP B-OC
. . O

INTRODUCTION NNP O
This DT O
study NN O
examined VBD O
whether IN O
( ( O
1 CD O
) ) O
postmenopausal NN B-POPU
breast NN I-POPU
cancer NN I-POPU
survivors NNS I-POPU
( ( I-POPU
BCS NNP I-POPU
) ) I-POPU
with IN I-POPU
bone NN I-POPU
loss NN I-POPU
taking VBG O
24 CD O
months NNS O
of IN O
risedronate NN B-INTV
, , I-INTV
calcium NN I-INTV
, , O
and CC O
vitamin NN B-INTV
D NNP I-INTV
had VBD O
increased VBN O
bone RB B-OC
mineral JJ I-OC
density NN I-OC
( ( I-OC
BMD NNP I-OC
) ) I-OC
at IN I-OC
the DT I-OC
total JJ I-OC
hip NN I-OC
, , I-OC
femoral JJ I-OC
neck NN I-OC
, , I-OC
L1-L4 NNP I-OC
spine NN I-OC
, , I-OC
total JJ I-OC
radius NN I-OC
and CC O
33 CD O
% NN O
radius NN O
, , O
and CC O
decreased VBD O
bone NN B-OC
turnover NN I-OC
; : I-OC
( ( O
2 CD O
) ) O
subjects NNS O
who WP O
also RB O
participated VBD O
in IN O
strength/weight JJ B-INTV
training NN I-INTV
( ( I-INTV
ST NNP I-INTV
) ) I-INTV
exercises NNS I-INTV
had VBD O
greater JJR O
increases NNS O
in IN O
BMD NNP B-OC
and CC O
greater JJR O
decreases NNS O
in IN O
bone NN B-OC
turnover NN I-OC
; : I-OC
and CC O
( ( O
3 CD O
) ) O
subjects NNS O
who WP O
also RB O
exercised VBD O
were VBD O
more RBR O
likely JJ O
to TO O
preserve VB O
( ( O
at IN O
least JJS O
maintain NN O
) ) O
BMD NNP B-OC
. . O

METHODS NNP O
Postmenopausal NNP B-POPU
BCS NNP I-POPU
( ( I-POPU
223 CD I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
exercise VB B-INTV
plus JJ I-INTV
medication NN I-INTV
or CC O
medication NN B-INTV
only RB O
groups NNS O
. . O

Both DT O
groups NNS O
received VBD O
24 CD O
months NNS O
of IN O
1,200 CD O
mg NN O
of IN O
calcium NN B-INTV
and CC O
400 CD O
IU NNP O
of IN O
vitamin NNP B-INTV
D NNP I-INTV
daily RB O
and CC O
35 CD O
mg NN O
of IN O
risedronate JJ B-INTV
weekly JJ O
, , O
and CC O
the DT O
exercise NN B-INTV
group NN O
additionally RB O
had VBD O
ST NNP B-INTV
exercises NNS I-INTV
twice RB O
weekly RB O
. . O

RESULTS NNP O
After IN O
24 CD O
months NNS O
, , O
women NNS O
who WP O
took VBD O
medications NNS B-INTV
without IN O
exercising VBG B-INTV
had VBD O
significant JJ O
improvements NNS O
in IN O
BMD NNP B-OC
at IN O
the DT O
total JJ O
hip NN O
( ( O
+1.81 CD O
% NN O
) ) O
and CC O
spine NN O
( ( O
+2.85 CD O
% NN O
) ) O
and CC O
significant JJ O
decreases NNS O
in IN O
Alkphase NNP B-OC
B NNP I-OC
( ( O
-8.7 NNP O
% NN O
) ) O
and CC O
serum JJ B-OC
NTx NNP I-OC
( ( O
-16.7 NNP O
% NN O
) ) O
. . O

Women NNS O
who WP O
also RB O
exercised VBD B-INTV
had VBD O
additional JJ O
increases NNS O
in IN O
BMD NNP B-OC
at IN O
the DT O
femoral JJ O
neck NN O
( ( O
+0.29 CD O
% NN O
) ) O
, , O
total JJ O
hip NN O
( ( O
+0.34 CD O
% NN O
) ) O
, , O
spine NN O
( ( O
+0.23 CD O
% NN O
) ) O
, , O
total JJ O
radius NN O
( ( O
+0.30 CD O
% NN O
) ) O
, , O
and CC O
additional JJ O
decreases NNS O
in IN O
Alkphase NNP B-OC
B NNP I-OC
( ( O
-2.4 NNP O
% NN O
) ) O
and CC O
Serum NNP B-OC
NTx NNP I-OC
( ( O
-6.5 NNP O
% NN O
) ) O
. . O

Additional JJ O
changes NNS B-OC
in IN I-OC
BMD NNP I-OC
and CC I-OC
bone NN I-OC
turnover NN I-OC
with IN O
exercise NN B-INTV
were VBD O
not RB O
significant JJ O
. . O

Subjects NNS O
who WP O
were VBD O
> NNP O
or CC O
=50 CD O
% NN O
adherent NN O
to TO O
exercise VB B-INTV
were VBD O
less RBR O
likely JJ O
to TO O
lose VB O
BMD NNP B-OC
at IN O
the DT O
total JJ O
hip NN O
( ( O
chi-square JJ O
[ NN O
1 CD O
] NNP O
= NNP O
4.66 CD O
, , O
p NN O
= NNP O
0.03 CD O
) ) O
and CC O
femoral JJ O
neck NN O
( ( O
chi-square JJ O
[ NN O
1 CD O
] NNP O
= NNP O
4.63 CD O
, , O
p NN O
= NNP O
0.03 CD O
) ) O
. . O

CONCLUSION NNP O
Strength/weight NNP B-INTV
training NN I-INTV
exercises NNS I-INTV
may MD O
prevent VB O
loss NN O
of IN O
BMD NNP B-OC
in IN O
postmenopausal NN B-POPU
BCS NNP I-POPU
at IN I-POPU
risk NN I-POPU
for IN I-POPU
bone NN I-POPU
loss NN I-POPU
. . O

-DOCSTART- -X- O O

Randomized VBN O
phase NN O
II NNP O
study NN O
of IN O
two CD O
different JJ O
schedules NNS O
of IN O
gemcitabine NN B-INTV
and CC O
oral JJ O
S-1 NNP B-INTV
in IN O
chemo-naïve JJ B-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
non-small JJ I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
. . O

INTRODUCTION NNP O
This DT O
study NN O
was VBD O
conducted VBN O
to TO O
evaluate VB O
the DT B-OC
efficacy NN I-OC
and CC I-OC
safety NN I-OC
and CC O
to TO B-OC
compare VB I-OC
dosing VBG I-OC
schedules NNS I-OC
of IN B-INTV
gemcitabine NN I-INTV
combined VBN O
with IN B-INTV
S-1 NNP I-INTV
in IN B-POPU
chemo-naïve JJ I-POPU
non-small JJ I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
. . O

METHODS NNP B-POPU
Patients NNPS I-POPU
with IN I-POPU
chemo-naïve JJ I-POPU
stage NN I-POPU
IIIB/IV NNP I-POPU
non-small NN I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
were VBD O
randomized VBN O
into IN O
two CD O
treatment NN O
arms NNS O
. . O

Patients NNS O
were VBD O
given VBN O
oral JJ B-INTV
S-1 NNP I-INTV
( ( O
60 CD O
mg/m/d NN O
, , O
twice RB O
a DT O
day NN O
) ) O
from IN O
days NNS O
1 CD O
to TO O
14 CD O
with IN B-INTV
gemcitabine NN I-INTV
( ( O
1000 CD O
mg/m/d NN O
) ) O
on IN O
days NNS O
1 CD O
and CC O
8 CD O
( ( O
arm VB O
A NNP O
) ) O
or CC O
on IN O
days NNS O
8 CD O
and CC O
15 CD O
( ( O
arm NN O
B NNP O
) ) O
. . O

This DT O
cycle NN O
was VBD O
repeated VBN O
every DT O
21 CD O
days NNS O
. . O

RESULTS VB B-POPU
A DT I-POPU
total NN I-POPU
of IN I-POPU
80 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
entered VBN I-POPU
in IN I-POPU
this DT I-POPU
trial NN I-POPU
. . O

The DT O
primary JJ O
end NN O
point NN O
of IN O
this DT O
study NN O
was VBD B-OC
response NN I-OC
rate NN I-OC
. . O

The DT B-OC
response NN I-OC
rates NNS I-OC
of IN O
arm NN O
A NNP O
and CC O
arm NN O
B NNP O
were VBD O
22.0 CD O
and CC O
28.9 CD O
% NN O
, , O
respectively RB O
( ( O
p JJ O
= NNP O
0.606 CD B-OC
) ) I-OC
. . O

Median JJ B-OC
time NN I-OC
to TO I-OC
treatment NN I-OC
failure NN I-OC
in IN O
arm NN O
A NN O
was VBD O
3.6 CD O
months NNS O
and CC O
4.8 CD O
months NNS O
in IN O
arm NN O
B NNP B-OC
. . O

Median JJ B-OC
time NN I-OC
to TO I-OC
progression NN I-OC
in IN O
arm NN O
A NN O
was VBD O
4.1 CD O
months NNS O
and CC O
5.5 CD O
months NNS O
in IN O
arm NN O
B NNP B-OC
. . O

Median JJ B-OC
survival JJ I-OC
time NN I-OC
in IN O
arm NN O
A NN O
and CC O
arm NN O
B NNP O
was VBD O
15.5 CD O
months NNS O
and CC O
18.8 CD O
months NNS O
, , O
respectively RB O
. . O

The DT B-OC
toxicity NN I-OC
profile NN I-OC
was VBD O
relatively RB O
mild JJ O
and CC O
did VBD O
not RB O
differ VB O
very RB O
much RB O
between IN O
two CD O
arms NNS O
. . O

CONCLUSION VB O
The DT O
combination NN O
of IN B-INTV
gemcitabine NN I-INTV
and CC I-INTV
S-1 NNP I-INTV
was VBD O
determined VBN O
to TO O
be VB B-OC
feasible JJ I-OC
and CC I-OC
effective JJ I-OC
for IN O
advanced JJ O
non-small JJ O
cell NN O
lung NN O
cancer NN O
. . O

We PRP O
selected VBD O
arm NN O
B NNP O
for IN O
further JJ O
studies NNS O
because IN O
of IN O
its PRP$ O
higher JJR B-OC
response NN I-OC
rate NN I-OC
and CC I-OC
survival NN I-OC
data NNS I-OC
. . O

-DOCSTART- -X- O O

Cryoprobe NNP B-INTV
biopsy NN I-INTV
increases VBZ O
the DT O
diagnostic JJ B-OC
yield NN I-OC
in IN O
endobronchial JJ B-POPU
tumor NN I-POPU
lesions NNS I-POPU
. . O

OBJECTIVE NNP O
Forceps NNP O
biopsy NN O
is VBZ O
the DT O
standard JJ O
method NN O
to TO O
obtain VB O
specimens NNS O
in IN O
endoscopically RB O
visible JJ O
lesions NNS O
. . O

It PRP O
is VBZ O
common JJ O
to TO O
combine VB O
forceps NNS O
biopsy VB O
with IN O
cytology NN O
methods NNS O
to TO O
increase VB O
the DT O
diagnostic JJ B-OC
yield NN I-OC
. . O

Although IN O
the DT O
flexible JJ O
cryoprobe NN B-INTV
has VBZ O
been VBN O
established VBN O
for IN O
bronchoscopic NN O
interventions NNS O
in IN O
malignant JJ O
stenosis NN O
, , O
the DT O
obtained JJ O
biopsies NNS O
, , O
called VBN O
" NN B-INTV
cryobiopsies NNS I-INTV
, , O
" NNS O
have VBP O
not RB O
been VBN O
investigated VBN O
in IN O
a DT O
large JJ O
cohort NN O
of IN O
patients NNS O
. . O

The DT O
aim NN O
of IN O
this DT O
feasibility NN O
study NN O
was VBD O
to TO O
prospectively RB O
evaluate VB O
the DT O
diagnostic JJ B-OC
yield NN I-OC
and CC O
safety NN B-OC
of IN O
cryobiopsy NN B-INTV
and CC O
forceps JJ B-INTV
biopsy NN I-INTV
. . O

METHODS NNP O
During IN O
a DT O
6-year JJ O
period NN O
, , O
296 CD B-POPU
patients NNS I-POPU
with IN I-POPU
visible JJ I-POPU
endoluminal JJ I-POPU
tumor NN I-POPU
lesions NNS I-POPU
were VBD I-POPU
included VBN I-POPU
in IN O
the DT O
study NN O
at IN O
the DT O
bronchoscopy NN B-POPU
unit NN I-POPU
of IN I-POPU
a DT I-POPU
university NN I-POPU
hospital NN I-POPU
. . O

In IN O
the DT O
first JJ O
consecutively RB O
conducted VBN O
55 CD O
cases NNS O
, , O
both DT O
techniques NNS O
, , O
forceps NNS B-INTV
biopsy NN I-INTV
and CC I-INTV
cryobiopsy NN I-INTV
, , O
were VBD O
applied VBN O
simultaneously RB O
. . O

Pathologic NNP B-OC
and CC I-OC
quantitative JJ I-OC
image NN I-OC
analyses NNS I-OC
were VBD O
performed VBN O
to TO O
evaluate VB O
the DT O
size NN B-OC
and CC I-OC
quality NN I-OC
of IN I-OC
the DT I-OC
obtained VBN I-OC
specimens NNS I-OC
. . O

We PRP O
evaluated VBD O
the DT O
safety NN B-OC
and CC O
diagnostic JJ B-OC
yield NN I-OC
to TO O
describe VB O
the DT O
feasibility NN B-OC
of IN O
cryobiopsy NN B-INTV
. . O

RESULTS NNP O
Comparative JJ O
analysis NN O
of IN O
the DT O
first JJ O
conducted VBN O
and CC O
randomly RB O
assigned VBD O
55 CD O
cases NNS O
revealed VBD O
a DT O
significantly RB O
higher RBR O
diagnostic JJ B-OC
yield NN I-OC
for IN O
cryobiopsy NN B-INTV
compared VBN O
with IN O
forceps NNS B-INTV
biopsy NNS I-INTV
( ( O
89.1 CD O
% NN O
vs JJ O
65.5 CD O
% NN O
, , O
P NNP O
< NNP O
.05 NNP O
) ) O
. . O

In IN O
this DT O
cohort NN O
, , O
quantitative JJ B-OC
image NN I-OC
analysis NN I-OC
showed VBD O
significantly RB O
larger JJR O
biopsies NNS O
regarding VBG O
size NN B-OC
and CC O
artifact-free JJ O
tissue NN O
sections NNS O
for IN O
cryobiopsy NN B-INTV
compared VBN O
with IN O
forceps NNS B-INTV
biopsy NN I-INTV
( ( O
P NNP O
< NNP O
.0001 NNP O
) ) O
. . O

The DT O
overall JJ B-OC
diagnostic JJ I-OC
yield NN I-OC
of IN O
cryobiopsy NN B-INTV
was VBD O
89.5 CD O
% NN O
. . O

Mild NNP O
bleeding VBG B-OC
occurred VBD O
in IN O
11 CD O
cases NNS O
( ( O
3.7 CD O
% NN O
) ) O
, , O
moderate JJ O
bleeding NN B-OC
occurred VBD O
in IN O
3 CD O
cases NNS O
( ( O
1.0 CD O
% NN O
) ) O
, , O
and CC O
severe JJ O
bleeding NN B-OC
occurred VBD O
in IN O
1 CD O
case NN O
( ( O
0.3 CD O
% NN O
) ) O
. . O

CONCLUSION NNP O
Cryobiopsy NNP B-INTV
is VBZ O
safe JJ B-OC
and CC O
increases VBZ O
the DT O
diagnostic JJ B-OC
yield NN I-OC
in IN O
endobronchial JJ O
tumor NN O
lesions NNS O
. . O

The DT O
method NN O
also RB O
is VBZ O
feasible JJ B-OC
under IN O
routine JJ O
conditions NNS O
. . O

-DOCSTART- -X- O O

Amonafide NN B-INTV
: : I-INTV
An DT O
active JJ O
agent NN O
in IN O
the DT O
treatment NN O
of IN O
previously RB B-POPU
untreated VBN I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
-- : I-POPU
a DT I-POPU
cancer NN O
and CC O
leukemia NN O
group NN O
B NNP O
study NN O
( ( O
CALGB NNP O
8642 CD O
) ) O
. . O

Amonafide NNP B-INTV
is VBZ O
a DT O
new JJ O
imide JJ O
derivative NN O
of IN O
naphthalic JJ O
acid NN O
. . O

The DT O
drug NN O
had VBD O
demonstrated VBN O
significant JJ O
activity NN O
in IN O
preclinical JJ O
studies NNS O
and CC O
some DT O
activity NN O
in IN O
Phase NNP O
I PRP O
trials NNS O
. . O

The DT O
drug NN O
is VBZ O
extensively RB O
metabolized VBN O
and CC O
detected VBN O
in IN O
plasma NN O
and CC O
urine NN O
. . O

Its PRP$ O
toxicity NN O
has VBZ O
previously RB O
been VBN O
correlated VBN O
to TO O
the DT O
formation NN O
of IN O
an DT O
active JJ O
metabolite NN O
, , O
N-acetyl-amonafide NNP O
. . O

Amonafide NNP B-INTV
was VBD O
chosen VBN O
for IN O
inclusion NN O
in IN O
the DT O
Cancer NNP O
and CC O
Leukemia NNP O
Group NNP O
B NNP O
( ( O
CALGB NNP O
) ) O
master NN O
metastatic JJ O
breast NN O
cancer NN O
protocol NN O
. . O

CALGB NNP O
8642 CD O
randomizes VBZ O
previously RB B-POPU
untreated VBN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
either CC O
to TO O
one CD O
of IN O
several JJ O
Phase NNP O
II NNP O
agents NNS O
given VBN O
for IN O
up IN O
to TO O
four CD O
cycles NNS O
and CC O
then RB O
followed VBN O
by IN O
standard JJ O
cyclophosphamide-doxorubicin-5-fluorouracil NN B-INTV
, , O
or CC O
to TO O
immediate VB O
treatment NN O
with IN O
standard JJ O
cyclophosphamide-doxorubicin-5-fluorouracil NN B-INTV
. . O

The DT O
end NN O
point NN O
of IN O
CALGB NNP O
8642 CD O
is VBZ O
to TO O
assess VB B-OC
the DT I-OC
difference NN I-OC
in IN I-OC
survival NN I-OC
, , I-OC
toxicity NN I-OC
, , I-OC
and CC I-OC
overall JJ I-OC
response NN I-OC
when WRB O
limited JJ O
exposure NN O
to TO O
Phase NNP O
II NNP O
agents NNS O
precedes VBZ O
standard JJ O
chemotherapy NN O
. . O

This DT O
report NN O
deals VBZ O
only RB O
with IN O
amonafide RB B-INTV
as IN O
a DT O
Phase NNP O
II NNP O
agent NN O
. . O

Comparisons NNS O
with IN O
the DT O
cyclophosphamide-doxorubicin-5-fluorouracil JJ B-INTV
arm NN O
will MD O
not RB O
be VB O
addressed VBN O
. . O

Patients NNS B-POPU
had VBD I-POPU
to TO I-POPU
have VB I-POPU
histologically RB I-POPU
documented VBN I-POPU
measurable JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
and CC I-POPU
a DT I-POPU
performance NN I-POPU
status NN I-POPU
of IN I-POPU
0-1 NNP I-POPU
. . O

Patients NNS B-POPU
could MD I-POPU
not RB I-POPU
have VB I-POPU
had VBN I-POPU
prior JJ I-POPU
chemotherapy NN I-POPU
for IN I-POPU
metastatic JJ I-POPU
disease NN I-POPU
. . O

Prior NNP B-POPU
adjuvant JJ I-POPU
chemotherapy NN I-POPU
was VBD I-POPU
permitted VBN I-POPU
. . O

Patients NNS B-POPU
could MD I-POPU
not RB I-POPU
have VB I-POPU
visceral JJ I-POPU
crisis NN I-POPU
. . O

Amonafide NNP B-INTV
was VBD O
given VBN O
at IN O
300 CD O
mg/m2/day JJ O
i.v NN O
. . O

for IN O
5 CD O
days NNS O
, , O
and CC O
repeated VBD O
at IN O
21-day JJ O
intervals NNS O
for IN O
a DT O
maximum NN O
of IN O
four CD O
cycles NNS O
. . O

Escalation NN O
and CC O
reduction NN O
in IN O
dose NN O
was VBD O
mandated VBN O
dependent NN O
on IN O
hematotoxicity NN O
or CC O
lack NN O
thereof NN O
. . O

Toxicity NN B-OC
was VBD O
primarily RB O
hematological JJ B-OC
and CC O
bimodal NN O
: : O
32 CD O
% NN O
had VBD O
grade VBN O
3 CD O
or CC O
4 CD O
leukopenia NN B-OC
and CC O
24 CD O
% NN O
had VBD O
grade VBN O
3 CD O
or CC O
4 CD O
thrombocytopenia NN B-OC
; : I-OC
22 CD O
% NN O
had VBD O
no DT O
leukopenia NN B-OC
and CC O
44 CD O
% NN O
had VBD O
no DT O
thrombocytopenia NN B-OC
. . O

The DT O
response NN B-OC
rate NN I-OC
was VBD O
18 CD O
% NN O
, , O
including VBG O
one CD O
complete JJ O
response NN O
. . O

When WRB O
response NN O
was VBD O
analyzed VBN O
by IN O
hematological JJ B-OC
toxicity NN I-OC
, , O
there EX O
was VBD O
a DT O
35.7 CD O
% NN O
response NN O
if IN O
patients NNS O
had VBD O
leukopenia VBN B-OC
grade NN O
3/4 CD O
( ( O
versus IN O
8.3 CD O
% NN O
, , O
P NNP O
= NNP O
0.08 CD O
) ) O
. . O

There EX O
was VBD O
a DT O
50 CD O
% NN O
response NN O
if IN O
patients NNS O
had VBD O
thrombocytopenia VBN B-OC
grade NN O
3/4 CD O
( ( O
versus IN O
7.1 CD O
% NN O
, , O
P NNP O
= NNP O
< NNP O
0.01 CD O
) ) O
. . O

We PRP O
conclude VBP O
that DT O
amonafide NN B-INTV
is VBZ O
somewhat RB O
active JJ O
in IN O
previously RB O
untreated VBN O
breast NN O
cancer NN O
patients NNS O
. . O

There EX O
may MD O
be VB O
a DT O
steep JJ O
dose-response NN O
curve NN O
, , O
based VBN O
on IN O
the DT O
significant JJ O
correlation NN O
between IN O
myelosuppression NN O
and CC O
response NN O
. . O

Rates NNS B-OC
of IN I-OC
responses NNS I-OC
in IN O
patients NNS O
adequately RB O
dosed VBN O
( ( O
i.e. FW O
, , O
with IN O
significant JJ O
hematotoxicity NN B-OC
) ) I-OC
with IN O
amonafide NN B-INTV
ranged VBD O
from IN O
35 CD O
to TO O
50 CD O
% NN O
. . O

Further JJ O
studies NNS O
will MD O
incorporate VB O
individualized JJ O
dosing NN O
based VBN O
on IN O
pretreatment NN O
acetylator NN O
phenotyping NN O
. . O

